MERSANA THERAPEUTICS, INC.
2022 Annual Report to Stockholders
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2022.
OR
For the transition period from to
Commission file number 001-38129
Mersana Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or Other Jurisdiction of Incorporation or Organization)
04-3562403
(I.R.S. Employer Identification No.)
840 Memorial Drive Cambridge, MA
(Address of Principal Executive Offices)
02139
(Zip Code)
Registrant’s telephone number, including area code (617) 498-0020
Title of each class
Common Stock, $0.0001 par value
Securities registered pursuant to Section 12(b) of the Act:
Trading symbol(s)
MRSN
Securities registered pursuant to Section 12(g) of the Act:
NONE
Name of each exchange on which registered
The Nasdaq Global Select Market
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that registrant was required to file such reports), and (2) has been subject to such filing requirements for the
past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such
files). Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an
emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company”
in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Non-accelerated filer
Accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its
audit report.
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing
reflect the correction of an error to previously issued financial statements.
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by
any of the registrant's executive officers during the relevant recovery period pursuant to § 240.10D-1(b).
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes No
As of June 30, 2022, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the registrant’s
common stock held by non-affiliates was $403,311,770, based on the last reported sale price of such stock on the Nasdaq Global Select Market as of such date.
As of February 24, 2023, the registrant had 108,026,074 shares of common stock outstanding at a par value $0.0001 per share.
Portions of the registrant’s definitive proxy statement that will be filed for the 2023 Annual Meeting of Stockholders within 120 days of the end of the
registrant’s fiscal year ended December 31, 2022 are incorporated by reference in Part III of this Annual Report on Form 10-K to the extent stated herein.
DOCUMENTS INCORPORATED BY REFERENCE
TABLE OF CONTENTS
Page
SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS
RISK FACTOR SUMMARY
ITEM 1.
BUSINESS
ITEM 1A.
RISK FACTORS
ITEM 1B.
UNRESOLVED STAFF COMMENTS
ITEM 2.
PROPERTIES
ITEM 3.
LEGAL PROCEEDINGS
ITEM 4.
MINE SAFETY DISCLOSURES
PART I
PART II
ITEM 5.
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
ITEM 6.
[RESERVED]
ITEM 7.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
ITEM 7A.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
ITEM 8.
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
ITEM 9.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
ITEM 9A.
CONTROLS AND PROCEDURES
ITEM 9B.
OTHER INFORMATION
ITEM 9C.
DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
PART III
ITEM 10.
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
ITEM 11
EXECUTIVE COMPENSATION
ITEM 12.
ITEM 13.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
AND RELATED STOCKHOLDER MATTERS
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE
ITEM 14.
PRINCIPAL ACCOUNTANT FEES AND SERVICES
PART IV
ITEM 15.
EXHIBIT AND FINANCIAL STATEMENT SCHEDULES
ITEM 16.
FORM 10-K SUMMARY
SIGNATURES
2
3
5
44
88
88
88
88
89
90
90
103
104
143
143
144
144
145
145
145
145
145
146
149
150
1
REFERENCES TO MERSANA
Throughout this Annual Report on Form 10-K, the “Company,” “Mersana,” “we,” “us,” and “our,” except where the context
requires otherwise, refer to Mersana Therapeutics, Inc. and its consolidated subsidiary, and “our board of directors” refers to the
board of directors of Mersana Therapeutics, Inc.
SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS
This Annual Report on Form 10-K contains forward-looking statements. Forward-looking statements are neither historical facts
nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, our clinical results and other future conditions. The words “aim,”
“anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “on track,” “plan,”
“possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would” or the negative of these terms or other
similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain
these identifying words.
These forward-looking statements include, among other things, statements about:
•
•
•
•
•
•
•
•
•
the initiation, cost, timing, progress and results of our current and future research and development activities,
preclinical studies and clinical trials, including the expected timing of reporting of data from our ongoing clinical
trials;
the adequacy of our inventory of upifitamab rilsodotin, or UpRi, XMT-1660, XMT-2056 and our other product
candidates to support our ongoing and planned clinical trials, as well as the outcome of planned manufacturing runs;
the timing of, and our ability to obtain and maintain, regulatory approvals for our product candidates;
unmet needs of patients with ovarian cancer, breast cancer and other cancer indications;
our ability to quickly and efficiently identify and develop additional product candidates;
our ability to advance any product candidate into, and successfully complete, clinical trials;
our intellectual property position, including with respect to our trade secrets;
the potential benefits of strategic collaborations and our ability to enter into selective strategic collaborations;
our estimates regarding expenses, future revenues, capital requirements, the sufficiency of our current and expected
cash resources and our need for additional financing; and
•
the potential impact of the ongoing COVID-19 pandemic.
We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should
not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the
cautionary statements included in this Annual Report on Form 10-K, particularly in the “Risk Factors” section, that we believe
could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking
statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we
may make.
The forward-looking statements contained herein represent our views as of the date of this Annual Report on Form 10-K and
we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law. We anticipate that subsequent events and developments will cause our views to
change. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent
to the date of this Annual Report on Form 10-K.
2
RISK FACTOR SUMMARY
Our business is subject to varying degrees of risk and uncertainty. Investors should consider the risks and uncertainties
summarized below, as well as the risks and uncertainties discussed in Part I, Item 1A, Risk Factors of this Annual Report on
Form 10-K.
Our business is subject to the following principal risks and uncertainties:
• We have incurred net losses since our inception, we have no products approved for commercial sale and we anticipate
that we will continue to incur substantial operating losses for the foreseeable future.
• We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital
when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.
• We have a credit facility that requires us to meet certain affirmative and negative covenants and places restrictions on
our operating and financial flexibility.
• We face substantial competition, which may result in others discovering, developing or commercializing products
before, or more successfully than, we do.
• We only have a limited number of product candidates being evaluated in clinical trials. A failure of any of our current
or future product candidates in clinical development could adversely affect our business and may require us to
discontinue development of other product candidates based on the same technology.
• We can provide no assurance that our product candidates will obtain regulatory approval or that the results of clinical
trials will be favorable.
• Drug discovery and development is a complex, time-consuming and expensive process that is fraught with risk and a
high rate of failure. We can provide no assurance of the successful and timely development of new antibody-drug
conjugate, or ADC, products.
•
If we fail to attract and retain senior management and key scientific personnel, we may be unable to successfully
develop our product candidates, conduct our clinical trials and commercialize our product candidates.
• We may encounter difficulties in managing our growth and expanding our operations successfully.
• Our activities, including our interactions with healthcare providers, third party payors, patients and government
officials, are, and will continue to be, subject to extensive regulation involving health care, anti-corruption, data
privacy and security and consumer protection laws. Failure to comply with applicable laws could result in substantial
penalties, contractual damages, reputational harm, diminished revenues and curtailment or restructuring of our
operations.
• We rely upon patents and other intellectual property rights to protect our technology. We may be unable to protect our
intellectual property rights, and we may be liable for infringing the intellectual property rights of others.
• Unfavorable global economic or geopolitical conditions could adversely affect our business, financial condition or
results of operations.
INDUSTRY DATA
This Annual Report on Form 10-K may include industry and market data, which we may obtain from our own internal estimates
and research, as well as from industry and general publications and research, surveys, and studies conducted by third parties.
Industry publications, studies, and surveys generally state that they have been obtained from sources believed to be reliable,
although they do not guarantee the accuracy or completeness of such information. While we believe that such studies and
publications are reliable, we have not independently verified market and industry data from third‑party sources.
3
NOTE REGARDING TRADEMARKS
We own various trademark registrations and applications, and unregistered trademarks, including our name and our corporate
logo. All other trade names, trademarks and service marks of other companies appearing in this report are the property of their
respective holders. Solely for convenience, the trademarks and trade names in this report may be referred to without the ®,™ or
© symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the
fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies' trademarks and
trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
4
ITEM 1.
BUSINESS
Overview
PART I
We are a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates, or ADCs, that offer a
clinically meaningful benefit for cancer patients with significant unmet need. We have leveraged over 20 years of industry
learning in the ADC field to develop three proprietary and differentiated platforms that enable us to develop ADCs designed to
have improved efficacy, safety and tolerability relative to existing ADCs and other approved therapies.
We believe that our innovative platforms and our proprietary payloads together enable a robust discovery pipeline for us and
our collaborators. Our investments in our novel and proprietary auristatin DolaLock payload, as well as our novel and
proprietary STING (stimulator of interferon genes) agonist ImmunoLock payload, together with the good manufacturing
practices supply chain established for our Dolaflexin, Dolasynthen and Immunosynthen platforms, enable our ability to apply
these platforms to new and different targets and antibodies to create new product candidates. We call this our product engine.
Our ADCs in preclinical studies and clinical trials include first-in-class molecules that target multiple tumor types with high
unmet medical need.
We have assembled a management team with extensive and relevant experience, including specific ADC experience, from prior
work at leading pharmaceutical companies such as Bayer AG; Bristol Myers Squibb, or BMS; Centocor Inc.; Constellation
Pharmaceuticals, Inc.; Cubist Pharmaceuticals, Inc.; GlaxoSmithKline plc; Millennium Pharmaceuticals, Inc.; Momenta
Pharmaceuticals, Inc.; Sanofi S.A.; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals, Inc., or Takeda; Tesaro, Inc. and
Vertex Pharmaceuticals Inc. We are supported by our board of directors and scientific advisory board, who offer complementary
experience in drug discovery, development and commercialization, business development and public company management.
We believe that our highly differentiated platforms, together with the team we have assembled, position us well to discover and
develop life-changing ADCs for patients fighting cancer.
Strategy
Our goal is to become a leading oncology company by leveraging the potential of our innovative and differentiated ADC
platforms and the experience and competencies of our management team to discover and develop promising ADC product
candidates and to commercialize cancer therapeutics that address unmet medical needs or provide significant benefit to patients.
We believe that executing against the following strategic objectives will help us achieve our goal:
• Build UpRi (upifitamab rilsodotin) into a Foundational Medicine in Ovarian Cancer. Our lead product candidate,
upifitamab rilsodotin, which we refer to as UpRi, is a first-in-class Dolaflexin ADC targeting NaPi2b, an antigen
broadly expressed in ovarian cancer and other cancers. We are currently evaluating UpRi in patients with platinum-
resistant ovarian cancer in a single-arm registrational trial, which we refer to as UPLIFT, for which we completed
enrollment of approximately 270 patients in October 2022. We expect to report top-line data from UPLIFT in mid-
2023 following the major oncology conferences scheduled for June, and, if the data are positive, to submit a biologics
license application, or BLA, to the U.S. Food and Drug Administration, or FDA, under the accelerated approval
pathway around the end of 2023. We also initiated screening of patients in UP-NEXT, our Phase 3 clinical trial of
UpRi as monotherapy maintenance treatment following treatment with platinum doublets in recurrent platinum-
sensitive ovarian cancer, in the third quarter of 2022, and we continue to enroll patients in this trial. If data from the
trial are positive, we believe UP-NEXT could serve as a post-approval confirmatory trial in the United States, support
potential approvals outside of the United States and support UpRi’s expansion into earlier lines of therapy.
Additionally, we are also conducting a Phase 1 combination trial, which we refer to as UPGRADE-A, exploring the
combination of UpRi with carboplatin, a standard platinum chemotherapy broadly used in the treatment of platinum-
sensitive ovarian cancer. We have completed the dose escalation portion of UPGRADE-A, initiated the dose expansion
portion of UPGRADE-A in January 2023, and expect to present interim data from the trial in the second half of 2023.
We may explore UpRi in combination with other therapies in a series of UPGRADE trials. Together, we believe that
data from all of our clinical trials of UpRi have the potential to establish the safety and efficacy of UpRi across a wide
range of ovarian cancer patients, from those who are platinum-resistant and heavily pre-treated to those in earlier lines
of treatment for the disease. The European Commission granted orphan medicinal product designation to UpRi for the
treatment of ovarian cancer in December 2022.
5
• Build Out Our Pipeline of Highly Impactful Cancer Medicines. We are investigating two additional ADC product
candidates, XMT-1660 and XMT-2056, in Phase 1 clinical trials. XMT-1660 is a B7-H4-directed Dolasynthen ADC
designed with a precise, target-optimized drug-to-antibody ratio, or DAR, of 6 and our DolaLock microtubule inhibitor
payload with controlled bystander effect. We are currently enrolling patients in our multicenter Phase 1 trial
investigating the safety, tolerability and anti-tumor activity of XMT-1660 in patients with breast, endometrial and
ovarian cancers, and began dosing patients in August 2022. We expect to complete the dose escalation portion of this
trial in 2023. The FDA has granted Fast Track designation to XMT-1660 for the treatment of adult patients with
advanced or metastatic triple-negative breast cancer. XMT-2056 is a systemically administered Immunosynthen
STING agonist ADC (DAR 8) that is designed to target a novel epitope of human epidermal growth factor receptor 2,
or HER2, distinct from that targeted by either trastuzumab or pertuzumab, and to locally activate STING signaling in
both tumor-resident immune cells and in tumor cells, providing the potential to treat patients with HER2-high or -low
tumors as monotherapy and in combination with standard-of-care agents. We initiated a multicenter Phase 1 open-label
trial of XMT-2056 in previously treated patients with advanced/recurrent solid tumors expressing HER2, including
breast, gastric, colorectal and non-small cell lung cancers, in January 2023. The FDA granted orphan drug designation
to XMT-2056 for the treatment of gastric cancer in May 2022.
• Build Innovation and Scientific Leadership in ADCs. We believe we are establishing a leading position in the field
of ADCs by leveraging our existing platforms, Dolaflexin, Dolasynthen and Immunosynthen, and continuing to
advance new innovations. Additionally, we are discovering new product candidates for ourselves and for collaborators
that we believe hold the potential to be first- and best-in-class medicines for patients with cancer in areas of high
unmet medical need. XMT-2068 and XMT-2175 are among our preclinical candidates that leverage our
Immunosynthen platform.
• Build Relationships with Strategic Collaborators. We aim to leverage our technical expertise and experience with
respect to our innovative and diversified platforms, to attract and cultivate strategic collaborations that facilitate our
ability to bring differentiated product candidates to patients. We have established strategic research and development
collaborations with Janssen Biotech, Inc., or Janssen, and Merck KGaA, Darmstadt, Germany, or Merck KGaA, and
its affiliate Ares Trading S.A., or MRKDG, for the development and commercialization of additional ADC product
candidates leveraging our proprietary Dolasynthen, Dolaflexin and Immunosynthen platform technologies against a
limited number of targets selected by our collaborators. We have also granted GlaxoSmithKline Intellectual Property
(No. 4) Limited, or GSK, an exclusive option for an exclusive global license to co-develop and commercialize XMT-
2056. We believe the potential of our ADC technologies, supported by our scientific and technical expertise and
enabled by our intellectual property strategy, all support our independent and collaborative efforts to discover and
develop life-changing ADCs for patients fighting cancer.
• Build Mersana with Top Talent. We aim to attract and retain talented team members with deep experience in drug
discovery, development, manufacturing, and commercialization as well as in general business and administration. Our
team is driven by a shared passion to advance therapies that can make a significant difference in the lives of cancer
patients. We will continue to cultivate the collaborative and passionate workplace culture and diverse workforce that
has allowed us to advance this mission.
6
Our current pipeline is summarized in the chart below:
ADC Background
ADCs are a validated therapeutic modality in oncology with 11 products currently approved for use by the FDA, and over 100
being tested in clinical trials. We believe that the field has not yet realized its full potential due to the limitations of first-
generation ADCs and a scarcity of clinically meaningful platform innovation.
First-generation ADCs were developed to deliver cytotoxic therapy specifically to neoplastic cells while sparing normal tissue.
A cytotoxic ADC consists of three components: the antibody, the cytotoxic payload, and a linker to join the two. The antibody
portion of the ADC achieves specific targeting by binding to an antigen that ideally has high expression on the surface of the
tumor cells and low expression in healthy tissues. Once the antibody binds to the target, the ADC enters the cell, and the
payload is typically released, killing the cell.
The payload, the DAR, the linker, and conjugation site of the linker with the antibody all can influence the overall efficacy and
tolerability of ADCs. There has been limited innovation in these ADC components since the development of first-generation
ADC platforms. We believe optimizing an ADC requires developing payload(s) with optimal properties, varying DAR for a
specific target, and optimizing the conjugation site, all of which can contribute to the overall drug-like properties. We believe
that our proprietary platforms improve upon first-generation ADC approaches in these aspects and have the potential to advance
the field and improve patient outcomes.
7
Our Technologies and Platforms
We believe the development of ADCs is not a one-size-fits-all approach. In fact, a number of diverse factors impact the
properties of an ADC, including payload, DAR, site of conjugation and homogeneity. For each target antigen, there may be an
optimal combination of these factors. Our novel and highly differentiated platforms are designed to allow us to optimize these
properties for a given target and develop ADCs that are designed to best address patient needs.
DolaLock Payload
We refer to the cytotoxic payload we use with our Dolaflexin and Dolasynthen platforms as our DolaLock payload. Our
DolaLock payload is a highly potent, proprietary auristatin anti-tubulin agent selectively toxic to rapidly dividing cells. The
DolaLock payload has been shown in in vitro and in vivo preclinical studies to control the bystander effect by locking the
cytotoxic drug inside cells after allowing a short period of antigen-independent diffusion throughout the tumor. As the drug
diffuses through neighboring cells, the DolaLock payload is metabolized to a form that is still highly potent but is designed to
no longer be able to cross the cell membrane. We believe this “controlled bystander effect” may allow for enhanced safety and
efficacy.
A common mechanism of resistance in cancer is the up-regulation of multi-drug resistance, or MDR, pumps, such as P-
glycoproteins, or PgPs, which can actively pump drugs out of cancer cells to help them survive. Once metabolized, our
DolaLock payload is not a substrate for PgPs, thereby avoiding this resistance mechanism. Our DolaLock payload, with its
controlled bystander effect, is designed to enable the creation of ADCs that have the potential of being highly potent, well-
tolerated and specifically targeted cancer therapies.
In addition, our proprietary auristatin payload has also been shown in preclinical studies to cause immunogenic cell death and
to stimulate the immune system through dendritic cell activation. Because of this, we have observed synergy with immuno-
oncology agents such as PD-1 inhibitors in preclinical models.
Dolaflexin Platform
The Dolaflexin platform was designed to increase the efficacy, safety and tolerability of ADCs. Dolaflexin utilizes our
proprietary Fleximer polymer, a biodegradable, highly biocompatible, water-soluble polymer that is able to carry multiple
payloads. Instead of direct conjugation to an antibody, payloads are attached through an optimized, cleavable linker to the
Fleximer scaffold, which is then conjugated to the antibody through a non-cleavable linker. Our Fleximer polymer allows for an
increased number of payloads carried by each ADC as compared to other ADC therapies and has demonstrated dramatically
improved drug solubility and pharmacokinetics with higher DAR.
As a result, we believe Dolaflexin has the potential to offer the following benefits relative to first-generation ADCs:
• Proprietary DolaLock Payload: Dolaflexin is loaded with our proprietary auristatin cytotoxic drug, which is a highly
potent anti-tubulin agent that is selectively toxic to rapidly dividing cells and has a controlled bystander effect.
• Higher Drug-to-Antibody Ratio: Historically, ADCs typically have been limited to a DAR of 3-4. The Dolaflexin
platform can deliver ADCs with DAR of approximately 10, which has enabled ADCs created using this platform to
demonstrate greater preclinical efficacy while also maintaining pharmacokinetics and drug-like properties.
• Expanded Range of Addressable Tumor Targets: The higher DAR enabled by Dolaflexin results in a higher amount
of cytotoxic drug released into the tumor cell for every ADC that is internalized. As a result, we believe that Dolaflexin
ADCs may demonstrate efficacy against tumor targets with lower levels of antigen expression that traditional ADCs
have been unable to address.
We believe Dolaflexin’s advantageous characteristics provide a substantial opportunity to address a broader range of cancers
than first generation ADC-based approaches. Our lead clinical candidate, UpRi, is a Dolaflexin ADC that targets NaPi2b. We
are currently evaluating UpRi in the UPLIFT, UP-NEXT and UPGRADE-A clinical trials.
Dolasynthen Platform
The Dolasynthen platform enables an iterative approach to designing customized ADCs for a given target while retaining the
use of our proprietary DolaLock payload for a controlled bystander effect. Dolasynthen ADCs consist of a proprietary synthetic
scaffold carrying an exact number of DolaLock payloads for precise control of DAR. The Dolasynthen scaffold is then
8
bioconjugated to the antibody in a site-specific manner. The Dolasynthen scaffold has been precisely designed to provide
optimal water solubility, charge balance, linker stability and DAR, which together offer an opportunity for our ADCs to have
superior physicochemical and pharmacokinetic properties relative to other ADC therapies.
We believe Dolasynthen ADCs have broad therapeutic potential as cancer therapies, and our preclinical data demonstrate the
ability of the Dolasynthen platform to generate and identify the optimal ADC for a given target and antibody.
We believe that Dolasynthen offers the benefits of Dolaflexin, including the proprietary DolaLock payload, while also
providing the following potential additional benefits relative to traditional ADC platforms:
• Precise Control of DAR: The optimal DAR may vary between different targets and antibodies. Dolasynthen uses a
proprietary scaffold that allows for precise DARs between two and 24, enabling optimization of the DAR for specific
antigens and antibodies.
• Site-Specific Bioconjugation: The site of scaffold bioconjugation to an antibody impacts the overall properties of that
ADC. Dolasynthen enables site-specific bioconjugation, allowing further ADC optimization.
• Homogenous ADC Development: The DAR and antibody bioconjugation is consistent for each ADC developed with
the Dolasynthen platform, allowing for consistent and precise drug delivery to targeted cancer cells. We believe this
homogeneity may allow for enhanced safety, tolerability and efficacy.
•
Increased Hydrophilicity: The precise optimization of the hydrophilic moiety on Dolasynthen ADCs allows for
increased aqueous solubility and enhanced pharmacokinetic properties.
We are currently conducting a Phase 1 clinical trial of XMT-1660, our B7-H4-targeted Dolasynthen ADC.
ImmunoLock Payload
We refer to the STING agonist that is used as the payload with our Immunosynthen platform as our ImmunoLock Payload. It
was designed to have very low cell permeability in order to control delivery and localization of its innate immune-activating
effect. STING is a well-studied innate immune pathway capable of inducing anti-tumor immune activity. Our preclinical data
show that the anti-tumor activity of Immunosynthen ADCs carrying the ImmunoLock payload is driven by the targeted
activation of the STING pathway in tumor-resident immune cells and in tumor cells, in a target-dependent manner. STING
pathway activation in both cell types within the tumor provides the potential for enhanced anti-tumor activity with a STING-
agonist ADC compared to other innate immune approaches, such as toll-like receptor, or TLR, agonists, that activate only the
immune cells and are not capable of activating the tumor cells.
Immunosynthen Platform
Immunosynthen is our novel immunostimulatory ADC platform designed to take ADCs beyond the delivery of traditional
cytotoxic payloads by enabling the targeted stimulation of the innate immune system. Through the tumor-targeted delivery of a
novel STING agonist, ADCs created with our Immunosynthen platform have the potential to address the challenges of efficacy,
delivery and tolerability posed by intratumoral or intravenous injection of free (unconjugated) STING agonists. We have
generated preclinical data across multiple, diverse targets by creating Immunosynthen ADCs based on a variety of antibodies
directed to those targets and evaluating them in a range of tumor models. In each case, we have demonstrated significant anti-
tumor activity in vivo (including complete tumor regressions) after a single low, well-tolerated dose. Additional
characterization has demonstrated increased cytokine expression and immune cell infiltration in the tumor microenvironment,
as well as the induction of immunological memory. We have demonstrated tolerability and characterized the favorable
pharmacokinetic profile of Immunosynthen ADCs in non-human primates after multiple intravenous doses and at exposures
significantly higher than those required for robust efficacy in mice.
Immunosynthen ADCs have been designed to overcome the limitations of free STING agonists and to offer a highly
differentiated approach from other innate immune activators due to the following:
• Non-Cell Permeable STING Agonist ImmunoLock Payload: Our novel and proprietary payload has very low cell
permeability, remaining in the cell to which it is delivered by the antibody, where it can exert its effect.
9
• Enhanced Pharmacokinetic Properties: The prolonged pharmacokinetics of ADCs and active transport into tumor
cells and tumor-resident immune cells can overcome pharmacokinetic and permeability issues of the free agonists,
resulting in more robust and sustained activation of the innate immune response in the tumor.
• Targeted Activation in Two Cell Types: Because STING, unlike other innate immune pathways, can be activated in
tumor cells and tumor-resident immune cells, target-dependent delivery can result in innate immune activation of both
cell types, providing potent and robust anti-tumor responses and the induction of immunological memory.
Together these features have the potential to improve the applicable therapeutic index by selectively activating the innate
immune system in the tumor environment and minimizing activation in other tissues. We are building a pipeline of
Immunosynthen ADC candidates applicable to a broad range of clinical indications. In January 2023, we initiated a Phase 1
clinical trial of our first Immunosynthen ADC product candidate, XMT-2056, which targets a novel epitope of HER2.
Our product candidates
We are leveraging our platforms to develop a robust pipeline of product candidates that have the potential to become clinically
meaningful cancer therapies. Our pipeline strategy focuses on targets that have been biologically validated (either through
ADCs or other modalities), where the advantages of our platforms may lead to clinically superior therapeutic benefits and
where we have the potential to achieve first-in-class status by pursuing fast-to-market development strategies. Our lead product
candidate, UpRi, is currently being evaluated in three clinical trials: UPLIFT, UP-NEXT and UPGRADE-A. We are also
advancing XMT-1660, a B7-H4-targeted Dolasynthen ADC, and XMT-2056, our first Immunosynthen ADC targeting a novel
epitope of HER2, both of which are currently in Phase 1 clinical trials. In addition, our collaborators have multiple ADC
product candidates in various stages of development. In May 2022, we decided to discontinue development of XMT-1592, a
Dolasynthen ADC targeting NaPi2b that had been in a Phase 1 dose exploration trial in patients with ovarian cancer and non-
small cell lung cancer, or NSCLC, and we closed this company-sponsored trial in September 2022.
UpRi: our NaPi2b-targeted Dolaflexin ADC
UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform
to deliver about 10 DolaLock payload molecules per antibody. We believe the NaPi2b antigen is broadly expressed in ovarian
cancer and other cancers with limited expression in normal tissue. NaPi2b is a member of the SLC34 family of sodium-
dependent transporters and plays an important role in maintaining phosphate homeostasis. We initiated a Phase 1/2 clinical trial
of UpRi in December 2017 with the primary objectives of determining the recommended Phase 2 dose and characterizing
UpRi’s efficacy, safety and tolerability. Our secondary objective was to assess the potential correlation of NaPi2b biomarker
expression and efficacy. The dose escalation portion of the trial established a dose of 43 mg/m2, up to a maximum of
approximately 80 mg, as the maximum tolerated dose. The expansion portion of the trial evaluated two dose levels, 36 mg/m2
and 43 mg/m2, up to a maximum of approximately 80 mg.
There are currently no tests approved by the FDA to measure NaPi2b expression on tumor cells. While our initial clinical trials
have not prospectively identified patients with NaPi2b-expressing tumors, our development plan for UpRi includes the
development of a proprietary immunohistochemistry assay to measure NaPi2b expression in tumors. Based on our retrospective
evaluation of tumors collected in the dose escalation and expansion portions of our initial UpRi Phase 1 trial, our evaluation of
patient tissue bank materials and other published data we believe that high NaPi2b expression is present in at least a majority of
ovarian cancer patients. We intend to continue developing our assay in order to confirm our estimates of the prevalence of
NaPi2b expression in our target patient populations while evaluating the correlation of those expression levels with the efficacy
observed in such patients. We are currently collaborating with a third party to create and obtain regulatory approval for our
assay as a commercial companion or complementary diagnostic, and we expect that the third party would seek such approval
simultaneously with our submission of a BLA, if any, for UpRi around the end of 2023. We are using and expect to continue to
use the assay to evaluate Tumor Proportion Score of greater than or equal to 75%, TPS75, to identify patients with tumors that
have high NaPi2b tumor expression and to help us enrich our data analyses based on biomarker expression. We refer to patients
with cancers with TPS75 as “NaPi2b positive.”
Over the course of 2020, we presented early Phase 1 UpRi clinical data, including presentations at the American Society of
Clinical Oncology and the European Society for Medical Oncology and in company presentations to investors. These data were
from the dose escalation and expansion portions of our UpRi Phase 1 trial, and they demonstrated encouraging clinical activity
in heavily pretreated patients with a safety profile differentiated from those of first-generation ADCs. In August 2020, the FDA
granted Fast Track Designation for UpRi for the treatment of patients with platinum-resistant high-grade serous ovarian cancer
who have received up to three prior lines of systemic therapy or patients who have received four prior lines of systemic therapy
regardless of platinum status. In January 2021, September 2021 and March 2022, we provided interim clinical data updates
from our expansion cohort. The interim data presented in September 2021 and March 2022 was based on approximately 100
10
ovarian cancer patients. All of the data from these patients were from our ongoing Phase 1/2 clinical trial. These data supported
UpRi’s clinically meaningful activity in heavily pretreated ovarian cancer patients with an ORR of approximately 34%,
including complete responses, in evaluable patients with NaPi2b positive tumors. The data also showed that UpRi was
generally well tolerated without the severe toxicities commonly seen with other ADCs such as neutropenia, ocular toxicities, or
peripheral neuropathy. The most common grade 3 or higher adverse events reported in this heavily pretreated trial population
included fatigue and transiently increased aspartate aminotransferase. Other adverse events of clinical interest included
infrequent, generally low-grade pneumonitis that generally resolves with dose reduction, delay, discontinuation and treatment
with steroids. Based on these safety and efficacy data and our population pharmacokinetics analyses of the overall group of
approximately 200 patients administered UpRi as of the data cut off, we determined that the Phase 2 recommended dose of
UpRi is 36 mg/m2, up to a total dose of approximately 80 mg. This is the dose that we are currently evaluating in UPLIFT.
In April 2021, we initiated UPLIFT to enroll patients with platinum-resistant ovarian cancer who had been treated with one to
four prior lines of therapy, without regard to NaPi2b expression. In this trial, we are seeking to confirm the potentially
predictive role of the Napi2b biomarker retrospectively using our novel diagnostic assay to identify NaPi2b positive patients.
Patients who had been treated with three to four prior lines of therapy were able to enroll without prior bevacizumab treatment,
accommodating differences in bevacizumab use in early disease. Additionally, patients who had experienced grade 1 or grade 2
neuropathy on previous treatments were eligible to enroll in UPLIFT. The primary endpoint is ORR in the NaPi2b positive
patient population, and the secondary endpoints are ORR in the overall population, duration of response and safety. In October
2022, we completed the enrollment of approximately 270 patients in UPLIFT at sites in the United States, Europe and
Australia. We expect to announce top-line data from UPLIFT in mid-2023 following the major oncology conferences scheduled
for June. If we achieve positive results from UPLIFT, we believe that the trial may enable us to submit a BLA for UpRi for the
treatment of patients with platinum-resistant ovarian cancer with one to four prior lines of therapy under the FDA's accelerated
approval pathway around the end of 2023.
In July 2021, we initiated UPGRADE-A, a Phase I open-label clinical trial in which we are evaluating the combination of UpRi
and carboplatin, a standard platinum chemotherapy used to treat patients with platinum-sensitive ovarian cancer, in patients
with platinum-sensitive high-grade serous ovarian cancer following one to three prior lines of treatment. Patients in the trial
receive combination treatment every four weeks for six cycles followed by UpRi as a single-agent maintenance therapy. While
patients in the trial are not preselected for NaPi2b-positive status, we are conducting a retrospective assessment of expression.
We have completed the dose escalation portion of the trial, which investigated carboplatin combined with UpRi doses up to 36
mg/m2. There were no dose-limiting toxicities at any dose level. In January 2023, we initiated the dose expansion portion of
UPGRADE-A, in which we are investigating a 30mg/m2 dose, up to a maximum of 66 mg, of UpRi. We expect to report
interim data from UPGRADE-A in the second half of 2023. We believe data from UPGRADE-A will inform further
development of UpRi both in combination with carboplatin and in combination with other therapies used in patients with
platinum-sensitive ovarian cancer, which we may explore in a series of UPGRADE trials.
We continue to enroll patients in our UP-NEXT clinical trial, for which we initiated patient dosing in late 2022. The design of
UP-NEXT was informed by discussions with the FDA and the Committee for Medicinal Products for Human Use, or CHMP.
UP-NEXT is enrolling recurrent platinum-sensitive ovarian cancer patients who have achieved an objective response or stable
disease after platinum therapy. Eligible patients with BRCA mutation must have received prior treatment with poly-adenosine
diphosphate ribose polymerase, or PARP, inhibitor therapy. Additionally, eligible patients must have NaPi2b positive tumor
expression. Due to the lack of a standard of care for patients in the recurrent ovarian cancer maintenance setting, the trial is
randomized against placebo and is investigating a 30 mg/m2 dose, up to a maximum of 66 mg, of UpRi. We believe that if the
data from the trial is positive, UP-NEXT could serve as a post-approval confirmatory trial in the United States, support
potential approvals outside of the United States and support the expansion of UpRi into earlier lines of therapy.
XMT-1660: our B7-H4-targeted Dolasynthen ADC candidate
XMT-1660 is our B7-H4-targeted ADC created with our Dolasynthen platform and equipped with our DolaLock payload
designed for differentiated tolerability without severe neutropenia, peripheral neuropathy or ocular toxicities associated with
other anti-tubulin payloads. We believe the expression profile of B7-H4, is well suited for our unique DolaLock payload. B7-
H4 can be expressed on tumor cells and on immunosuppressive tumor associated macrophages, or TAMs, which may lead to
additional processing of the ADC and more payload in the tumor environment. We believe DolaLock’s direct cytotoxic effect,
as well as its immunostimulatory effect through immunogenic cell death and dendritic cell activation, are well suited to the
biology of the B7-H4 target. We have generated favorable preclinical efficacy data and non-human primate tolerability data
with Dolasynthen ADCs targeting B7-H4 with precise DARs of 2 and 6. We selected the DAR6 variant based on these
preclinical data, as well as a comparison to preclinical data generated with a B7-H4 Dolaflexin ADC with a DAR of
approximately 12. We believe that targeting B7-H4 with XMT-1660 provides significant opportunities for development in areas
of high unmet need. We are currently investigating XMT-1660 in a multicenter Phase 1 clinical trial in patients with breast,
endometrial and ovarian cancers.
11
XMT-2056: our First Immunosynthen ADC candidate
XMT-2056 is our first Immunosynthen STING-agonist ADC. As described above, the therapeutic rationale of an
Immunosynthen ADC is to selectively deliver the STING agonist to tumor cells and tumor-resident immune cells in a target-
dependent manner while avoiding delivery to healthy tissues. XMT-2056 is designed to offer a differentiated and
complementary therapeutic approach to the treatment of HER2-expressing tumors. XMT-2056 targets a novel HER2 epitope
that is distinct from the epitopes targeted by trastuzumab or pertuzumab, providing an opportunity for development as a
monotherapy as well as in combination with well-established or investigational anti-HER2 agents. In preclinical studies, XMT-
2056 was generally well-tolerated in non-human primate studies with no adverse findings in clinical pathology or
histopathology after repeat doses as high as 36 mg/kg. In January 2023, we initiated a multicenter Phase 1 open-label clinical
trial of XMT-2056 in patients with advanced/recurrent solid tumors expressing HER2, including breast, gastric, colorectal and
NSCLC.
Ovarian cancer unmet need and epidemiology
According to the World Cancer Research Fund International, in 2020, the incidence of ovarian cancer worldwide was
approximately 314,000, with the disease causing an estimated 207,000 deaths. With a U.S. incidence of approximately 20,000
and mortality of 13,000 in 2022 according to the National Cancer Institute Surveillance, Epidemiology and End Results
Program, ovarian cancer was the second most common gynecologic malignancy and the most common cause of gynecologic
cancer death in the United States. Diagnosis is made histologically, and evaluation is commonly performed following surgical
removal of an ovary or fallopian tube or biopsies of the peritoneum. The ovarian cancer standard of care is characterized by
initial surgery followed by platinum-containing chemotherapy followed by either observation or maintenance treatment.
Approximately 80% of ovarian cancer patients typically relapse following initial treatment. Subsequent treatment depends on
the duration of response to initial platinum treatment. Ovarian cancer patients who progress within six months of completion of
platinum-based therapy are considered to have platinum-resistant disease. Unmet medical need is significant for patients with
platinum-resistant ovarian cancer as treatment options are mainly limited to single-agent chemotherapies such as pegylated
liposomal doxorubicin, topotecan or paclitaxel. Multiple Phase 3 trials of single agent chemotherapies in patients with
platinum-resistant disease and one to three prior therapies have exhibited an overall response rate of 4-12% and median
progression-free survival of 3-4 months. In 2022, mirvetuximab soravtansine was approved under an accelerated approval
pathway in the United States for patients with FRα positive, platinum-resistant ovarian cancer who have received one to three
prior systemic treatment regimens. Only a minority of ovarian cancer patients are FRα positive, and the unmet need remains
high for the majority of platinum-resistant ovarian cancer patients. In addition, mirvetuximab soravtansine is associated with
significant toxicities, including a boxed warning for ocular toxicity.
With targeted agents approved in platinum-resistant disease increasingly being prescribed in earlier lines of therapy, the unmet
need in later lines is expected to remain severe. Bevacizumab in combination with chemotherapy is indicated in the United
States to treat a subset of platinum-resistant ovarian cancer patients with no more than two prior therapies, but it is not always
well-tolerated and has not shown an overall survival benefit. Use of bevacizumab in combination with platinum-containing
chemotherapy in the frontline and platinum-sensitive recurrent settings means an increasing number of platinum-resistant
patients are pre-treated with bevacizumab. Previously, PARP inhibitors had been approved for heavily pretreated ovarian cancer
including platinum-resistant disease. Recently, the indications for PARP inhibitors in the United States were changed so that
they are no longer approved for use in platinum-resistant ovarian cancer. They are currently approved only for use as
maintenance treatment in the frontline or platinum-sensitive ovarian cancer setting, in patients who are responding to platinum-
based chemotherapy. In addition, they are increasingly restricted to use in a subset of patients with cancers harboring BRCA1
and BRCA2 mutations in the recurrent setting.
Breast cancer unmet need and epidemiology
Worldwide, breast cancer was the most common cancer, with an incidence of approximately 2.3 million and estimated 685,000
deaths in 2020. The U.S. incidence was approximately 288,000 new cases with approximately 43,250 deaths in 2022. While
patients with localized disease typically have a relatively good prognosis, the five-year survival of patients with distant
metastasis is only 29%. There are four main female breast cancer subtypes, which are, in order of prevalence: Hormone
Receptor, or HR, positive (HR+)/HER2 negative (HER2-), which is referred to as Luminal A; HR negative (HR-)/HER2-,
which is referred to as Triple Negative; HR+/HER2 positive (HER+), which is referred to as Luminal B; and HR-/HER2+,
which is referred to as HER2-enriched. This categorization of patients is being revisited given the approval of trastuzumab
deruxtecan for the treatment of HER2-low metastatic breast cancer in 2022. Treatment choice is driven by both subtype and
stage of disease. Surgical resection offers the best opportunity for long-term survival and cure in patients with resectable early-
stage disease. Some patients receive radiation therapy and/or systemic therapy post-surgery, with treatment choice driven by
cancer subtype.
12
Systemic therapy is the mainstay of treatment for metastatic breast cancer. Once again, the treatment choice is determined by
cancer subtype and by what treatments patients have received previously. The primary treatment option for patients who are
HR+ is endocrine therapy, including aromatase inhibitors. Patients who are HER2+ are usually treated with HER2-targeting
agents such as trastuzumab and pertuzumab, among others. In 2022, the HER2 targeting therapy trastuzumab deruxtecan was
approved for the treatment of patients with HER2-low metastatic breast cancer. Other targeted agents that are used in metastatic
breast cancer include CDK4/6 inhibitors, mTOR inhibitors, PARP inhibitors, phosphoinositide 3-kinase, or PI3K, inhibitors,
immunotherapy and ADCs. Patients can also receive chemotherapies, alone or in combination with other agents. In addition, a
number of new therapeutic options are under clinical investigation. Despite the availability of these treatment options, outcomes
in metastatic breast cancer continue to be poor, and new treatments that improve survival and quality of life are urgently
needed.
Strategic Collaborations
We view business development as a core pillar of our overall corporate strategy, and our platforms and product candidates allow
us to consider multiple potential types of strategic collaborations. We believe that our ADC platforms have broad applicability
across a number of targets, allowing us to consider collaborations in which a partner provides proprietary antibodies for a select
number of targets and we utilize our platforms to discover novel ADC product candidates. Under these collaboration
agreements, we own the rights to any improvements to our ADC platform(s). For instance, we have entered into two discovery
collaborations with Merck KGaA and a separate discovery collaboration with Janssen. We believe platform-based
collaborations allow us to leverage the potential of our platforms, provide near-term capital and help us potentially bring
important new therapeutic options to patients.
We also have internally developed ADC product candidates that allow us to consider arrangements in which a collaborator may
assume certain preclinical, clinical and/or commercial responsibilities. For instance, we have granted GSK an exclusive option
for an exclusive global license to co-develop and commercialize XMT-2056. We believe product-focused collaborations could
provide near-term funding, allow us to advance and broaden preclinical, clinical or commercial development efforts beyond
those we could independently, and potentially bring new therapeutic options to patients.
2022 Merck KGaA Collaboration
In December 2022, we entered into a collaboration and commercial license agreement with Ares Trading S.A., or MRKDG, a
wholly owned subsidiary of Merck KGaA, or the 2022 Merck KGaA Agreement. Pursuant to the 2022 Merck KGaA
Agreement, we will grant MRKDG an exclusive license to use our proprietary technology to develop, manufacture and
commercialize Immunosynthen ADCs directed to up to two specific target antigens, or the Designated Targets, selected by
MRKDG within a certain period following the effectiveness of the 2022 Merck KGaA Agreement. MRKDG has already
selected the first Designated Target under the 2022 Merck KGaA Agreement.
Under the terms of the 2022 Merck KGaA Agreement, the parties will conduct up to two research programs. Each research
program will involve activities related to Immunosynthen ADCs for a selected Target (with each such ADC developed under the
2022 Merck KGaA Agreement being a Licensed ADC) until the submission of an investigational new drug application, or IND,
(or foreign equivalents) for a Licensed ADC directed at such Designated Target, or each an MRKDG Licensed Product, or until
the earlier expiration of the defined research period. Each research program will follow a research plan agreed between the
parties. For each Designated Target, MRKDG is responsible for providing up to a specified number of antibodies against such
Designated Target, and we are responsible for conjugating such antibodies using our Immunosynthen platform to create
Licensed ADCs. Each party will be responsible for their own costs under the research programs. In addition, we will be
responsible for certain chemistry, manufacturing and controls development and certain manufacturing activities for the
Licensed ADCs, up to and including manufacturing of drug substance for Licensed ADCs to be used in certain preclinical
studies and clinical trials, in each case at MRKDG’s expense, some of which will be prepaid by MRKDG. Except as provided
above, MRKDG is solely responsible for in vitro and in vivo characterization of any Licensed ADCs, other preclinical work,
and all clinical development and potential commercialization activities relating to any resulting MRKDG Licensed Products.
Under the terms of the 2022 Merck KGaA Agreement, we received an upfront payment of $30.0 million in February 2023.
Certain development and regulatory milestones will be payable by MRKDG to us for the research programs, including upon
certain discovery milestones, initiation of certain clinical trials, and regulatory approval of MRKDG Licensed Products in
certain geographies, with an aggregate total of up to $200 million in the event MRKDG advances MRKDG Licensed Products
directed to both Designated Targets to regulatory approval.
In the event the commercialization of the MRKDG Licensed Product results in commercial sales, commercial milestones will
be payable by MRKDG to us for each program upon the achievement of specified aggregate sales thresholds for an MRKDG
Licensed Product for the applicable Designated Target, with an aggregate total of up to $600 million in the event MRKDG
Licensed Products directed to both Designated Targets are commercialized by MRKDG. In addition, we are eligible to receive
13
tiered royalties at percentages ranging from the single digits to the low double digits on future net sales of MRKDG Licensed
Products.
MRKDG’s royalty obligations continue with respect to each country and each MRKDG Licensed Product until the latest of (i)
the date on which such MRKDG Licensed Product is no longer covered by certain intellectual property rights in such country,
(ii) the 10th anniversary of the first commercial sale of such MRKDG Licensed Product in such country and (iii) the expiration
of marketing or data exclusivity for such MRKDG Licensed Product in such country.
Under the terms of the 2022 Merck KGaA Agreement, subject to certain exceptions and for an agreed period of time, we will
not, either ourselves or through third parties, research, develop, manufacture or commercialize other ADCs utilizing our
Immunosynthen platform that are directed to the Designated Targets. We and MRKDG will form a joint research committee,
joint manufacturing committee, and joint intellectual property committee responsible for coordinating activities pursuant to the
2022 Merck KGaA Agreement.
Each party has the right to sublicense its rights under the 2022 Merck KGaA Agreement subject to certain conditions. The 2022
Merck KGaA Agreement will continue, unless earlier terminated, until the expiration of the last-to-expire royalty term for the
last MRKDG Licensed Product or, if MRKDG does not advance any MRKDG Licensed Products, upon the expiration of the
last-to-expire research program. MRKDG may, at its convenience, terminate the 2022 Merck KGaA Agreement in its entirety or
on a Designated Target-by-Designated Target basis upon certain notice to us. Either we or MRKDG may terminate the 2022
Merck KGaA Agreement for the other party’s insolvency or certain uncured breaches. In lieu of terminating the 2022 Merck
KGaA Agreement, in the event MRKDG is entitled to terminate the 2022 Merck KGaA Agreement due to our uncured material
breach, MRKDG may make an election, as its sole and exclusive remedy with respect to our applicable material breach of the
2022 Merck KGaA Agreement, to invoke a specified financial penalty impacting one or more future payments that may become
payable to us following such uncured material breach. We may terminate the 2022 Merck KGaA Agreement with respect to a
Designated Target in the event of certain failures by MRKDG to progress the corresponding research program. Additionally, we
may terminate the 2022 Merck KGaA Agreement if MRKDG or any of its sublicensees or affiliates challenge, subject to certain
exceptions, the validity, enforceability, of patentability of certain of our patents.
GSK Collaboration
In August 2022, we entered into a collaboration, option and license agreement with GSK, or the GSK Agreement, to provide
GSK with an exclusive option to obtain an exclusive global license to co-develop and to commercialize products containing
XMT-2056, or Licensed Products, exercisable within a specified time period, or the Option Period, after we deliver to GSK a
data package, or the Option Data Package, resulting from completion of dose escalation with enrichment for breast cancer
patients in a Phase 1 single-agent clinical trial of XMT-2056. GSK’s exercise of the Option may require clearance under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Clearance. Upon GSK’s exercise of the Option following any
applicable HSR Clearance, or the GSK Option Exercise, GSK is obligated to pay us an option exercise payment of $90.0
million.
We will lead research and development activities related to our XMT-2056 program prior to the GSK Option Exercise, if any,
and we are obligated to use commercially reasonable efforts to generate the Option Data Package by an agreed time. Prior to the
GSK Option Exercise, we will be responsible for the costs of manufacturing, research and early clinical development activities
related to the XMT-2056 program.
Following the GSK Option Exercise, if any, GSK may elect to manufacture XMT-2056, and we and GSK will co-develop
XMT-2056 in accordance with a joint development plan to be established by the parties and aimed at approval of Licensed
Products in the United States and the European Union, with GSK being responsible for the majority of the development
activities and costs. GSK will be responsible for all of the development costs aimed solely at gaining approval outside the
United States and the European Union. Subject to certain exceptions set forth in the GSK Agreement, our aggregate share of
U.S.- and E.U.-focused development costs pursuant to this cost-sharing arrangement is capped at a fixed amount, or the
Mersana Development Cost Cap. We may also, subject to certain limitations provided in the GSK Agreement, elect to opt out of
sharing in development costs for certain later-stage clinical trials of Licensed Products requested by GSK, subject to certain
payment obligations in the event that data from any such later-stage clinical trial for which we have opted out of sharing in
development costs results in certain marketing approvals for a Licensed Product in the United States or European Union, or a
Deemed Buy-In Payment. Any development costs in excess of the Mersana Development Cost Cap, including any amounts
arising from any Deemed Buy-In Payments, will be borne by GSK unless and until we exercise our Profit Share Election (as
defined below). Development costs in excess of the Mersana Development Cost Cap will accrue interest at a variable rate equal
to the prime rate plus a specified margin and will later either be repaid by us or offset against future regulatory and sales
milestone or royalty payments that may become due to us. If we exercise our Profit Share Election, the Mersana Development
Cost Cap will no longer apply, we must pay any then-outstanding excess plus accrued interest, and we shall continue to share in
further U.S.- and E.U.-focused development costs.
14
Following the GSK Option Exercise, if any, we will have the option, during a specified time period following our receipt of
certain later-stage clinical data and other data and information from GSK, to elect to receive (or bear) a specified share of U.S.
profits (or losses) for any Licensed Products, or the Profit Share Election. Additionally, if we exercise our Profit Share Election,
we may also simultaneously elect to co-promote any Licensed Products in the United States. The co-promotion arrangement
may be terminated by either party, notwithstanding the continued effectiveness of the rest of the GSK Agreement, in the event
of certain breaches by the other party, or by GSK, in the event of certain specified changes of control of Mersana. In addition, in
the event of certain specified changes of control of Mersana, GSK can prohibit us from executing development activities that
are initiated under the GSK Agreement following such change of control.
We received an upfront payment of $100 million from GSK for the Option. We are eligible to receive up to $30 million upon
satisfaction of early clinical development milestones that may occur prior to the GSK Option Exercise. Subject to the GSK
Option Exercise, if we do not exercise our Profit Share Election, we will be eligible to receive additional future clinical
development and regulatory milestone payments of up to $592 million, commercial milestone payments of up to $652 million
and tiered double-digit royalties up to the mid-twenty percent range on global sales of Licensed Products, if approved, subject
to customary reductions. If we exercise our Profit Share Election, we will, in lieu of the foregoing regulatory and commercial
milestone amounts, be eligible to receive reduced regulatory and commercial milestone payments and reduced royalty rates on
sales outside of the United States. Additionally, whether or not we exercise our Profit Share Election, GSK will be responsible
for certain milestone payments or royalties due to specified third parties with which we currently have agreements that relate to
the XMT-2056 program.
GSK’s royalty obligations continue with respect to each country and each Licensed Product until the latest of (i) the date on
which such Licensed Product is no longer covered by certain intellectual property rights in such country, (ii) the 12th
anniversary of the first commercial sale of such Licensed Product in such country and (iii) the expiration of regulatory
exclusivity for such Licensed Product in such country.
Under the terms of the GSK Agreement, subject to certain exceptions and for an agreed period of time, we and GSK will not,
either directly or through third parties, develop or commercialize other products or compounds that (a) comprise or contain an
ADC that is conjugated with a STING agonist and (b) are directed to HER2. In addition, we have granted GSK a right of first
negotiation for future ADCs that are conjugated to payloads other than STING agonists and directed to HER2. Following the
GSK Option Exercise, if any, we and GSK will form a joint steering committee, joint development committee, joint
manufacturing committee, joint commercialization committee, and financial working group responsible for coordinating all
activities under the GSK Agreement, with GSK having final decision-making authority over most issues, subject to certain
enumerated exceptions.
The GSK Agreement will terminate at the end of the Option Period if GSK does not exercise its Option. If GSK exercises its
Option but we do not obtain HSR Clearance within specified time periods following the latest date on which the parties have
made their respective applicable filings related to such HSR Clearance, each party has a right to terminate the GSK Agreement.
In the event of the GSK Option Exercise, the GSK Agreement will continue in effect on a Licensed Product-by-Licensed
Product and country-by-country basis until the expiration of the obligation to make payments under the GSK Agreement with
respect to such Licensed Product in such country, unless earlier terminated by either party pursuant to the terms of the GSK
Agreement. Either we or GSK may terminate the GSK Agreement for the other party’s insolvency, and each party may
terminate the GSK Agreement for certain uncured breaches by the other party. In lieu of terminating the GSK Agreement, in the
event of certain uncured material breaches by us, GSK may make a one-time election, in addition to other contractual remedies
available at law or in equity, to invoke a specified financial penalty impacting one or more future payments that may become
payable to the Company following such uncured material breach. We may terminate GSK’s license to certain of our patents if
GSK or any of its sublicensees or affiliates challenge the validity, enforceability, of patentability of such patents. GSK may
terminate the GSK Agreement for convenience upon certain notice to us.
Janssen Collaboration
In February 2022, we entered into a research collaboration and license agreement with Janssen, or the Janssen Agreement,
pursuant to which we granted Janssen an exclusive license to use our proprietary Dolasynthen platform and other technology to
develop, manufacture and commercialize antibody-drug conjugates directed to up to three targets selected by Janssen. Our
responsibilities are to perform bioconjugation activities to create ADCs for Janssen based on antibodies provided by Janssen.
We will also perform certain chemistry, manufacturing and controls development and early stage manufacturing activities for
ADCs that Janssen progresses through development, up to and including the manufacturing of clinical drug substance, at
Janssen’s cost. Except with respect to this limited manufacturing, Janssen will be responsible for the further development,
manufacturing and commercialization of the ADCs developed under the Janssen Agreement, including obtaining any necessary
regulatory approvals, at Janssen’s cost.
15
Under the terms of the Janssen Agreement, we received an upfront payment of $40 million. Certain development and regulatory
milestones will also be payable by Janssen for the research programs, including upon certain discovery milestones, initiation of
certain clinical trials, and regulatory approval of certain licensed products in certain geographies, with an aggregate total of up
to $501 million in the event ADCs directed to all three targets are advanced by Janssen. In the event the ADCs developed by
Janssen are commercialized, we are eligible to receive certain commercial milestones for each program upon the achievement
of specified aggregate sales thresholds based on all ADCs for an applicable target, with an aggregate total of up to
approximately $530 million in the event ADCs directed to all three targets are commercialized by Janssen. In addition, we are
eligible to receive tiered royalties at percentages ranging from the mid-single digits to the low-double digits on future net sales
of ADCs.
The Janssen Agreement will remain in effect, unless earlier terminated, until the expiration of the last-to-expire royalty term for
the last ADC. Royalty term means on an ADC-by-ADC and country-by-country basis, the period commencing upon the first
commercial sale of an ADC in such country and ending upon the latest to occur of: (a) the date of expiration of the last royalty-
bearing patent claim with respect to such ADC in such country; (b) the expiration of regulatory exclusivity for such ADC in
such country, if any; and (c) the tenth (10th) anniversary of the first commercial sale of such ADC in such country. Upon the
expiration of the royalty term with respect to an ADC in a country, Janssen’s license becomes a perpetual, irrevocable, non-
exclusive, fully-paid and royalty-free right and license, with the right to grant sublicenses, under the relevant platform
technology and our interest in any joint technology to develop, manufacture, commercialize and otherwise exploit such ADC in
such country.
2014 Merck KGaA Collaboration
In June 2014, we entered into a collaboration and commercial license agreement with Merck KGaA, or the 2014 Merck KGaA
Agreement, under which we formed a strategic relationship with Merck KGaA because of their expertise in oncology drug
development. Under the 2014 Merck KGaA Agreement, we are responsible for generating ADC product candidates against
Merck KGaA-selected target antigens. Merck KGaA received rights to select up to six target antigens, of which it has selected
all six. Merck KGaA is responsible for generating antibodies against the target antigens, and we are responsible for generating
Dolaflexin and conjugating this to such antibodies to create the ADC product candidates. With respect to each target antigen
selected by Merck KGaA, we granted Merck KGaA an exclusive, worldwide license under certain of our Fleximer ADC-related
patents and know-how to develop, manufacture and commercialize ADC product candidates directed to such target antigen.
Merck KGaA is then responsible for the further development and commercialization of these ADC product candidates. In
addition, if Merck KGaA advances candidates, we are responsible for manufacturing these ADC product candidates for good
laboratory practices toxicology studies and Phase 1 clinical trials at Merck KGaA’s expense and Merck KGaA is responsible for
all further manufacture of these ADC product candidates. Merck KGaA is required to pay its own costs in the development,
commercialization and manufacture of these ADC product candidates and to reimburse us for our costs incurred in performing
our research activities under this agreement.
Through December 31, 2022, we have received an upfront payment of $12 million and milestone payments of $3 million under
the 2014 Merck KGaA Agreement. If products are successfully developed and commercialized against all six target antigens,
we would be entitled to receive future development, regulatory and commercial milestones of up to $777 million. We are
entitled to receive tiered royalties in the low- to mid-single digit percentages on net sales of products targeting Merck KGaA’s
target antigens during the applicable royalty term if products are successfully developed and commercialized by Merck KGaA
under the 2014 Merck KGaA Agreement.
Unless earlier terminated, the 2014 Merck KGaA Agreement will expire upon the expiration of the last royalty term for a
product under the agreement in all countries or, if Merck KGaA does not designate any ADC product candidates produced by us
under the agreement as preclinical development candidates, upon the expiration of the last-to-expire research program. The
royalty term means, on a product-by-product and country-by-country basis, the period commencing upon the first commercial
sale of a product and ending upon the later to occur of: (i) the expiration of the last Mersana patent right that covers or claims
the exploitation of such product in such country, or (ii) 10 years from the date of first commercial sale of such product in such
country. Upon the expiration of each royalty term for each product on a country-by-country basis, Merck KGaA’s exclusive
license will convert to a perpetual, non-exclusive, royalty-free license with respect to such product in such country. Merck
KGaA may terminate the 2014 Merck KGaA Agreement in its entirety or with respect to any target antigen for convenience
upon 60 days’ prior written notice. Each party may terminate the 2014 Merck KGaA Agreement in its entirety upon an uncured
material breach of the agreement by the other party.
Asana Biosciences Collaboration
16
In March 2012, we entered into a collaboration agreement with Asana Biosciences, or Asana (by assignment from Endo
Pharmaceuticals Inc.). Pursuant to the terms of this agreement, we used Asana’s novel antibodies to develop novel ADCs using
our Fleximer technology. Asana is responsible for product development, manufacturing and commercialization of any ADC
products.
Strategic relationships to access antibodies and develop new platforms to progress our proprietary pipeline
Our focus is to progress our proprietary pipeline of ADCs. For this reason, we have collaborated with biotechnology companies
that have the capability to generate high quality antibodies or that have existing antibodies that we can license for inclusion in
our ADCs. We have also entered into license agreements with biotechnology companies that own certain patent rights and
related know-how that enable us to develop new ADC platforms. These strategic relationships have facilitated the advancement
of our proprietary pipeline.
Recepta license for the NaPi2b antibody
In July 2015, we entered into a license agreement with Recepta Biopharma S.A., or Recepta, a Brazilian biopharmaceutical
company, licensing Recepta’s NaPi2b antibody for use in UpRi and our former product candidate XMT-1592 and granting
Recepta the exclusive right to commercialize UpRi and XMT-1592 in Brazil, which was amended in September 2021. We refer
to this as the Recepta License. Under the Recepta License, Recepta granted us an exclusive license and sub-license with respect
to certain patents licensed by Recepta from Ludwig Institute for Cancer Research and technology owned by Recepta to develop
and exploit products containing Recepta’s NaPi2b antibody, including UpRi and XMT-1592, worldwide for the diagnosis,
prophylaxis and treatment of human cancer. We granted Recepta an exclusive license under our rights in such patents and
technology and certain of our ADC-related patents and technology to commercialize any such products developed by us,
including UpRi and XMT-1592, in Brazil. We are responsible for using commercially reasonable efforts to develop and
commercialize products under the Recepta License globally, with at least one trial site in our Phase 3 clinical trials, and at our
own expense in certain major markets. Recepta may conduct development activities in Brazil at its own expense after providing
us the opportunity to first conduct such activities at Recepta’s expense. If a product is successfully developed and
commercialized by Recepta in Brazil, we will use diligent efforts to enter into an agreement for the supply of such products to
Recepta for sale in Brazil.
Under the Recepta License, we paid Recepta an upfront payment of $1 million during the year ended December 31, 2015 and
are obligated to pay Recepta up to $65.5 million in development, regulatory and commercial milestones and tiered royalties in
the low-single digit percentages on net sales of products outside of Brazil until the expiration of the royalty term if products are
successfully developed and commercialized. We have incurred and paid $4.0 million in development milestones. We are
entitled to receive tiered royalties in the low- to mid-single digit percentages on net sales of products in Brazil until the
expiration of the royalty term if products are successfully developed and commercialized. The royalty term means, on a
product-by-product and country-by-country basis, the period ending upon the later of (i) with respect to products
commercialized by Mersana, the expiration of the last-to-expire Recepta patent that covers the product in such country
(including the term of any applicable supplementary protection certificate) or with respect to products commercialized by
Recepta, the expiration of the last-to-expire Mersana patent that covers the product in Brazil (including the term of any
applicable supplementary protection certificate) or (ii) 10 years from the date of first commercial sale of such product in such
country. Upon the expiration of each royalty term in each country for each applicable product, the exclusive licenses granted to
each party under the agreement will become fully-paid up and royalty-free. The Recepta License will remain in effect until
otherwise terminated as set forth below. We may terminate the Recepta License for convenience in its entirety or on a country-
by-country basis (except with respect to Brazil) or product-by-product basis upon 180 days’ prior written notice for a
termination in its entirety or upon 45 days’ prior written notice for a termination in part. Each party may terminate the Recepta
License in its entirety upon bankruptcy or similar proceedings of the other party, upon a patent challenge by the other party or
upon an uncured material breach of the agreement by the other party. However, if such breach only relates to one country, the
Recepta License may only be terminated with respect to such country.
Synaffix commercial license agreement
In January 2019, we entered into a commercial license agreement with Synaffix B.V., or Synaffix, which we amended and
restated in November 2021 to expand our relationship with Synaffix and amended again in February 2022 in connection with
our collaboration with Janssen. We refer to the amended and restated agreement as the Synaffix License. Under the Synaffix
License, we have the right to develop, manufacture and commercialize ADCs directed to targets using Synaffix’s proprietary
site-specific conjugation technology for up to twelve targets. We have licensed five targets in connection with our development
programs and collaborations, and we have the right to license up to six additional targets. We have paid $6.8 million related to
17
the Synaffix License, comprised of $4.0 million in reservation and license fees, $1.8 million in milestone payments and $1.0
million which may be applied to future reservation and license fees, as well as certain portions of potential future development
milestones. We will be obligated to pay in the range of $48.0 million to $132.0 million for development, regulatory and
commercial milestones.
Upon commencement of commercial sales of any ADC product directed to a licensed target, if any, we are required to pay to
Synaffix tiered royalties in the low-single digit percentages on net sales of the respective products. The Synaffix License
remains in effect on a country-by-country and licensed product-by-licensed product basis until the expiration of the last-to-
expire valid claim in a patent licensed under the Synaffix License covering such product in such country. Upon the expiration of
the Synaffix License for each licensed product in each country, the licenses granted to us for such product in such country will
become fully paid-up and perpetual. We may terminate the Synaffix License in its entirety or on a licensed product-by-licensed
product basis at any time. Either party may terminate the Synaffix License, subject to a specified notice and cure period, for a
breach by the other party of a material provision of the agreement or upon an insolvency-related event experienced by the other
party.
Manufacturing
We do not own or operate and currently have no plans to establish any current good manufacturing practices, or cGMP,
compliant manufacturing facilities. We currently rely, and expect to continue to rely, on external Contract Manufacturing
Organizations, or CMOs, for the manufacture of product to support our activities through regulatory approval and commercial
manufacturing. We have personnel with pharmaceutical development and manufacturing experience who are responsible for the
relationships with our CMOs. In the future, we expect to use these CMOs to manufacture commercial supply of our products,
which will require these CMOs to increase scale of production. We do not currently have qualified alternate suppliers in the
event the current CMOs that we utilize are unable to scale production for commercial manufacturing. The Dolaflexin,
Dolasynthen and Immunosynthen manufacturing processes involve readily available starting materials and use unit operations
that are well-precedented in the field of chemical/pharmaceutical production. The current UpRi supply chain utilizes the same
vendors that we could use for commercialization. The current supply chains for XMT-1660 and XMT-2056 have several
vendors in common, and based on what we know today, we believe we could use these vendors or would be able to identify and
contract with other vendors on commercially reasonable terms for commercialization purposes.
Government regulation
The research, development, testing, manufacture, quality control, packaging, labeling, storage, record-keeping, distribution,
import, export, promotion, advertising, marketing, sale, pricing and reimbursement of drug and biologic products are
extensively regulated by governmental authorities in the United States and other countries. The processes for obtaining
regulatory approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable
statutes and regulations and other regulatory requirements, both pre-approval and post-approval, require the expenditure of
substantial time and financial resources. The regulatory requirements applicable to biological product development, approval
and marketing are subject to change, and regulations and administrative guidance often are revised or reinterpreted by the
agencies in ways that may have a significant impact on our business.
U.S. government regulation of biological products
In the United States, the FDA licenses biological products, or biologics, under the Public Health Service Act, or the PHSA, and
regulates such products under the Food, Drug and Cosmetic Act, or FDCA. A company, institution, or organization which takes
responsibility for the initiation and management of a clinical development program for such products, and for their regulatory
approval, is typically referred to as a sponsor. A sponsor seeking approval to market and distribute a new biologic in the United
States must satisfactorily complete each of the following steps:
•
•
•
completion of preclinical laboratory tests, animal studies and formulation studies according to good laboratory
practices, or GLP, regulations or other applicable regulations;
design of a clinical protocol and submission to the FDA of an IND, which must become effective before human
clinical trials may begin and must be updated when certain changes are made;
approval by an independent institutional review board, or IRB, or ethics committee representing each clinical trial site
before each clinical trial may be initiated;
18
•
•
•
•
•
performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations,
good clinical practices, or GCPs, and other clinical-trial related regulations to evaluate the safety and efficacy of the
investigational product for each proposed indication;
preparation and submission to the FDA of a BLA requesting marketing approval for one or more proposed indications,
including payment of application user fees;
review of the BLA by an FDA advisory committee, where applicable;
satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the biologic
is produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are
adequate to preserve the product’s identity, strength, quality and purity;
satisfactory completion of any FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of
the clinical data submitted in support of the BLA; and
• FDA review and approval of the BLA, which may be subject to additional post- approval requirements, including the
potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and any post- approval
clinical trials required by the FDA.
Preclinical studies
Before a sponsor begins testing a product candidate with potential therapeutic value in humans, the product candidate enters the
preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well
as other studies to evaluate, among other things, the toxicity of the product candidate. These studies are often referred to as
IND-enabling studies. The conduct of the preclinical tests and formulation of the compounds for testing must comply with
federal regulations and requirements, including GLP regulations and standards and the United States Department of
Agriculture’s Animal Welfare Act, if applicable. The results of the preclinical tests, together with manufacturing information
and analytical data, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of
reproductive adverse events and carcinogenicity, and long-term toxicity studies, may continue after the IND is submitted.
The IND and IRB processes
An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for
use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans.
An IND must be secured prior to interstate shipment and administration of any product candidate that is not the subject of an
approved BLA. In support of a request for an IND, sponsors must submit a protocol for each clinical trial and any subsequent
protocol amendments must be submitted to the FDA as part of the IND. An IND automatically becomes effective 30 days after
receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials
and places the trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns
before the clinical trial may proceed. As a result, submission of an IND may not result in the FDA allowing clinical trials to
commence.
Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on
that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an
ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND.
For example, a partial clinical hold might state that a specific protocol or part of a protocol may not proceed, while other parts
of a protocol or other protocols may do so. No more than 30 days after the imposition of a clinical hold or partial clinical hold,
the FDA will provide the sponsor a written explanation of the basis for the hold. Following the issuance of a clinical hold or
partial clinical hold, a clinical investigation may only resume once the FDA has notified the sponsor that the investigation may
proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously
cited or otherwise satisfying the FDA that the investigation can proceed or recommence. Occasionally, clinical holds are
imposed due to manufacturing issues that may present safety issues for the clinical trial subjects.
19
A sponsor may choose, but is not required, to conduct a foreign clinical trial under an IND. When a foreign clinical trial is
conducted under an IND, all IND requirements must be met unless waived by the FDA. When a foreign clinical trial is not
conducted under an IND, the sponsor must ensure that the trial complies with certain regulatory requirements of the FDA in
order to use the trial data as support for an IND or application for marketing approval. Specifically, the trials must be conducted
in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee, or IEC, and
seeking and receiving informed consent from subjects. GCP requirements encompass both ethical and data integrity standards
for clinical trials. The FDA’s regulations are intended to help ensure the protection of human subjects enrolled in non-IND
foreign clinical trials, as well as the quality and integrity of the resulting data.
In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must
review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing
review and re-approve the trial at least annually. The IRB, which must operate in compliance with FDA regulations, must
review and approve, among other things, the clinical trial protocol and informed consent information to be provided to trial
subjects and must monitor the trial until completed. An IRB can suspend or terminate approval of a clinical trial at its
institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB’s requirements
or if the product candidate has been associated with unexpected serious harm to patients.
Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a
data safety monitoring board, or DSMB. This group provides authorization as to whether or not a trial may move forward at
designated checkpoints based on review of available data from the trial, to which only the DSMB maintains access. Suspension
or termination of development during any phase of a clinical trial can occur if the DSMB determines that the participants or
patients are being exposed to an unacceptable health risk.
Expanded access
Expanded access, sometimes called “compassionate use,” is the use of investigational new products outside of clinical trials to
treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory
alternative treatment options. The rules and regulations related to expanded access are intended to improve access to
investigational products for patients who may benefit from investigational therapies. FDA regulations allow access to
investigational products under an IND by the company or the treating physician for treatment purposes on a case-by-case basis
for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings);
intermediate-size patient populations; and larger populations for use of the investigational product under a treatment protocol or
Treatment IND Application.
When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or
a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following
criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or
satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the
potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the
expanded use of the investigational product for the requested treatment will not interfere with the initiation, conduct or
completion of clinical investigations that could support marketing approval of the product or otherwise compromise the
potential development of the product.
There is no obligation for a sponsor to make its investigational products available for expanded access; however, as required by
amendments to the FDCA included in the 21st Century Cures Act, or the Cures Act, passed in 2016, if a sponsor has a policy
regarding how it responds to expanded access requests with respect to product candidates in development to treat serious
diseases or conditions, it must make that policy publicly available. Sponsors are required to make such policies publicly
available upon the earlier of initiation of a Phase 2 or Phase 3 trial for a covered investigational product; or 15 days after the
investigational product receives designation from the FDA as a breakthrough therapy, fast track product, or regenerative
medicine advanced therapy.
In addition, on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal
framework for certain patients to access certain investigational new products that have completed a Phase 1 clinical trial and
that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without
enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no
obligation for a manufacturer to make its products available to eligible patients as a result of the Right to Try Act, but the
manufacturer must develop an internal policy and respond to patient requests according to that policy.
20
Human clinical trials
Clinical trials involve the administration of the investigational product candidate to human subjects under the supervision of a
qualified investigator in accordance with GCP requirements which include, among other things, the requirement that all
research subjects provide their informed consent in writing before they participate in any clinical trial. Clinical trials are
conducted under written clinical trial protocols detailing, among other things, the objectives of the trial, inclusion and exclusion
criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol, and any
subsequent material amendment to the protocol, must be submitted to the FDA as part of the IND, and progress reports
detailing the status of the clinical trials must be submitted to the FDA annually. The FDA has issued regulations authorizing a
sponsor to transfer certain responsibilities for the conduct of a clinical trial to a contract research organization, or CRO.
Human clinical trials are typically conducted in three sequential phases, but the phases may overlap or be combined. Additional
trials may also be required after approval.
Phase 1 clinical trials are initially conducted in a limited population, which may be healthy volunteers or subjects with the
target disease, to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism,
distribution, excretion and pharmacodynamics in healthy humans or in patients. During Phase 1 clinical trials, information
about the product candidate’s pharmacokinetics and pharmacological effects may be obtained to permit the design of well-
controlled and scientifically valid Phase 2 clinical trials.
Phase 2 clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety
risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal
dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and
more costly Phase 3 clinical trials. Phase 2 clinical trials are typically well-controlled and closely monitored.
Phase 3 clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially
effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken using a larger patient population to further
evaluate dosage, provide substantial evidence of clinical efficacy and further test for safety in an expanded and diverse patient
population at multiple geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 clinical trial
may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved,
how to appropriately label a new biologic product. Such Phase 3 clinical trials are referred to as “pivotal” trials.
A clinical trial may combine the elements of more than one phase and the FDA often requires more than one Phase 3 trial to
support marketing approval of a product candidate. A company’s designation of a clinical trial as being of a particular phase is
not necessarily indicative that the trial will be sufficient to satisfy the FDA requirements of that phase because this
determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Moreover, as noted
above, a pivotal trial is a clinical trial that is believed to satisfy FDA requirements for the evaluation of a product candidate’s
safety and efficacy such that it can be used, alone or with other pivotal or non-pivotal trials, to support regulatory approval.
Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable
assessment of clinical benefit, particularly in an area of unmet medical need.
In some cases, the FDA may approve a BLA for a product candidate but require the sponsor to conduct additional clinical trials
to further assess the product candidate’s safety and effectiveness after approval. Such post-approval trials, typically referred to
as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience
from the treatment of a larger number of patients in the intended treatment group. In certain instances, the FDA may mandate
the performance of Phase 4 clinical trials, such as to verify clinical benefit in the case of products approved under accelerated
approval regulations. Failure to exhibit due diligence with regard to conducting mandatory Phase 4 clinical trials could result in
withdrawal of FDA approval for products. In December 2022, with the passage of the Food and Drug Omnibus Reform Act, or
FDORA, Congress required sponsors to develop and submit a diversity action plan for each phase 3 clinical trial or any other
“pivotal study” of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient
populations in late-stage clinical trials of FDA-regulated products. Specifically, action plans must include the sponsor’s goals
for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them. In
addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans.
In March 2022, the FDA released final guidance entitled “Expansion Cohorts: Use in First-In-Human Clinical Trials to
Expedite Development of Oncology Drugs and Biologics,” which outlines how developers can utilize an adaptive trial design
commonly referred to as a seamless trial design in early stages of oncology biological product development (i.e., the first-in-
human clinical trial) to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial.
Information to support the design of individual expansion cohorts are included in IND applications and assessed by FDA.
21
Expansion cohort trials can potentially bring efficiency to product development and reduce developmental costs and
time.Finally, sponsors of clinical trials are required to register and disclose certain clinical trial information on a public registry
(clinicaltrials.gov) maintained by the U.S. National Institutes of Health, or NIH. In particular, information related to the
product, patient population, phase of investigation, clinical trial sites and investigators and other aspects of the clinical trial is
made public as part of the registration of the clinical trial. The NIH’s Final Rule on registration and reporting requirements for
clinical trials became effective in 2017. Although the FDA has historically not enforced these reporting requirements due to the
long delay of the U.S. Department of Health and Human Services, or HHS, in issuing final implementing regulations, those
regulations have now been issued and the FDA has issued several Notices of Noncompliance to manufacturers since April 2021.
Interactions with FDA during the clinical development program
Following the clearance of an IND and the commencement of clinical trials, the sponsor will continue to have interactions with
the FDA. Progress reports detailing the results of clinical trials must be submitted annually within 60 days of the anniversary
dates that the IND went into effect and more frequently if serious adverse events occur. These reports must include a
development safety update report, or DSUR. In addition, IND safety reports must be submitted to the FDA for any of the
following: serious and unexpected suspected adverse reactions; findings from other trials or animal or in vitro testing that
suggest a significant risk in humans exposed to the product; and any clinically important increase in the occurrence of a serious
suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials
may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical
sites to assure compliance with GCP and the integrity of the clinical data submitted.
In addition, sponsors are given opportunities to meet with the FDA at certain points in the clinical development program.
Specifically, sponsors may meet with the FDA prior to the submission of an IND (Pre-IND meeting), at the end of Phase 2
clinical trial (EOP2 meeting) and before a BLA is submitted (Pre-BLA meeting). Meetings at other times may also be
requested. There are four types of meetings that occur between sponsors and the FDA. Type A meetings are those that are
necessary for an otherwise stalled product development program to proceed or to address an important safety issue. Type B
meetings include pre-IND and pre-BLA meetings, as well as end of phase meetings such as EOP2 meetings. A Type C meeting
is any meeting other than a Type A or Type B meeting regarding the development and review of a product, including for
example meetings to facilitate early consultations on the use of a biomarker as a new surrogate endpoint that has never been
previously used as the primary basis for product approval in the proposed context of use. Finally, a Type D meeting is focused
on a narrow set of issues, which should be limited to no more than two focused topics, and should not require input from more
than three disciplines or divisions.
Manufacturing and other regulatory requirements
Concurrent with clinical trials, sponsors usually complete additional animal safety studies, develop additional information about
the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing commercial
quantities of the product candidate in accordance with cGMP requirements. The manufacturing process must be capable of
consistently producing quality batches of the product candidate and, among other criteria, the sponsor must develop methods
for testing the identity, strength, quality, and purity of the finished product. Additionally, appropriate packaging must be
selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo
unacceptable deterioration over its shelf life.
Specifically, the FDA’s regulations require that pharmaceutical products be manufactured in specific approved facilities and in
accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and
facilities, equipment, control of components and product containers and closures, production and process controls, packaging
and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products.
Manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to
register their establishments with the FDA and some state agencies, and they are subject to periodic unannounced inspections
by the FDA for compliance with cGMPs and other requirements. The PREVENT Pandemics Act, which was enacted in
December 2022, clarifies that foreign drug manufacturing establishments are subject to registration and listing requirements
even if a drug or biologic undergoes further manufacture, preparation, propagation, compounding, or processing at a separate
establishment outside the United States prior to being imported or offered for import into the United States.
Inspections must follow a “risk-based schedule” that may result in certain establishments being inspected more frequently.
Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying,
denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. Changes to the
manufacturing process, specifications or container closure system for an approved product are strictly regulated and often
require prior FDA approval before being implemented. The FDA’s regulations also require, among other things, the
22
investigation and correction of any deviations from cGMP and the imposition of reporting and documentation requirements
upon the sponsor and any third-party manufacturers involved in producing the approved product.
Pediatric trials
Under the Pediatric Research Equity Act, or PREA, applications and certain types of supplements to applications must contain
data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric
subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and
effective. The sponsor must submit an initial Pediatric Study Plan, or PSP, within 60 days of an end-of-phase 2 meeting or as
may be agreed between the sponsor and the FDA. Those plans must contain an outline of the proposed pediatric clinical trial or
trials that the sponsor plans to conduct, including trial objectives and design, age groups, relevant endpoints and statistical
approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments
or a full or partial waiver of the requirement to provide data from pediatric trials along with supporting information. The
sponsor and the FDA must reach agreement on a final plan. A sponsor can submit amendments to an agreed-upon initial PSP at
any time if changes to the pediatric plan need to be considered based on data collected from nonclinical studies, early phase
clinical trials, and/or other clinical development programs.
For investigational products intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request
of a sponsor, meet to discuss preparation of the initial PSP or to discuss deferral or waiver of pediatric assessments. In addition,
the FDA will meet early in the development process to discuss pediatric study plans with sponsors, and the FDA must meet
with sponsors by no later than the end-of-phase 1 meeting for serious or life-threatening diseases and by no later than ninety
days after the FDA’s receipt of the PSP.
The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data
until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral
may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in
adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the
pediatric trials begin. The law now requires the FDA to send a PREA Non-Compliance letter to sponsors who have failed to
submit their pediatric assessments required under PREA, have failed to seek or obtain a deferral or deferral extension or have
failed to request approval for a required pediatric formulation. Unless otherwise required by regulation, the pediatric data
requirements do not apply to products with orphan designation, although FDA has recently taken steps to limit what it considers
abuse of this statutory exemption in PREA. The FDA also maintains a list of diseases that are exempt from PREA requirements
due to low prevalence of disease in the pediatric population.
Expedited review programs
The FDA is authorized to expedite the review of applications in several ways. Under the Fast Track program, the sponsor of a
product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent
with or after the filing of the IND. Candidate products are eligible for Fast Track designation if they are intended to treat a
serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track
designation applies to the combination of the product candidate and the specific indication for which it is being studied. In
addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections
of a Fast Track application before the application is complete, a process known as rolling review.
Any product candidate submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other
types of FDA programs intended to expedite development and review, such as breakthrough therapy designation, priority
review and accelerated approval.
• Breakthrough therapy designation. To qualify for the breakthrough therapy program, product candidates must be
intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that
such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints
over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives
intensive guidance on an efficient development program, intensive involvement of senior managers and experienced
staff on a proactive, collaborative and cross-disciplinary review and rolling review.
• Priority review. A product candidate is eligible for priority review if it treats a serious condition and, if approved, it
would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared
to marketed products. FDA aims to complete its review of priority review applications within six months as opposed to
10 months for standard review.
23
• Accelerated approval. Biologic products studied for their safety and effectiveness in treating serious or life-threatening
illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval.
Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled
clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to
predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity
or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the
availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a
biologic product candidate receiving accelerated approval perform adequate and well controlled post-marketing
clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of
promotional materials.
With passage of FDORA in December 2022, Congress modified certain provisions governing accelerated approval of
drug and biologic products. Specifically, the new legislation authorized the FDA to: require a sponsor to have its
confirmatory clinical trial underway before accelerated approval is awarded; require a sponsor of a product granted
accelerated approval to submit progress reports on its post-approval studies to the FDA every six months, until the
study is completed; and use expedited procedures to withdraw accelerated approval of a new drug application or BLA
after the confirmatory trial fails to verify the product’s clinical benefit. Further, FDORA requires the agency to publish
on its website “the rationale for why a post-approval study is not appropriate or necessary” whenever it decides not to
require such a study upon granting accelerated approval.
• Regenerative advanced therapy. With passage of the 21st Century Cures Act, or the Cures Act, in December 2016,
Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced
therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat,
modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates
that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits
of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and
review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval
based on surrogate or intermediate endpoints.
None of these expedited programs changes the standards for approval but each may help expedite the development or approval
process governing product candidates.
Submission and filing of BLAs
Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, along
with information relating to the product’s chemistry, manufacturing, controls, safety updates, patent information, abuse
information and proposed labeling, are submitted to the FDA as part of an application requesting approval to market the product
candidate for one or more indications. To support marketing approval, the data submitted must be sufficient in quality and
quantity to establish the safety, potency and purity of the biological product to the satisfaction of the FDA. The fee required for
the submission and review of an application under the Prescription Drug User Fee Act, or PDUFA, is substantial (for example,
for FY2023 this application fee is approximately $3.25 million), and the sponsor of an approved application is also subject to an
annual program fee, currently more than $394,000 per eligible prescription product. These fees are typically adjusted annually,
and exemptions and waivers may be available under certain circumstances, including where the applicant is a small business
submitting its first human therapeutic application for review.
The FDA conducts a preliminary review of all applications within 60 days of receipt and must inform the sponsor at that time or
before whether an application is sufficiently complete to permit substantive review. In pertinent part, FDA’s regulations state
that an application “shall not be considered as filed until all pertinent information and data have been received” by the FDA. In
the event that FDA determines that an application does not satisfy this standard, it will issue a Refuse to File, or RTF,
determination to the applicant. Typically, an RTF will be based on administrative incompleteness, such as clear omission of
information or sections of required information such that substantive and meaningful review is precluded. The FDA may
request additional information rather than accept an application for filing. In this event, the application must be resubmitted
with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.
After the submission is accepted for filing, the FDA begins an in-depth substantive review of the application. The FDA reviews
the application to determine, among other things, whether the proposed product is safe and effective for its intended use,
whether it has an acceptable purity profile and whether the product is being manufactured in accordance with cGMP. Under the
goals and policies agreed to by the FDA under PDUFA, the FDA has ten months from the filing date in which to complete its
initial review of a standard application that is a new molecular entity, and six months from the filing date for an application with
24
“priority review.” The review process may be extended by the FDA for three additional months to consider new information or
in the case of a clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the
original submission. Despite these review goals, it is not uncommon for FDA review of an application to extend beyond the
PDUFA goal date.
In connection with its review of an application, the FDA will typically submit information requests to the applicant and set
deadlines for responses thereto. The FDA will also conduct a pre-approval inspection of the manufacturing facilities for the new
product to determine whether the manufacturing processes and facilities comply with cGMPs. The FDA will not approve the
product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are
adequate to assure consistent production of the product within required specifications.
The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with IND and GCP
requirements and the integrity of the clinical data submitted to the FDA. With passage of FDORA, Congress clarified the FDA’s
authority to conduct inspections by expressly permitting inspections of facilities involved in the preparation, conduct, or
analysis of clinical and non-clinical studies submitted to the FDA as well as other persons holding study records or involved in
the study process.
Additionally, the FDA may refer an application, including applications for novel product candidates which present difficult
questions of safety or efficacy, to an advisory committee for review, evaluation and recommendation as to whether the
application should be approved and under what conditions. Typically, an advisory committee is a panel of independent experts,
including clinicians and other scientific experts that reviews, evaluates and provides a recommendation as to whether the
application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory
committee, but it considers such recommendations when making final decisions on approval.
The FDA also may require submission of a REMS if it determines that a REMS is necessary to ensure that the benefits of the
product outweigh its risks and to assure the safe use of the product. The REMS could include medication guides, physician
communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient
registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS
provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the application must submit a
proposed REMS and the FDA will not approve the application without a REMS.
Decisions on BLAs
After evaluating the application and all related information, including the advisory committee recommendations, if any, and
inspection reports of manufacturing facilities and clinical trial sites, the FDA will issue either a Complete Response Letter, or
CRL, or an approval letter. To reach this determination, the FDA must determine that the expected benefits of the proposed
product outweigh its potential risks to patients. This assessment is informed by the severity of the underlying condition and how
well patients’ medical needs are addressed by currently available therapies; uncertainty about how the premarket clinical trial
evidence will extrapolate to real-world use of the product in the post-market setting; and whether risk management tools are
necessary to manage specific risks.
A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present
form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information
in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal
Phase 3 clinical trial(s) and/or other significant and time- consuming requirements related to clinical trials, preclinical studies or
manufacturing. If a CRL is issued, the applicant will have one year to respond to the deficiencies identified by the FDA, at
which time the FDA can deem the application withdrawn or, in its discretion, grant the applicant an additional six month
extension to respond. The FDA has committed to reviewing resubmissions in response to an issued CRL in either two or six
months depending on the type of information included. Even with the submission of this additional information, however, the
FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.
An approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for
specific indications. That is, the approval will be limited to the conditions of use (e.g., patient population, indication) described
in the FDA-approved labeling. Further, depending on the specific risk(s) to be addressed, the FDA may require that
contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including Phase
4 clinical trials, be conducted to further assess a product’s safety after approval, require testing and surveillance programs to
monitor the product after commercialization or impose other conditions, including distribution and use restrictions or other risk
management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The
FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs.
25
After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and
additional labeling claims, are subject to further testing requirements and FDA review and approval.
Post-approval requirements
Following approval of a new prescription product, the manufacturer, the approved product and the product’s manufacturing
locations are subject to pervasive and continuing regulation by the FDA, governing, among other things, monitoring and
record-keeping activities, reporting of adverse experiences with the product and product problems to the FDA, product
sampling and distribution, manufacturing and promotion and advertising. Although physicians may prescribe legally available
products for unapproved uses or patient populations (i.e., “off-label uses”), manufacturers may not market or promote such
uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a
company that is found to have improperly promoted off-label uses may be subject to significant liability. In September 2021,
the FDA published final regulations which describe the types of evidence that the agency will consider in determining the
intended use of a biologic.
It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in non-promotional, non-
misleading communication regarding off-label information, such as distributing scientific or medical journal information.
Moreover, with passage of the Pre-Approval Information Exchange Act in December 2022, sponsors of products that have not
been approved may proactively communicate to payors certain information about products in development to help expedite
patient access upon product approval. Previously, such communications were permitted under FDA guidance but the new
legislation explicitly provides protection to sponsors who convey certain information about products in development to payors,
including unapproved uses of approved products.
If a company is found to have promoted off-label uses, it may become subject to administrative and judicial enforcement by the
FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as
well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact,
including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or
distributes products, as well as adverse public relations and reputational harm. The federal government has levied large civil
and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent
decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.
Further, if there are any modifications to the product, including changes in indications, labeling or manufacturing processes or
facilities, the sponsor may be required to submit and obtain FDA approval of a new application or supplement, which may
require the sponsor to develop additional data or conduct additional preclinical studies and clinical trials. Securing FDA
approval for new indications is similar to the process for approval of the original indication and requires, among other things,
submitting data from adequate and well-controlled clinical trials to demonstrate the product’s safety and efficacy in the new
indication. Even if such trials are conducted, the FDA may not approve any expansion of the labeled indications for use in a
timely fashion, or at all. There also are continuing, annual user fee requirements that are now assessed as program fees for
certain products.
In addition, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or
if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product,
including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with
regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information, imposition
of post-market clinical trials requirement to assess new safety risks or imposition of distribution or other restrictions under a
REMS program.
Other potential consequences include, among other things:
•
•
restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or
product recalls;
safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other
safety information about a product;
• mandated modification of promotional materials and labeling and issuance of corrective information;
•
fines, warning letters, untitled letters or other enforcement-related letters or clinical holds on post-approval clinical
trials;
26
•
•
•
•
refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of product approvals;
product seizure or detention, or refusal to permit the import or export of products;
injunctions or the imposition of civil or criminal penalties; and
consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs.
Regulatory exclusivity governing biologics
When a biological product is licensed for marketing by FDA with approval of a BLA, the product may be entitled to certain
types of market and data exclusivity barring FDA from approving competing products for certain periods of time. In March
2010, the Patient Protection and Affordable Care Act was enacted in the United States and included the Biologics Price
Competition and Innovation Act of 2009, or the BPCIA. The BPCIA amended the PHSA to create an abbreviated approval
pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. To
date, the FDA has approved a number of biosimilars and the first interchangeable biosimilar product was approved on July 30,
2021 and a second product previously approved as a biosimilar was designated as interchangeable in October 2021.
Under the BPCIA, a manufacturer may submit an application for a product that is “biosimilar to” a previously approved
biological product, which the statute refers to as a “reference product.” In order for the FDA to approve a biosimilar product, it
must find that there are no clinically meaningful differences between the reference product and the proposed biosimilar product
in terms of safety, purity and potency. The biosimilar sponsor may demonstrate that its product is biosimilar to the reference
product on the basis of data from analytical studies, animal studies and one or more clinical trials to demonstrate safety, purity
and potency in one or more appropriate conditions of use for which the reference product is approved.
For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find not only that the
product is biosimilar to the reference product but also that it can be expected to produce the same clinical results as the
reference product such that the two products may be switched without increasing safety risks or risks of diminished efficacy
relative to exclusive use of the reference biologic. Upon licensure by the FDA, an interchangeable biosimilar may be
substituted for the reference product without the intervention of the health care provider who prescribed the reference product.
Following approval of the interchangeable biosimilar product, the FDA may not grant interchangeability status for any second
biosimilar until one year after the first commercial marketing of the first interchangeable biosimilar product. Congress clarified
through FDORA that the FDA may approve multiple first interchangeable biosimilar biological products so long as the products
are all approved on the first day on which such a product is approved as interchangeable with the reference product.
A reference biological product is granted 12 years of exclusivity from the time of first licensure of the product, and the FDA
will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four
years after the date of first licensure of the reference product. Even if a product is considered to be a reference product eligible
for exclusivity, however, another company could market a competing version of that product if the FDA approves a full BLA
for such product containing the sponsor’s own preclinical data and data from adequate and well‑controlled clinical trials to
demonstrate the safety, purity, and potency of their product. There have been recent government proposals to reduce the 12-year
reference product exclusivity period, but none has been enacted to date. At the same time, since passage of the BPCIA, many
states have passed laws or amendments to laws, which address pharmacy practices involving biosimilar products.
Orphan drug designation and exclusivity
Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for treatment of
rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects
fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for
which there is no reasonable expectation that the cost of developing and making available the product for the disease or
condition will be recovered from sales of the product in the United States.
Orphan drug designation qualifies a company for tax credits and potentially market exclusivity for seven years following the
date of the product’s approval if granted by the FDA. An application for designation as an orphan product can be made any time
prior to the filing of an application for approval to market the product. A product becomes an orphan when it receives orphan
drug designation from the Office of Orphan Products Development at the FDA based on acceptable confidential requests. The
product must then go through the review and approval process like any other product.
27
A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already
marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug
may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present
a plausible hypothesis that its product may be clinically superior to the first approved product. More than one sponsor may
receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan
drug designation must file a complete request for designation.
If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such
designation or for a select indication or use within the rare disease or condition for which it was designated, the product
generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor’s
marketing application for the same product for the same disease or condition for seven years, except in certain limited
circumstances. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than
what was designated in its orphan drug application, it may not be entitled to exclusivity.
The period of market exclusivity begins on the date that the marketing application is approved by the FDA and applies only to
the disease or condition for which the product has been designated. Orphan drug exclusivity will not bar approval of another
product under certain circumstances, including if the company with orphan drug exclusivity is not able to meet market demand
or the subsequent product is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or
providing a major contribution to patient care. Under Omnibus legislation signed by President Trump on December 27, 2020,
the requirement for a product to show clinical superiority applies to drug products that received orphan drug designation before
enactment of amendments to the FDCA in 2017 but have not yet been approved by FDA.
In September 2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of market
exclusivity, the term “same disease or condition” in the statute means the designated “rare disease or condition” and could not
be interpreted by the FDA to mean the “indication or use.” Thus, the court concluded, orphan drug exclusivity applies to the
entire designated disease or condition rather than the “indication or use.” Although there have been legislative proposals to
overrule this decision, they have not been enacted into law. On January 23, 2023, the FDA announced that, in matters beyond
the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or
indications for which the orphan drug was approved.
Pediatric exclusivity
Pediatric exclusivity is a type of non‑patent marketing exclusivity in the United States and, if granted, provides for the
attachment of an additional six months of exclusivity. For biologic products, the six month period may be attached to any
existing regulatory exclusivities but not to any patent terms. The conditions for pediatric exclusivity include the FDA’s
determination that information relating to the use of a new product in the pediatric population may produce health benefits in
that population, the FDA making a written request for pediatric clinical trials, and the sponsor agreeing to perform, and
reporting on, the requested clinical trials within the statutory timeframe. This six‑month exclusivity may be granted if a sponsor
submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the
product to be effective in the pediatric population studied. If reports of requested pediatric studies are submitted to and accepted
by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patents that cover the
product are extended by six months. Although this is not a patent term extension, it effectively extends the regulatory period
during which the FDA cannot approve another application.
Patent term restoration and extension
In the United States, a patent claiming a new product, its method of use or its method of manufacture may be eligible for a
limited patent term extension under the Hatch‑Waxman Act, which permits a patent extension of up to five years for patent term
lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought,
the restoration period for a patent covering a product is typically one‑half the time between the effective date of the IND
involving human beings and the submission date of the BLA, plus the time between the submission date of the application and
the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14
years from the product’s approval date in the United States. Only one patent applicable to an approved product is eligible for
the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension
is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of
the approvals. The USPTO reviews and approves the application for any patent term extension in consultation with the FDA.
28
Companion diagnostics
In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products
and in vitro companion diagnostics. According to the guidance, for novel biologics, a companion diagnostic device and its
corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic
product’s labeling. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately
evaluated and has adequate performance characteristics in the intended population. In July 2016, the FDA issued a draft
guidance intended to assist sponsors of the therapeutic product and in vitro companion diagnostic device on issues related to co-
development of the products.
The 2014 guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a
biologic product candidate generally will be considered an investigational device, unless it is employed for an intended use for
which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the
diagnostic device generally will be considered a significant risk device under the FDA’s Investigational Device Exemption, or
IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to
the guidance, if a diagnostic device and a product are to be studied together to support their respective approvals, both products
can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND
regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit
an IND application alone, or both an IND- and IDE-application.
In April 2020, the FDA issued additional guidance which describes considerations for the development and labeling of
companion diagnostic devices to support the indicated uses of multiple biological oncology products, when appropriate. This
guidance builds upon existing policy regarding the labeling of companion diagnostics. In its 2014 guidance, the FDA stated that
if evidence is sufficient to conclude that the companion diagnostic is appropriate for use with a specific group of therapeutic
products, the companion diagnostic’s intended use/indications for use should name the specific group of therapeutic products,
rather than specific products. The 2020 guidance expands on the policy statement in the 2014 guidance by recommending that
companion diagnostic developers consider a number of factors when determining whether their test could be developed, or the
labeling for approved companion diagnostics could be revised through a supplement, to support a broader labeling claim such
as use with a specific group of oncology therapeutic products (rather than listing an individual therapeutic product(s)).
Under the FDCA, in vitro diagnostics, including companion diagnostics, are regulated as medical devices. In the United States,
the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things,
medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and
listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import and post-market
surveillance. Unless an exemption applies, diagnostic tests require pre-notification marketing clearance or approval from the
FDA prior to commercial distribution.The FDA previously has required in vitro companion diagnostics intended to select the
patients who will respond to the product candidate to obtain pre-market approval, or PMA, simultaneously with approval of the
therapeutic product candidate. The PMA process, including the gathering of clinical and preclinical data and the submission to
and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the sponsor
must prepare and provide the FDA with reasonable assurance of the device’s safety and effectiveness and information about the
device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are
subject to an application fee. PMA applications are subject to an application fee. For federal fiscal year 2023, the standard fee is
$441,547 and the small business fee is $110,387.
Healthcare compliance
In the United States, biopharmaceutical manufacturers and their products are subject to extensive regulation at the federal and
state level, such as laws intended to prevent fraud and abuse in the healthcare industry. Healthcare providers and third-party
payors play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing
approval. Arrangements with providers, consultants, third-party payors, and customers are subject to broadly applicable fraud
and abuse, anti-kickback, false claims laws, reporting of payments to healthcare providers and patient privacy laws and
regulations and other healthcare laws and regulations that may constrain our business and/or financial arrangements.
Restrictions under applicable federal and state healthcare laws and regulations, including certain laws and regulations
applicable only if we have marketed products, include the following:
•
federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person
from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly
making, or causing to be made, a false statement to get a false claim paid;
29
•
•
•
•
•
•
•
federal healthcare program anti-kickback law, which prohibits, among other things, persons from offering, soliciting,
receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for, or the
purchasing or ordering of, a good or service for which payment may be made under federal healthcare programs such
as Medicare and Medicaid;
the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, in addition to privacy
protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any
healthcare benefit program or making false statements relating to healthcare matters;
federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or
provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement
under government healthcare programs;
federal Open Payments (or federal “sunshine” law), which requires pharmaceutical and medical device companies to
monitor and report certain financial interactions with certain healthcare providers to the Center for Medicare &
Medicaid Services, or CMS, within the HHS for re-disclosure to the public, as well as ownership and investment
interests held by physicians and their immediate family members;
federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities
that potentially harm consumers;
analogous state laws and regulations, including: state anti-kickback and false claims laws; state laws requiring
pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between
pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related
to payments to health care providers or marketing expenditures; and state laws governing privacy, security and
breaches of health information in certain circumstances, many of which differ from each other in significant ways and
often are not preempted by HIPAA, thus complicating compliance efforts; and
laws and regulations prohibiting bribery and corruption such as the Foreign Corrupt Practices Act, which, among other
things, prohibits U.S. companies and their employees and agents from authorizing, promising, offering, or providing,
directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials,
employees of public international organizations or foreign government-owned or affiliated entities, candidates for
foreign public office, and foreign political parties or officials thereof.
Violations of these laws are punishable by criminal and/or civil sanctions, including, in some instances, exclusion from
participation in federal and state health care programs, such as Medicare and Medicaid. Ensuring compliance is time consuming
and costly. Similar healthcare laws and regulations exist in the European Union and other jurisdictions, including reporting
requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of
personal information.
Healthcare reform
A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and
state proposals during the last few years regarding the pricing of pharmaceutical products, limiting coverage and reimbursement
for medical products and other changes to the healthcare system in the United States.
In March 2010, the United States Congress enacted the Patient Protection and Affordable Care Act, as amended by the Health
Care and Education Reconciliation Act of 2010, or collectively the PPACA, which, among other things, includes changes to the
coverage and payment for pharmaceutical products under government healthcare programs. Other legislative changes have been
proposed and adopted since the PPACA was enacted. In August 2011, the Budget Control Act of 2011, among other things,
created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with
recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required
goals, thereby triggering the legislation’s automatic reduction to several government programs. These changes included
aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and
will remain in effect through 2031. These Medicare sequester reductions were suspended and reduced through the end of June
2022, with the full 2% cut resuming thereafter.
30
Since enactment of the PPACA, there have been, and continue to be, numerous legal challenges and Congressional actions to
repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, or the Tax Act,
which was signed by President Trump on December 22, 2017, Congress repealed the “individual mandate.” The repeal of this
provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. On December
14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the PPACA
is an essential and inseverable feature of the PPACA, and therefore because the mandate was repealed as part of the Tax Act, the
remaining provisions of the PPACA are invalid as well. The U.S. Supreme Court heard this case on November 10, 2020 and, on
June 17, 2021, dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the
ACA. Litigation and legislation over the PPACA are likely to continue, with unpredictable and uncertain results.
The Trump Administration also took executive actions to undermine or delay implementation of the PPACA, including
directing federal agencies with authorities and responsibilities under the PPACA to waive, defer, grant exemptions from, or
delay the implementation of any provision of the PPACA that would impose a fiscal or regulatory burden on states, individuals,
healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however,
President Biden rescinded those orders and issued a new executive order that directs federal agencies to reconsider rules and
other policies that limit access to healthcare, and consider actions that will protect and strengthen that access. Under this order,
federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions,
including complications related to COVID‑19; demonstrations and waivers under Medicaid and the PPACA that may reduce
coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace
or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and under the PPACA; and
policies that reduce affordability of coverage or financial assistance, including for dependents.
Pharmaceutical prices
The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There
have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to,
among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and
manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020, President
Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders
have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation
model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest
price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a
nationwide preliminary injunction and, on December 29, 2021, CMS issued a final rule to rescind it. With issuance of this rule,
CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve
beneficiaries' access to evidence-based care.
In addition, in October 2020, the HHS and the FDA published a final rule allowing states and other entities to develop a Section
804 Importation Program, or SIP, to import certain prescription products from Canada into the United States. The final rule is
currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New
Hampshire) have passed laws allowing for the importation of products from Canada with the intent of developing SIPs for
review and approval by the FDA. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection
for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy
benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden
administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe
harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements
between pharmacy benefit managers and manufacturers, the implementation of which has been delayed by the Biden
administration until January 1, 2026 by the Infrastructure Investment and Jobs Act.
On July 9, 2021, President Biden signed Executive Order 14063, which focuses on, among other things, the price of
pharmaceuticals. The Order directs the HHS to create a plan within 45 days to combat “excessive pricing of prescription
pharmaceuticals and enhance domestic pharmaceutical supply chains, to reduce the prices paid by the federal government for
such pharmaceuticals, and to address the recurrent problem of price gouging.” On September 9, 2021, HHS released its plan to
reduce pharmaceutical prices. The key features of that plan are to: (a) make pharmaceutical prices more affordable and
equitable for all consumers and throughout the health care system by supporting pharmaceutical price negotiations with
manufacturers; (b) improve and promote competition throughout the prescription pharmaceutical industry by supporting market
changes that strengthen supply chains, promote biosimilars, and increase transparency; and (c) foster scientific innovation to
31
promote better healthcare and improve health by supporting public and private research and making sure that market incentives
promote discovery of valuable and accessible new treatments.
More recently, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law by President Biden. The
new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare
Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug
coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare
beginning in 2026, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare
Part D to penalize price increases that outpace inflation first due in 2023; and replaces the Part D coverage gap discount
program with a new discounting program beginning in 2025. The IRA permits the Secretary of HHS to implement many of
these provisions through guidance, as opposed to regulation, for the initial years.
Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly
single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare
Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by
15 additional Part D drugs in 2027, 15 additional Part B or Part D drugs in 2028, and 20 additional Part B or Part D drugs in
2029 and beyond. This provision applies to drug products that have been approved for at least nine years and biologics that
have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or
condition. Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing
to comply with the legislation by offering a price that is not equal to or less than the negotiated “maximum fair price” under the
law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in
Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an
estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.
At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to
control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts,
restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to
encourage importation from other countries and bulk purchasing. A number of states, for example, require pharmaceutical
manufacturers and other entities in the supply chain, including health carriers, pharmacy benefit managers, wholesale
distributors, to disclose information about pricing of pharmaceuticals. In addition, regional healthcare organizations and
individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers
will be included in their prescription pharmaceutical and other healthcare programs. These measures could reduce the ultimate
demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal
healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state
governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or
additional pricing pressures.
Federal and state data privacy laws
There are multiple privacy and data security laws that may impact our business activities, in the United States and in other
countries where we conduct trials or where we may do business in the future. These laws are evolving and may increase both
our obligations and our regulatory risks in the future. In the health care industry generally, under HIPAA, the HHS has issued
regulations to protect the privacy and security of protected health information, or PHI, used or disclosed by covered entities
including certain healthcare providers, health plans and healthcare clearinghouses. HIPAA also regulates standardization of data
content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers.
HIPAA also imposes certain obligations on the business associates of covered entities that obtain protected health information
in providing services to or on behalf of covered entities. HIPAA may apply to us in certain circumstances and may also apply to
our business partners in ways that may impact our relationships with them. Our clinical trials are regulated by the Common
Rule, which also includes specific privacy-related provisions. In addition to federal privacy regulations, there are a number of
state laws governing confidentiality and security of health information that may be applicable to our business. In addition to
possible federal civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for
damages or injunctions in federal courts to enforce HIPAA and seek attorney’s fees and costs associated with pursuing federal
civil actions. In addition, state attorneys general (along with private plaintiffs) have brought civil actions seeking injunctions
and damages resulting from alleged violations of HIPAA’s privacy and security rules. State attorneys general also have
authority to enforce state privacy and security laws. New laws and regulations governing privacy and security may be adopted
in the future as well.
32
At the state level, California has enacted legislation that has been dubbed the first “GDPR-like” law in the United States.
Known as the California Consumer Privacy Act, or CCPA, it creates new individual privacy rights for consumers (as that word
is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of
consumers or households. The CCPA went into effect on January 1, 2020 and requires covered companies to provide new
disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and
allow for a new cause of action for data breaches. Additionally, effective starting on January 1, 2023, the California Privacy
Rights Act, or CPRA, significantly modified the CCPA, including by expanding consumers’ rights with respect to certain
sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and
enforce the CCPA and the CPRA. The CCPA and CPRA could impact our business activities depending on how it is interpreted
and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related
to personal data and individually identifiable health information. These provisions may apply to some of our business activities.
In addition, other states, including Virginia and Colorado, already have passed state privacy laws and other states will likely be
considering similar laws in the near future.
Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under
such laws, it is possible that some of our current or future business activities, including certain clinical research, sales and
marketing practices and the provision of certain items and services to our customers, could be subject to challenge under one or
more of such privacy and data security laws. The heightening compliance environment and the need to build and maintain
robust and secure systems to comply with different privacy compliance and/or reporting requirements in multiple jurisdictions
could increase the possibility that a healthcare company may fail to comply fully with one or more of these requirements. If our
operations are found to be in violation of any of the privacy or data security laws or regulations described above that are
applicable to us, or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal,
civil and administrative penalties, damages, fines, contractual damages, reputational harm, diminished profits and future
earnings, additional reporting requirements and/or oversight if we become subject to a consent decree or similar agreement to
resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which
could adversely affect our ability to operate our business and our results of operations. To the extent that any product candidates
we may develop, once approved, are sold in a foreign country, we may be subject to similar foreign laws.
Approval and regulation of medical products in the European Union
In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and
commercial sales and distribution of our products outside of the United States. Whether or not we obtain FDA approval for a
product candidate, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas,
such as the 27-member European Union, before we may commence clinical trials or market products in those countries or areas.
In the European Union, our product candidates also may be subject to extensive regulatory requirements. As in the United
States, medicinal products can be marketed only if a marketing authorization from the competent regulatory agencies has been
obtained. Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject
to significant regulatory controls.
With the exception of the European Union and European Economic Area, or EEA, applying the harmonized regulatory rules for
medicinal products, the approval process and requirements governing the conduct of clinical trials, product licensing, pricing
and reimbursement vary greatly between countries and jurisdictions and can involve additional testing and additional
administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and
be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure
regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may
negatively impact the regulatory process in others.
Clinical trials
On January 31, 2022, the new Clinical Trials Regulation (EU) No 536/2014, or the Clinical Trials Regulation, became effective
in the European Union and replaced the prior Clinical Trials Directive 2001/20/EC. The new regulation aims at simplifying and
streamlining the authorization, conduct and transparency of clinical trials in the European Union. Under the new coordinated
procedure for the approval of clinical trials, the sponsor of a clinical trial to be conducted in more than one Member State of the
European Union, or EU Member State, will only be required to submit a single application for approval. The submission will be
made through the Clinical Trials Information System, a new clinical trials portal overseen by the EMA and available to clinical
trial sponsors, competent authorities of the EU Member States and the public. Beyond streamlining the process, the Clinical
Trials Regulation includes a single set of documents to be prepared and submitted for the application as well as simplified
reporting procedures for clinical trial sponsors, and a harmonized procedure for the assessment of applications for clinical trials,
33
which is divided into two parts. Part I is assessed by the competent authorities of all EU Member States in which an application
for authorization of a clinical trial has been submitted where EU Member States are concerned. Part II is assessed separately by
each EU Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The
role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the
concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials Regulation.
The new regulation did not change the preexisting requirement that a sponsor must obtain prior approval from the competent
national authority of the EU Member State in which the clinical trial is to be conducted. If the clinical trial is conducted in
different EU Member States, the competent authorities in each of these EU Member States must provide their approval for the
conduct of the clinical trial. Furthermore, the sponsor may only start a clinical trial at a specific clinical site after the applicable
ethics committee has issued a favorable opinion.
Parties conducting certain clinical trials must, as in the United States, post clinical trial information in the European Union at
the EudraCT website: https://eudract.ema.europa.eu.
Marketing authorization in the European Union
Marketing authorization applications, or MAAs, can be filed either under the so-called centralized or national authorization
procedures, albeit through the mutual recognition or decentralized procedure for a product to be authorized in more than one
EU Member State.
The centralized procedure provides for the grant of a single marketing authorization following a favorable opinion by the
European Medicines Agency, or EMA, that is valid in all EU Member States, as well as Iceland, Liechtenstein and Norway,
which are part of the EEA. The centralized procedure is compulsory for medicines produced by specified biotechnological
processes, products designated as orphan medicinal products, advanced-therapy medicines (such as gene-therapy, somatic cell-
therapy or tissue-engineered medicines) and products with a new active substance indicated for the treatment of specified
diseases, such as HIV/ AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune
dysfunctions and viral diseases. The centralized procedure is optional for products that represent a significant therapeutic,
scientific or technical innovation, or whose authorization would be in the interest of public health. Under the centralized
procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops, when
additional written or oral information is to be provided by the sponsor in response to questions asked by the Committee for
Medicinal Products for Human Use, or the CHMP. Accelerated assessment might be granted by the CHMP in exceptional cases,
when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic
innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is of 150 days, excluding
stop-clocks.
There are also two other possible routes to authorize medicinal products in several EU countries, which are available for
investigational medicinal products that fall outside the scope of the centralized procedure:
• Decentralized procedure. Using the decentralized procedure, a sponsor may apply for simultaneous authorization in
more than one EU country of medicinal products that have not yet been authorized in any EU country and that do not
fall within the mandatory scope of the centralized procedure. The sponsor may choose a member state as the reference
member State to lead the scientific evaluation of the application.
• Mutual recognition procedure. In the mutual recognition procedure, a medicine is first authorized in one EU Member
State (which acts as the reference member state), in accordance with the national procedures of that country. Following
this, further marketing authorizations can be progressively sought from other EU countries in a procedure whereby the
countries concerned agree to recognize the validity of the original, national marketing authorization produced by the
reference member state.
Under the above-described procedures, before granting the marketing authorization, the EMA or the competent authorities of
the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria
concerning its quality, safety and efficacy.
Conditional approval
In particular circumstances, EU legislation (Article 14–a Regulation (EC) No 726/2004 (as amended by Regulation (EU)
2019/5 and Regulation (EC) No 507/2006 on Conditional Marketing Authorizations for Medicinal Products for Human Use)
enables sponsors to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for
34
an application for a full marketing authorization. Such conditional approvals may be granted for product candidates (including
medicines designated as orphan medicinal products) if (1) the product candidate is intended for the treatment, prevention or
medical diagnosis of seriously debilitating or life-threatening diseases; (2) the product candidate is intended to meet unmet
medical needs of patients; (3) a marketing authorization may be granted prior to submission of comprehensive clinical data
provided that the benefit of the immediate availability on the market of the medicinal product concerned outweighs the risk
inherent in the fact that additional data are still required; (4) the risk-benefit balance of the product candidate is positive, and (5)
it is likely that the sponsor will be in a position to provide the required comprehensive clinical trial data. A conditional
marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including
obligations with respect to the completion of ongoing or new clinical trials and with respect to the collection of
pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-
benefit balance remains positive, and after an assessment of the need for additional or modified conditions or specific
obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of
applications for a conditional marketing authorization.
Pediatric trials
Prior to obtaining a marketing authorization in the European Union, sponsors have to demonstrate compliance with all
measures included in an EMA-approved Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population,
unless the EMA has granted a product-specific waiver, a class waiver or a deferral for one or more of the measures included in
the PIP. The respective requirements for all marketing authorization procedures are set forth in Regulation (EC) No 1901/2006,
which is referred to as the Pediatric Regulation. This requirement also applies when a company wants to add a new indication,
pharmaceutical form or route of administration for a medicine that is already authorized. The Pediatric Committee of the EMA,
or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine in children until
there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when
development of a medicine in children is not needed or is not appropriate because (a) the product is likely to be ineffective or
unsafe in part or all of the pediatric population; (b) the disease or condition occurs only in adult population; or (c) the product
does not represent a significant therapeutic benefit over existing treatments for pediatric population. Before a marketing
authorization application can be filed, or an existing marketing authorization can be amended, the EMA determines that
companies actually comply with the agreed studies and measures listed in each relevant PIP.
PRIME designation
In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for
which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage product
development in areas of unmet medical need and provides accelerated assessment of products representing substantial
innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises, or SMEs, may
qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates
with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent
discussions on clinical trial designs and other development program elements, and accelerated marketing authorization
application assessment once a dossier has been submitted. Importantly, a dedicated agency contact and rapporteur from the
CHMP or Committee for Advanced Therapies are appointed early in the PRIME scheme, facilitating increased understanding of
the product at EMA’s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary
experts at the EMA to provide guidance to the sponsor on the overall development and regulatory strategies.
Periods of authorization and renewals
A marketing authorization is valid for five years in principle and the marketing authorization may be renewed after five years
on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member
state. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated
version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization
was granted, at least nine months before the marketing authorization ceases to be valid. Once renewed, the marketing
authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified
grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not
followed by the actual placing of the product on the EU market (in case of centralized procedure) or on the market of the
authorizing member state within three years after authorization ceases to be valid (the so-called sunset clause).
35
Regulatory requirements after marketing authorization
As in the United States, both marketing authorization holders and manufacturers of medicinal products are subject to
comprehensive regulatory oversight by the EMA and the competent authorities of the individual EU Member States both before
and after grant of the manufacturing and marketing authorizations. The holder of an EU marketing authorization for a medicinal
product must, for example, comply with EU pharmacovigilance legislation and its related regulations and guidelines which
entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal
products. The manufacturing process for medicinal products in the European Union is also highly regulated and regulators may
shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing
authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU
laws, including compliance with EU cGMP standards when manufacturing medicinal products and active pharmaceutical
ingredients.
In the European Union, the advertising and promotion of approved products are subject to EU Member States’ laws governing
promotion of medicinal products, interactions with clinicians, misleading and comparative advertising and unfair commercial
practices. In addition, other legislation adopted by individual EU Member States may apply to the advertising and promotion of
medicinal products. These laws require that promotional materials and advertising in relation to medicinal products comply
with the product’s Summary of Product Characteristics, or SmPC, as approved by the competent authorities. Promotion of a
medicinal product that does not comply with the SmPC is considered to constitute off-label promotion, which is prohibited in
the European Union.
Regulatory exclusivity
In the European Union, new products authorized for marketing (i.e., reference products) qualify for eight years of data
exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period
prevents generic sponsors from relying on the preclinical and clinical trial data contained in the dossier of the reference product
when applying for a generic marketing authorization in the European Union during a period of eight years from the date on
which the reference product was first authorized in the European Union. The market exclusivity period prevents a successful
generic sponsor from commercializing its product in the European Union until ten years have elapsed from the initial
authorization of the reference product in the European Union. The ten-year market exclusivity period can be extended to a
maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an
authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are
held to bring a significant clinical benefit in comparison with existing therapies.
Orphan drug designation and exclusivity
The criteria for designating an orphan medicinal product in the European Union are similar in principle to those in the United
States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1) it is intended for
the diagnosis, prevention or treatment of a life- threatening or chronically debilitating condition, (2) either (a) such condition
affects no more than five in 10,000 persons in the European Union when the application is made, or (b) the product, without the
benefits derived from orphan status, would not generate sufficient return in the European Union to justify investment and (3)
there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the
European Union, or if such a method exists, the product will be of significant benefit to those affected by the condition. The
term ‘significant benefit’ is defined in Regulation (EC) 847/2000 to mean a clinically relevant advantage or a major
contribution to patient care.
Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a
marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. During this ten year
market exclusivity period, the EMA or the competent authorities of the Member States of the EEA, cannot accept an application
for a marketing authorization for a similar medicinal product for the same indication. A similar medicinal product is defined as
a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product,
and which is intended for the same therapeutic indication. The application for orphan designation must be submitted before the
application for marketing authorization. The sponsor will receive a fee reduction for the marketing authorization application if
the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is
submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval
process.
The ten-year market exclusivity in the European Union may be reduced to six years if, at the end of the fifth year, it is
established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently
36
profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar
product for the same indication at any time if: (1) the second sponsor can establish that its product, although similar, is safer,
more effective or otherwise clinically superior; (2) the sponsor consents to a second orphan medicinal product application; or
(3) the sponsor cannot supply enough orphan medicinal product.
Pediatric exclusivity
If a sponsor obtains a marketing authorization in all EU Member States, or a marketing authorization granted in the centralized
procedure by the European Commission, and the trial results for the pediatric population are included in the product
information, even when negative, the medicine is then eligible for an additional six-month period of qualifying patent
protection through extension of the term of the Supplementary Protection Certificate, or SPC, or alternatively a one year
extension of the regulatory market exclusivity from ten to eleven years, as selected by the marketing authorization holder.
Patent term extensions
The European Union also provides for patent term extension through Supplementary Protection Certificates, or SPCs. The rules
and requirements for obtaining a SPC are similar to those in the United States. An SPC may extend the term of a patent for up
to five years after its originally scheduled expiration date and can provide up to a maximum of fifteen years of marketing
exclusivity for a product. In certain circumstances, these periods may be extended for six additional months if pediatric
exclusivity is obtained. Although SPCs are available throughout the European Union, sponsors must apply on a
country‑by‑country basis. Similar patent term extension rights exist in certain other foreign jurisdictions outside the European
Union.
Reimbursement and pricing of prescription pharmaceuticals
In the European Union, similar political, economic and regulatory developments to those in the United States may affect our
ability to profitably commercialize our product candidates, if approved. In markets outside of the United States and the
European Union, reimbursement and healthcare payment systems vary significantly by country and many countries have
instituted price ceilings on specific products and therapies. In many countries, including those of the European Union, the
pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations
with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain
reimbursement or pricing approval in some countries, pharmaceutical firms may be required to conduct a clinical trial that
compares the cost-effectiveness of the product to other available therapies.
Approval of companion diagnostic devices
In the European Union, medical devices such as companion diagnostics must comply with the General Safety and Performance
Requirements, or SPRs, detailed in Annex I of the EU Medical Devices Regulation (Regulation (EU) 2017/745), or MDR
which came into force on May 26, 2021 and replaced the previously applicable EU Medical Devices Directive (Council
Directive 93/42/EEC). Compliance with SPRs and additional requirements applicable to companion medical devices is a
prerequisite to be able to affix the CE Mark of Conformity to medical devices, without which they cannot be marketed or sold.
To demonstrate compliance with the SPRs, a manufacturer must undergo a conformity assessment procedure, which varies
according to the type of medical device and its classification. The MDR is meant to establish a uniform, transparent,
predictable, and sustainable regulatory framework across the European Union for medical devices.
Separately, the regulatory authorities in the European Union also adopted a new In Vitro Diagnostic Regulation, or IVDR, (EU)
2017/746, which became effective in May 2022. The new regulation replaces the In Vitro Diagnostics Directive (IVDD)
98/79/EC. Manufacturers wishing to apply to a notified body for a conformity assessment of their in vitro diagnostic medical
device had until May 2022 to update their Technical Documentation to meet the requirements and comply with the new, more
stringent Regulation. The regulation, among other things, strengthens the rules on placing devices on the market and reinforce
surveillance once they are available; establishes explicit provisions on manufacturers’ responsibilities for the follow-up of the
quality, performance, and safety of devices placed on the market; improves the traceability of medical devices throughout the
supply chain to the end-user or patient through a unique identification number; sets up a central database to provide patients,
healthcare professionals and the public with comprehensive information on products available in the European Union; and
strengthens rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional
check by experts before they are placed on the market.
37
General Data Protection Regulation
Many countries outside of the United States maintain rigorous laws governing the privacy and security of personal information.
The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding
individuals who are located in the EEA, and the processing of personal data that takes place in the EEA, is subject to the
General Data Protection Regulation, or GDPR, which became effective on May 25, 2018. The GDPR is wide-ranging in scope
and imposes numerous requirements on companies that process personal data, and it imposes heightened requirements on
companies that process health and other sensitive data, such as requiring in many situations that a company obtain the consent
of the individuals to whom the sensitive personal data relate before processing such data. Examples of obligations imposed by
the GDPR on companies processing personal data that fall within the scope of the GDPR include providing information to
individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal
data, appointing a data protection officer, providing notification of data breaches and taking certain measures when engaging
third-party processors.
The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the United States,
and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to
€20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data
subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain
compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and time-intensive
process that may increase the cost of doing business or require companies to change their business practices to ensure full
compliance. In July 2020, the Court of Justice of the European Union, or the CJEU, invalidated the EU-U.S. Privacy Shield
framework, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States. The
CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual
clauses, for transfers of personal data from the EEA to the United States. Following the withdrawal of the United Kingdom
from the European Union, the U.K. Data Protection Act 2018 applies to the processing of personal data that takes place in the
United Kingdom and includes parallel obligations to those set forth by GDPR.
Additionally, in October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework,
which would serve as a replacement to the EU-U.S. Privacy Shield. The European Commission initiated the process to adopt an
adequacy decision for the EU-U.S. Data Privacy Framework in December 2022. It is unclear if and when the framework will be
finalized and whether it will be challenged in court. The uncertainty around this issue may further impact our business
operations in the European Union.
Brexit and the regulatory framework in the United Kingdom
The United Kingdom’s withdrawal from the European Union took place on January 31, 2020. The European Union and the
United Kingdom reached an agreement on their new partnership in the Trade and Cooperation Agreement, or the Agreement,
which was applied provisionally beginning on January 1, 2021 and which became effective on May 1, 2021. The Agreement
focuses primarily on free trade by ensuring no tariffs or quotas on trade in goods, including healthcare products such as
medicinal products. Thereafter, the European Union and the United Kingdom will form two separate markets governed by two
distinct regulatory and legal regimes. As such, the Agreement seeks to minimize barriers to trade in goods while accepting that
border checks will become inevitable as a consequence that the United Kingdom is no longer part of the single market. As of
January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or the MHRA, became responsible for supervising
medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law whereas
Northern Ireland continues to be subject to EU rules under the Northern Ireland Protocol. The MHRA will rely on the Human
Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has
incorporated into the domestic law the body of EU law instruments governing medicinal products that pre-existed prior to the
United Kingdom’s withdrawal from the European Union.
Since a significant proportion of the regulatory framework for pharmaceutical products in the United Kingdom covering the
quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and
distribution of pharmaceutical products is derived from EU directives and regulations, Brexit may have a material impact upon
the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our
product candidates in the United Kingdom. For example, the United Kingdom is no longer covered by the centralized
procedures for obtaining EU-wide marketing authorization from the EMA, and a separate marketing authorization will be
required to market our product candidates in the United Kingdom. However, until December 31, 2023, it is possible for the
MHRA to rely on a decision taken by the European Commission and EMA’s CHMP on the approval of MAA or variations via
the centralized procedure, or the so called “Reliance Procedure.”
38
Intellectual property
We actively seek to protect the proprietary technology that we consider important to our business, including pursuing patents
that cover our ADC platforms, proprietary compositions of matter, ADC product candidates and methods of using and
manufacturing the same, as well as any other relevant inventions and improvements that are considered commercially important
to the development of our business. We also rely on trade secrets, know-how and continuing technological innovation to
develop and maintain our proprietary and intellectual property position.
Our commercial success will depend significantly on our ability to obtain and maintain patents and other proprietary protection
for the technology, inventions and improvements we consider important to our business, and to defend our patents, preserve the
confidentiality of our trade secrets and operate without infringing the patents and proprietary rights of third parties. Our policy
is to seek to protect our proprietary and intellectual property position by, among other methods, filing U.S., international (under
Patent Cooperation Treaty, or PCT) and foreign patent applications related to our proprietary technology, inventions and
improvements that we consider to be important to the development and implementation of our business. We also believe in
protecting our unpatented trade secrets and know-how and continuing our technological innovation to develop our business and
to maintain our competitive position.
The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most
countries, including the United States, the patent term is 20 years from the earliest filing date of a non-provisional patent
application. In the United States, a patent’s term may be lengthened by patent term adjustment, which compensates a patentee
for administrative delays by the USPTO in examining and granting a patent or may be shortened if a patent is terminally
disclaimed over an earlier filed patent. The term of a patent that covers a drug or biological product may also be eligible for
patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. In the future, if
and when our drug candidates receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent term
extensions on issued patents covering those drugs, depending upon the length of the clinical trials for each drug and other
factors. There can be no assurance that any of our pending patent applications will issue or that we will benefit from any patent
term extension or favorable adjustments to the terms of any of our patents.
As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual
property position for our drug candidates and technologies will depend on our success in obtaining effective patent claims and
enforcing those claims if granted. However, our pending patent applications, and any patent applications that we may in the
future file or license from third parties, may not result in the issuance of patents. We also cannot predict the breadth of claims
that may be allowed or enforced in our patents. Any issued patents that we may currently own or license or may receive in the
future may be challenged, invalidated, circumvented or have the scope of their claims narrowed. For example, we cannot be
certain of the priority of inventions covered by pending third party patent applications. If third parties prepare and file patent
applications in the United States that also claim technology or therapeutics to which we have rights, we may have to participate
in interference proceedings in the USPTO to determine priority of invention, which could result in substantial costs to us, even
if the eventual outcome is favorable to us, which is highly unpredictable. In addition, because of the extensive time required for
clinical development and regulatory review of a drug candidate we may develop, it is possible that, before any of our drug
candidates can be commercialized, any related patent may expire or remain in force for only a short period following
commercialization, thereby limiting the protection such patent would afford the respective product and any competitive
advantage such patent may provide. For more information regarding the risks related to our intellectual property, please see
“Risk factors—Risks related to our intellectual property.”
As of December 31, 2022, we owned, in all of our patent portfolios, 24 issued U.S. patents, 18 pending non-provisional U.S.
patent applications (including two allowed U.S. patent applications), seven pending provisional U.S. patent applications, 131
issued foreign patents, three pending PCT patent applications and 209 pending foreign patent applications (including three
allowed foreign patent applications), in a number of foreign jurisdictions, including, but not limited to, Algeria, Argentina,
Australia, Brazil, Canada, Chile, China, Colombia, Europe, Eurasia, Egypt, Gulf Cooperation Council, Hong Kong, India,
Indonesia, Israel, Japan, Mexico, Macau, Malaysia, Nigeria, Pakistan, New Zealand, Philippines, Russia, Saudi Arabia,
Singapore, South Korea, South Africa, Taiwan, Thailand, United Arab Emirates and Vietnam. Our 10 issued U.S. patents
covering our Fleximer ADC platform are projected to expire in 2032, excluding any additional term for patent term adjustments
or patent term extensions; our two issued U.S. patents covering our Dolaflexin ADC platform are projected to expire in 2034
and 2038, excluding any additional term for patent term adjustments or patent term extensions; our two issued U.S. patents
covering UpRi are projected to expire in 2037 and 2039, excluding any additional term for patent term adjustments or patent
term extensions; our one issued U.S. patent covering our Dolasynthen ADC platform is projected to expire in 2037, excluding
any additional term for patent term adjustments or patent term extensions; our three issued U.S. patents covering our novel
HER2 antibody are projected to expire in 2035, excluding any additional term for patent term adjustments or patent term
39
extensions; our one issued U.S. patent covering our STING agonist payload is projected to expire in 2040, excluding any
additional term for patent term adjustments or patent term extensions; our additional five issued U.S. patents are projected to
expire between 2033 and 2037, excluding any additional term for patent term adjustments or patent term extensions; and any
patent that may issue from our pending U.S. applications are projected to expire between 2032 and 2043, in each case,
excluding any additional term for patent term adjustments or patent term extensions. In addition, we have exclusively in-
licensed four issued U.S. patents and one issued European patent for the NaPi2b antibody from Recepta, which Recepta
licensed from the Ludwig Institute for Cancer Research. These in-licensed issued U.S. and European patents are projected to
expire in 2029, excluding any additional term for patent term adjustments or patent term extensions. Recepta still owns one
pending Brazilian patent application for the NaPi2b antibody, which is not licensed to us. A patent issuing from this Brazilian
patent application is projected to expire in 2029, excluding any additional term for patent term adjustments or patent term
extensions. We have also non-exclusively in-licensed from Synaffix certain patents and patent applications for their proprietary
site-specific conjugation technology. These in-licensed Synaffix patents and patent applications are eight issued US patents,
three pending non-provisional U.S. patent applications, thirteen issued foreign patents, and 14 pending foreign patent
applications, in a number of foreign jurisdictions, including, but not limited to, China, Europe, India, Japan, and Netherlands
These in-licensed issued U.S. and European patents are projected to expire from 2031 to 2040, excluding any additional term
for patent term adjustments or patent term extensions. We have so far not filed for patent protection in all national and regional
jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent
applications before they are granted. Finally, the grant proceeding of each national or regional patent is an independent
proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant
registration authorities, while granted by others. It is also quite common that depending on the country, various scopes of patent
protection may be granted on the same product candidate or technology.
The intellectual property portfolio of our ADC platforms, our ADC product candidates and components thereof, and companion
or complementary diagnostics are summarized below. Some of these portfolios are in very early stages, and prosecution has yet
to commence on some of the pending patent applications. Prosecution is a lengthy process, during which the scope of the
claims initially submitted for examination by the USPTO may be narrowed (sometimes significantly) by the time they issue, if
they issue at all. We expect this to be the case with respect to our pending patent applications referred to below.
Fleximer ADC platform
The intellectual property portfolio for our Fleximer ADC platform is directed to compositions of matter for the Fleximer ADCs,
as well as methods of using and making these novel conjugates, compositions of matter for Fleximer drug conjugates prior to
conjugation with the antibody or antibody fragment and methods of making the same, and compositions of matter for our
proprietary auristatin DolaLock compounds and conjugates thereof (e.g., to Fleximer and/or an antibody or antibody fragment).
As of December 31, 2022, we owned 10 issued U.S. patents, one pending non-provisional U.S. patent application, 50 issued
foreign patents and two pending foreign patent applications, in a number of foreign jurisdictions, including, but not limited to,
Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, Macau, Mexico, Russia, South Korea, and Taiwan.
Any U.S. or foreign patent issuing from the pending applications covering the Fleximer ADC platform is projected to expire in
2032, excluding any additional term for patent term adjustments or patent term extensions.
Dolaflexin ADC platform
The intellectual property portfolio for our Dolaflexin ADC platform is directed to compositions of matter for the Dolaflexin
ADCs, as well as methods of using and making these novel conjugates, compositions of matter for Dolaflexin drug conjugates
prior to conjugation with the antibody or antibody fragment and methods of making the same. As of December 31, 2022, we
owned two issued U.S. patents, 36 issued foreign patents, and nine pending foreign patent applications, in a number of foreign
jurisdictions, including, but not limited to, Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan,
South Korea, Mexico, South Africa and Taiwan. Any U.S. or foreign patent issuing from the pending applications covering
Dolaflexin ADC platform is projected to expire in 2034, excluding any additional term for patent term adjustments or patent
term extensions, and any U.S. or foreign patent issuing from the pending applications covering the method of making the
Dolaflexin ADC is projected to expire in 2038, excluding any additional term for patent term adjustments or patent term
extensions.
UpRi ADC
The intellectual property portfolio for UpRi, our leading NaPi2b ADC product candidate is directed to compositions of matter
for our novel ADC based on exclusively in-licensed NaPi2b antibody and our Dolaflexin platform, as well as methods of using
and making these novel conjugates, methods of administration and companion or complementary diagnostics. As of December
31, 2022, we owned two issued U.S. patents, five pending non-provisional U.S. patent applications (including one allowed U.S.
patent application), two pending provisional U.S. patent applications, five issued foreign patents, 52 pending foreign patent
applications (including two allowed foreign patent applications), in a number of foreign jurisdictions, including, but not limited
40
to, Argentina, Australia, Brazil, Canada, China, Eurasia, Europe, Japan, Gulf Cooperation Council, Israel, India, Mexico, New
Zealand, Pakistan, South Africa, South Korea, Macau, Hong Kong, Taiwan, and two pending PCT applications directed to the
composition of matter for UpRi, methods of using and making same, companion or complementary diagnostics for the UpRi
ADC and UpRi dosing regimens. We also intend to enter the national/regional phase of the pending PCT patent applications in
foreign jurisdictions, including, but not limited to, Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India,
Japan, Saudi Arabia, Singapore, South Korea, Macau, Mexico, New Zealand, South Africa and United Arab Emirates. Any U.S.
or foreign patent issuing from the pending applications covering the composition of matter of UpRi is projected to expire in
2037, excluding any additional term for patent term adjustments or patent term extensions, and any U.S. or foreign patent
issuing from the pending applications covering UpRi companion or complementary diagnostics is projected to expire in 2038,
excluding any additional term for patent term adjustments or patent term extensions, and any U.S. or foreign patent issuing
from the pending applications covering the UpRi dosing regimens is projected to expire in 2039, 2042, and 2043, excluding any
additional term for patent term adjustments or patent term extensions.
In addition, as mentioned above, we have exclusively in-licensed four issued U.S. patents and one issued European patent for
the novel NaPi2b antibody from Recepta, which Recepta licensed from the Ludwig Institute for Cancer Research. These in-
licensed issued U.S. and European patents are projected to expire in 2029, excluding any additional term for patent term
adjustments or patent term extensions. Recepta still owns one pending Brazilian patent application for the NaPi2b antibody,
which is not licensed to us. A patent issuing from this Brazilian patent application is projected to expire in 2029, excluding any
additional term for patent term adjustments or patent term extensions.
Dolasynthen ADC platform
The intellectual property portfolio for our novel Dolasynthen platform is directed to compositions of matter for the novel
scaffold and ADCs thereof, as well as methods of using and making these novel conjugates and scaffolds. As of December 31,
2022, we owned one issued U.S. patent, three pending non-provisional U.S. patent applications and 51 pending foreign patent
applications, in a number of foreign jurisdictions, including, but not limited to, Argentina, Australia, Brazil, Canada, China,
Eurasia, Europe, Hong Kong, Israel, India, Japan, Mexico, New Zealand, Pakistan, Saudi Arabia, Singapore, South Korea,
Taiwan, and United Arab Emirates. Any U.S. or foreign patent issuing from the pending applications covering the novel
Dolasynthen platform is projected to expire between 2037 and 2041, excluding any additional term for patent term adjustments
or patent term extensions.
XMT-1660 ADC
The intellectual property portfolio for XMT-1660, our site-specific B7-H4 ADC product candidate is directed to compositions
of matter for our novel ADC based on our novel B7-H4 antibody and our Dolasynthen platform, as well as methods of using,
making these novel conjugates and administration of these novel conjugates. As of December 31, 2022, we owned one pending
non-provisional U.S. patent application, two pending provisional applications, three pending foreign patent applications in a
number of foreign jurisdictions including, but not limited to, Taiwan, Argentina, and Pakistan, and one pending PCT patent
application. We intend to enter the national/regional phase of the PCT patent application in a number of foreign jurisdictions,
including, but not limited to, Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan, Macau,
Mexico, South Korea, New Zealand, Singapore, South Africa, Saudi Arabia, and United Arab Emirates. Any U.S. or foreign
patent issuing from the pending applications covering XMT-1660 is projected to expire in 2042 and 2043, excluding any
additional term for patent term adjustments or patent term extensions.
Immunosynthen ADC platform
The intellectual property portfolio for our novel Immunosynthen platform is directed to compositions of matter for the novel
STING agonists and ADCs thereof, as well as methods of using and methods of making these novel payloads and ADCs. As of
December 31, 2022, we owned one issued U.S. patent, one pending non-provisional U.S. patent applications, 19 pending
foreign patent applications in a number of foreign jurisdictions, including, but not limited to, Argentina, Australia, Brazil,
Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan, Mexico, New Zealand, Saudi Arabia, South Korea, South
Africa, Taiwan and United Arab Emirates related to our novel STING agonists, and two pending non-provisional U.S. patent
applications and 29 pending foreign patent applications in a number of foreign jurisdictions, including, but not limited to,
Algeria, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Europe, Eurasia, Egypt, India, Indonesia, Israel, Japan,
Mexico, Malaysia, Nigeria, Pakistan, New Zealand, Philippines, Saudi Arabia, Singapore, South Korea, South Africa, Taiwan,
Thailand, United Arab Emirates and Vietnam, related to our Immunosynthen platform. Any U.S. or foreign patent issuing from
the pending applications covering the novel STING agonists is projected to expire in 2040, excluding any additional term for
patent term adjustments or patent term extensions, and any U.S. or foreign patent issuing from the pending applications
covering the Immunosynthen platform is projected to expire in 2041, excluding any additional term for patent term adjustments
or patent term extensions.
41
XMT-2056 ADC
The intellectual property portfolio for XMT-2056, our HER2-targeted novel Immunosynthen ADC, is directed to the
compositions of matter for our novel ADC based on our novel HER2 antibody and our Immunosynthen platform, as well as
methods of using, making these novel conjugates, combination comprising XMT-2056 and administration of XMT-2056. As of
December 31, 2022, we owned one pending non-provisional U.S. patent application, three pending provisional U.S. patent
applications and 23 pending foreign patent applications in a number of foreign jurisdictions, including, but not limited to,
Argentina, Australia, Brazil, Chile, Colombia, Europe, Eurasia, Egypt, India, Indonesia, Israel, Japan, Mexico, Malaysia,
Nigeria, Pakistan, New Zealand, Philippines, Saudi Arabia, South Korea, South Africa, Taiwan and United Arab Emirates. Any
U.S. or foreign patent issuing from the pending applications covering the composition of matter of XMT-2056 is projected to
expire in 2041, excluding any additional term for patent term adjustments or patent term extensions, any U.S. or foreign patent
issuing from the pending applications covering combinations comprising XMT-2056 is projected to expire in 2043, excluding
any additional term for patent term adjustments or patent term extensions, and any U.S. or foreign patent issuing from the
pending applications covering the XMT-2056 dosing regimens is projected to expire in 2043, excluding any additional term for
patent term adjustments or patent term extensions.
In addition to the above with respect to XMT-2056, as of December 31, 2022, we owned three issued U.S. patents, one pending
non-provisional U.S. patent application, 19 issued foreign patents and seven pending foreign patent applications (including one
allowed foreign patent application), in a number of foreign jurisdictions, including, but not limited to, Argentina, Australia,
Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan, Macau, Mexico, South Korea, New Zealand and
Taiwan, directed to the novel HER2 antibody. Any U.S. or foreign patent issuing from the pending applications covering the
novel HER2 antibody is projected to expire in 2035, excluding any additional term for patent term adjustments or patent term
extensions.
In addition to patents, we rely upon unpatented trade secrets and know-how and continuing technological innovation to develop
and maintain our competitive position. We seek to protect our proprietary information, in part, by executing confidentiality and
assignment of inventions agreements with our employees and consultants, which agreements may also include appropriate non-
competition and non-solicit agreements depending on level and role, as well as confidentiality agreements with our
collaborators and scientific advisors. We have also executed agreements requiring assignment of inventions with selected
scientific advisors and collaborators. The confidentiality agreements we enter into are designed to protect our proprietary
information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of
technologies that are developed through our relationship with the respective counterparty. We cannot guarantee, however, that
we will have executed such agreements with all applicable employees and contractors, or that these agreements will afford us
adequate protection of our intellectual property and proprietary information rights. Trade secrets and know-how can be difficult
to protect. In particular, we anticipate that with respect to our technology platforms, trade secrets and know-how will over time
be disseminated within the industry through independent development and public presentations describing the methodology.
For more information regarding the risks associated with our trade secrets, please see “Risk factors—Risks related to our
intellectual property—Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of
trade secrets and other proprietary information.”
Competition
The biotechnology and biopharmaceutical industries, and the oncology subsector, are characterized by rapid evolution of
technologies, fierce competition and strong defense of intellectual property. Any product candidates that we successfully
develop and commercialize will have to compete with existing therapies and new therapies that may become available in the
future. While we believe that our proprietary ADC platforms and scientific expertise provide us with competitive advantages, a
wide variety of institutions, including large biopharmaceutical companies, specialty biotechnology companies, academic
research departments and public and private research institutions, are actively developing potentially competitive products and
technologies. These competitors generally fall within the following categories:
New cancer treatments: Many global pharmaceutical companies, as well as medium and small biotechnology companies, are
pursuing new cancer treatments whether small molecules, biologics or ADCs. Any of these treatments could prove to be
superior clinically to our products.
ADC platforms: Although Dolaflexin, Dolasynthen, Immunosynthen and certain initiatives we have underway are highly
differentiated and proprietary, many companies continue to invest in innovation in the ADC field including new payload
classes, new conjugation approaches and new targeting moieties. Any of these initiatives could lead to a platform that has
superior properties to ours. We are also aware of multiple companies with ADC technologies that may be competitive to our
platforms, including Daiichi Sankyo Company, Limited; ImmunoGen, Inc.; Gilead Sciences, Inc.; Pfizer Inc.; and Seagen Inc.
These companies or their partners and collaborators, including Astellas Pharma Inc.; AstraZeneca plc; AbbVie Inc.; Genentech,
42
a member of the Roche Group; and Takeda, may develop product candidates that compete in the same indications as our current
and future product candidates. Multiple companies are also developing ADCs that could compete with our Immunosynthen
product candidates, including Bolt Biotherapeutics, Inc. and Takeda, albeit with differing immune stimulating approaches. We
expect to compete based on our innovative technology and the efficacy, safety and tolerability profile of our ADCs compared to
other product candidates, but if our ADCs are not demonstrably superior in these respects, we may not be able to compete
effectively.
Ovarian cancer: The first indication that we are targeting for UpRi, our most advanced clinical candidate, is ovarian cancer.
There are multiple therapies currently available to treat both newly diagnosed and relapsed ovarian cancer, including platinum
agents, non-platinum chemotherapy, PARP inhibitors, bevacizumab and mirvetuximab soravtansine. In addition, multiple
investigational product candidates are in development to treat these ovarian cancer patients, including MORAb-202 (Eisai Co.,
Ltd. and BMS) and STRO-002 (Sutro Biopharma, Inc.), which are investigational ADCs. There are also ongoing Phase 3
clinical trials of agents and treatment modalities including Tumor Treating Fields (Novocure GmbH) and AVB-500 (Aravive,
Inc.), which, if successful, could alter the treatment landscape for platinum resistant ovarian cancer. Our ability to compete
effectively with these and other emerging ovarian cancer treatments will depend on our ability to differentiate UpRi from these
other therapies based on target patient selection, efficacy and tolerability. If we are unable to effectively differentiate UpRi, this
will negatively impact our ability to compete in ovarian cancer.
Breast Cancer: We are planning to evaluate two of our product candidates currently in clinical development, XMT-2056 and
XMT-1660, in patients with breast cancer indications. Multiple therapies are currently available to treat metastatic breast cancer
across newly diagnosed and relapsed settings, including but not limited to aromatase inhibitors, CDK 4/6 inhibitors, HER2-
targeted therapies, anti-PD-1 inhibitors, PI3K inhibitors and ADCs targeting HER2 and Trop-2. Additional classes of therapies
currently in development include oral selective estrogen receptor degraders (known as SERDs), Akt inhibitors, and ADCs,
among others. The metastatic breast cancer treatment paradigm is evolving with the introduction of a newly defined subset of
HER2-low breast cancer, following the FDA approval of trastuzumab deruxtecan. Our ability to compete effectively in the
breast cancer market will depend on evolving standards of care across patient subsets (based on HER2 and hormone receptor
status), and our ability to differentiate XMT-2056 and XMT-1660 from other available therapies based on efficacy and
tolerability.
Many of our competitors, either alone or with strategic partners, have substantially greater financial, technical and human
resources than we do. Accordingly, our competitors may be more successful than us in obtaining approval for treatments and
achieving widespread market acceptance, rendering our treatments obsolete or non-competitive. Accelerated merger and
acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being
concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining
qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials and
acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to
be significant competitors, particularly through collaborative arrangements with large and established companies. Our
commercial opportunity could be substantially limited in the event that our competitors develop and commercialize products
that are more effective, safer, more convenient or less expensive than our comparable products. In geographies that are critical
to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a
strong market position in advance of our products’ entry. We believe the factors determining the success of our programs will be
the efficacy, safety and tolerability of our product candidates.
Employees and Human Capital
As of December 31, 2022, we had 228 full time employees, including 151 with M.D., Ph.D. or other advanced degrees. Of
these employees, 171 are engaged in research and development and 57 are engaged in general and administrative activities.
None of our employees are represented by a labor union or covered by a collective bargaining agreement. We consider our
relationship with our employees to be good.
We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees.
Our human capital objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing
and additional employees, and focusing on employee well-being and workplace safety. We provide our employees with
competitive salaries and bonuses, opportunity for equity ownership, development programs that enable continued learning and
growth, and a robust employment package that promotes wellness across all aspects of their lives, including healthcare,
retirement planning, and paid time off.
We also believe that fostering diversity, equity, and inclusion is a key element to discovering, developing and bringing therapies
to patients with cancer. As of December 31, 2022, 57% of our global workforce identified as female. We strive to build a
43
workforce representative of the communities and patients we serve and to nurture an inclusive culture where all voices are
welcomed, heard, and respected.
Facilities
Our corporate headquarters are located in Cambridge, Massachusetts. We occupy approximately 45,000 square feet of office
and laboratory space that we lease in the multi-tenant building in which our corporate headquarters are located. The lease for
the substantial majority of this space expires in March 2026. We have an option to extend the lease term for an additional five
years thereafter. We believe that this office and laboratory space is sufficient to meet our current needs and that suitable
additional space will be available as and when needed.
Corporate Information
We were incorporated in 2001 as a Delaware corporation. Our principal executive offices are located at 840 Memorial Drive,
Cambridge, MA 02139, and our telephone number is 617-498-0020. Our internet site is www.mersana.com. We routinely make
available important information free of charge, including copies of our Annual Reports on Form 10-K, Quarterly Reports on
Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d)
of the Exchange Act, as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC.
We recognize our website as a key channel of distribution to reach public investors and as a means of disclosing material non-
public information to comply with our disclosure obligations under SEC Regulation FD. Information contained on our website
shall not be deemed incorporated into, or to be part of this Annual Report on Form 10-K, and any website references are not
intended to be made through active hyperlinks.
ITEM 1A.
RISK FACTORS
Our operations and financial results are subject to various risks and uncertainties, including those described below. The
following information about these risks and uncertainties, together with the other information appearing elsewhere in this
Annual Report on Form 10-K, including our consolidated financial statements and related notes thereto, should be carefully
considered before making any decision to invest in our common stock. The risks and uncertainties described below are not the
only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial
may also adversely affect our business or cause our actual results to differ materially from those contained in forward-looking
statements we have made in this report and those we may make from time to time. If any of the following risks occur, our
business, financial condition, results of operations and future growth prospects could be materially and adversely affected. We
cannot provide assurance that any of the events discussed below will not occur.
Risks Related to Development and Approval of Our ADC Product Candidates
Failure of a discovery program or product candidate may occur at any stage of preclinical or clinical development, and,
because our and our collaborators' discovery programs and our product candidates are in early stages of preclinical or
clinical development, there is a high risk of failure. We or our collaborators may never succeed in obtaining regulatory
approval and generating revenue from such discovery programs or product candidates.
The early clinical results for our lead product candidate, upifitamab rilsodotin, or UpRi, the results from our preclinical studies
of XMT-1660 and XMT-2056 and the early results from preclinical studies or clinical trials of any other current or future
product candidates are not necessarily predictive of the results from our ongoing or future discovery programs, preclinical
studies or clinical trials. Promising results in preclinical studies and early encouraging clinical results of a drug candidate may
not be predictive of similar results in later-stage preclinical studies or in humans during clinical trials. Many companies in the
pharmaceutical and biotechnology industries have suffered significant setbacks in clinical trials after achieving positive results
in earlier stages of clinical development, and we cannot be certain that we will not face similar setbacks. These companies’
setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or
efficacy events in preclinical or clinical trials, including previously unreported adverse events. Similarly, the design of a clinical
trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not
become apparent until the clinical trial is well advanced.
Any clinical trials that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to
market our product candidates. In addition, clinical trial results for one of our product candidates, or for competitor products
utilizing similar technology, may raise concerns about the safety or efficacy of other product candidates in our pipeline. If the
results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of our product candidates, if we do
not meet the clinical endpoints with statistical significance or if there are safety concerns or adverse events associated with our
44
product candidates, we may be prevented from or delayed in obtaining marketing approval for our product candidates. For
example, patients in our ongoing clinical trials of UpRi have experienced serious adverse events, or SAEs, including, without
limitation, death, pneumonitis, renal impairment, abdominal pain, fatigue, vomiting, sepsis and pyrexia. We expect that certain
patients in our ongoing clinical trials of UpRi, XMT-1660 and XMT-2056 and in future clinical trials will experience additional
SAEs, including those that may result in death, as our product candidates progress through clinical development.
There can be significant variability in safety or efficacy results between different clinical trials of the same product candidate
due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the
patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout
among clinical trial participants. Moreover, preclinical and clinical data are often susceptible to varying interpretations and
analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical
trials have nonetheless failed to obtain U.S. Food and Drug Administration, or FDA, approval. Even if we or our collaborators
believe that the results of clinical trials of our product candidates warrant marketing approval, the FDA or comparable foreign
regulatory authorities may disagree and may not grant marketing approval of our product candidates.
Alternatively, even if we obtain regulatory approval, that approval may be for indications or patient populations that are not as
broad as intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings.
We may also be required to perform additional or unanticipated clinical trials to obtain approval or be subject to additional post-
marketing testing requirements to maintain regulatory approval. In addition, regulatory authorities may withdraw their approval
of a product or impose restrictions on its distribution, such as in the form of a risk evaluation and mitigation strategy, or REMS,
program. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations or a product
withdrawal would negatively impact our business, results of operations and financial condition.
Preliminary, interim and top-line data from our clinical trials that we announce or publish from time to time may change as
more patient data become available and are subject to audit and verification procedures that could result in material
changes in the final data.
From time to time, we may announce or publish preliminary, interim or top-line data from our clinical trials. Positive
preliminary data may not be predictive of such trial’s subsequent or overall results. Interim data from clinical trials that we may
complete do not necessarily predict final results and are subject to the risk that one or more of the clinical outcomes may
materially change as patient enrollment continues and more patient data become available. For example, we have reported
interim data from our ongoing Phase 1b/2 clinical trial of UpRi, but we have not yet reported final data from the trial.
Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being
materially different from the preliminary or top-line data we may publish. As a result, preliminary, interim and top-line data
should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and
final data could significantly harm our business prospects.
We are currently evaluating a limited number of ADC product candidates in clinical trials. A failure of any of our product
candidates in clinical development would adversely affect our business and may require us to discontinue development of
other ADC product candidates based on the same technology.
UpRi, XMT-1660 and XMT-2056 are currently our only product candidates in clinical trials. While we have certain other
preclinical programs in development, it will take additional investment and time, and regulatory clearance, for such programs to
reach the clinical stage of development. In addition, we have other product candidates in our current pipeline that are based on
the same platforms as UpRi, XMT-1660 and XMT-2056. If a product candidate fails in development as a result of any
underlying problem with our platforms, then we may be required to discontinue development of the product candidates that are
based on the same technologies. If we were required to discontinue development of UpRi, XMT-1660 or XMT-2056 or of any
other current or future product candidate, or if UpRi, XMT-1660 or XMT-2056 or any other current or future product candidate
were to fail to receive regulatory approval or were to fail to achieve sufficient market acceptance, we could be prevented from
or significantly delayed in achieving profitability.
Events that may delay or prevent successful commencement, enrollment or completion of clinical trials of our product
candidates could result in increased costs to us as well as a delay in obtaining, or failure to obtain, regulatory approval, or
cause us to suspend or terminate a clinical trial, which could prevent us from commercializing our product candidates on a
timely basis, or at all.
45
We cannot guarantee that clinical trials, including our ongoing and any future additional clinical trials of UpRi, XMT-1660,
XMT-2056 or any of our other current or future product candidates, will be conducted as planned or completed on schedule, if
at all. A failure of one or more clinical trials can occur at any stage of testing, and other events may cause us to temporarily or
permanently cease a clinical trial. Events that may prevent successful or timely commencement, enrollment or completion of
clinical development include, among others:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
delays in reaching a consensus with regulatory agencies on trial design;
delays in reaching, or failing to reach, agreement on acceptable terms with prospective clinical research organizations,
or CROs, site management organizations, or SMOs, and clinical trial sites;
difficulties in obtaining required Institutional Review Board, or IRB, or Ethics Committee, or EC, approval at each
clinical trial site;
challenges in recruiting and enrolling suitable patients to participate in clinical trials that meet the criteria of the
protocol for the clinical trial;
imposition of a clinical hold by regulatory agencies, IRBs or ECs for any reason, including safety concerns or after an
inspection of clinical operations or trial sites;
delays in necessary screenings caused by third parties with which we or any of our vendors or suppliers contract;
failure by CROs, SMOs, other third parties or us to adhere to clinical trial requirements;
failure to perform in accordance with the FDA’s good clinical practices, or GCP, or applicable regulatory guidelines in
other countries;
inadequate quantity or quality of a product candidate or other materials necessary to conduct clinical trials, including,
for example, delays in the testing, validation, manufacturing or delivery of the product candidates to the clinical sites;
patients not completing participation in a trial or not returning for post-treatment follow-up, including as a result of the
ongoing COVID-19 pandemic;
expected or unexpected safety issues, including occurrence of SAEs, associated with any product candidate in clinical
trials that are viewed as outweighing the product candidate’s potential benefits or reports that may arise from
preclinical or clinical testing of other similar cancer therapies that raise safety or efficacy concerns about our product
candidates;
changes in regulatory requirements or guidance that require amending or submitting new clinical protocols or
submitting additional data;
lack of adequate funding to continue one or more clinical trials; or
geopolitical or other events, including the ongoing COVID-19 pandemic and the current conflict between Russia and
Ukraine, that unexpectedly disrupt, delay or generally interfere in regional or worldwide operations of our clinical trial
sites, CROs, SMOs or other operations applicable to the conduct of relevant development activities.
Delays, including delays caused by the above factors, can be costly and could negatively affect our ability to commence, enroll
or complete our current and anticipated clinical trials. If we or our collaborators are not able to successfully complete clinical
trials, we or they will not be able to obtain regulatory approval and will not be able to commercialize our product candidates or
our collaborators’ product candidates based on our technology.
An inability to enroll sufficient numbers of patients in our clinical trials could result in increased costs and longer
development periods for our product candidates.
Clinical trials require sufficient patient enrollment, which is a function of many factors, including:
•
the size and nature of the patient population;
46
•
•
•
•
•
•
•
•
•
the severity of the disease under investigation;
the nature and complexity of the trial protocol, including eligibility criteria for the trial;
the design of the trial;
the number of clinical trial sites and the proximity of patients to those sites;
the standard of care in the diseases under investigation;
the ability and commitment of clinical investigators to identify eligible patients;
clinicians’ and patients’ perceptions of the potential advantages and risks of the drug being studied in relation to other
available therapies, including any new drugs that may be approved for the indications we are investigating;
the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they are late-
stage cancer patients, that they will not survive the full terms of the clinical trials; and
the ability of our clinical trial sites to continue key activities, such as clinical trial site data monitoring and patient
visits, due to factors related to the ongoing COVID-19 pandemic or other worldwide events.
In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas
as our current and future product candidates. This competition will reduce the number and types of patients available to us,
because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial conducted by one of our
competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at
the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our
clinical trials at such sites. Moreover, because our current and future product candidates represent a departure from more
commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional
therapies, such as chemotherapy, rather than enroll patients in our ongoing or any future clinical trials.
Challenges in recruiting and enrolling suitable patients to participate in clinical trials that meet the criteria of the protocol could
increase costs and result in delays to our current development plans for UpRi, XMT-1660, XMT-2056 or any other current or
future product candidate.
Our product candidates or ADCs developed or commercialized by our competitors may cause undesirable side effects or
have other properties that halt their clinical development, delay or prevent regulatory approval of our product candidates or
limit their commercial potential.
Undesirable side effects caused by our product candidates or ADCs being developed or commercialized by our collaborators or
competitors could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive
label, the denial of regulatory approval by the FDA or other regulatory authorities and potential product liability claims.
Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and
limited duration of exposure, rare and severe side effects of our product candidates or those of our competitors may only be
uncovered with a significantly larger number of patients exposed to the drug. SAEs, including death, deemed to be caused by
our product candidates or those of our competitors, either before or after receipt of marketing approval, could have a material
adverse effect on the development of our product candidates and our business as a whole.
Patients in our ongoing clinical trials have experienced SAEs, including, without limitation, death, pneumonitis, renal
impairment, abdominal pain, fatigue, vomiting, sepsis and pyrexia. We expect that certain patients in ongoing and future trials
will experience additional SAEs, including those that may result in death, as our product candidates progress through clinical
development. These or additional undesirable side effects caused by our product candidates or those of our competitors, either
before or after receipt of marketing approval, could result in a number of potentially significant negative consequences,
including:
•
•
our clinical trials may be put on hold;
treatment-related side effects could affect patient recruitment for our clinical trials;
47
• we may be unable to obtain regulatory approval for our product candidates;
•
•
•
regulatory authorities may withdraw or limit their approvals of our product candidates;
regulatory authorities may require the addition of labeling statements, such as a contraindication, black box warnings
or additional warnings;
the FDA may require development of a REMS with Elements to Assure Safe Use as a condition of approval or post-
approval;
• we may decide to remove such product candidates from the marketplace;
• we may be subject to regulatory investigations and government enforcement actions;
• we could be sued and held liable for harm caused to patients; and
•
our reputation may suffer.
Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could
substantially increase commercialization costs.
We may choose not to develop a potential product candidate, or we may suspend or terminate one or more discovery or
preclinical programs or product candidates.
At any time and for any reason, we may determine that one or more of our discovery programs, preclinical programs or product
candidates does not have sufficient potential to warrant the allocation of resources toward such program or product candidate.
Furthermore, because we have limited financial and personnel resources, we have placed significant focus on the development
of our lead product candidate, UpRi, and a limited number of other product candidates, including XMT-1660 and XMT-2056
and historically including XMT-1592. Accordingly, we may choose not to develop a product candidate or elect to suspend or
terminate one or more of our discovery or preclinical programs. If we suspend or terminate a program or product candidate in
which we have invested significant resources, we will have expended resources on a program or product candidate that will not
provide a full return on our investment. For example, in May 2022, we decided to discontinue development of XMT-1592 based
in part on the lower prevalence of the NaPi2b biomarker in non-small cell lung cancer, or NSCLC, and the increasingly
competitive nature of such indication. We may also cease developing a product candidate for a particular indication. For
example, in November 2021, we determined to cease developing UpRi as a single agent in patients with NSCLC and
determined to focus development on patients with ovarian cancer. As a result, we may have missed an opportunity to have
allocated the resources originally used to develop UpRi as a single agent in patients with NSCLC and to develop XMT-1592 to
potentially more productive uses, including existing or future programs or product candidates. If we do not accurately evaluate
the commercial potential or target market for a particular future product candidate, we may relinquish valuable rights to future
product candidates through collaboration, licensing or other royalty arrangements.
We or our collaborators may fail to discover and develop additional potential product candidates.
Our and our collaborators’ research programs to identify new product candidates will require substantial technical, financial and
human resources, and we or our collaborators may be unsuccessful in our or their efforts to identify new product candidates. If
we or our collaborators are unable to identify suitable additional product candidates for preclinical and clinical development,
our or their ability to develop product candidates and our ability to obtain revenues from commercializing our products or to
receive royalties from our collaborators’ sales of their products in future periods could be compromised, which could result in
significant harm to our financial position and adversely impact our stock price.
Risks Related to our Financial Position and Need for Additional Capital
We have incurred net losses since our inception, we have no products approved for commercial sale and we anticipate that
we will continue to incur substantial operating losses for at least the next several years. We may never achieve or sustain
profitability.
We have incurred net losses since our inception. Our net loss was $204.2 million, $170.1 million, and $88.0 million,
respectively, for the years ended December 31, 2022, 2021, and 2020, respectively. As of December 31, 2022, we had an
accumulated deficit of $654.7 million. Our losses have resulted principally from costs incurred in our discovery and
48
development activities. Our net losses may fluctuate significantly from quarter to quarter and year to year. To date, we have not
commercialized any products or generated any revenues from the sale of products, and we do not expect to generate any
product revenues in 2023, nor may we generate any product revenues thereafter if we are unable to apply for or obtain
marketing approvals or gain market acceptance for any approved product(s). Absent the realization of sufficient revenues from
product sales, we may never achieve profitability in the future.
We have devoted most of our financial resources to research and development, including our clinical and preclinical
development activities. To date, we have financed our operations primarily with the proceeds from our strategic collaborations,
private placements of our preferred stock and public offerings of our common stock, including our initial public offering, our
follow-on public offerings in 2019 and 2020 and our at-the-market, or ATM, equity offering programs. The amount of our
future net losses will depend, in part, on the rate of our future expenditures. We have not completed pivotal clinical trials for
any product candidate and have only a limited number of product candidates in current or planned clinical trials. It will be
several years, if ever, before we have a product candidate ready for commercialization. Even if we obtain regulatory approval to
market a product candidate, our future revenues would depend upon the size of the market or markets in which our product
candidates received such approval and our ability to achieve sufficient market acceptance, reimbursement from third-party
payors and adequate market share for our product candidates in those markets.
We expect to continue to incur significant expenses and operating losses over the next several years. We anticipate that our
expenses will increase significantly in connection with our ongoing activities, as we:
•
•
•
•
•
•
continue clinical development activities for our lead product candidate, UpRi, and for XMT-1660 and XMT-2056;
continue to develop a diagnostic assay for the NaPi2b biomarker;
continue activities to discover, validate and develop additional product candidates;
obtain marketing approvals for our current and future product candidates for which we complete clinical trials and
obtain marketing approvals, either ourselves or through a third party, for any necessary companion or complementary
diagnostics;
develop a sustainable and scalable manufacturing process for our product candidates, including establishing and
maintaining commercially viable supply and manufacturing relationships with third parties;
address any competing technological and market developments;
• maintain, expand and protect our intellectual property portfolio; and
•
hire additional research, development and general and administrative personnel.
If we are required by the FDA or any equivalent foreign regulatory authority to perform clinical trials or preclinical trials in
addition to those we currently expect to conduct, or if there are any delays in completing the clinical trials of UpRi or any other
current or future product candidates, our expenses could increase.
To become and remain profitable, we must succeed in developing our product candidates, obtaining regulatory approval for
them, and manufacturing, marketing and selling those products for which we may obtain regulatory approval. We may not
succeed in these activities, and we may never generate revenue from product sales or strategic collaborations in an amount
sufficient to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in
subsequent periods. Our failure to become or remain profitable would depress our market value and could impair our ability to
raise capital, expand our business, discover or develop other product candidates or continue our operations.
We have a credit facility that requires us to comply with certain affirmative and negative covenants and places restrictions
on our operating and financial flexibility.
In October 2021, we entered into a Loan and Security Agreement, or the New Credit Facility, with Oxford Finance LLC as the
collateral agent and a lender, SVB as a lender, and the other lenders party thereto, or together the Lenders. Pursuant to the New
Credit Facility, as amended to date, we may borrow up to an aggregate of $100 million, which includes $40 million available in
up to four principal advances through June 30, 2023, $40 million in up to one principal advance through September 30, 2023,
subject to meeting certain development milestones, and an additional tranche of $20 million, which is subject to conditional
approval from the Lenders. The New Credit Facility is secured by substantially all of our personal property owned or later
49
acquired, excluding intellectual property (but including the right to payments and proceeds from intellectual property), and a
negative pledge on intellectual property.
The New Credit Facility also includes customary representations and warranties, affirmative and negative covenants and
conditions to drawdowns, as well as customary events of default. Certain of the customary negative covenants limit our ability,
among other things, to incur future debt, grant liens, make investments, make acquisitions, distribute dividends, make certain
restricted payments and sell assets, subject in each case to certain exceptions. Our failure to comply with these covenants would
result in an event of default under the Loan and Security Agreement and could result in the acceleration of the obligations we
owe pursuant to the New Credit Facility.
We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when
needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.
Our cash, cash equivalents and marketable securities were $280.7 million as of December 31, 2022. We have utilized
substantial amounts of cash since our inception and expect that we will continue to expend substantial resources for the
foreseeable future developing UpRi, XMT-1660, XMT-2056 and any other current or future product candidates. These
expenditures may include costs associated with research and development, conducting preclinical studies and clinical trials,
potentially obtaining regulatory approvals and manufacturing products, as well as marketing and selling products approved for
sale, if any, and potentially acquiring new technologies. In addition, other unanticipated costs may arise. Because the outcome
of our planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to
successfully complete the development and commercialization of our product candidates. Our costs will increase if we
experience any delays in our clinical trials for UpRi or any other current or future product candidates, including delays in
enrollment of patients. We also incur costs associated with operating as a public company, hiring additional personnel and
expanding our facilities.
Our future capital requirements depend on many factors, including:
•
•
•
•
•
•
•
•
•
the scope, progress, results and costs of researching and developing UpRi, XMT-1660, XMT-2056 and any other
current or future product candidates and conducting preclinical studies and clinical trials;
the timing of, and the costs involved in, obtaining regulatory approvals for UpRi, XMT-1660, XMT-2056 and any
other current or future product candidates if preclinical studies and clinical trials are successful;
the cost of manufacturing UpRi, XMT-1660, XMT-2056 and any other current or future product candidates for clinical
trials in preparation for regulatory approval and in preparation for commercialization;
the cost of commercialization activities for UpRi, XMT-1660, XMT-2056 and any other current or future product
candidates, if any product candidates are approved for sale, including manufacturing, marketing, sales and distribution
costs;
our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of
such agreements;
the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including
litigation costs and the outcome of any such litigation;
the timing, receipt and amount of sales of, or royalties on, our future products, if any, or products developed by our
collaborators;
the emergence of competing cancer therapies and other adverse market developments; and
the requirement for or the cost of developing companion diagnostics and/or complementary diagnostics.
50
We currently have the option to borrow $15 million under the New Credit Facility. We believe that our current cash, cash
equivalents and marketable securities, which reflects the receipt in 2023 of a $30 million up-front payment from Merck KGaA
related to our December 2022 collaboration, plus the available borrowings under the New Credit Facility will be sufficient to
fund our current operating plan commitments into the second half of 2024. However, we have based these estimates on
assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to
us and we may need additional funds sooner than planned. Additional funds may not be available when we need them on terms
that are acceptable to us, or at all. Our ability to borrow funds under the New Credit Facility is subject to us complying with the
applicable covenants at the time we request a drawdown. If adequate funds are not available to us on a timely basis, we may be
required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for one or more of
our product candidates or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other
activities that may be necessary to commercialize our product candidates. Even if we believe we have sufficient funds for our
current or future operating plans, we may seek additional capital due to favorable market conditions or strategic considerations.
Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish
rights to our technologies or ADC product candidates.
Until such time, if ever, as we can generate substantial product revenues, we expect to finance our capital need through a
variety of means, including through private and public equity offerings, debt financings, collaborations, strategic alliances and
licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
the ownership interests of our common stockholders will be diluted, and the terms of such equity or convertible debt securities
may include liquidation or other preferences that are senior to or otherwise adversely affect the rights of our common
stockholders. Additional debt financing, if available, may involve agreements that include covenants limiting or restricting our
ability to take certain actions, such as incurring future debt, making capital expenditures, declaring dividends or encumbering
our assets to secure future indebtedness, each of which could adversely impact our ability to conduct our business and execute
our operating plan. If we raise additional funds through strategic collaborations with third parties, we may have to relinquish
valuable rights to our technologies, including our platforms, or product candidates, or grant licenses on terms that are not
favorable to us. If we are unable to raise additional funds through equity or debt financing when needed, we may be required to
delay, limit, reduce or terminate our product development or commercialization efforts for UpRi, XMT-1660, XMT-2056 or any
other current or future product candidates or grant rights to third parties to develop and market product candidates that we
would otherwise prefer to develop and market ourselves.
We may expend our resources to pursue a particular product candidate and fail to capitalize on product candidates that may
be more profitable or for which there is a greater likelihood of success.
Because we have limited financial and managerial resources, we focus on specific product candidates. As a result, we may
forgo or delay pursuit of opportunities with other product candidates that later prove to have greater commercial potential. Our
resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market
opportunities. Failure to properly assess potential product candidates could result in our focus on product candidates with low
market potential, which would harm our business and financial condition. Our spending on current and future research and
development programs and product candidates for specific indications may not yield any commercially viable product
candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we
may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases
in which it would have been more advantageous for us to retain sole development and commercialization rights to such product
candidate.
51
Risks Related to Our Reliance on Third Parties
Because we rely on third-party manufacturers and suppliers, our supply of research and development, preclinical and
clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.
We rely on third-party contract manufacturers to manufacture our preclinical and clinical trial product supplies, and we lack the
internal resources and the capability to manufacture any product candidates on a clinical or commercial scale. The facilities
used by our contract manufacturers to manufacture the active pharmaceutical ingredient and final drug product must be
acceptable to the FDA and other comparable foreign regulatory agencies pursuant to inspections that would be conducted after
we submit our marketing application or relevant foreign regulatory submission to the applicable regulatory agency. There can
be no assurance that our preclinical and clinical development product supplies will be sufficient, uninterrupted or of satisfactory
quality or continue to be available at acceptable prices. If our contract manufacturers cannot successfully manufacture material
that conforms to our specifications and the strict regulatory requirements of the FDA or applicable foreign regulatory agencies,
they will not be able to secure or maintain regulatory approval for their manufacturing facilities. Any replacement of our
manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements.
The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and
manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests
required by regulatory authorities in order to comply with regulatory standards, such as current good manufacturing practices.
We have no direct control over our contract manufacturers’ ability to maintain adequate quality control, quality assurance and
qualified personnel. In the event that any of our manufacturers fails to comply with regulatory requirements or to perform its
obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited
or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have
the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable
terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique
or proprietary to the original manufacturer, and we may have difficulty transferring such skills or technology to another third
party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to
obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are
required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities
and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated
with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner
or within budget. Our reliance on contract manufacturers also exposes us to the possibility that they, or third parties with access
to their facilities, will have access to and may appropriate our trade secrets or other proprietary information.
We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the
extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third
parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those
related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product
candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product
candidates successfully. Our or a third party’s failure to execute on our manufacturing requirements and comply with cGMP
could adversely affect our business in a number of ways, including:
•
•
•
•
•
•
•
a delay or inability to initiate or continue clinical trials of product candidates under development;
delay in submitting regulatory applications, or delay or failure to receive regulatory approvals, for product candidates;
loss of the cooperation of an existing or future strategic collaborator;
subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory
authorities;
a requirement to cease distribution or to recall batches of our product candidates;
in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands
for our products; and
fines, adverse publicity, and civil and criminal enforcement and sanctions.
52
We, or our third-party manufacturers, may be unable to successfully scale-up manufacturing of our ADC product
candidates in sufficient quality and quantity, which would delay or prevent us from developing our ADC product candidates
and commercializing approved products, if any.
In order to conduct clinical trials of our product candidates and commercialize any approved product candidates, we, or our
third-party manufacturers, will need to manufacture them in large quantities. We, or our third-party manufacturers, may be
unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective
manner, or at all. In addition, quality issues may arise during scale-up activities. If we or any third-party manufacturer are
unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development,
testing and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch
of any resulting product may be delayed or not obtained, which could significantly harm our business. We have evaluated
which third-party manufacturers to engage for scale-up to commercial supply of our product candidates, including UpRi, and
we have begun to transfer and scale-up certain manufacturing activities. If we are unable to obtain or maintain third-party
manufacturing for commercial supply of our product candidates, or to do so on commercially reasonable terms, we may not be
able to develop and commercialize our product candidates successfully.
We rely on third parties to conduct preclinical studies and clinical trials for UpRi, XMT-1660, XMT-2056 and our other
product candidates, and if such third parties do not properly, timely and successfully perform their obligations to us, we may
not be able to obtain regulatory approvals for UpRi, XMT-1660, XMT-2056 or any other current or future ADC product
candidates.
We designed the ongoing and planned clinical trials for UpRi, XMT-1660 and XMT-2056, as well as the trial for XMT-1592
that closed in September 2022, and we intend to design any future clinical trials for any future product candidates that we may
develop if preclinical studies are successful and we do not have a strategic collaborator responsible for such trial design.
However, we rely on CROs, SMOs, clinical sites, investigators and other third parties to assist in managing, monitoring and
otherwise carrying out many of these trials. As a result, we have less direct control over the conduct, timing and completion of
these clinical trials and the management of data developed through clinical trials than would be the case if we were relying
entirely upon our own staff. These CROs, SMOs, investigators and other third parties are not our employees, and we have
limited control over the amount of time and resources that they dedicate to our programs. We compete with many other
companies for the resources of these third parties. These third parties may have contractual relationships with other entities,
some of which may be our competitors, which may draw time and resources from our programs. The third parties with whom
we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, or complying with
current good laboratory practices or current good clinical practices, as applicable, resulting in the preclinical studies or clinical
trials being delayed or unsuccessful.
The third parties on whom we rely generally may terminate their engagements at any time, and having to enter into alternative
arrangements would delay development and commercialization of our product candidates. Communicating with outside parties
can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:
•
•
•
•
•
have staffing difficulties;
fail to comply with contractual obligations;
experience regulatory compliance issues;
undergo changes in priorities or become financially distressed; or
form relationships with other entities, some of which may be our competitors.
The FDA and comparable foreign regulatory authorities require compliance with regulations and standards, including GCP, for
designing, conducting, monitoring, recording, analyzing and reporting the results of clinical trials to assure that the data and
results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Although we
rely, and intend to continue to rely, on third parties to conduct our clinical trials, they are not our employees, and we are
responsible for ensuring that each of these clinical trials is conducted in accordance with its general investigational plan,
protocol and other requirements. Our reliance on these third parties for research and development activities will reduce our
control over these activities but will not relieve us of our responsibilities. For any violations of laws or regulations during the
conduct of our clinical trials, we could be subject to untitled and warning letters or enforcement action that may include civil
penalties up to and including criminal prosecution.
53
If these third parties do not successfully carry out their duties under their agreements, if the quality or accuracy of the data they
obtain is compromised due to their failure to adhere to clinical trial protocols or to regulatory requirements, or if they otherwise
fail to comply with clinical trial protocols or meet expected deadlines, the clinical trials of our product candidates may not meet
regulatory requirements. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors, principal
investigators and trial sites. If we or our CROs fail to comply with applicable GCPs or other regulatory requirements, the
clinical data generated in our clinical trials may be deemed unreliable, third parties may need to be replaced, we may be subject
to negative publicity, fines and civil or criminal sanctions, and preclinical development activities or clinical trials may be
extended, delayed, suspended or terminated. If any of these events occur, we may not be able to obtain regulatory approval of
our product candidates on a timely basis or at all.
We depend on strategic relationships with other companies to assist in the research, development and commercialization of
our ADC platforms and ADC product candidates. If our existing collaborators do not perform as expected, this may
negatively affect our ability to commercialize our ADC product candidates or generate revenues through technology
licensing or may otherwise negatively affect our business.
We have established strategic collaborations and intend to continue to establish strategic collaborations and other relationships
with third parties to research, develop and commercialize our platforms and existing and future product candidates. In
December 2022, we entered into a collaboration and license agreement with Ares Trading, S.A., an affiliate of Merck KGaA,
for the research, development and commercialization of ADC product candidates leveraging our Immunosynthen platform, and
in February 2022, we entered into a collaboration agreement with Janssen Biotech, Inc. for the research, development and
commercialization of ADC product candidates leveraging our Dolasynthen platform. We had also entered into a collaboration
agreement with Merck KGaA for the development and commercialization of ADC product candidates leveraging our Dolaflexin
platform. Additionally, in August 2022, we entered into an option, collaboration and license agreement, or the GSK Agreement,
with GlaxoSmithKline Intellectual Property (No. 4) Limited, or GSK, pursuant to which we granted GSK an exclusive option to
obtain an exclusive license to co-develop and to commercialize products containing XMT-2056. Under these arrangements, we
will depend on our collaborators to design and conduct their clinical trials. As a result, we will not be able to control or oversee
the conduct of these programs by our collaborators and those programs may not be successful, which may negatively impact
our business operations. In addition, if any of these collaborators withdraw support for these programs or proposed products or
otherwise impair their development or experience negative results, our business and our product candidates could be negatively
affected.
Our collaborators may terminate their agreements with us for cause under certain circumstances or at will in certain cases and
discontinue use of our technologies. In addition, we cannot control the amount and timing of resources our collaborators may
devote to products utilizing or incorporating our technology. Moreover, our relationships with our collaborators may divert
significant time and effort of our scientific staff and management team and require effective allocation of our resources to
multiple internal and collaborative projects. Our collaborators may fail to perform their obligations under the collaboration
agreements or may not perform their obligations in a timely manner. If conflicts arise between our collaborators and us, the
other party may act in a manner adverse to us and could limit our ability to implement our strategies. If any of our collaborators
terminate or breach our agreements with them, or otherwise fail to complete their obligations in a timely manner, or if GSK
ultimately decides not to exercise its option for a license to co-develop and commercialize XMT-2056, it may have a
detrimental effect on our financial position by reducing or eliminating the potential for us to receive technology access and
license fees, milestones and royalties, reimbursement of development costs, as well as possibly requiring us to devote additional
efforts and incur costs associated with pursuing internal development of product candidates. Furthermore, if our collaborators
do not prioritize and commit sufficient resources to programs associated with our product candidates or collaboration product
candidates, we or our collaborators may be unable to commercialize these product candidates, which would limit our ability to
generate revenue and become profitable.
Our collaborators may separately pursue competing products, therapeutic approaches or technologies to develop treatments for
the diseases targeted by us or our collaborators. Competing products, either developed by our collaborators or to which our
collaborators have rights, may result in the withdrawal of collaborators support for our product candidates. Even if our
collaborators continue their contributions to the strategic relationships, they may nevertheless determine not to actively pursue
the development or commercialization of any resulting products. Additionally, if our collaborators pursue different clinical or
regulatory strategies with their product candidates based on our platforms or technologies, adverse events with their product
candidates could negatively affect our product candidates utilizing similar technologies. Any of these developments could harm
our product development efforts.
To date, we have depended on a small number of collaborators for a substantial portion of our revenue. The loss of any one
of these collaborators could result in non-achievement of our expected revenue payments.
54
We have entered into strategic collaborations with a limited number of companies. To date, a substantial portion of our revenue
has resulted from payments made under agreements with our strategic collaborators, and we expect that a portion of our
revenue will continue to come from strategic collaborations. The loss of any of our collaborators, or the failure of our
collaborators to perform their obligations under their agreements with us, including paying license or technology fees,
milestone payments, royalties or reimbursements, could have a material adverse effect on our financial performance. Payments
under our existing and future strategic collaborations are also subject to significant fluctuations in both timing and amount,
which could cause our revenue to fall below the expectations of securities analysts and investors and cause a decrease in our
stock price.
We may seek to establish additional strategic collaborations, and if we are not able to establish them on commercially
reasonable terms, or maintain them, we may have to alter our development and commercialization plans.
We continue to strategically evaluate our collaborations and, as appropriate, we expect to enter into additional strategic
collaborations in the future, including potentially with major biotechnology or biopharmaceutical companies. We face
significant competition in seeking appropriate collaborators for our product candidates and platforms, and the negotiation
process is time-consuming and complex. In order for us to successfully collaborate with a third-party to leverage our platforms
or advance our product candidates, potential collaborators must view these platforms and product candidates as economically
valuable in markets they determine to be attractive in light of the terms that we are seeking and other available platforms and
products for licensing by other companies. Even if we are successful in our efforts to establish strategic collaborations, the
terms that we agree upon may not be favorable to us, and we may not be able to maintain such strategic collaborations if, for
example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. Any
delay in entering into strategic collaboration agreements related to our product candidates or platforms could delay the
development and commercialization of existing or future product candidates and reduce their competitiveness even if they
reach the market. If we are not able to generate revenue under our strategic collaborations when and in accordance with our
expectations or the expectations of industry analysts, this failure could harm our business and have an immediate adverse effect
on the trading price of our common stock.
If we fail to establish and maintain additional strategic collaborations related to our product candidates for which we have not
yet entered into a strategic collaboration, we will bear all of the risk and costs related to the development of any such product
candidate, and we may need to seek additional financing, hire additional employees and otherwise develop expertise, such as
regulatory expertise, for which we have not budgeted. If we are not successful in seeking additional financing, hiring additional
employees or developing additional expertise, if necessary, our cash burn rate would increase or we would need to take steps to
reduce our rate of product candidate development. This could negatively affect the development of any product candidate for
which we do not currently have a collaborator.
Risks Related to Commercialization of Our ADC Product Candidates
Our future commercial success depends upon attaining significant market acceptance of our ADC product candidates, if
approved, among physicians, patients and health care payors.
Even if we obtain regulatory approval for UpRi or any other current or future product candidates that we may develop or
acquire in the future, the product candidate may not gain market acceptance among physicians, health care payors, patients and
the broader healthcare community. Market acceptance of any approved products depends on a number of factors, including:
•
•
•
•
•
•
•
the efficacy and safety of the product, as demonstrated in clinical trials;
the indications for which the product is approved and the label approved by regulatory authorities for use with the
product, including any warnings that may be required on the label;
acceptance by physicians and patients of the product as a safe and effective treatment;
the cost, safety and efficacy of treatment in relation to alternative treatments;
the availability of adequate reimbursement and pricing by third-party payors and government authorities;
relative convenience and ease of administration;
the prevalence and severity of adverse side effects; and
55
•
the effectiveness of our sales and marketing efforts.
Perceptions of any product are influenced by perceptions of competitors’ products. As a result, adverse public perception of our
competitors’ products may negatively impact the market acceptance of our product candidates. Market acceptance is critical to
our ability to generate significant revenue and become profitable. Any therapeutic candidate, if approved and commercialized,
may be accepted in only limited capacities or not at all. If any approved products are not accepted by the market to the extent
that we expect, we may not be able to generate significant revenue and our business would suffer.
The incidence and prevalence for target patient populations of our drug candidates have not been established with precision.
If the market opportunities for our drug candidates, including particularly UpRi, are smaller than we estimate, or if any
approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve
profitability will be adversely affected, possibly materially.
The precise incidence and prevalence of ovarian cancer with NaPi2b expression are uncertain. Our estimates of both the
number of people who have this disease, as well as the subset of people with ovarian cancer who have the potential to benefit
from treatment with UpRi, are based on estimates. The total addressable market opportunity for UpRi for the treatment of
ovarian cancer with NaPi2b positive expression, if UpRi is approved for sale for this indication, will ultimately depend upon,
among other things, the diagnosis criteria included in the final label for UpRi, acceptance by the medical community, the
approval and availability of a commercial diagnostic assay to identify patients with NaPi2b positive ovarian cancer, and patient
access, drug pricing and reimbursement. The number of patients who can be treated with UpRi or any of our other current or
future product candidates may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our
drugs, we may face increasing difficulties in identifying or gaining access to new patients, or diagnostic assays to help identify
patients may not be available, all of which would adversely affect our results of operations and our business.
If we are unable to establish sales, marketing and distribution capabilities, we may not be successful in commercializing our
product candidates if and when they are approved.
We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of products. To
achieve commercial success for any product for which we have obtained marketing approval, we will need to establish a sales
and marketing organization or pursue a collaborative arrangement for such sales and marketing.
In the future, we expect to build a focused sales and marketing infrastructure to market UpRi and XMT-1660 and any other
current or future product candidates in the United States and certain foreign jurisdictions, if and when they are approved, and
we may potentially do so for XMT-2056. There are risks involved with establishing our own sales, marketing and distribution
capabilities.
For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the
commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or
does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This
may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.
Factors that may inhibit our efforts to commercialize our products on our own include:
•
•
•
•
•
our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;
the inability of sales personnel to obtain access to physicians;
the lack of adequate numbers of physicians to prescribe any future products;
the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage
relative to companies with more extensive product lines; and
unforeseen costs and expenses associated with creating an independent sales and marketing organization.
If we are unable to establish our own sales, marketing and distribution capabilities and enter into arrangements with third
parties to perform these services, our product revenues and our profitability, if any, are likely to be lower than if we were to
market, sell and distribute any products that we develop ourselves.
In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute certain of
our product candidates outside of the United States or may be unable to do so on terms that are favorable to us. We likely will
56
have limited control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and
market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our
own or in collaboration with third parties, we will not be successful in commercializing our product candidates.
Reimbursement may be limited or unavailable in certain market segments for our ADC product candidates, which could
make it difficult for us to sell our products profitably.
In both domestic and foreign markets, sales of any of our product candidates, if approved, will depend, in part, on the extent to
which the costs of our products will be covered by third-party payors, such as government health programs, commercial
insurance and managed health care organizations. These third-party payors decide which drugs will be covered and establish
reimbursement levels for those drugs. The containment of health care costs has become a priority of foreign and domestic
governments as well as private third-party payors. The prices of drugs have been a focus in this effort. Governments and private
third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular
medications, which could affect our ability to sell our product candidates profitably. Cost-control initiatives could cause us to
decrease the price we might establish for products, which could result in lower than anticipated product revenues.
Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor’s determination
that use of a product is:
•
•
•
•
•
a covered benefit under its health plan;
safe, effective and medically necessary;
appropriate for the specific patient;
cost-effective; and
neither experimental nor investigational.
Adverse pricing limitations may hinder our ability to recoup our investment in UpRi, XMT-1660, XMT-2056 or any other
current or future product candidates, even if such product candidates obtain marketing approval.
Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time
consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the
use of our products to the payor. Further, there is significant uncertainty related to third-party payor coverage and
reimbursement of newly approved drugs. We may not be able to provide data sufficient to gain acceptance with respect to
coverage and reimbursement. We cannot be sure that coverage or adequate reimbursement will be available for any of our
product candidates. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our
products. If reimbursement is not available or is available only to limited levels, we may not be able to commercialize certain of
our products. In addition, in the United States, third-party payors are increasingly attempting to contain health care costs by
limiting both coverage and the level of reimbursement of new drugs. As a result, significant uncertainty exists as to whether and
how much third-party payors will reimburse patients for their use of newly approved drugs, which in turn will put pressure on
the pricing of drugs. Manufacturers further may be required to offer price concessions to achieve sales or favorable coverage.
Price controls may be imposed in foreign markets, which may adversely affect our future profitability.
In some countries, including member states of the European Union, the pricing of prescription drugs is subject to governmental
control. Additional countries may adopt similar approaches to the pricing of prescription drugs. In such countries, pricing
negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In
addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels,
including as part of cost containment measures. Political, economic and regulatory developments may further complicate
pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by
various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member
states, can further reduce prices. In some countries, we may be required to conduct a clinical trial or other trials that compare
the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or
pricing approval. We cannot be sure that such prices and reimbursement will be acceptable to us or our strategic collaborators.
Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels
within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our
57
products is unavailable or limited in scope or amount, our revenues from sales by us or our strategic collaborators and the
potential profitability of our product candidates in those countries would be negatively affected.
We face substantial competition, and if our competitors develop and market products that are more effective, safer or less
expensive than any of our current or future product candidates, our commercial opportunities will be negatively impacted.
The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition
and a strong emphasis on proprietary products. Many third parties compete with us in developing various approaches to cancer
therapy. They include pharmaceutical companies, biotechnology companies, academic institutions and other research
organizations. Any treatments developed by our competitors could be superior to our product candidates. It is possible that
these competitors will succeed in developing technologies that are more effective than our platforms or product candidates or
that would render our platforms obsolete, noncompetitive or not economical. We anticipate that we will face increased
competition in the future as additional companies enter our market and scientific developments surrounding other cancer
therapies continue to accelerate.
We are also aware of multiple companies with ADC technologies that may be competitive to our platforms, including Daiichi
Sankyo Company, Limited; ImmunoGen, Inc.; Gilead Sciences, Inc.; Pfizer Inc.; and Seagen Inc. These companies or their
partners and collaborators, including Astellas Pharma Inc.; AstraZeneca plc; AbbVie Inc.; Genentech, a member of the Roche
Group; and Takeda Pharmaceuticals, Inc., to Takeda, may develop product candidates that compete in the same indications as
our current and future product candidates. Multiple companies are also developing ADCs that could compete with our
Immunosynthen product candidates, including Bolt Biotherapeutics, Inc. and Takeda, albeit with differing immune stimulating
approaches. We expect to compete based on our innovative technology and the efficacy, safety and tolerability profile of our
ADCs compared to other product candidates, but if our ADCs are not demonstrably superior in these respects, we may not be
able to compete effectively. Products we may develop in the future are also likely to face competition from other products and
therapies, some of which we may not currently be aware.
Many of our competitors have significantly greater financial resources and expertise in research and development,
manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approval and marketing than we do. In
addition, many of these competitors are active in seeking patent protection and licensing arrangements in anticipation of
collecting royalties for use of technology that they have developed. Large pharmaceutical companies, in particular, have
extensive experience in clinical testing, obtaining marketing approvals, establishing clinical trial sites, recruiting patients and in
manufacturing pharmaceutical products and may succeed in discovering, developing and commercializing products in our field
before we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through strategic
relationships with large and established companies. These third parties compete with us in recruiting and retaining qualified
scientific and management personnel, as well as in acquiring technologies complementary to our programs.
In addition, if our product candidates are approved and commercialized, we may face competition from biosimilars. The route
to market for biosimilars was established with the passage of the Health Care Reform Act in March 2010. The Biologics Price
Competition and Innovation Act of 2009, or BPCIA, establishes a pathway for FDA approval of follow-on biologics and
provides 12 years of data exclusivity for reference products. The BPCIA is complex and continues to be interpreted and
implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity
period. Further, since the BPCIA was enacted as part of the overall Health Care Reform Act, current litigation challenges to that
Act, discussed more in full below, could impact the validity of the BPCIA. As a result, there still remains significant uncertainty
as to the ultimate impact, implementation and regulatory interpretation of the BPCIA.
In Europe, the European Medicines Agency, or EMA, has issued guidelines for approving products through an abbreviated
pathway, and biosimilars have been approved in Europe. If a biosimilar version of one of our potential products were approved
in the United States or Europe, it could have a negative effect on sales and gross profits of the potential product and our
financial condition.
With respect to our current and potential future product candidates, we believe that our ability to compete effectively and
develop products that can be manufactured cost-effectively and marketed successfully will depend on our ability to:
•
•
•
advance our technology platforms;
obtain and maintain intellectual property protection for our technologies and products;
obtain required government and other public and private approvals on a timely basis;
58
•
•
•
•
•
attract and retain key personnel;
commercialize effectively;
obtain reimbursement for our products in approved indications;
comply with applicable laws, regulations and regulatory requirements and restrictions with respect to the
commercialization of our products, including with respect to any changed or increased regulatory restrictions; and
enter into additional strategic collaborations to advance the development and commercialization of our product
candidates.
Risks Related to Our Intellectual Property
If we are unable to obtain or protect intellectual property rights related to our technology and ADC product candidates, or if
our intellectual property rights are inadequate, we may not be able to compete effectively.
Our success depends in large part on our ability to obtain and maintain protection with respect to our intellectual property and
proprietary technology. We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect
the intellectual property related to our platforms and our product candidates, including UpRi, XMT-1660 and XMT-2056. The
patent position of biopharmaceutical companies is generally uncertain because it involves complex legal and factual
considerations and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity,
enforceability and commercial value of our patent rights is highly uncertain. The standards applied by the United States Patent
and Trademark Office, or USPTO, and foreign patent offices in granting patents are not always applied uniformly or
predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims
allowable in patents. In addition, changes in either the patent laws or interpretation of the patent laws in the United States and
other countries may diminish the value of our patents or narrow the scope of our patent protection. The patent prosecution
process is expensive, complex and time-consuming, and we may not be able to file, prosecute, maintain, enforce or license all
necessary or desirable patents and patent applications at a reasonable cost or in a timely manner. It is also possible that we fail
to identify patentable aspects of our research and development output before it is too late to obtain patent protection. There is no
assurance that all potentially relevant prior art relating to our patents and patent applications has been found. We may be
unaware of prior art that could be used to invalidate an issued patent or prevent our pending patent applications from issuing as
patents.
The patent applications that we own or in-license may fail to result in issued patents, and even if they do issue as patents, such
patents may not cover our platforms and product candidates in the United States or in other countries. The issuance of a patent
is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or
patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being
narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar
or identical technology and products, or limit the duration of the patent protection of our technology and product candidates.
For example, even if patent applications we license or own do successfully issue as patents and even if such patents cover our
platforms and product candidates, third parties may challenge their validity, enforceability or scope, which may result in such
patents being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not
provide adequate protection or exclusivity for our ADC platform or product candidates, prevent others from designing around
our claims or otherwise provide us with a competitive advantage. Any of these outcomes could impair our ability to prevent
competition from third parties, which may have an adverse impact on our business.
If patent applications we own or have in-licensed with respect to our platforms or our product candidates fail to issue as patents,
if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity, it could dissuade
companies from collaborating with us. We cannot offer any assurances about which, if any, patents will issue, the breadth of
any such patents or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties.
Any successful challenge to these patents or any other patents owned by or licensed to us could deprive us of rights necessary
for the successful development and commercialization of any product candidate. Since patent applications in the United States
and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain
that we were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such
patent applications, an interference proceeding in the United States can be initiated by the USPTO or a third-party to determine
who was the first to invent any of the subject matter covered by the patent claims of our applications. In addition, patents have a
limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions
may be available; however, the life of a patent and the protection it affords is limited. Given the amount of time required for the
59
development, testing and regulatory review of new product candidates, our owned or in-licensed patents protecting such
candidates might expire before or shortly after such candidates are commercialized. If we encounter delays in obtaining
regulatory approvals, the period of time during which we could market a drug under patent protection could be further reduced.
Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to
competition from similar or generic products. The launch of a generic version of one of our products in particular would be
likely to result in an immediate and substantial reduction in the demand for our product, which could have a material adverse
effect on our business, financial condition, results of operations and prospects.
On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith
Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent
applications are prosecuted, redefine prior art, may affect patent litigation and switch the U.S. patent system from a “first-to-
invent” system to a “first-to-file” system. Under a first-to-file system, assuming the other requirements for patentability are met,
the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether
another inventor had made the invention earlier. These provisions also allow third-party submission of prior art to the USPTO
during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post
grant proceedings. The USPTO developed additional regulations and procedures to govern administration of the Leahy-Smith
Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and, in particular, the first-to-file
provisions, became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have
on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs
surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could
have a material adverse effect on our business, financial condition, results of operations and prospects.
Any loss of patent protection could have a material adverse impact on our business. We may be unable to prevent competitors
from entering the market with a product that is similar to or the same as our product candidates.
Issued patents covering UpRi, XMT-1660, XMT-2056 and any other current or future ADC product candidates could be
found invalid or unenforceable if challenged in court or before the USPTO or comparable foreign authority.
If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering UpRi, XMT-
1660, XMT-2056 or any other current or future product candidates, the defendant could counterclaim that the patent covering
our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging
invalidity or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity
or unenforceability of a patent. Grounds for a validity challenge could be, among other things, an alleged failure to meet any of
several statutory requirements, including lack of novelty, obviousness, lack of written description or non-enablement. Grounds
for an unenforceability assertion could be, among other things, an allegation that someone connected with prosecution of the
patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may
also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such
mechanisms include re-examination, inter partes review, post-grant review, interference proceedings, derivation proceedings
and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation,
cancellation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The
outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity of our
patents, for example, we cannot be certain that there is no invalidating prior art of which we, our licensors, our patent counsel
and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or
unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our product candidates.
Any such loss of patent protection could have a material adverse impact on our business, financial condition, results of
operations and prospects.
If we fail to comply with our obligations under any license, strategic collaboration or other agreements, we may be required
to pay damages and could lose intellectual property rights that are necessary for developing and protecting our ADC product
candidates.
60
We rely, in part, on license, collaboration and other agreements. We may need to obtain additional licenses from others to
advance our research or allow commercialization of our product candidates and it is possible that we may be unable to obtain
additional licenses at a reasonable cost or on reasonable terms, if at all. The licensing or acquisition of third party intellectual
property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third
party intellectual property rights that we may consider attractive. These established companies may have a competitive
advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In
addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to use. We also may be
unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return
on our investment.
In addition, our existing licenses and collaboration agreements, including our licenses with Ares Trading S.A., a wholly owned
subsidiary of Merck KGaA, Darmstadt, Germany, or Merck KGaA, and Merck KGaA for intellectual property covering the
Immunosynthen and Dolaflexin platforms; our potential license with GlaxoSmithKline Intellectual Property (No. 4) Limited, or
GSK, for intellectual property covering XMT-2056; our license with Janssen Biotech, Inc., or Janssen, for intellectual property
covering the Dolasynthen platform; our license with with Recepta Biopharma S.A., or Recepta, for intellectual property
covering the NaPi2b antibody in UpRi; and our license with Synaffix B.V., or Synaffix, for intellectual property covering
components included in the Dolasynthen platform, impose, and any future licenses, collaborations or other agreements we enter
into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing,
insurance, patent prosecution and enforcement or other obligations on us. If we breach any of these obligations, or use the
intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have
the right to terminate the license, including, in the case of our agreements with Merck KGaA, the license for the rights covering
the Immunosynthen and Dolaflexin platforms; in the case of our agreement with GSK, the potential license for the rights
covering XMT-2056; in the case of our agreement with Janssen, the license for the rights covering the Dolasynthen platform; in
the case of our agreement with Recepta, the license for the rights covering the NaPi2b antibody in UpRi; and, in the case of our
agreement with Synaffix, the license for the rights covering components in the Dolasynthen platform. Any of the foregoing
could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology or enable
a competitor to gain access to the licensed technology. Disputes may arise regarding intellectual property subject to a licensing,
collaboration or other agreements, including:
•
•
•
•
•
the scope of rights granted under the license agreement and other interpretation related issues;
the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to
the licensing agreement;
the sublicensing of patent and other rights under our collaborative development relationships;
our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
the inventorship and ownership of inventions and know how resulting from the joint creation or use of intellectual
property by our licensors and us and our collaborators; and
•
the priority of invention of patented technology.
In addition, the agreements under which we currently license intellectual property or technology to or from third parties are
complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any
contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant
intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant
agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and
prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our
current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and
commercialize the affected product candidates.
In some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to
maintain the patents, covering the technology that we license from third parties. For example, pursuant to our license agreement
with Recepta, Ludwig Institute for Cancer Research Ltd., a co-owner of the intellectual property, retains control of such
activities. Therefore, we cannot be certain that these patents and applications will be prosecuted, maintained and enforced in a
manner consistent with the best interests of our business. If our licensors fail to obtain or maintain such intellectual property, or
lose rights to such intellectual property, the rights we have licensed and our exclusivity may be reduced or eliminated and our
right to develop and commercialize any of our products that are subject to such licensed rights could be adversely affected.
61
Moreover, our rights to our in-licensed patents and patent applications are dependent, in part, on inter-institutional or other
operating agreements between the joint owners of such in-licensed patents and patent applications. If one or more of such joint
owners breaches such inter-institutional or operating agreements, our rights to such in-licensed patents and patent applications
may be adversely affected. In addition, while we cannot currently determine the amount of the royalty obligations we would be
required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations
will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if
any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain
profitability. Any of the foregoing could have a material adverse effect on our competitive position, business, financial
conditions, results of operations and prospects.
If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing
intellectual property rights we have, we may have to abandon development of the relevant program or product candidate and
our business, financial condition, results of operations and prospects could suffer.
We may become involved in lawsuits to protect or enforce our intellectual property or to defend against intellectual property
claims, which could be expensive, time consuming and unsuccessful.
Competitors and other third parties may infringe our patents or misappropriate or otherwise violate our owned and in-licensed
intellectual property rights. To counter infringement or unauthorized use, litigation or other intellectual property proceedings
may be necessary to enforce or defend our owned and in-licensed intellectual property rights, to protect our trade secrets or to
determine the validity and scope of our own intellectual property rights or the proprietary rights of others. Such litigation or
proceedings can be expensive and time consuming, and any such claims could provoke defendants to assert counterclaims
against us, including claims alleging that we infringe their patents or other intellectual property rights. We may not have
sufficient financial or other resources to adequately conduct such litigation or proceedings. Many of our current and potential
competitors have the ability to dedicate substantially greater resources to litigate intellectual property rights than we can and
have more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to
prevent third parties from infringing upon or misappropriating our intellectual property. Even if resolved in our favor, litigation
or other intellectual property proceedings could result in substantial costs and diversion of management attention and resources,
which could harm our business and financial results.
In addition, in a litigation or other proceeding, a court or administrative judge may decide that a patent owned by or licensed to
us is invalid or unenforceable, or a court may refuse to stop the other party from using the technology at issue on the grounds
that our patents do not cover the technology in question. An adverse result in any litigation or other proceeding could put one or
more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation and other proceedings, there is a risk
that some of our confidential information could be compromised by disclosure during this type of litigation. During the course
of any patent or other intellectual property litigation or other proceeding, there could be public announcements of the results of
hearings, rulings on motions and other interim proceedings or developments and if securities analysts or investors regard these
announcements as negative, the perceived value of our product candidates, programs or intellectual property could be
diminished. Accordingly, the market price of our common stock may decline. Any of the foregoing could have a material
adverse effect on our business, financial conditions, results of operations and prospects.
Third-party claims of intellectual property infringement or misappropriation may prevent or delay our development and
commercialization efforts.
Our commercial success depends in part on our ability and the ability of our strategic collaborators to develop, manufacture,
market and sell product candidates and use our proprietary technologies without infringing, misappropriating or otherwise
violating the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside
the United States, involving patent and other intellectual property rights in the biopharmaceutical industries, including patent
infringement lawsuits, interferences, oppositions, reexamination, inter partes review, derivation and post grant review
proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and
pending patent applications owned by third parties exist in the fields in which we are developing and may develop our product
candidates. As the biopharmaceutical industries expand and more patents are issued, the risk increases that our product
candidates may be subject to claims of infringement of the patent rights of third parties.
Third parties may assert that we, our customers, licensees or parties indemnified by us are employing their proprietary
technology without authorization or have infringed upon, misappropriated or otherwise violated their intellectual property or
other rights, regardless of their merit. For example, we may be subject to claims that we are infringing the patent, trademark or
copyright rights of third parties, or that our employees have misappropriated or divulged their former employers’ trade secrets
62
or confidential information. There may be third-party patents or patent applications with claims to materials, formulations,
methods of manufacture or methods for treatment related to the use or manufacture of our product candidates, that we failed to
identify. For example, applications filed before November 29, 2000 and certain applications filed after that date that will not be
filed outside the United States remain confidential until issued as patents. Except for certain exceptions, including the preceding
exceptions, patent applications in the United States and elsewhere are generally published only after a waiting period of
approximately 18 months after the earliest filing, and sometimes not at all. Therefore, patent applications covering our
platforms or our product candidates could have been filed by others without our knowledge. Additionally, pending patent
applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our
platforms, our product candidates or the use or manufacture of our product candidates.
Even if we believe a third party’s claims against us are without merit, a court of competent jurisdiction could hold that such
third party’s patent is valid, enforceable and covers aspects of our product candidates, including the materials, formulations,
methods of manufacture, methods of analysis, or methods for treatment, in which case, such third party would be able to block
our ability to develop and commercialize the applicable technology or product candidate until such patent expired or unless we
obtain a license and we may be required to pay such third-party monetary damages, which could be substantial. Such licenses
may not be available on acceptable terms, if at all. Even if we were able to obtain a license, the rights may be nonexclusive,
which could result in our competitors gaining access to the same intellectual property and it could require us to make
substantial licensing and royalty payments. Ultimately, we could be prevented from commercializing a product, or be forced to
cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to
enter into licenses on acceptable terms.
Parties making claims against us may also obtain injunctive or other equitable relief, which could effectively block our ability
to further develop and commercialize our technologies or one or more of our product candidates. Defending against claims of
patent infringement, misappropriation of trade secrets or other violations of intellectual property could be costly and time
consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle at an early stage, such litigation
could burden us with substantial unanticipated costs. In addition, litigation or threatened litigation could result in significant
demands on the time and attention of our management team, distracting them from the pursuit of other company business. In
the event of a successful claim of infringement against us, in addition to potential injunctive relief, we may have to pay
substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our
infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and
monetary expenditure.
We may face a claim of misappropriation if a third party believes that we inappropriately obtained and used trade secrets of
such third party. If we are found to have misappropriated a third party’s trade secrets, we may be prevented from further using
such trade secrets, limiting our ability to develop our product candidates, we may be required to obtain a license to such trade
secrets which may not be available on commercially reasonable terms or at all and may be non-exclusive, and we may be
required to pay damages, which could be substantial. Any of the foregoing could have a material adverse effect on our business,
financial condition, results of operations and prospects.
We may not be able to protect our intellectual property and proprietary rights throughout the world.
Filing, prosecuting and defending patents on product candidates in all countries throughout the world where we expect there to
be significant markets for our products could be prohibitively expensive, and the laws of foreign countries may not protect our
rights to the same extent as the laws of the United States. In addition, our intellectual property license agreements may not
always include worldwide rights. For example, certain U.S. and foreign issued patents and patent applications are licensed to us
by Recepta on a worldwide basis, except that Recepta retains exclusive rights in such patents and patent applications in Brazil.
Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United
States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their
own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses
but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or
other intellectual property rights may not be effective or sufficient to prevent them from competing.
Additionally, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the
United States, and many companies have encountered significant problems in protecting and defending such rights in foreign
jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of
patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for
us to stop the infringement of our licensed and owned patents or marketing of competing products in violation of our
intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in
foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business,
63
could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing
as patents, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and
the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our
intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage
from the intellectual property that we develop or license.
Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third
parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors.
In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we
or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our
competitive position may be impaired, and our business, financial condition, results of operations and prospects may be
adversely affected.
Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and
other proprietary information.
In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect
proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce
and any other elements of our platform technology and discovery and development processes that involve proprietary know-
how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to
protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees,
consultants and outside scientific advisors, contractors and collaborators. We cannot guarantee that we have entered into such
agreement with each party that may have or have had access to our trade secrets or proprietary technology and processes.
Additionally, our confidentiality agreements and other contractual protections may not be adequate to protect our intellectual
property from unauthorized disclosure, third-party infringement or misappropriation. We may not have adequate remedies in
the case of a breach of any such agreements, and our trade secrets and other proprietary information could be disclosed to our
competitors or others may independently develop substantially equivalent or superior proprietary information and techniques or
otherwise gain access to our trade secrets or disclose such technologies.
Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming,
and the outcome is unpredictable. In addition, some courts outside and within the United States sometimes are less willing to
protect trade secrets. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and
may have a material adverse effect on our business.
We may be subject to claims by third parties asserting that our licensors, employees, consultants, advisors or we have
misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
Many of our and our licensors’ employees, including our senior management, consultants or advisors are currently, or
previously were, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or
potential competitors. Some of these employees, including members of our senior management, executed proprietary rights,
non-disclosure and non-competition agreements, or similar agreements, in connection with such previous employment.
Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of
others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property,
including trade secrets or other proprietary information, of any such individual’s current or former employer. Litigation may be
necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we
may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be
awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or
products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in
defending against such claims, litigation could result in substantial costs and be a distraction to management. Any of the
foregoing may have a material adverse effect on our business, financial condition, results of operations and prospects.
In addition, while it is our policy to require our employees and contractors who may be involved in the conception or
development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful
in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our
own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached,
and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the
ownership of what we regard as our intellectual property.
64
If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may
be materially harmed.
Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop,
one or more of our owned or in-licensed U.S. patents may be eligible for limited patent term extension under the Drug Price
Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments
permit a patent term extension of up to five years as compensation for the patent term lost during the FDA regulatory review
process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of
product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or
a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing
to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines,
failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the
applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent
term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing
products following our patent expiration, and our business, financial condition, results of operations and prospects could be
materially harmed.
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee
payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or
eliminated for non-compliance with these requirements.
Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and patent applications will
be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our
owned or licensed patents and applications. In certain circumstances, we rely on our licensing partners to pay these fees due to
U.S. and non-U.S. patent agencies. The USPTO and various non-U.S. government agencies require compliance with several
procedural, documentary, fee payment and other similar provisions during the patent application process. We are also dependent
on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual
property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the
applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or
patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential
competitors might be able to enter the market with similar or identical products or technology, which could have a material
adverse effect on our business, financial condition, results of operations and prospects.
Intellectual property rights do not necessarily address all potential threats.
The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have
limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:
•
others may be able to make ADC products that are similar to any product candidates we may develop or utilize similar
ADC-related technology but that are not covered by the claims of the patents that we license or may own in the future;
• we, or our license partners or current or future strategic collaborators, might not have been the first to make the
inventions covered by the issued patent or pending patent application that we license or may own in the future;
• we, or our license partners or current or future strategic collaborators, might not have been the first to file patent
applications covering certain of our or their inventions;
•
•
•
•
others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our owned or licensed intellectual property rights;
it is possible that our pending licensed patent applications or those that we may own in the future will not lead to
issued patents;
issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by
our competitors;
our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in our major
commercial markets;
65
• we may not develop additional proprietary technologies that are patentable;
•
the patents of others may harm our business; and
• we may choose not to file a patent in order to maintain certain trade secrets or know how, and a third party may
subsequently file a patent covering such intellectual property.
Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of
operations and prospects.
Risks Related to Regulatory Approval and Other Legal Compliance Matters
Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time
consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our
product candidates. As a result, we cannot predict when or if, and in which territories, we will obtain marketing approval to
commercialize a product candidate.
The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of products are subject
to extensive regulation by the FDA and comparable foreign regulatory authorities. We are not permitted to market our product
candidates in the United States or in other countries until we receive approval of a biologics license application, or BLA, from
the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in
various stages of development and are subject to the risks of failure inherent in development. We have not submitted an
application for or received marketing approval for any of our product candidates in the United States or in any other
jurisdiction. While we have announced that we expect data from our UPLIFT clinical trial of UpRi in mid-2023 which, if
positive, we expect would support our submission of a BLA for UpRi for the treatment of platinum-resistant ovarian cancer
under the FDA's accelerated approval pathway around the end of 2023, there can be no guarantee that these data will be
positive or sufficient to support approval of UpRi by the FDA. Additionally, we have no experience as a company in filing and
supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this
process.
The process of obtaining marketing approvals, both in the United States and abroad, is lengthy, expensive and uncertain. It may
take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type,
complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of extensive
preclinical and clinical data and supporting information, including manufacturing information, to regulatory authorities for each
therapeutic indication to establish the product candidate’s safety and efficacy. The FDA or other regulatory authorities may
determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended
side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial
use.
In addition, changes in marketing approval policies during the development period, changes in or the enactment or
promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product
application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in
the approval process and varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or
prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to
restrictions or post-approval commitments that render the approved product not commercially viable.
Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed
abroad. Any approval we may be granted for our product candidates in the United States would not assure approval of our
product candidates in foreign jurisdictions and any of our product candidates that may be approved for marketing in a
foreign jurisdiction will be subject to risks associated with foreign operations.
66
We intend to market our current product candidates, UpRi, XMT-1660 and XMT-2056, if approved, in international markets
either directly or through collaborations. In order to market and sell our products in the European Union and other foreign
jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements.
The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may
differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States
generally includes all of the risks associated with obtaining FDA approval. We may not obtain approvals from regulatory
authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory
authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure
approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may file for marketing approvals but
not receive necessary approvals to commercialize our products in any market.
In many countries outside the United States, a product candidate must also be approved for reimbursement before it can be sold
in that country. In some cases, the price that we intend to charge for our products, if approved, is also subject to approval.
Obtaining non-U.S. regulatory approvals and compliance with non-U.S. regulatory requirements could result in significant
delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. In
addition, if we fail to obtain the non-U.S. approvals required to market our product candidates outside the United States or if we
fail to comply with applicable non-U.S. regulatory requirements, our target markets will be reduced and our ability to realize
the full market potential of our product candidates will be harmed and our business, financial condition, results of operations
and prospects may be adversely affected.
In addition, following the result of a referendum in 2016, the United Kingdom left the European Union on January 31, 2020,
commonly referred to as Brexit. After lapse of a transition period, the United Kingdom is no longer part of the European Single
Market and European Union Customs Union as of January 1, 2021. A trade and cooperation agreement that outlined the future
trading relationship between the United Kingdom and the European Union was agreed to in December 2020 and entered into
force on May 1, 2021. As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or the MHRA,
became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales
under domestic law, whereas Northern Ireland will continue to be subject to EU rules under the Northern Ireland Protocol. The
MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for
regulating medicines. The HMR has incorporated into the domestic law of the body of EU law instruments governing medicinal
products that pre-existed prior to the United Kingdom’s withdrawal from the European Union.
Since a significant proportion of the regulatory framework for pharmaceutical products in the United Kingdom covering the
quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and
distribution of pharmaceutical products is derived from EU directives and regulations, Brexit may have a material impact upon
the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our
product candidates in the United Kingdom. For example, the United Kingdom is no longer covered by the centralized
procedures for obtaining EU-wide marketing authorization from the EMA, and a separate marketing authorization will be
required to market our product candidates in the United Kingdom. Until December 31, 2023, it is possible for the MHRA to
rely on a decision taken by the European Commission on the approval of a new marketing authorization via the centralized
procedure. However, it is unclear whether the MHRA in the United Kingdom is sufficiently prepared to handle the increased
volume of marketing authorization applications that it is likely to receive after such time. Any delay in obtaining, or an inability
to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory
approval in the United Kingdom for our product candidates, which could significantly and materially harm our business.
We expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing
approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including
inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration
and labor laws for employees living or traveling abroad; foreign currency fluctuations, which could result in increased
operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce
uncertainty in countries where labor unrest is more common than in the United States.
Any product candidate for which we obtain marketing approval is subject to ongoing regulation and could be subject to
restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with
regulatory requirements, when and if any of our product candidates are approved.
Any product candidate for which we obtain marketing approval will be subject to continual requirements of and review by the
FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information
and reports, registration and listing requirements, cGMP requirements relating to quality control and manufacturing, quality
67
assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to
physicians and recordkeeping. In addition, the approval may be subject to limitations on the indicated uses for which the
product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and
surveillance to monitor the safety or efficacy of the medicine, including the requirement to implement a risk evaluation and
mitigation strategy. Accordingly, if we receive marketing approval for one or more of our product candidates, we will continue
to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product
surveillance and quality control. If we fail to comply with these requirements, we could have the marketing approvals for our
products withdrawn by regulatory authorities and our ability to market any products could be limited, which could adversely
affect our ability to achieve or sustain profitability.
We must also comply with requirements concerning advertising and promotion for any of our product candidates for which we
obtain marketing approval. Promotional communications with respect to prescription products are subject to a variety of legal
and regulatory restrictions and must be consistent with the information in the product’s approved labeling. Thus, we will not be
able to promote any products we develop for indications or uses for which they are not approved. The FDA and other agencies,
including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to
ensure that they are marketed and distributed only for the approved indications and in accordance with the provisions of the
approved labeling. In September 2021, the FDA published final regulations which describe the types of evidence that the
agency will consider in determining the intended use of a drug or biologic. Moreover, with passage of the Pre-approval
Information Exchange Act in December 2022, sponsors of products that have not been approved may proactively communicate
to payors certain information about products in development to help expedite patient access upon product approval. Violations
of the Federal Food, Drug, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and
advertising of prescription products may lead to investigations and enforcement actions alleging violations of federal and state
health care fraud and abuse laws, as well as state consumer protection laws.
Failure to comply with regulatory requirements, may yield various results, including:
•
•
•
•
restrictions on such products, manufacturers or manufacturing processes;
restrictions on the labeling or marketing of a product;
restrictions on distribution or use of a product;
requirements to conduct post-marketing studies or clinical trials;
• warning letters or untitled letters;
• withdrawal of the products from the market;
•
•
•
•
•
•
•
•
•
•
refusal to approve pending applications or supplements to approved applications that we submit;
recall of products;
damage to relationships with collaborators;
unfavorable press coverage and damage to our reputation;
fines, restitution or disgorgement of profits or revenues;
suspension or withdrawal of marketing approvals;
refusal to permit the import or export of our products;
product seizure;
injunctions or the imposition of civil or criminal penalties; and
litigation involving patients using our products.
68
Similar restrictions apply to the approval of our products in the European Union. The holder of a marketing authorization is
required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal
products. These include compliance with the European Union’s stringent pharmacovigilance or safety reporting rules, which
can impose post-authorization studies and additional monitoring obligations; the manufacturing of authorized medicinal
products, for which a separate manufacturer’s license is mandatory; and the marketing and promotion of authorized drugs,
which are strictly regulated in the European Union and are also subject to EU Member State laws.
Accordingly, in connection with our currently approved products and assuming we, or our collaborators, receive marketing
approval for one or more of our product candidates, we, and our collaborators, and our and their contract manufacturers will
continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product
surveillance and quality control. If we, and our collaborators, are not able to comply with post-approval regulatory
requirements, our or our collaborators’ ability to market any future products could be limited, which could adversely affect our
ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative
effect on our operating results and financial condition.
We may seek certain designations for our product candidates, including but not limited to Breakthrough Therapy, Fast
Track and Priority Review designations in the United States, and PRIME Designation in the European Union, but we might
not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory
review or approval process.
We have in the past sought and may also in the future seek certain designations for one or more of our product candidates that
could expedite review and approval by the FDA. A Breakthrough Therapy product is defined as a product that is intended, alone
or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that
the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints,
such as substantial treatment effects observed early in clinical development. For products that have been designated as
Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the
most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.
The FDA may also designate a product for Fast Track review if it is intended, whether alone or in combination with one or
more other products, for the treatment of a serious or life threatening disease or condition, and it demonstrates the potential to
address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions
with the FDA and the FDA may initiate review of sections of a Fast Track product’s application before the application is
complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by
the sponsor, that a Fast Track product may be effective. The FDA has granted Fast Track designation for UpRi for the treatment
of patients with platinum-resistant high-grade serous ovarian cancer who have received up to three prior lines of systemic
therapy or patients who have received four prior lines of systemic therapy regardless of platinum status, and the FDA has
granted Fast Track designation for XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative
breast cancer.
We may also seek a priority review designation for one or more of our product candidates. If the FDA determines that a product
candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate
the product candidate for priority review. A priority review designation means that the goal for the FDA to review an
application is six months, rather than the standard review period of ten months.
These designations are within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates
meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. Further,
even if we receive a designation, the receipt of such designation for a product candidate may not result in a faster development
or regulatory review or approval process compared to products considered for approval under conventional FDA procedures
and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualifies for these
designations, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide
that the time period for FDA review or approval will not be shortened.
In the European Union, we may seek PRIME designation for our product candidates in the future. PRIME is a voluntary
program aimed at enhancing the EMA’s role to reinforce scientific and regulatory support in order to optimize development and
enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet
medical needs. The program focuses on medicines that target conditions for which there exists no satisfactory method of
treatment in the European Union or even if such a method exists, it may offer a major therapeutic advantage over existing
treatments. PRIME is limited to medicines under development and not authorized in the European Union and the applicant
intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME,
69
a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation
based on information that is capable of substantiating the claims.
The benefits of a PRIME designation include the appointment of a CHMP rapporteur to provide continued support and help to
build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development
milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on
approvability to be issued earlier in the application process. PRIME enables an applicant to request parallel EMA scientific
advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME designation for
any of our product candidates, the designation may not result in a materially faster development process, review or approval
compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of
EMA’s grant of a marketing authorization.
We have received orphan drug designations for XMT-2056 and UpRi, but we may not be able to obtain orphan drug
exclusivity for any additional product candidates, and even if we do, that exclusivity may not prevent the FDA or EMA from
approving other competing products.
Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a
rare disease or condition. A similar regulatory scheme governs approval of orphan products by the EMA in the European Union.
Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the
indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the
FDA or EMA from approving another marketing application for the same product for the same therapeutic indication for that
time period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity
period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation,
in particular if the product is sufficiently profitable so that market exclusivity is no longer justified.
In order for the FDA to grant orphan drug exclusivity to one of our products, the agency must find that the product is indicated
for the treatment of a condition or disease with a patient population of fewer than 200,000 individuals annually in the United
States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this
standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from
competition because different products can be approved for the same condition. In particular, the concept of what constitutes
the “same drug” for purposes of orphan drug exclusivity remains in flux in the context of gene therapies, and the FDA issued
final guidance suggesting that it would not consider two genetic medicine products to be different drugs solely based on minor
differences in the transgenes or vectors within a given vector class. In addition, even after an orphan drug is approved, the FDA
can subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically
superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity
may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer
is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition. In May
2022, the FDA granted orphan drug designation to XMT-2056 for the treatment of patients with gastric cancer, and in
December 2022, the European Commission granted orphan medicinal product designation to UpRi for the treatment of ovarian
cancer, but we may not be able to obtain orphan drug exclusivity for any additional product candidates in the future.
In 2017, Congress passed FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA’s pre-
existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is
otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. Under
Omnibus legislation signed by President Trump on December 27, 2020, the requirement for a product to show clinical
superiority applies to drugs and biologics that received orphan drug designation before enactment of FDARA in 2017 but have
not yet been approved or licensed by the FDA.
The FDA and Congress may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly
true in light of a decision from the Court of Appeals for the 11th Circuit in September 2021 finding that, for the purpose of
determining the scope of exclusivity, the term “same disease or condition” means the designated “rare disease or condition” and
could not be interpreted by the FDA to mean the “indication or use.” The court concluded that orphan drug exclusivity applies
to the entire designated disease or condition rather than the “indication or use.” Although there have been legislative proposals
to overrule this decision, they have not been enacted into law. On January 23, 2023, the FDA announced that, in matters beyond
the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or
indications for which the orphan drug was approved. We do not know if, when, or how the FDA or Congress may change the
orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on
what changes the FDA may make to its orphan drug regulations and policies, we may lose any expected benefits of the orphan
drug designation we have received for XMT-2056, and our business could be adversely impacted.
70
Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other
disruptions to these agencies’ operations, could hinder their ability to hire and retain key leadership and other personnel,
prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those
agencies from performing normal business functions on which the operation of our business may rely, which could
negatively impact our business.
The ability of the FDA to review and approve new products can be affected by a variety of factors, including government
budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory
and policy changes. Average review times at the agency have fluctuated in recent years as a result. Disruptions at the FDA and
other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary
government agencies, which would adversely affect our business. In addition, government funding of the SEC and other
government agencies on which our operations may rely, including those that fund research and development activities, is
subject to the political process, which is inherently fluid and unpredictable.
Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or
approved by necessary government agencies, which would adversely affect our business. For example, over the last several
years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had
to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government
shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions,
which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to
access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.
Separately, in response to the COVID-19 pandemic, a number of companies announced receipt of complete response letters due
to the FDA’s inability to complete required inspections for their applications. As of May 26, 2021, the FDA noted it was
continuing to ensure timely reviews of applications for medical products during the ongoing COVID-19 pandemic in line with
its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of
manufacturing facilities with FDA quality standards. However, the FDA may not be able to continue its current pace and review
timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to
the ongoing COVID-19 pandemic and travel restrictions, the FDA is unable to complete such required inspections during the
review period. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in
response to the COVID-19 pandemic and may experience delays in their regulatory activities.
On January 30, 2023, the Biden Administration announced that it will end the public health emergency declarations related to
COVID-19 on May 11, 2023. On January 31, 2023, the FDA indicated that it would soon issue a Federal Register notice
describing how the termination of the public health emergency will impact the agency’s COVID-19 related guidance, including
the clinical trial guidance and updates thereto. At this point, it is unclear how, if at all, these developments will impact our
efforts to develop and commercialize our product candidates. If a prolonged government shutdown or other disruption occurs, it
could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a
material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such
as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary,
and our ability to access the public markets.
We are currently conducting clinical trials for UpRi, and may conduct future clinical trials for our other product candidates,
at sites outside of the United States. The FDA may not accept data from trials conducted in such locations, or the complexity
of regulatory burdens may otherwise adversely impact us.
We are currently conducting clinical trials for UpRi outside of the United States, and we plan to continue to conduct clinical
trials for UpRi and our current and future other product candidates outside of the United States. Although the FDA may accept
data from clinical trials conducted outside the United States, acceptance of these data is subject to conditions imposed by the
FDA. For example, the clinical trial must be well designed and conducted and be performed by qualified investigators in
accordance with GCPs. If the foreign data is the sole basis for a marketing application, then the data must be applicable to the
U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful and the FDA must be able to
validate the data through an on-site inspection, if necessary. In addition, while these clinical trials are subject to the applicable
local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S.
laws and regulations. If the FDA does not accept the data from any clinical trial that we conduct outside the United States, it
would likely result in the need for additional clinical trials, which would be costly and time-consuming and could delay or
permanently halt our development of the applicable product candidates.
71
Our ability to successfully initiate, enroll and complete a clinical trial in any country outside of the United States is subject to
numerous additional risks unique to conducting business in jurisdictions outside the United States, including:
•
•
•
•
•
•
•
•
•
difficulty in establishing or managing relationships with qualified CROs, physicians and clinical trial sites;
different local standards for the conduct of clinical trials;
difficulty in complying with various and complex import laws and regulations when shipping drug to certain countries;
the potential burden of complying with a variety of laws, medical standards and regulatory requirements, including the
regulation of pharmaceutical and biotechnology products and treatments;
lack of consistency in standard of care from country to country;
diminished protection of intellectual property in some countries;
foreign exchange fluctuations;
cultural differences in medical practice and clinical research; and
changes in country or regional regulatory requirements.
Furthermore, the ongoing COVID-19 pandemic and the current conflict between Russia and Ukraine may also have an impact
on our ability to successfully conduct trials outside of the United States. For example, we are conducting UPLIFT in countries
where clinical trial site staff continue to be diverted to care for COVID-19 patients and where regulatory authorities are short
staffed, due in part to continuing impacts of the COVID-19 pandemic. Additionally, we do business with a CRO that has had
employees and operations in Ukraine that have been adversely impacted by Russian hostilities, though such employees and
operations are not directly involved with our clinical trials. If we have difficulty conducting our clinical trials in jurisdictions
outside the United States as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which
could have a material adverse effect on our business.
Accelerated approval by the FDA, even if granted for UpRi or any other current or future product candidates, may not lead
to a faster development or regulatory review or approval process and it does not increase the likelihood that our product
candidates will receive marketing approval.
We intend to seek approval of UpRi and may seek approval any of our other current and future product candidates using the
FDA’s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious or life-threatening
condition, generally provides a meaningful advantage over available therapies, and demonstrates an effect on a surrogate
endpoint that is reasonably likely to predict clinical benefit. The FDA or other applicable regulatory agency makes the
determination regarding whether a surrogate endpoint is reasonably likely to predict long-term clinical benefit.
Prior to seeking such accelerated approval, we will seek feedback from the FDA and otherwise evaluate our ability to seek and
receive such accelerated approval. As a condition of approval, the FDA requires that a sponsor of a product receiving
accelerated approval perform an adequate and well-controlled post-marketing confirmatory clinical trial or trials. These
confirmatory trials must be completed with due diligence and we may be required to evaluate different or additional endpoints
in these post-marketing confirmatory trials. These confirmatory trials may require enrollment of more patients than we
currently anticipate and will result in additional costs, which may be greater than the estimated costs we currently anticipate. In
addition, the FDA currently requires as a condition for accelerated approval preapproval of promotional materials, which could
adversely impact the timing of the commercial launch of the product.
There can be no assurance that the FDA will agree with any proposed surrogate endpoints or that we will decide to pursue or
submit an BLA for accelerated approval or any other form of expedited development, review or approval for UpRi or any of our
other current or future product candidates. Similarly, there can be no assurance that, after feedback from FDA, we will continue
to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially
decide to do so. Furthermore, if we decide to submit an application for accelerated approval or under another expedited
regulatory designation, there can be no assurance that such submission or application will be accepted or that any expedited
review or approval will be granted on a timely basis, or at all.
72
The FDA may withdraw approval of a product candidate approved under the accelerated approval pathway if, for example, the
trial required to verify the predicted clinical benefit of our product candidate fails to verify such benefit or does not demonstrate
sufficient clinical benefit to justify the risks associated with the drug. The FDA may also withdraw approval if other evidence
demonstrates that our product candidate is not shown to be safe or effective under the conditions of use, we fail to conduct any
required post approval trial of our product candidate with due diligence or we disseminate false or misleading promotional
materials relating to our product candidate. A failure to obtain accelerated approval or any other form of expedited
development, review or approval for our product candidates, or withdrawal of a product candidate, would result in a longer time
period for commercialization of such product candidate, could increase the cost of development of such product candidate and
could harm our competitive position in the marketplace.
With passage of the Food and Drug Omnibus Reform Act, or FDORA, in December 2022, Congress modified certain
provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA
to: require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded, require a sponsor
of a product granted accelerated approval to submit progress reports on its post-approval studies to the FDA every six months
until the study is completed; and use expedited procedures to withdraw accelerated approval of a new drug application or BLA
after the confirmatory trial fails to verify the product’s clinical benefit. Further, FDORA requires the agency to publish on its
website “the rationale for why a post-approval study is not appropriate or necessary” whenever it decides not to require such a
study upon granting accelerated approval.
Accordingly, even if we do receive accelerated approval, we may not experience a faster development or regulatory review or
approval process, and receiving accelerated approval does not provide assurance of ultimate full FDA approval.
If we or our third-party collaborators are unable to successfully develop and commercialize any required companion
diagnostics or appropriate complementary diagnostics for our product candidates or to engage a third party to do so, or we
or they experience significant delays in doing so, we may not realize the full potential of our product candidates.
We expect that that a companion or complementary diagnostic may be necessary in connection with UpRi, and a companion or
complementary diagnostic may be necessary in connection with any of our other current or future product candidates. If a
companion diagnostic is required for the label of any of our product candidates, our ability to market such product candidates
will be conditioned on the commercial availability of an approved companion diagnostic. Similarly, if a complementary
diagnostic is necessary for any of our product candidates, we may not realize the full potential of such product candidates if
such complementary diagnostic is not available.
We may seek approval for any such companion diagnostic or complementary diagnostic, or we may contract with third parties
to create and obtain approval for a companion or complementary diagnostic, including our NaPi2b assay. To be successful in
developing and commercializing such a companion or complementary diagnostic, we need to address a number of scientific,
technical and logistical challenges. We have little experience in the development and commercialization of companion or
complementary diagnostics and may not be successful in developing and commercializing either our NaPi2b assay or any other
appropriate companion or complementary diagnostics to pair with UpRi or any of our other current or future product
candidates. Companion and complementary diagnostics are subject to regulation by the FDA and equivalent foreign regulatory
authorities as medical devices and require separate regulatory approval prior to commercialization. Given our limited
experience in developing diagnostics, we will rely in part or in whole on third parties for their design, manufacture and
commercialization. We, our collaborators or such third parties may encounter difficulties in developing and obtaining approval
for the companion or complementary diagnostics, including issues relating to selectivity/specificity, analytical validation,
reproducibility or clinical validation. Any delay or failure by us, our collaborators or such third parties to develop or obtain
regulatory approval of the companion or complementary diagnostics could delay or prevent approval or limit our ability to
recognize the full potential of our product candidates. If we, or any third parties that we may contract with to assist us, are
unable to successfully develop and commercialize companion or complementary diagnostics for our product candidates, or
experience delays in doing so:
•
our product candidates may not receive marketing approval if safe and effective use of a product candidate depends on
the availability of a companion diagnostic and such diagnostic is not commercially available or otherwise approved or
cleared by the appropriate regulatory authority; and
• we may not realize the full commercial potential of any product candidates that receive marketing approval if, among
other reasons, we are unable to appropriately select patients who are likely to benefit from therapy with our products,
if approved.
73
If any of these events were to occur, our business would be harmed, possibly materially.
In addition, third-party collaborators may encounter production difficulties that could constrain the supply of the companion or
complementary diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion
diagnostics or complementary in the clinical community. If such companion or complementary diagnostics fail to gain market
acceptance, it would have an adverse effect on our ability to derive revenues from sales of our product candidates, if approved.
In addition, any diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion
diagnostic or complementary that we anticipate using in connection with development and commercialization of our product
candidates or our relationship with such diagnostic company may otherwise terminate. Additionally, we may need to enter into
contracts with more than one third party in order to gain widespread availability and acceptance of any companion or
complementary diagnostic. We may not be able to enter into arrangements with another or additional diagnostic company to
obtain supplies of additional or an alternative diagnostic test for use in connection with the development and commercialization
of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the
development or commercialization of our product candidates.
Our activities, including our interactions with healthcare providers, third party payors, patients and government officials,
are, and will continue to be, subject to extensive regulation involving health care, anti-corruption, data privacy and security
and consumer protection laws. Failure to comply with applicable laws could result in substantial penalties, contractual
damages, reputational harm, diminished revenues and curtailment or restructuring of our operations.
Our activities may now or in the future be directly or indirectly subject to various federal and state laws related to health care,
anti-corruption, data privacy and security consumer protection. If we obtain FDA approval for any of our product candidates
and begin commercializing those products in the United States, our potential exposure under such laws will increase
significantly, and our costs associated with compliance with such laws are also likely to increase. These laws include, but are
not limited to:
•
•
•
•
•
•
•
•
federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person
from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly
making, or causing to be made, a false statement to get a false claim paid;
the federal anti-kickback law, which prohibits, among other things, persons from offering, soliciting, receiving or
providing any remuneration, directly or indirectly, to induce, either the referral of an individual for, or the purchasing
or ordering of a good or service, for which payment may be made under federal health care programs such as the
Medicare and Medicaid;
the federal anti-kickback prohibition known as Eliminating Kickbacks in Recovery Act, enacted in 2018, which
prohibits certain payments related to referrals of patients to certain providers (recovery homes, clinical treatment
facilities and laboratories) and applies to services reimbursed by private health plans as well as government health care
programs;
the federal law known as Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, in addition to
privacy protections to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare
benefit program (which may include private health plans) or making false statements relating to healthcare matters;
the Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug marketing, prohibits
manufacturers from marketing such products for off-label use and regulates the distribution of samples;
federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or
provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement
under government healthcare programs;
the so-called “federal sunshine” law, which requires pharmaceutical and medical device companies to monitor and
report certain financial interactions with teaching hospitals, physicians and certain non-physician practitioners to the
federal government for re-disclosure to the public;
the privacy, security and breach provisions of HIPAA, which impose obligations on certain “covered entities”
(healthcare providers, health plans and healthcare clearinghouses) and certain of their “business associate” contractors
with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
74
•
•
•
•
federal and state laws and regulations, including state security breach notification laws, state health information
privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure and protection of
health-related and other personal information.
federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities
that potentially harm consumers;
the Foreign Corrupt Practices Act, or FCPA, a United States law which regulates certain financial relationships with
foreign government officials (which could include, for example, certain medical professionals); and
state law analogues of each of the above federal laws, such as anti-kickback and false claims laws which may apply to
items or services reimbursed by any third-party payor, including private health plans, state privacy laws, state
consumer protection laws, and state laws regulating interactions between pharmaceutical manufacturers and healthcare
providers, requiring disclosure of such financial interactions or mandating adoption of certain compliance standards,
many of which differ from each other in significant ways and often are not preempted by federal laws, thus
complicating compliance efforts.
In addition, the regulatory approval and commercialization of any of our product candidates outside the United States will also
likely subject us to foreign equivalents of the health care laws mentioned above, among other foreign laws. Efforts to ensure
that our business arrangements will comply with applicable health care laws may involve substantial costs. It is possible that
governmental and enforcement authorities will conclude that our business practices may not comply with current or future
statutes, regulations or case law interpreting applicable fraud and abuse or other health care laws and regulations. If our
operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to
us, we may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages,
monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal health care
programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of
our operations.
Current and future legislation may increase the difficulty and cost for us to obtain reimbursement for our product
candidates.
In the United States and some foreign jurisdictions, there have been and continue to be a number of legislative and regulatory
changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing
approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any
products for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that
may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price
that we may receive for any approved products. If reimbursement of our products is unavailable or limited in scope, our
business could be materially harmed.
In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health
Care and Education Affordability Reconciliation Act, collectively the ACA. In addition, other legislative changes have been
proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created
measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a
targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby
triggering the legislation’s automatic reduction to several government programs. These changes included aggregate reductions
to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect
through 2031 under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. These Medicare sequester
reductions were suspended and reduced through the end of June 2022, with the full 2% cut resuming thereafter. The American
Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of
limitations period for the government to recover overpayments to providers from three to five years. These laws may result in
additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our
products or product candidates for which we may obtain regulatory approval or the frequency with which any such product is
prescribed or used.
Since enactment of the ACA, there have been and continue to be, numerous legal challenges and Congressional actions to
repeal and replace provisions of the law. For example, with enactment of the Tax Cuts for Jobs Act, or the Tax Act, in 2017,
Congress repealed the “individual mandate.” The repeal of this provision, which requires most Americans to carry a minimal
level of health insurance, became effective in 2019. Further, on December 14, 2018, a U.S. District Court judge in the Northern
District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA and
75
therefore because the mandate was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. The
U.S. Supreme Court heard this case on November 10, 2020 and on June 17, 2021, dismissed this action after finding that the
plaintiffs do not have standing to challenge the constitutionality of the ACA. Litigation and legislation over the ACA are likely
to continue, with unpredictable and uncertain results.
The Trump Administration also took executive actions to undermine or delay implementation of the ACA, including directing
federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from or delay the
implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare
providers, health insurers or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President
Biden revoked those orders and issued a new Executive Order which directs federal agencies to reconsider rules and other
policies that limit Americans’ access to health care and consider actions that will protect and strengthen that access. Under this
order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions,
including complications related to COVID-19; demonstrations and waivers under Medicaid and the ACA that may reduce
coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace
or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the ACA; and policies that
reduce affordability of coverage or financial assistance, including for dependents.
We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may
result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment
methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of
reimbursement physicians receive for administering any approved product we might bring to market. Reductions in
reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or
administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction
in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue
from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our
overall financial condition and ability to develop or commercialize product candidates.
The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable
legislative and executive actions and could impact the prices we obtain for our products, if and when licensed.
The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There
have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to,
among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and
manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020, President
Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders
have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation
model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest
price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a
nationwide preliminary injunction and, on December 29, 2021, the Center for Medicare & Medicaid Services, or CMS, issued a
final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments
for Medicare Part B pharmaceuticals and improve beneficiaries' access to evidence-based care.
In addition, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section
804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. The final rule is
currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New
Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review
and approval by the FDA. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for
price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit
managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden
administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe
harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements
between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed by the Biden
administration until January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price
reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy
benefit managers and manufacturers, the implementation of which has been delayed under January 1, 2026, by the
Infrastructure Investment and Jobs Act.
On July 9, 2021, President Biden signed Executive Order 14063, which focuses on, among other things, the price of
pharmaceuticals. The order directs the Department of Health and Human Services, or HHS, to create a plan within 45 days to
76
combat “excessive pricing of prescription pharmaceuticals and enhance domestic pharmaceutical supply chains, to reduce the
prices paid by the federal government for such pharmaceuticals, and to address the recurrent problem of price gouging.” On
September 9, 2021, HHS released its plan to reduce pharmaceutical prices. The key features of that plan are to: (a) make
pharmaceutical prices more affordable and equitable for all consumers and throughout the health care system by supporting
pharmaceutical price negotiations with manufacturers; (b) improve and promote competition throughout the prescription
pharmaceutical industry by supporting market changes that strengthen supply chains, promote biosimilars and generic drugs,
and increase transparency; and (c) foster scientific innovation to promote better healthcare and improve health by supporting
public and private research and making sure that market incentives promote discovery of valuable and accessible new
treatments.
More recently, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law by President Biden. The
new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare
Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug
coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare
(beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare
Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount
program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and
Human Service, or HHS, to implement many of these provisions through guidance, as opposed to regulation, for the initial
years.
Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly
single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare
Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by
15 additional Medicare Part D drugs in 2027, 15 additional Medicare Part B or Part D drugs in 2028, and 20 additional
Medicare Part B or Part D drugs per year in 2029 and beyond. This provision applies to drug products that have been approved
for at least nine years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have
been approved for a single rare disease or condition. Nonetheless, since CMS may establish a maximum price for these
products in price negotiations, we would be fully at risk of government action if our products are the subject of Medicare price
negotiations. Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that
we would not be able to achieve the expected return on any of our product candidates, if approved, or the full value of our
patents protecting any such approved drug products if prices are set after any such approved products have been on the market
for nine years.
Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply
with the legislation by offering a price that is not equal to or less than the negotiated “maximum fair price” under the law or for
taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare
Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000
a year in 2024 and, thereafter beginning in 2025, at $2,000 a year. In addition, the IRA potentially raises legal risks with respect
to individuals participating in a Medicare Part D prescription drug plan who may experience a gap in coverage if they required
coverage above their initial annual coverage limit before they reached the higher threshold, or “catastrophic period” of the plan.
Individuals requiring services exceeding the initial annual coverage limit and below the catastrophic period, must pay 100% of
the cost of their prescriptions until they reach the catastrophic period. Among other things, the IRA contains many provisions
aimed at reducing this financial burden on individuals by reducing the co-insurance and co-payment costs, expanding eligibility
for lower income subsidy plans, and price caps on annual out-of-pocket expenses, each of which could have potential pricing
and reporting implications. Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with
certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent
regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely
affect our business, results of operations and financial condition.
At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to
control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts,
restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to
encourage importation from other countries and bulk purchasing. In addition, regional healthcare organizations and individual
hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be
included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our
products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform
measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for
healthcare products and services, which could result in reduced demand for our product candidates or additional pricing
pressures.
77
In the European Union, similar political, economic and regulatory developments may affect our ability to profitably
commercialize our product candidates, if approved. In markets outside of the United States and the European Union,
reimbursement and healthcare payment systems vary significantly by country and many countries have instituted price ceilings
on specific products and therapies. In many countries, including those of the European Union, the pricing of prescription
pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental
authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing
approval in some countries, we or our collaborators may be required to conduct a clinical trial that compares the cost-
effectiveness of our product to other available therapies. If reimbursement of our products is unavailable or limited in scope or
amount or if pricing is set at unsatisfactory levels, our business could be materially harmed.
We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related
to data privacy and security, and a failure to comply with such requirements could subject us to significant fines and
penalties, which may have a material adverse effect on our business, financial condition or results of operations.
We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of
personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and
transmission of personal information, including comprehensive regulatory systems in the United States, European Union and
United Kingdom. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions
worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our
business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including
fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our
reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results
of operations or prospects.
There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In
particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure
of individually identifiable health information, or protected health information, and require the implementation of
administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the
confidentiality, integrity and availability of electronic protected health information. Determining whether protected health
information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex
and may be subject to changing interpretation. These obligations may be applicable to some or all of our business activities now
or in the future.
If we are unable to properly protect the privacy and security of protected health information, we could be found to have
breached our contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and
security standards, we could face civil and criminal penalties. HHS enforcement activity can result in financial liability and
reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state
attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that
threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our
operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing
efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing
modifications to our policies, procedures and systems.
Similar to the laws in the United States, there are significant privacy and data security laws that apply in Europe and other
countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data,
regarding individuals who are located in the European Economic Area, or the EEA, and the processing of personal data that
takes place in the EEA, is regulated by the General Data Protection Regulation, or GDPR, which went into effect in May 2018
and which imposes obligations on companies that operate in our industry with respect to the processing of personal data and the
cross-border transfer of such data. The GDPR imposes onerous accountability obligations requiring data controllers and
processors to maintain a record of their data processing and policies. If our or our collaborators’ or service providers’ privacy or
data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations,
enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of
the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by
affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.
The GDPR places restrictions on the cross-border transfer of personal data from the European Union to countries that have not
been found by the European Commission to offer adequate data protection legislation, such as the United States. There are
ongoing concerns about the ability of companies to transfer personal data from the European Union to other countries. In July
78
2020, the Court of Justice of the European Union, or the CJEU, invalidated the EU-U.S. Privacy Shield, one of the mechanisms
used to legitimize the transfer of personal data from the EEA to the United States. The CJEU decision also drew into question
the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data
from the EEA to the United States. While we were not self-certified under the Privacy Shield, this CJEU decision may lead to
increased scrutiny on data transfers from the EEA to the United States generally and increase our costs of compliance with data
privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors and
business partners.
Laws and regulations governing any international operations we may have in the future may preclude us from developing,
manufacturing and selling certain products outside of the United States and require us to develop and implement costly
compliance programs.
If we further expand our operations outside the United States, we will need to dedicate additional resources to comply with U.S.
laws regarding international operations and the laws and regulations in each jurisdiction in which we operate and plan to
operate. The FCPA prohibits any U.S. individual or business from paying, offering or authorizing payment or offering of
anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any
act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA
also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring
the company to maintain books and records that accurately and fairly reflect all transactions of the company, including
international subsidiaries and to devise and maintain an adequate system of internal accounting controls for international
operations.
Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In
addition, the FCPA presents particular challenges in the pharmaceutical industry because in many countries, hospitals are
operated by the government and doctors and other hospital employees are considered foreign officials. Certain payments to
hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials
and have led to FCPA enforcement actions.
Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States or the sharing
with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and
technical data relating to those products. Further, the provision of benefits or advantages to physicians to induce or encourage
the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the
European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of
E.U. Member States, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and
imprisonment. Payments made to physicians in certain E.U. Member States must be publicly disclosed. Moreover, agreements
with physicians often must be the subject of prior notification and approval by the physician’s employer, his or her competent
professional organization and/or the regulatory authorities of the individual E.U. Member States. These requirements are
provided in the national laws, industry codes or professional codes of conduct applicable in the E.U. Member States. Failure to
comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or
imprisonment.
If we expand our presence outside of the United States , it will require us to dedicate additional resources to comply with these
laws and these laws may preclude us from developing, manufacturing or selling certain products and product candidates outside
of the United States, which could limit our growth potential and increase our development costs. The failure to comply with
laws governing international business practices may result in substantial civil and criminal penalties and suspension or
debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges
for violations of the FCPA’s accounting provisions.
We and our third-party contract manufacturers must comply with environmental, health and safety laws and regulations,
and failure to comply with these laws and regulations could expose us to significant costs or liabilities.
We and our third-party manufacturers are subject to numerous environmental, health and safety laws and regulations, including
those governing laboratory procedures and the use, generation, manufacture, distribution, storage, handling, treatment,
remediation and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological
materials, are involved in certain aspects of our business, and we cannot eliminate the risk of injury or contamination from the
use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In the
event of contamination or injury, or failure to comply with environmental, health and safety laws and regulations, we could be
held liable for any resulting damages and any such liability could exceed our assets and resources. We could also incur
significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.
79
Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our
employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential
liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in
connection with our storage or disposal of biological, hazardous or radioactive materials.
Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur substantial
costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future
laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and
regulations also may result in substantial fines, penalties or other sanctions.
Further, with respect to the operations of our third-party contract manufacturers, it is possible that if they fail to operate in
compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with
our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the
manufacture and supply of our product candidates or products.
Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards
and requirements and insider trading.
We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures
to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have
established, to comply with federal and state healthcare fraud and abuse laws and regulations, to report financial information or
data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the
healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other
abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and
promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also
involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and
serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take
to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us
from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or
regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none
occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights,
those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative
penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other
federal health care programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or
restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of
operations.
Risks Related to our Business and Industry
If we fail to attract and retain senior management and key scientific personnel, we may be unable to successfully develop
our ADC product candidates, conduct our clinical trials and commercialize our ADC product candidates.
Our ability to compete in the highly competitive biotechnology and biopharmaceutical industries depends upon our ability to
attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on members
of our senior management, including Anna Protopapas, our President and Chief Executive Officer. The loss of the services of
any of our senior management could impede the achievement of our research, development and commercialization objectives.
Also, each of these persons may terminate their employment with us at any time. We do not maintain “key person” insurance
for any of our executives or other employees.
Recruiting and retaining qualified scientific, clinical, sales and marketing personnel will also be critical to our success. We
conduct our operations at our facility in Cambridge, Massachusetts, in a region that is headquarters to many other
biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and the
turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.
We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous
pharmaceutical and biotechnology companies for similar personnel. In addition, we rely on consultants and advisors, including
scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our
consultants and advisors may be employed or have commitments under consulting or advisory contracts with other entities that
may limit their availability to us.
80
We may encounter difficulties in managing our growth and expanding our operations successfully.
As we seek to advance our product candidates through clinical trials and commercialization, we will need to expand our
development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these
capabilities for us. As our operations expand, we have needed to and expect that we will continue to need to manage additional
relationships with various strategic collaborators, suppliers and other third parties. Future growth will impose significant added
responsibilities on members of management. Our future financial performance and our ability to commercialize our product
candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end,
we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate additional
management, administrative and, if necessary, sales and marketing personnel. Due to our limited financial resources and the
limited experience of our management team in managing a company with such anticipated growth, we may not be able to
accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing our company or
disrupt our operations.
If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit
commercialization of our ADC product candidates.
We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even
greater risk if we commercialize any products. For example, we may be sued if any product we develop causes, or is perceived
to cause, injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such
product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers
inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state
consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial
liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require
significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:
•
•
injury to our reputation;
decreased demand for our product candidates or products that we may develop;
• withdrawal of clinical trial participants;
•
•
•
•
•
•
•
costs to defend the related litigations;
a diversion of management’s time and our resources;
substantial monetary awards to clinical trial participants or patients;
product recalls, withdrawals or labeling, marketing or promotional restrictions;
loss of revenue;
the inability to commercialize our product candidates; and
a decline in our stock price.
Failure to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product
liability claims could prevent or inhibit the commercialization of products we develop. We currently carry product liability
insurance covering our clinical trials in the amount of $10 million in the aggregate. Although we maintain such insurance, any
claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or
in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various
exclusions, and we may be subject to a product liability claim for which we have no coverage. In such instance, we might have
to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered
by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. If we are unable to obtain
or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims,
it could prevent or inhibit the development and commercial production and sale of our product candidates, which could
adversely affect our business, financial condition, results of operations and prospects.
We may acquire assets or form strategic alliances in the future, and we may not realize the benefits of such acquisitions.
81
We may acquire additional technologies and assets, form strategic alliances or create joint ventures with third parties that we
believe will complement or augment our existing business. If we acquire assets with promising markets or technologies, we
may not be able to realize the benefit of acquiring such assets if we are unable to successfully integrate them with our existing
technologies. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting
from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business.
We cannot be assured that, following any such acquisition, we will achieve the expected synergies to justify the transaction. Our
internal computer systems, or those of our strategic and other third-party collaborators or other contractors or consultants, may
fail or suffer security breaches, which could adversely affect our business, including through material disruptions of our
programs or business operations.
Our internal information technology systems and those of our current or future strategic and other third-party collaborators and
other contractors and consultants are vulnerable to service interruptions or security breaches, including from cyber-attacks,
computer viruses, ransomware, malware, unauthorized access, natural disasters, terrorism, war and telecommunication and
electrical failures. If a failure, accident or security breach were to occur and cause interruptions in our operations or the
operations of those third parties with which we contract, it could result in a material disruption of our programs and our
business operations. We could lose access to our trade secrets or other proprietary information or experience other disruptions,
which could require a substantial expenditure of resources to remedy. For example, the loss of clinical trial data for our product
candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce
the data.
We could also be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release
or loss of information maintained in our information systems and networks, including personal information of our employees or
others. Outside parties may attempt to penetrate our systems or those of the third parties with which we contract or to coerce or
fraudulently induce our employees or employees of such third parties to disclose sensitive information to gain access to our
data. The number and complexity of these threats continue to increase over time. Although we develop and maintain systems
and controls designed to prevent these events from occurring, and we have a process to identify and mitigate threats, such risks
cannot be eliminated. Furthermore, there can be no assurance that we, or those third parties with which we contract, will
promptly detect any such disruption or security breach, if at all. Additionally, the development and maintenance of these
systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to
overcome security measures become more sophisticated. To the extent that any disruption or security breach results in a loss of
or damage to our data or applications or other data or applications relating to our technology or product candidates, or
inappropriate disclosure of confidential or proprietary information, we could incur liabilities, our competitive position and the
market perception of the effectiveness of our security measures could be harmed, our credibility could be damaged and the
further development of our product candidates could be delayed.
Risks Related to Our Common Stock
If our stock price is volatile, our stockholders could incur substantial losses.
Our stock price has been and may continue to be volatile. During the period from February 24, 2020 to February 24, 2023, the
closing price of our common stock ranged from a high of $27.59 per share to a low of $2.84 per share. The market price of
shares of our common stock could be subject to wide fluctuations in response to many risk factors listed in this “Risk Factors”
section, and others beyond our control, including:
•
•
•
•
•
•
•
results and timing of preclinical studies and clinical trials of our current or future product candidates, including UpRi,
XMT-1660 and XMT-2056;
results of clinical trials of our competitors’ products;
failure to adequately protect our trade secrets;
the terms on which we raise additional capital or our ability to raise it;
commencement or termination of any strategic collaboration or licensing arrangement;
regulatory developments, including actions with respect to our products or our competitors’ products;
actual or anticipated fluctuations in our financial condition and operating results;
82
•
•
•
•
•
•
•
•
•
•
•
•
publication of research reports by securities analysts about us or our competitors or our industry;
our failure or the failure of our competitors to meet analysts’ projections or guidance that we or our competitors may
give to the market;
additions and departures of key personnel;
strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic
investments or changes in business strategy;
the passage of legislation or other regulatory developments affecting us or our industry;
changes in the structure of healthcare payment systems;
fluctuations in the valuation of companies perceived by investors to be comparable to us;
sales of our common stock by us (including pursuant to outstanding warrants or through our ATM offering programs),
our insiders or our other stockholders;
speculation in the press or investment community;
announcement or expectation of additional financing efforts;
changes in market conditions for biopharmaceutical stocks; and
changes in general market and economic conditions.
In addition, the stock market has historically experienced significant volatility, particularly with respect to pharmaceutical,
biotechnology and other life sciences company stocks. The volatility of pharmaceutical, biotechnology and other life sciences
company stocks often does not relate to the operating performance of the companies represented by the stock. As a result of this
volatility, stockholders may not be able to sell their common stock at or above the price for which they paid for their shares. As
we operate in a single industry, we are especially vulnerable to these factors to the extent that they affect our industry or our
products, or to a lesser extent our markets. Furthermore, as a result of this volatility, we may not be able to maintain compliance
with listing requirements of the Nasdaq Stock Market. In the past, securities class action litigation has often been initiated
against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and
divert our management’s attention and resources, and could also require us to make substantial payments to satisfy judgments
or to settle litigation.
We do not expect to pay any cash dividends for the foreseeable future.
We do not anticipate that we will pay any cash dividends to holders of our common stock in the foreseeable future. Instead, we
plan to retain any earnings to maintain and expand our operations. In addition, our New Credit Facility contains terms and any
future debt financing arrangement may contain additional terms prohibiting or limiting the amount of dividends that may be
declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price
appreciation, which may never occur, as the only way to realize any return on their investment.
Provisions in our amended and restated certificate of incorporation, as amended, our amended and restated by-laws and
Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition
would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current
management.
Our amended and restated certificate of incorporation, as amended, amended and restated by-laws and Delaware law contain
provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our
management that stockholders may consider favorable, including transactions in which our stockholders might otherwise
receive a premium for their shares. Our amended and restated certificate of incorporation, as amended, and amended and
restated by-laws include provisions that:
83
•
•
•
•
•
•
•
•
•
•
authorize “blank check” preferred stock, which could be issued by our board of directors without stockholder approval
and may contain voting, liquidation, dividend and other rights superior to our common stock;
create a classified board of directors whose members serve staggered three-year terms;
specify that special meetings of our stockholders can be called only by our board of directors;
prohibit stockholder action by written consent;
establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our
stockholders, including proposed nominations of persons for election to our board of directors;
provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even
though less than a quorum;
provide that our directors may be removed only for cause;
specify that no stockholder is permitted to cumulate votes at any election of directors;
expressly authorize our board of directors to have discretion to modify, alter or repeal our amended and restated by-
laws; and
require supermajority votes of the holders of our common stock to amend specified provisions of our amended and
restated certificate of incorporation, as amended, and amended and restated by-laws.
In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section 203 of the
General Corporation Law of the State of Delaware, or the DGCL, which prohibits a person who owns in excess of 15% of our
outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in
which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a
prescribed manner.
Any provision of our amended and restated certificate of incorporation, as amended, amended and restated by-laws or Delaware
law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a
premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our
common stock.
Our ability to use net operating losses and certain tax credit carryforwards may be subject to certain limitations.
For the years ended December 31, 2022, 2021 and 2020, we recorded no income tax benefit for the net operating losses, or
NOLs, incurred in each year, due to the uncertainty of realizing a benefit from those items. We have incurred NOLs since our
inception. As of December 31, 2022 , we have federal NOLs of approximately $432.8 million and state NOLs of approximately
$365.3 million. Of the $432.8 million of federal NOLs, $34.1 million expire at various dates through 2037. The remaining
$398.7 million of federal NOLs do not expire. The state NOLs will expire at various dates through 2042. As of December 31,
2022, we had federal and state research and development tax credit carryforwards of approximately $17.4 million and $5.1
million, respectively, which expire at various dates through 2042. Under the Tax Act, federal NOLs incurred in 2018 and in
future years may be carried forward indefinitely, but the deductibility of such federal NOLs is limited. It is uncertain if and to
what extent various states will conform to the Tax Act. In addition, under Section 382 of the Internal Revenue Code, or the
Code, and corresponding provisions of state law, if a corporation undergoes an “ownership change,” which is generally defined
as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation’s ability to use its pre-
change NOLs and other pre-change tax attributes to offset its post-change income or taxes may be limited. Our past issuances
of stock and other changes in our stock ownership may have resulted in ownership changes within the meaning of Section 382
of the Code; accordingly, our pre-change NOLs may be subject to limitation under Section 382. If we determine that we have
not undergone an ownership change, the Internal Revenue Service could challenge our analysis, and our ability to use our
NOLs to offset taxable income could be limited by Section 382 of the Code. Future changes in our stock ownership, some of
which are outside of our control, could result in ownership changes under Section 382 of the Code further limiting our ability to
utilize our NOLs. Our NOLs may also be impaired under state law. Accordingly, we may not be able to utilize a material
portion of our NOLs. We have determined that ownership changes have occurred since our inception and that certain NOLs and
research and development tax credit carryforwards will be subject to limitation. We may also have incurred subsequent
ownership changes. Furthermore, our ability to utilize our NOLs and research and development tax credit carryforwards is
84
conditioned upon our attaining profitability and generating U.S. federal taxable income. We have incurred net losses since our
inception and anticipate that we will continue to incur significant losses for at least the next several years; thus, we do not know
when we will generate the U.S. federal taxable income necessary to utilize our NOLs. We have recorded a full valuation
allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future
benefits of those assets.
Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.
Changes in tax law may adversely affect our business or financial condition. The Tax Act, as amended by the CARES Act,
significantly revises the Code. The Tax Act, among other things, contains significant changes to corporate taxation, including
reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% and limitation of the deduction for
NOLs to 80% of current year taxable income for losses arising in taxable years beginning after December 31, 2017, though any
such NOLs may be carried forward indefinitely. In addition, beginning in 2022, the Tax Act eliminates the option to deduct
research and development expenditures currently and requires corporations to capitalize and amortize them over five years.
In addition to the CARES Act, as part of Congress’ response to the COVID-19 pandemic, economic relief legislation was
enacted in 2020 and 2021 containing tax provisions. The IRA, which was signed into law in August 2022, also introduced new
tax provisions, including a one percent excise tax imposed on certain stock repurchases by publicly traded corporations. The
one percent excise tax generally applies to any acquisition of stock by the publicly traded corporation (or certain of its affiliates)
from a stockholder of the corporation in exchange for money or other property (other than stock of the corporation itself),
subject to a de minimis exception. Thus, the excise tax could apply to certain transactions that are not traditional stock
repurchases.
Regulatory guidance under the Tax Act, the IRA, and additional legislation is and continues to be forthcoming, and such
guidance could ultimately increase or lessen their impact on our business and financial condition. In addition, it is uncertain if
and to what extent various states will conform to the Tax Act, the IRA, and additional tax legislation.
Our amended and restated certificate of incorporation, as amended, designates the state or federal courts within the State of
Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders,
which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers
or employees.
Our amended and restated certificate of incorporation, as amended, provides that, subject to limited exceptions, the Court of
Chancery of the State of Delaware will be the exclusive forum for (1) any derivative action or proceeding brought on our
behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees
to us or our stockholders, (3) any action asserting a claim against us arising pursuant to any provision of the DGCL, our
amended and restated certificate of incorporation, as amended, or our amended and restated by-laws, (4) any action to interpret,
apply, enforce or determine the validity of our amended and restated certificate of incorporation, as amended, or amended and
restated by-laws or (5) any other action asserting a claim against us that is governed by the internal affairs doctrine, in each case
subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. Any
person or entity that purchases or otherwise acquires any interest in shares of our capital stock shall be deemed to have notice of
and to have consented to the provisions of our amended and restated certificate of incorporation, as amended, described above.
This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for
disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors,
officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of
incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we
may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our
business and financial condition.
This exclusive forum provision would not apply to suits brought to enforce a duty or liability created by the Securities
Exchange Act of 1934, as amended, which provides for exclusive jurisdiction of the federal courts. It could apply, however, to a
suit that falls within one or more of the categories enumerated in the exclusive forum provision and asserts claims under the
Securities Act of 1933, as amended, or the Securities Act, inasmuch as Section 22 of the Securities Act creates concurrent
jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the
rules and regulations thereunder, provided, that with respect to claims under the Securities Act, our stockholders will not be
deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.
If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our
stock, the price of our stock and trading volume could decline.
85
The trading market for our common stock depends, in part, on the research and reports that industry or financial analysts
publish about us or our business. If one or more of the analysts covering our business downgrade their evaluations of our stock,
the price of our stock could decline. If one or more of these analysts cease to cover our stock or fail to regularly publish reports
on us, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.
A portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price
of our common stock to decline significantly, even if our business is doing well.
Sales of a significant number of shares of our common stock in the public market could occur at any time. These sales, or the
perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the
market price of our common stock.
We have registered substantially all shares of common stock that we may issue under our equity compensation plans. These
shares can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to
affiliates. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market
price of our common stock could decline.
General Risk Factors
Unfavorable global economic or geopolitical conditions could adversely affect our business, financial condition or results of
operations.
Our results of operations could be adversely affected by general conditions in the global economy, geopolitical considerations
and global financial market conditions, including changes in inflation, interest rates and overall economic conditions and
uncertainties. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets.
We cannot assure stockholders that deterioration of the global credit and financial markets would not negatively impact our
stock price, our current portfolio of cash equivalents or investments, or our ability to meet our financing objectives. If the
current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly,
and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material
adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical
development plans. A weak or declining economy, could also strain our suppliers and vendors involved in our clinical
development activities.
Additionally, Russia’s invasion of Ukraine in February 2022 and the global response, including the imposition of sanctions by
the United States and other countries, could create or exacerbate risks facing our business. We have evaluated our operations,
vendor contracts and clinical trial arrangements, and at present we do not expect the conflict to directly have a materially
adverse effect on our financial condition or results of operations. However, if the hostilities persist, escalate or expand, other
risks we have identified in this report may be exacerbated. For example, if our supply arrangements or clinical sites are
disrupted due to expanded sanctions or involvement of countries where we have operations or relationships, our business could
be materially disrupted. Further, the use of state-sponsored cyberattacks could expand as part of the conflict, which could
adversely affect our ability to maintain or enhance our cyber security and data protection measures. Any of the foregoing could
harm our business, and we cannot anticipate all of the ways in which the current economic and geopolitical climate and
financial market conditions could adversely impact our business.
We, or the third parties upon whom we depend, may be adversely affected by serious disasters.
Any unplanned event, such as a flood, fire, explosion, earthquake, extreme weather condition, medical epidemic, power
shortage, telecommunication failure or other natural or human-made accident or incident that results in us being unable to fully
use our facilities, or the facilities of third parties with which we contract, may have a material and adverse effect on our ability
to operate our business and may have significant negative consequences on our financial and operating conditions. Loss of
access to these facilities or operations may result in increased costs, delays in the development of our current or future product
candidates or the interruption of our business operations for a substantial period of time.
There can be no assurance that the amounts of insurance that we maintain will be sufficient to satisfy any damages and losses in
the event a serious disaster or similar event occurs. If our facilities, or the manufacturing facilities of our third-party contract
manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time,
any or all of our research and development programs and commercialization efforts may be harmed.
86
Our business is subject to risks arising from the outbreaks of disease, such as epidemics or pandemics, including the
ongoing COVID-19 pandemic.
The widespread infection of COVID-19 in the United States and abroad has caused significant volatility and uncertainty in U.S.
and international markets, which could result in a prolonged economic downturn that may disrupt our business, including by
adversely affecting our ability to conduct financings on terms acceptable to us, if at all.
In addition, we may experience disruptions that could severely impact our business, preclinical studies and clinical trials,
including:
• Our clinical trials may be adversely affected, delayed or interrupted, including, for example, site initiation, patient
recruitment and enrollment, availability of clinical trial materials, and data analysis. Some patients and clinical
investigators may not be able to comply with clinical trial protocols and patients may choose to withdraw from our
trials or we may have to pause enrollment or we may choose to or be required to pause enrollment and or patient
dosing in our ongoing clinical trials in order to preserve health resources and protect clinical trial participants, which
could delay our clinical trials or impact the strength or validity of our clinical trial data. It is unknown how long these
pauses or disruptions could continue.
• We currently rely on third parties to, among other things, manufacture raw materials, manufacture our product
candidates for our clinical trials, ship investigational drugs and clinical trial samples, perform quality testing and
supply other goods and services to run our business. If any such third party in our supply chain for materials are
adversely impacted by restrictions resulting from the coronavirus pandemic, including staffing shortages, raw material
supplies, production slowdowns or disruptions in delivery systems, our supply chain may be disrupted, limiting our
ability to manufacture our product candidates for our clinical trials and conduct our research and development
operations.
• Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or
otherwise adversely impact our business. In addition, this could increase our cyber security risk, create data
accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely
impact our business operations or delay necessary interactions with local and federal regulators, ethics committees,
manufacturing sites, research or clinical trials sites and other important agencies and contractors.
• Our employees and contractors conducting research and development activities may not be able to access our
laboratory for an extended period of time as a result of the closure of our offices and the possibility that governmental
authorities further modify current restrictions. As a result, this could delay timely completion of preclinical activities,
including completing IND-enabling studies or our ability to select future development candidates, and initiation of
additional clinical trials for other of our development programs.
• Health regulatory agencies globally may experience disruptions in their operations as a result of the COVID-19
pandemic. The FDA and comparable foreign regulatory agencies may have slower response times or be under-
resourced to continue to monitor our clinical trials and, as a result, review, inspection, and other timelines may be
materially delayed. It is unknown how long these disruptions could continue, were they to occur. Any prolongation or
de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially
affect the development of our product candidates. For example, regulatory authorities may require that we not
distribute a product candidate lot until the relevant agency authorizes its release. Such release authorization may be
delayed as a result of the COVID-19 pandemic and could result in delays to our clinical trials.
• The ongoing COVID-19 pandemic may cause the trading prices for shares of our common stock and other
biopharmaceutical companies' shares to be highly volatile. As a result, we may face difficulties raising capital through
sales of shares of our common stock, or such sales may be on unfavorable terms. In addition, a recession, depression
or other sustained adverse market event resulting from the spread of the coronavirus could materially and adversely
affect our business and the value of our common stock.
The COVID-19 pandemic continues to evolve. The ultimate impact of the coronavirus pandemic on our business operations is
highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted,
including the duration of the pandemic, the emergence and severity of new variants of the virus, additional or modified
government actions, new information that will emerge concerning the severity and impact of COVID-19, the timing,
availability, efficacy, adoption and distribution of vaccines or other preventative treatments and other actions taken to contain
coronavirus or address its impact in the short and long term, among others. We do not yet know and are unable to predict the
87
full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the
global economy.
ITEM 1B.
UNRESOLVED STAFF COMMENTS.
None.
ITEM 2.
PROPERTIES.
Our corporate headquarters are located in Cambridge, Massachusetts. We occupy approximately 45,000 square feet of office
and laboratory space that we lease in a multi-tenant building in which our corporate headquarters are located. The lease for the
substantial majority of this space expires in March 2026. We have an option to extend the lease term for an additional five years
thereafter. We believe that this office and laboratory space is sufficient to meet our current needs and that suitable additional
space will be available as and when needed.
ITEM 3.
LEGAL PROCEEDINGS.
From time to time, we may become subject to various legal proceedings and claims that arise in the ordinary course of our
business activities. We are not currently party to any material legal proceedings. Additionally, although the results of litigation
and claims cannot be predicted with certainty, as of the date of this Annual Report on Form 10-K, we do not believe we are
party to any claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be
reasonably expected to have a material adverse effect on our business.
ITEM 4.
MINE SAFETY DISCLOSURES.
Not applicable.
88
PART II
ITEM 5.
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS
AND ISSUER PURCHASES OF EQUITY SECURITIES
Certain Information Regarding the Trading of Our Common Stock
Our common stock trades under the symbol “MRSN” on the Nasdaq Global Select Market. As of February 24, 2023, there were
19 holders of record of shares of our common stock. The actual number of stockholders is greater than this number of record
holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other
nominees.
Dividend Policy
We have never declared nor paid cash dividends on our common stock. We currently intend to retain all of our future earnings,
if any, to finance the growth and development of our business. We do not intend to pay cash dividends in respect of our
common stock in the foreseeable future. In addition, our current credit facility contains restrictive covenants that prohibit us,
subject to certain exceptions, from paying dividends on our common stock. Any future determination to pay cash dividends will
be made at the discretion of our board of directors and will depend on restrictions and other factors our board of directors may
deem relevant. Investors should not purchase our common stock with the expectation of receiving cash dividends.
Stock Performance Graph
The following performance graph and related information shall not be deemed to be “soliciting material” or to be “filed” with
the Securities and Exchange Commission, or SEC, for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, or the Exchange Act, nor shall such information be incorporated by reference into any future filing under the
Exchange Act or Securities Act of 1933, as amended, or the Securities Act, except to the extent that we specifically incorporate
it by reference into such filing.
The following graph compares the performance of our common stock to the Nasdaq Composite Index and to the Nasdaq
Biotechnology Index from December 31, 2017 through December 31, 2022, which was the last trading day of the year. The
comparison assumes $100 was invested in our common stock and in each of the foregoing indices after the market closed on
December 31, 2017, and it assumes reinvestment of dividends, if any. The stock price performance included in this graph is not
necessarily indicative of future stock price performance.
89
Recent Sales of Unregistered Securities
None.
Purchases of Equity Securities by the Issuer and Affiliates Purchasers
Neither we nor any affiliated purchaser or anyone acting on behalf of us or an affiliated purchaser made any purchases of shares
of our common stock during the fourth quarter of 2022.
ITEM 6.
[RESERVED]
ITEM 7.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with
our audited financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K.
Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or
indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future
performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in
which we operate may differ materially from the forward-looking statements contained in this Annual Report. In addition, even
if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are
consistent with the forward-looking statements contained in this Annual Report, they may not be predictive of results or
developments in future periods.
The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in
this Annual Report on Form 10-K, including those risks identified under Part II, Item 1A. Risk Factors.
We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date
they are made. We disclaim any obligation, except as specifically required by law and the rules of the Securities and Exchange
Commission, or SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events,
conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
For our discussion and analysis of the year ended December 31, 2021 compared to the year ended December 31, 2020, please
refer to “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual
Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on February 28, 2022.
Overview
We are a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates, or ADCs, that offer a
clinically meaningful benefit for cancer patients with significant unmet need. We have leveraged over 20 years of industry
learning in the ADC field to develop three proprietary and differentiated technology platforms that enable us to develop ADCs
designed to have improved efficacy, safety and tolerability relative to existing ADCs and other approved therapies. We believe
that our innovative platforms and our proprietary payloads together enable a robust discovery pipeline for us and our
collaborators. Our investments in our novel and proprietary auristatin DolaLock payload, as well as our novel and proprietary
STING (stimulator of interferon genes) agonist ImmunoLock payload, together with the GMP supply chain established for
Dolaflexin, Dolasynthen and Immunosynthen all enable our ability to apply these platforms to new and different targets and
antibodies to create new product candidates. We call this our product engine. Our ADCs in preclinical studies and clinical trials
include first-in-class molecules that target multiple tumor types with high unmet medical need.
Our goal is to become a leading oncology company by leveraging the potential of our innovative and differentiated ADC
platforms and the experience and competencies of our management team to discover and develop promising ADC product
candidates and to commercialize cancer therapeutics that address unmet medical needs or provide significant benefits to
patients.
90
Our lead product candidate, upifitamab rilsodotin, which we refer to as UpRi, is a first-in-class Dolaflexin ADC targeting
NaPi2b, an antigen broadly expressed in ovarian cancer and other cancers. We are currently evaluating UpRi in platinum-
resistant ovarian cancer in a single-arm registrational trial, which we refer to as UPLIFT, for which we completed enrollment of
approximately 270 patients in October 2022. We expect to report top-line data from UPLIFT in mid-2023 following the major
oncology conferences scheduled for June, and, if the data are positive, to submit a biologics license application, or BLA, to the
U.S. Food and Drug Administration, or FDA, under the accelerated approval pathway around the end of 2023. We also initiated
screening of patients in UP-NEXT, our Phase 3 clinical trial of UpRi as monotherapy maintenance treatment following
treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer, in the third quarter of 2022, and we continue to
enroll patients in this trial. If data from the trial are positive, we believe UP-NEXT could serve as a post-approval confirmatory
trial in the United States, support potential approvals outside of the United States and support UpRi’s expansion into earlier
lines of therapy. Additionally, we are also conducting a Phase 1 combination trial, which we refer to as UPGRADE-A,
exploring the combination of UpRi with carboplatin, a standard platinum chemotherapy broadly used in the treatment of
platinum-sensitive ovarian cancer. We have completed the dose escalation portion of UPGRADE-A, initiated the dose
expansion portion of UPGRADE-A in January 2023, and expect to present data from the trial in the second half of 2023. We
may explore UpRi in combination with other therapies in a series of UPGRADE trials. Together, data from all of our clinical
trials of UpRi have the potential to establish the safety and efficacy of UpRi across a wide range of ovarian cancer patients,
from those who are platinum-resistant and heavily pre-treated to those in earlier lines of the disease.
We are investigating two additional ADCs, XMT-1660 and XMT-2056, in Phase 1 clinical trials. XMT-1660 is a B7-H4-
directed Dolasynthen ADC designed with a precise, target-optimized drug-to-antibody ratio, or DAR, of 6 and our DolaLock
microtubule inhibitor payload with controlled bystander effect. We are currently enrolling patients in our multicenter Phase 1
trial investigating the safety, tolerability and anti-tumor activity of XMT-1660 in patients with breast, endometrial and ovarian
cancers, for which trial we began dosing patients in August 2022. The FDA has granted Fast Track designation to XMT-1660
for the treatment of adult patients with advanced or metastatic triple-negative breast cancer. XMT-2056 is a systemically
administered Immunosynthen STING agonist ADC (DAR 8) that is designed to target a novel epitope of human epidermal
growth factor receptor 2, or HER2, distinct from that targeted by either trastuzumab or pertuzumab, and to locally activate
STING signaling in both tumor-resident immune cells and in tumor cells, providing the potential to treat patients with HER2-
high or -low tumors as monotherapy and in combination with standard-of-care agents. We initiated a multicenter Phase 1 open-
label trial of XMT-2056 in previously treated patients with advanced/recurrent solid tumors expressing HER2, including breast,
gastric, colorectal and non-small cell lung cancers, in January 2023.
We also have two earlier stage preclinical candidates, which we refer to as XMT-2068 and XMT-2175, that leverage our
Immunosynthen platform.
In May 2022, we made the decision to discontinue the development of XMT-1592, a Dolasynthen ADC that had been in a
Phase 1 dose exploration trial in patients with ovarian cancer and NSCLC, and to close this company-sponsored trial, which
was completed in September 2022.
We have entered into a global collaboration providing GlaxoSmithKline Intellectual Property (No. 4) Limited, or GSK, an
exclusive option to co-develop and commercialize XMT-2056. In addition, we have established strategic research and
development collaborations with Janssen Biotech, Inc., or Janssen, and Merck KGaA, Darmstadt, Germany, or Merck KGaA,
and its affiliates for the development and commercialization of additional ADC product candidates leveraging our proprietary
Dolasynthen, Dolaflexin and Immunosynthen platforms against a limited number of targets selected by our collaborators. We
believe the potential of our ADC product candidates and platforms, supported by our scientific and technical expertise and
enabled by our intellectual property strategy, all support our independent and collaborative efforts to discover and develop life-
changing ADCs for patients fighting cancer.
Since inception, our operations have focused on building our platforms, identifying potential product candidates, producing
drug substance and drug product material for use in preclinical studies, conducting preclinical and toxicology studies,
manufacturing clinical trial material and conducting clinical trials, establishing and protecting our intellectual property, staffing
our company and raising capital. We do not have any products approved for sale and have not generated any revenue from
product sales. We have funded our operations primarily through our strategic collaborations, private placements of our
convertible preferred stock and public offerings of our common stock, including through our at-the-market, or ATM, equity
offering programs.
91
Since inception, we have incurred significant cumulative operating losses. Our net losses were $204.2 million and $170.1
million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated
deficit of $654.7 million. We expect to continue to incur significant expenses and operating losses over the next several years.
We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:
•
•
•
•
continue clinical development and manufacturing activities for UpRi, XMT-1660 and XMT-2056;
prepare for a potential BLA submission for UpRi around the end of 2023 and engage in preparations for a potential
commercial launch of UpRi, if approved, in 2024;
continue diagnostic development efforts with respect to the NaPi2b biomarker;
continue activities to discover, validate and develop additional product candidates, including XMT-2068 and XMT-
2175;
• maintain, expand and protect our intellectual property portfolio; and
•
hire additional research, development and general and administrative personnel.
92
Financial Operations Overview
Revenue
To date, we have not generated any revenue from the sale of products. All of our revenue has been generated from strategic
collaborations.
In December 2022, we entered into a collaboration and commercial license agreement, or the 2022 Merck KGaA Agreement,
with Ares Trading S.A., or MRKDG, a wholly-owned subsidiary of Merck KGaA, for the development and commercialization
of ADC product candidates utilizing our Immunosynthen platform for up to two target antigens. MRKDG is responsible for
generating antibodies against the target antigens, and we are responsible for performing bioconjugation activities to create
ADCs as well as certain chemistry, manufacturing and controls development and early-stage manufacturing activities at their
cost. MRKDG has the exclusive right to and is responsible for the further development and commercialization of these ADC
product candidates. We did not recognize revenue related to the 2022 Merck KGaA Agreement during the year ended
December 31, 2022.
In August 2022, we entered into a collaboration, option and license agreement, or the GSK Agreement, with GSK to provide
GSK with an exclusive option to obtain an exclusive license to co-develop and to commercialize products containing XMT-
2056, or Licensed Products. We are responsible for manufacturing, research and early clinical development related to our XMT-
2056 program prior to GSK's exercise, if any, of its option. If GSK exercises its option, GSK will have the exclusive right to
and will be responsible for the further co-development and commercialization of Licensed Products. During the year ended
December 31, 2022, we recognized $2.0 million of collaboration revenue related to the GSK Agreement.
In February 2022, we entered into a research collaboration and license agreement, or the Janssen Agreement, with Janssen for
the development and commercialization of ADC product candidates utilizing our Dolasynthen platform for up to three target
antigens. Janssen is responsible for generating antibodies against the target antigens, and we are responsible for performing
bioconjugation activities to create ADCs as well as certain chemistry, manufacturing and controls development and early-stage
manufacturing activities at Janssen's cost. Janssen has the exclusive right to and is responsible for the further development and
commercialization of these ADC product candidates. During the year ended December 31, 2022, we recognized $24.2 million
of collaboration revenue related to performance under the Janssen Agreement and an associated development milestone.
In June 2014, we entered into a collaboration and commercial license agreement, or the 2014 Merck KGaA Agreement, with
Merck KGaA for the development and commercialization of ADC product candidates utilizing our Dolaflexin platform for up
to six target antigens. Merck KGaA is responsible for generating antibodies against the target antigens, and we are responsible
for generating Dolaflexin and conjugating this to such antibodies to create the ADC product candidates. Merck KGaA has the
exclusive right to and is responsible for the further development and commercialization of these ADC product candidates. In
May 2018, we entered into a supply agreement, or the Merck KGaA Supply Agreement, with Merck KGaA for the supply of
materials that could be used for investigational new drug, or IND, -enabling studies and clinical trials. For each of the years
ended December 31, 2022 and 2021, we recognized an immaterial amount of revenue related to the 2014 Merck KGaA
Agreement and Merck KGaA Supply Agreement.
During the year ended December 31, 2022, we recognized $0.3 million of revenue related to services provided to Asana
BioSciences, LLC, or Asana Biosciences. We did not recognize revenue related to Asana Biosciences during the year ended
December 31, 2021.
For the foreseeable future, we expect substantially all of our revenue to be generated from our collaboration agreements with
GSK, Janssen, Merck KGaA and its affiliate, MRKDG, and Asana BioSciences. Given the uncertain nature and timing of
clinical development, we cannot predict when or whether we will receive further milestone payments or any royalty payments
under these collaborations.
93
Expenses
Research and development expenses
Research and development expenses include our drug discovery efforts, manufacturing, and the development of our product
candidates, which consist of:
•
•
•
•
•
employee-related expenses, including salaries, benefits and stock-based compensation expense;
costs of funding research and development performed by third parties that conduct research, preclinical activities,
manufacturing and clinical trials on our behalf;
laboratory supplies;
facility costs, including rent, depreciation and maintenance expenses; and
upfront and milestone payments under our third-party licensing agreements.
Research and development costs are expensed as incurred. Costs of certain activities, such as manufacturing, preclinical studies
and clinical trials, are generally recognized based on an evaluation of the progress to completion of specific tasks. Costs for
certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of
specific tasks using data such as patient enrollment, clinical site activations and information provided to us by the third parties
with whom we contract.
Research and development activities are central to our business model. Product candidates in later stages of clinical
development generally have higher development costs than those in earlier stages of clinical development, primarily due to the
increased size and duration of later-stage clinical trials and manufacturing costs. We expect that our future research and
development costs will continue to increase over current levels, depending on the progress of our clinical development
programs. There are numerous factors associated with the successful development and commercialization of any of our product
candidates, including future trial design and various regulatory requirements, many of which cannot be determined with
accuracy at our current stage of development. Additionally, future commercial and regulatory factors beyond our control may
impact our clinical development programs and plans.
We have not historically allocated all of our internal research and development expenses on a program-by-program basis as our
employees and other resources are deployed across multiple projects under development. Internal research and development
expenses are presented as one total. Our internal research and development costs are primarily personnel-related costs, stock-
based compensation costs, and facility costs, including depreciation and lab consumables.
We incur significant external costs for manufacturing our product candidates and platforms and for clinical research
organizations that conduct clinical trials on our behalf. We capture these external expenses for each product candidate in clinical
development. Costs for our platforms with an associated product candidate in clinical development are typically allocated to our
most clinically advanced product candidate based on that platform. In light of our decision to discontinue further clinical
development of XMT-1592 in the second quarter of 2022, all costs associated with our Dolasynthen platform were
prospectively re-allocated to XMT-1660, which is now our lead Dolasynthen-based product candidate, following such decision.
All external research and development expenses not attributable to our product candidates in clinical development are captured
within preclinical and discovery costs. These costs relate to our product candidates XMT-2068 and XMT-2175 and additional
earlier discovery stage programs and certain unallocated costs. The following table summarizes our external research and
development expenses, presented by program as described above, for each of the years ended December 31, 2022, 2021, and
2020.
94
(in thousands)
UpRi external costs
XMT-1660 external costs
XMT-2056 external costs
XMT-1592 external costs
Preclinical and discovery costs
Internal research and development costs
Total research and development costs
Year Ended
December 31,
2021
2022
66,119 $
15,032
4,981
3,802
14,991
68,460
173,385 $
45,511 $
—
—
9,126
28,464
48,912
132,013 $
$
$
2020
18,689
—
—
7,180
9,883
31,284
67,036
The successful development of our product candidates is highly uncertain. As such, we cannot reasonably estimate or know the
nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development of our
product candidates. We are also unable to predict when, if ever, we will generate revenue from commercialization and sale of
any of our product candidates that obtain regulatory approval. This is due to the numerous risks and uncertainties associated
with developing drugs, including the uncertainty of:
•
•
•
•
•
•
•
successful completion of preclinical studies and IND-enabling studies;
successful enrollment in and completion of clinical trials;
receipt of marketing approvals from applicable regulatory authorities;
establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;
commercializing the product candidates, if and when approved, whether alone or in collaboration with others; and
continued acceptable safety profile of the drugs following approval.
A change in the outcome of any of these variables with respect to the development, manufacture or commercialization of any of
our product candidates would significantly change the costs, timing and viability associated with the development of that
product candidate.
We expect our research and development expenses to increase as we continue our clinical development and manufacturing of
UpRi, XMT-1660 and XMT-2056, advance our preclinical pipeline and invest in improvements in our ADC technologies.
General and administrative expenses
General and administrative expenses consist primarily of salaries and other employee-related costs, including stock-based
compensation, for personnel in executive, finance, accounting, business development, legal operations, information technology
and human resources functions. Other significant costs include facility costs not otherwise included in research and
development expenses, legal fees relating to patent and corporate matters and fees for accounting and consulting services.
We expect our general and administrative expenses to increase in the future to support continued research and development
activities, including increased costs related to the hiring of additional personnel, fees to outside consultants and patent costs,
among other expenses.
Other income (expense)
Other income (expense) consists primarily of interest expense related to borrowings under our credit facility and associated
amortization of the deferred financing costs and the accretion of debt discount. Interest income includes interest earned on cash
equivalents and marketable securities.
95
Results of Operations
Comparison of Years Ended December 31, 2022 and 2021
The following table summarizes our results of operations for the years ended December 31, 2022 and 2021, together with the
changes in those items:
(in thousands)
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Other income (expense):
Interest income
Interest expense
Total other expense, net
Net loss
Collaboration Revenue
Year Ended
December 31,
2022
$
26,581 $
2021
Dollar Change
26,538
43 $
173,385
56,963
230,348
132,013
36,888
168,901
2,883
(3,328)
(445)
(204,212) $
65
(1,267)
(1,202)
(170,060) $
$
41,372
20,075
61,447
2,818
(2,061)
757
(34,152)
Collaboration revenue increased by $26.5 million during the year ended December 31, 2022 as compared to the year ended
December 31, 2021, primarily due to collaboration revenue of $24.2 million recognized under the Janssen Agreement and $2.0
million recognized under the GSK Agreement.
Research and Development Expense
Research and development expense increased by $41.4 million from $132.0 million for the year ended December 31, 2021 to
$173.4 million for the year ended December 31, 2022.
The increase in research and development expense was primarily due to the following:
•
•
•
•
•
•
an increase of $21.6 million related to manufacturing and clinical development activities for UpRi;
an increase of $14.5 million related to employee compensation (excluding stock-based compensation), primarily due
to an increase in headcount supporting the growth of our research and development activities;
an increase of $2.3 million related to clinical development activities for XMT-1660;
an increase of $2.2 million related to manufacturing activities for XMT-1660 and the Dolasynthen platform;
an increase of $1.5 million related to manufacturing and clinical development activities for XMT-2056; and
an increase of $1.4 million related to consulting and professional fees.
These increased costs were partially offset by a decrease of $3.4 million related to manufacturing and clinical development
activities for XMT-1592.
Stock-based compensation expense included in research and development expenses increased by $1.4 million primarily as a
result of increased headcount.
96
General and Administrative Expense
General and administrative expense increased by $20.1 million from $36.9 million for the year ended December 31, 2021 to
$57.0 million for the year ended December 31, 2022. The increase in general and administrative expense was primarily due to
an increase of $11.1 million related to consulting and professional fees and an increase of $7.1 million related to employee
compensation (excluding stock-based compensation) due to an increase in headcount. Stock-based compensation increased by
$1.7 million, also primarily as a result of increased headcount.
Total Other Expense, Net
Total other expense, net was $0.4 million and $1.2 million for the years ended December 31, 2022 and 2021, respectively. The
increase to the net balance was primarily due to an increase in interest income earned on marketable securities partially
offsetting an increase in interest expense related to borrowings under the New Credit Facility, as defined below.
Liquidity and Capital Resources
Sources of Liquidity
We have financed our operations to date primarily through our strategic collaborations, private placements of our convertible
preferred stock and public offerings of our common stock, including our initial public offering, our follow-on public offerings
in 2019 and 2020 and our ATM equity offering programs.
In May 2020, we established an ATM equity offering program, the 2020 ATM, pursuant to which we were able to offer and sell
to the public through Cowen and Company, LLC, or Cowen, as sales agent, up to $100.0 million of our common stock from
time to time at prevailing market prices. During the year ended December 31, 2021, we sold approximately 4.0 million shares
of common stock under the 2020 ATM, resulting in net proceeds of $43.1 million. During the year ended December 31, 2022,
we sold approximately 11.7 million shares of common stock under the 2020 ATM, resulting in gross proceeds and net proceeds
of $55.9 million and $54.8 million, respectively. No shares were sold under the 2020 ATM during the quarter ended December
31, 2022. As of December 31, 2022, there were no amounts remaining unsold and available for sale under the 2020 ATM.
In February 2022, we entered into a new sales agreement, or the February 2022 ATM, with Cowen, as sales agent, under which
we are able to offer and sell to the public through Cowen up to $100.0 million of our common stock from time to time at
prevailing market prices. During the quarter ended December 31, 2022, we sold approximately 6.0 million shares of common
stock under the February 2022 ATM, resulting in gross proceeds and net proceeds of $40.7 million and $39.9 million,
respectively. During the year ended December 31, 2022, we sold approximately 18.8 million shares of common stock under the
February 2022 ATM, resulting in gross proceeds and net proceeds of $98.4 million and $96.4 million, respectively.
Approximately $1.6 million remained unsold and available for sale under the February 2022 ATM as of December 31, 2022.
In November 2022, we entered into an additional sales agreement, or the November 2022 ATM, with Cowen, as sales agent,
under which we are able to offer and sell up to the public through Cowen to $150.0 million of our common stock from time to
time at prevailing market prices. As of December 31, 2022, we had not sold any shares of common stock under the November
2022 ATM.
On May 8, 2019, we entered into a loan and security agreement, or the Prior Credit Facility, with Silicon Valley Bank, or SVB,
which was subsequently amended on June 29, 2019, August 28, 2020 and August 27, 2021. On October 29, 2021, we entered
into a loan and security agreement, or the New Credit Facility, with Oxford Finance LLC as the collateral agent and a lender,
SVB as a lender, and the other lenders from time to time a party thereto, or together the Lenders. The New Credit Facility, as
amended on February 17, 2022, October 17, 2022, and December 27, 2022, provides in aggregate up to $100 million in credit,
which includes (i) $40 million available at our option in up to four principal advances through June 30, 2023, (ii) an additional
$40 million in one principal advance, if we reach certain development milestone events, through September 30, 2023 and (iii)
an additional tranche of $20 million, subject to conditional approval from the Lenders. On May 8, 2019, we drew $25 million
from the facility, of which $5.5 million was used to repay in full the existing balance and satisfy our existing obligations to
SVB under the Prior Credit Facility. The New Credit Facility is secured by substantially all of our personal property owned or
later acquired, excluding intellectual property (but including the right to payments and proceeds of intellectual property), and a
negative pledge on intellectual property, which ensures that the Lenders' rights to repayment would be senior to the rights of the
holders of our common stock in the event of liquidation. Upon entering into the New Credit Facility, we terminated all
commitments by SVB to extend further credit under the Prior Credit Facility and all guarantees and security interests granted by
us to SVB under the Prior Credit Facility.
97
As of December 31, 2022, we had cash and cash equivalents and marketable securities of $280.7 million. In February 2023, we
received the $30 million upfront payment due to us from MRKDG. In addition to our existing cash and cash equivalents and
marketable securities, and available borrowings under the New Credit Facility, we are eligible to earn milestone and other
payments under our collaboration agreements with GSK, Janssen, Merck KGaA and its affiliate MRKDG and Asana
Biosciences. Our ability to earn the milestone payments and the timing of earning these amounts are dependent upon the timing
and outcome of our development, regulatory and commercial activities and, as such, are uncertain at this time.
Cash Flows
The following table provides information regarding our cash flows for the years ended December 31, 2022, 2021 and 2020:
(in thousands)
Net cash used in operating activities
Net cash (used in) provided by investing activities
Net cash provided by financing activities
Increase (decrease) in cash, cash equivalents and restricted cash
Net Cash Used in Operating Activities
Year Ended
December 31,
2021
(139,988) $
(648)
63,646
(76,990) $
2022
(49,363) $
(152,716)
153,017
(49,062) $
$
$
2020
(74,696)
37,027
230,412
192,743
Net cash used in operating activities was $49.4 million for the year ended December 31, 2022 and primarily consisted of a net
loss of $204.2 million adjusted for changes in our net working capital, deferred revenue related to our collaboration agreements,
and other non-cash items, including stock-based compensation of $21.5 million. Net cash used in operating activities was
$140.0 million for the year ended December 31, 2021 and primarily consisted of a net loss of $170.1 million adjusted for
changes in our net working capital and other non-cash items including stock-based compensation of $18.4 million and
depreciation of $0.9 million.
Net Cash Used in Investing Activities
Net cash used in investing activities was $152.7 million during the year ended December 31, 2022 as compared to net cash used
in investing activities of $0.6 million during the year ended December 31, 2021. During the year ended December 31, 2022, net
cash used in investing activities consisted primarily of purchases of marketable securities, partially offset by maturities of
marketable securities. Net cash used in investing activities for the year ended December 31, 2021 consisted primarily of the
purchase of property and equipment.
Net Cash Provided by Financing Activities
Net cash provided by financing activities was $153.0 million during the year ended December 31, 2022 as compared to
$63.6 million during the year ended December 31, 2021. During the year ended December 31, 2022 net cash provided by
financing activities consisted primarily of proceeds from the use of our 2020 ATM and February 2022 ATM of $150.9 million.
During the year ended December 31, 2021, cash provided by financing activities consisted primarily of the proceeds from the
use of the 2020 ATM of $43.1 million and issuance of debt, net of issuance costs, of $24.0 million under the New Credit
Facility, as well as proceeds from exercise of stock options of $1.8 million, partially offset by repayment of debt of $5.5 million
to repay the Prior Credit Facility.
Funding Requirements
We expect our cash expenditures to increase in connection with our ongoing activities, particularly as we continue the research
and development and manufacturing of, initiate clinical trials of and seek marketing approval for our product candidates. In
addition, as we prepare for and if we obtain marketing approval for any of our product candidates, we expect to incur
significant commercialization expenses related to drug sales, marketing, manufacturing and distribution to the extent that such
sales, marketing and distribution are not the responsibility of potential collaborators.
98
As of December 31, 2022, we had cash, cash equivalents and marketable securities of $280.7 million, and we subsequently
received the $30 million up-front payment from MRKDG under the 2022 Merck KGaA Agreement. In addition, we currently
have the option to borrow $15 million under the New Credit Facility. We believe our currently available funds plus available
borrowings on the New Credit Facility will be sufficient to fund our current operating plan commitments into the second half of
2024. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a
forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors.
We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources
sooner than we currently expect. Our future capital requirements will depend on many factors, including:
•
•
•
•
•
•
•
•
•
•
the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials
for our product candidates;
the scope, prioritization and number of our research and development programs;
the costs, timing and outcome of regulatory review of our product candidates;
our ability to establish and maintain collaborations on favorable terms, if at all;
the achievement of milestones or occurrence of other developments that trigger payments under any collaboration
agreements we obtain;
the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future
collaboration agreements, if any;
the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property
rights and defending intellectual property-related claims;
the extent to which we acquire or in-license other product candidates and technologies;
the costs of securing manufacturing arrangements for clinical and commercial production; and
the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market
our product candidates.
Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive
and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to
obtain marketing approval and achieve drug sales. In addition, our product candidates, if approved, may not achieve
commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be
commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to
achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.
Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a
combination of strategic collaborations, licensing arrangements, equity offerings and debt financings. To the extent that we raise
additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders
will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of
our common stockholders. We currently have access to the New Credit Facility, as described above, along with funds to
potentially be earned in connection with our agreements with GSK, Janssen, Merck KGaA and its affiliate MRKDG and Asana
BioSciences, if research and development activities are successful under our collaborations with those parties. Future additional
debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making capital expenditures or declaring dividends.
If we raise funds through additional strategic collaborations or licensing arrangements with third parties, we may have to
relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant
licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings
when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts
or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
99
Contractual Obligations
Our material cash requirements from known contractual obligations as of December 31, 2022 primarily consist of operating and
finance lease liabilities and principal and interest payments under our New Credit Facility. Our total future minimum lease
payments for our finance and operating leases are included in Note 12, Leases, in the Notes to Consolidated Financial
Statements. The total future undiscounted minimum lease payments, including operating and finance leases, were $14.0 million
as of December 31, 2022. Our total future minimum principal payments under our New Credit Facility are included in Note 8,
Debt, in the Notes to Consolidated Financial Statements. The total future minimum principal payments under our New Credit
Facility were $25.0 million as of December 31, 2022.
We enter into agreements in the normal course of business with third parties to assist us with preclinical, clinical,
manufacturing, and other products and services for operating purposes. These agreements are generally cancellable at any time
by us upon reasonable notice, and certain of these agreements include termination rights subject to termination fees or wind
down costs. The exact amounts of such obligations are dependent on the timing of termination and the exact terms of the
relevant agreement and cannot be reasonably estimated.
We also have obligations to make future payments to third parties that become due and payable on the achievement of certain
milestones, including future payments to third parties with whom we have entered into license agreements. We have not
included these commitments on our balance sheet because the achievement and timing of these milestones is not fixed and
determinable.
In July 2015, we entered into a license agreement with Recepta Biopharma S.A., or Recepta, for the NaPi2b antibody. We refer
to this license agreement, as amended, as the Recepta License. Under the Recepta License, we paid Recepta an upfront payment
of $1.0 million and are obligated to pay Recepta up to $65.5 million in development, regulatory and commercial milestones and
tiered royalties in the low-single digit percentages on net sales of products outside of Brazil until the expiration of the royalty
term. Upon the expiration of each royalty term in each country for each applicable product, the exclusive licenses granted to
each party under the Recepta License will become fully-paid up and royalty-free. We have incurred and paid $4.0 million in
development milestone payments under the Recepta License.
In January 2019, we entered into a commercial license agreement with Synaffix B.V., or Synaffix, which we amended and
restated in November 2021 and February 2022 to expand our relationship with Synaffix. We refer to the amended and restated
agreement as the Synaffix License. Under the Synaffix License, we have the right to develop, manufacture and commercialize
ADCs directed to targets using Synaffix’s proprietary site-specific conjugation technology. We have licensed five targets in
connection with our development programs and collaborations, and we have the right to license up to six additional targets. We
have paid $6.8 million related to the Synaffix License, comprised of $4.0 million in reservation and license fees, $1.8 million in
milestone payments and $1.0 million which may be applied to future reservation and license fees, as well as certain portions of
potential future development milestones. We will be obligated to pay in the range of $48.0 million to $132.0 million for
issuance, development, regulatory and commercial milestones. Upon commencement of commercial sales of any ADC product
directed to a licensed target, if any, we are required to pay to Synaffix tiered royalties in the low-single digit percentages on net
sales of the respective products. The Synaffix License remains in effect on a country-by-country and licensed product-by-
licensed product basis until the expiration of the last-to-expire valid claim in a patent licensed under the Synaffix License
covering such product in such country. Upon the expiration of the Synaffix License for each licensed product in each country,
the licenses granted to us for such product in such country will become fully paid-up and perpetual. We may terminate the
Synaffix License in its entirety or on a licensed product-by-licensed product basis at any time. Either party may terminate the
Synaffix License, subject to a specified notice and cure period, for a breach by the other party of a material provision of the
agreement or upon an insolvency-related event experienced by the other party.
Critical Accounting Policies and Significant Judgements and Estimates
Our management's discussion and analysis of our financial condition and results of operations are based on our financial
statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of
these financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities,
revenues, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates
on historical experience, known trends and events, and various other factors that are believed to be reasonable under the
circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis,
we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. The effects of material
revisions in estimates, if any, will be reflected in the financial statements prospectively from the date of change in estimates.
100
We believe that our most critical accounting policies are those relating to revenue recognition and accrued research and
development expenses as discussed in the Notes to Consolidated Financial Statements included in this Annual Report on Form
10-K.
Revenue Recognition
We enter into collaboration agreements which are within the scope of Accounting Standards Update 2014-09, Revenue from
Contracts with Customers, or ASC 606, under which we license rights to our technology and certain of our product candidates
and perform research and development services for third parties. The terms of these arrangements typically include payment of
one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; development,
regulatory and commercial milestone payments; and royalties on net sales of licensed products.
Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount
that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the
appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, we perform
the following five steps: (i) identification of contract(s) with a customer; (ii) determination of whether the promised goods or
services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable
consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or
as) we satisfy each performance obligation. We only apply the five-step model to contracts when it is probable that the entity
will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.
The promised good or services in our arrangements typically consist of license rights to our intellectual property and research
and development services. We also have optional additional items in contracts, which are considered marketing offers and are
accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a
material right which would not be provided without entering into the contract. Performance obligations are promised goods or
services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct
when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii)
the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised
goods or services are distinct, we consider factors such as the stage of development of the underlying intellectual property, the
capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily
available.
We estimate the transaction price based on the amount expected to be received for transferring the promised goods or services
in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each
arrangement that includes variable consideration and at each reporting period, we evaluate the amount of potential payment and
the likelihood that the payments will be received. We utilize either the most likely amount method or expected amount method
to estimate the amount expected to be received based on which method better predicts the amount expected to be received. If it
is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price.
Our contracts often include development and regulatory milestone payments. At contract inception and at each reporting period,
we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the
transaction price using the most likely amount method. If it is not probable that a significant revenue reversal would not occur,
the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the
licensee’s control, such as regulatory approvals, are not included in the transaction price. At the end of each subsequent
reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and
if necessary, adjust our estimate of the overall transaction price.
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is
deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales
occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or
partially satisfied).
We allocate the transaction price based on the estimated standalone selling price of the underlying performance obligations or in
the case of certain variable consideration to one or more performance obligations. We must develop assumptions that require
judgment to determine the standalone selling price for each performance obligation identified in the contract. We utilize key
assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in
negotiating the transaction and the estimated costs to complete the respective performance obligation. Certain variable
consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable
101
consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance
obligation are consistent with the amounts we would expect to receive for each performance obligation.
For performance obligations consisting of licenses and other promises, we utilize judgment to assess the nature of the combined
performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time
and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-
front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and
related revenue recognition. If the license to our intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, we will recognize revenue from non-refundable, up-front fees allocated to the license
when the license is transferred to the customer and the customer is able to use and benefit from the license.
Collaborative Arrangements
We record the elements of our collaboration agreements that represent joint operating activities in accordance with ASC
808, Collaborative Arrangements. Accordingly, the elements of the collaboration agreements that represent activities in which
both parties are active participants and to which both parties are exposed to the significant risks and rewards that are dependent
on the commercial success of the activities, are recorded as collaborative arrangements. We consider the guidance in ASC 606
in determining the appropriate treatment for the transactions between us and our collaborators and the transactions between us
and third parties. Generally, the classification of transactions under the collaborative arrangements is determined based on the
nature and contractual terms of the arrangement along with the nature of the operations of the participants. To the extent
revenue is generated from a collaboration, we will recognize our share of the net sales on a gross basis if we are deemed to be
the principal in the transactions with customers, or on a net basis if we are instead deemed to be the agent in the transactions
with customers, consistent with the guidance in ASC 606.
Accrued Research and Development Expenses
As part of the process of preparing our financial statements, we are required to estimate our accrued expenses as of each
balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to
identify services that have been performed on our behalf and estimating the level of service performed and the associated cost
incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service
providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of
our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically
confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in
our accrued research and development expenses include the costs incurred for services performed by our vendors in connection
with research and development activities for which we have not yet been invoiced.
We record our expenses related to research and development activities based upon our estimates of the services received and
efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The
financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment
flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a
prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services
will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the
actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrued or prepaid
expense balance accordingly. Although we do not expect our estimates to be materially different from amounts actually
incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services
performed, we may report amounts that are too high or too low in any particular period. To date, there have been no material
differences from our estimates to the amounts actually incurred. Significant judgement is involved in making the above
estimates.
Recent accounting pronouncements
See Note 2, Recently Issued Accounting Pronouncements, in the Notes to Consolidated Financial Statements for a description of
recent accounting pronouncements applicable to our business.
102
ITEM 7A.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Risks
We are exposed to market risk related to changes in interest rates. As of December 31, 2022, we had cash, cash equivalents and
marketable securities of $280.7 million. Our primary exposure to market risk is interest rate sensitivity, which is affected by
changes in the general level of U.S. interest rates, particularly because our investments, including cash equivalents and
marketable securities are invested in U.S. Treasury obligations, commercial paper, corporate bonds and U.S. government
agency securities. However, we believe that due to the short-term duration of our investment portfolio and low-risk profile of
our investments, an immediate 100 basis points change in the prime rate would not have a material effect on the fair market
value of our investments portfolio.
The interest rate on our New Credit Facility is sensitive to changes in interest rates. Interest accrues on borrowings under the
credit facility at a floating rate equal to the greater of (i) 8.50% and (ii) the prime rate plus 5.25%. We do not currently engage
in any hedging activities against changes in interest rates. As of December 31, 2022, there was $25.0 million outstanding under
the New Credit Facility, and a potential change in the associated interest rates would be immaterial to the results of our
operations.
Foreign Currency Exchange Rate Risks
We are currently not exposed to market risk related to changes in foreign currency exchange rates, but we may contract with
vendors that are located in Asia and Europe and may be subject to fluctuations in foreign currency rates at that time.
103
ITEM 8.
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Mersana Therapeutics, Inc.
Index to Consolidated Financial Statements
Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)
Consolidated Balance Sheets
Consolidated Statements of Operations and Comprehensive Loss
Consolidated Statements of Stockholders’ Equity
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements
Page
105
107
108
109
110
111
104
Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of Mersana Therapeutics, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Mersana Therapeutics, Inc. (the Company) as of December
31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, consolidated statement of
stockholders’ equity, and consolidated statement of cash flows for each of the three years in the period ended December 31,
2022, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and
2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in
conformity with U.S. generally accepted accounting principles.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on
the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in
accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to
error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over
financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting
but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting.
Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due
to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial
statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that
was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that
are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The
communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken
as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit
matter or on the accounts or disclosures to which it relates.
105
Accrued & Prepaid Clinical Expenses
Description of
the Matter
As summarized in Note 7 to the consolidated financial statements, the Company’s accrual for clinical
expenses totaled $14.8 million as of December 31, 2022. In addition, the Company’s Prepaid Expenses
and Other Current Assets totaled $8.5 million, which included amounts that were paid in advance of
services pursuant to clinical trials as of December 31, 2022. As discussed in Note 2 to the consolidated
financial statements, the Company is required to estimate clinical costs incurred and related accruals or
remaining prepaid expenses based on certain information, including actual costs incurred or level of effort
expended, as provided by its vendors. Payments for such activities are based on the terms of the
individual arrangements, which may differ from the pattern of costs incurred.
Auditing the Company’s accrued and prepaid clinical expenses was complex and judgmental, as the
amounts are based on various estimates from third-party vendors, as well as other inputs estimated by
members of management, such as, actual costs incurred but not yet billed, estimated project timelines,
and the costs associated with these services. Furthermore, due to the duration of the Company’s ongoing
research and development activities and the timing of invoicing received from third parties, the actual
amounts incurred are not typically known by the date the financial statements are issued.
How We
Addressed the
Matter in Our
Audit
To test the accrued and prepaid clinical expenses, our audit procedures included, among others, testing
the accuracy and completeness of the underlying data used to estimate the amounts recorded. We
corroborated the progress of research and development activities through discussion with the Company’s
research and development personnel that oversee the research and development projects. We also
inspected the Company’s contracts with third parties and any pending change orders to assess the impact
on amounts recorded. Additionally, we independently confirmed and/or reviewed information received by
the Company directly from certain sites and other third parties, which included third parties’ estimates of
costs incurred to date. We also performed analytical procedures over fluctuations in accrued and prepaid
clinical expenses by vendor, study, or other significant work order throughout the period subject to audit
and inspected subsequent invoices received from third parties to assess the impact to the accrued and
prepaid balances.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2013.
Boston, Massachusetts
February 28, 2023
106
Mersana Therapeutics, Inc.
Consolidated Balance Sheets
(in thousands, except share and per share data)
Assets
Current assets:
Cash and cash equivalents
Short-term marketable securities
Accounts receivable
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Other assets, noncurrent
Total assets
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
Accrued expenses
Deferred revenue
Operating lease liabilities
Other current liabilities
Total current liabilities
Operating lease liabilities, noncurrent
Long-term debt, net
Deferred revenue, noncurrent
Other liabilities, noncurrent
Total liabilities
Commitments (Note 15)
Stockholders' equity
Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and
outstanding at December 31, 2022 and December 31, 2021, respectively
Common stock, $0.0001 par value; 350,000,000 and 175,000,000 shares authorized at
December 31, 2022 and December 31, 2021, respectively; 105,144,864 and 73,709,056 shares
issued and outstanding at December 31, 2022 and December 31, 2021, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
December 31,
2022
December 31,
2021
$
$
$
128,885 $
151,827
30,000
8,507
319,219
3,985
10,475
661
334,340 $
13,951 $
43,184
30,610
2,798
990
91,533
8,575
24,929
117,043
203
242,283
177,947
—
—
10,951
188,898
1,968
12,889
2,356
206,111
12,321
28,716
3,944
2,303
239
47,523
11,247
24,626
—
974
84,370
—
—
11
746,889
(152)
(654,691)
92,057
334,340 $
7
572,213
—
(450,479)
121,741
206,111
$
The accompanying notes are an integral part of these consolidated financial statements.
107
Mersana Therapeutics, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Other income (expense):
Interest income
Interest expense
Total other income (expense), net
Net loss
Other comprehensive loss:
Unrealized loss on marketable securities
Comprehensive loss
Net loss attributable to common stockholders — basic and diluted
Net loss per share attributable to common stockholders — basic and diluted
Weighted-average number of shares of common stock used in net loss per share
attributable to common stockholders — basic and diluted
Year ended December 31,
2021
2020
2022
$
26,581 $
43 $
828
173,385
56,963
230,348
132,013
36,888
168,901
2,883
(3,328)
(445)
(204,212) $
65
(1,267)
(1,202)
(170,060) $
(152)
(204,364) $
(204,212) $
(2.18) $
—
(170,060) $
(170,060) $
(2.41) $
$
$
$
$
67,036
21,902
88,938
424
(359)
65
(88,045)
(25)
(88,070)
(88,045)
(1.43)
93,654,243 70,580,949 61,485,205
The accompanying notes are an integral part of these consolidated financial statements.
108
.
c
n
I
,
s
c
i
t
u
e
p
a
r
e
h
T
a
n
a
s
r
e
M
y
t
i
u
q
E
’
s
r
e
d
l
o
h
k
c
o
t
S
f
o
s
t
n
e
m
e
t
a
t
S
d
e
t
a
d
i
l
o
s
n
o
C
)
a
t
a
d
e
r
a
h
s
r
e
p
d
n
a
e
r
a
h
s
t
p
e
c
x
e
,
s
d
n
a
s
u
o
h
t
n
i
(
y
t
i
u
q
E
'
s
r
e
d
l
o
h
k
c
o
t
S
d
e
t
a
l
u
m
u
c
c
A
t
i
c
i
f
e
D
r
e
h
t
O
d
e
t
a
l
u
m
u
c
c
A
s
s
o
L
e
v
i
s
n
e
h
e
r
p
m
o
C
l
a
n
o
i
t
i
d
d
A
n
i
-
d
i
a
P
l
a
t
i
p
a
C
8
1
3
,
8
7
7
7
9
,
2
6
1
9
9
,
3
6
1
—
8
3
1
3
,
1
6
5
2
7
1
7
,
)
5
2
(
)
5
4
0
8
8
(
,
7
8
0
,
8
2
2
)
9
5
2
(
0
4
6
7
8
0
,
3
4
7
3
8
1
,
9
0
4
,
8
1
)
0
6
0
0
7
1
(
,
1
4
7
,
1
2
1
—
—
1
3
3
1
,
2
6
7
,
0
5
1
)
2
5
1
(
5
6
0
1
,
2
2
5
,
1
2
)
2
1
2
4
0
2
(
,
7
5
0
,
2
9
$
)
4
7
3
2
9
1
(
,
$
5
2
$
2
6
6
,
0
7
2
$
—
—
—
—
—
—
—
)
5
4
0
8
8
(
,
$
)
9
1
4
0
8
2
(
,
$
—
—
—
—
—
)
0
6
0
0
7
1
(
,
$
)
9
7
4
0
5
4
(
,
$
—
—
—
—
—
—
—
)
2
1
2
4
0
2
(
,
—
—
—
—
—
—
)
5
2
(
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
)
2
5
1
(
6
7
9
,
2
6
0
9
9
,
3
6
1
—
8
3
1
,
3
1
6
5
2
7
1
,
7
—
—
$
9
9
4
,
8
0
5
$
7
8
0
,
3
4
7
3
8
,
1
)
9
5
2
(
0
4
6
—
9
0
4
,
8
1
$
3
1
2
,
2
7
5
$
1
3
3
,
1
8
5
7
,
0
5
1
—
—
—
—
5
6
0
,
1
2
2
5
,
1
2
$
)
1
9
6
4
5
6
(
,
$
)
2
5
1
(
$
9
8
8
,
6
4
7
$
5
1
1
—
—
—
—
—
—
7
—
—
—
—
—
—
7
4
—
—
—
—
—
—
—
1
1
k
c
o
t
S
n
o
m
m
o
C
t
n
u
o
m
A
s
e
r
a
h
S
$
3
2
0
,
8
8
3
,
5
4
9
1
0
2
,
1
3
r
e
b
m
e
c
e
D
t
a
e
c
n
a
l
a
B
—
—
—
9
9
5
,
0
0
9
,
0
1
0
0
0
,
0
0
2
,
9
1
7
9
,
4
7
5
,
2
8
2
4
,
7
9
6
7
6
2
,
0
8
$
8
8
2
,
1
4
8
,
8
6
—
—
1
8
3
,
1
2
4
0
6
0
,
7
0
4
3
5
2
,
8
7
4
7
0
,
1
6
9
,
3
$
6
5
0
,
9
0
7
,
3
7
—
—
—
4
1
9
,
4
1
4
4
5
6
,
6
1
1
9
5
,
5
3
2
4
7
7
,
0
7
2
5
7
8
,
7
9
4
,
0
3
$
4
6
8
,
4
4
1
,
5
0
1
e
c
n
a
u
s
s
i
f
o
t
e
n
,
s
n
o
i
t
c
a
s
n
a
r
t
t
e
k
r
a
m
-
e
h
t
-
t
a
m
o
r
f
k
c
o
t
s
n
o
m
m
o
c
f
o
e
c
n
a
u
s
s
I
6
7
1
,
2
$
f
o
s
t
s
o
c
f
o
s
t
s
o
c
e
c
n
a
u
s
s
i
f
o
t
e
n
,
g
n
i
r
e
f
f
o
c
i
l
b
u
p
r
e
d
n
u
k
c
o
t
s
n
o
m
m
o
c
f
o
e
c
n
a
u
s
s
I
,
9
0
8
0
1
$
k
c
o
t
s
n
o
m
m
o
c
r
o
f
e
g
n
a
h
c
x
e
n
i
t
n
a
r
r
a
w
k
c
o
t
s
n
o
m
m
o
c
f
o
e
s
i
c
r
e
x
E
P
P
S
E
r
e
d
n
u
k
c
o
t
s
n
o
m
m
o
c
f
o
e
s
a
h
c
r
u
P
e
s
n
e
p
x
e
n
o
i
t
a
s
n
e
p
m
o
c
d
e
s
a
b
-
k
c
o
t
S
s
n
o
i
t
p
o
k
c
o
t
s
f
o
e
s
i
c
r
e
x
E
s
s
o
l
e
v
i
s
n
e
h
e
r
p
m
o
c
r
e
h
t
O
s
s
o
l
t
e
N
0
2
0
2
,
1
3
r
e
b
m
e
c
e
D
t
a
e
c
n
a
l
a
B
e
c
n
a
u
s
s
i
f
o
t
e
n
,
s
n
o
i
t
c
a
s
n
a
r
t
t
e
k
r
a
m
-
e
h
t
-
t
a
m
o
r
f
k
c
o
t
s
n
o
m
m
o
c
f
o
e
c
n
a
u
s
s
I
8
8
9
$
f
o
s
t
s
o
c
e
c
n
a
u
s
s
i
f
o
t
e
n
,
s
n
o
i
t
c
a
s
n
a
r
t
t
e
k
r
a
m
-
e
h
t
-
t
a
m
o
r
f
k
c
o
t
s
n
o
m
m
o
c
f
o
e
c
n
a
u
s
s
I
6
7
4
,
3
$
f
o
s
t
s
o
c
n
o
i
t
a
g
i
l
b
o
x
a
t
e
e
y
o
l
p
m
e
f
o
t
e
n
,
s
t
i
n
u
k
c
o
t
s
d
e
t
c
i
r
t
s
e
r
f
o
g
n
i
t
s
e
V
s
n
o
i
t
p
o
k
c
o
t
s
f
o
e
s
i
c
r
e
x
E
P
P
S
E
r
e
d
n
u
k
c
o
t
s
n
o
m
m
o
c
f
o
e
s
a
h
c
r
u
P
e
s
n
e
p
x
e
n
o
i
t
a
s
n
e
p
m
o
c
d
e
s
a
b
-
k
c
o
t
S
1
2
0
2
,
1
3
r
e
b
m
e
c
e
D
t
a
e
c
n
a
l
a
B
s
s
o
l
t
e
N
109
P
P
S
E
r
e
d
n
u
k
c
o
t
s
n
o
m
m
o
c
f
o
e
s
a
h
c
r
u
P
e
s
n
e
p
x
e
n
o
i
t
a
s
n
e
p
m
o
c
d
e
s
a
b
-
k
c
o
t
S
t
n
a
r
r
a
w
k
c
o
t
s
n
o
m
m
o
c
f
o
e
s
i
c
r
e
x
E
s
t
i
n
u
k
c
o
t
s
d
e
t
c
i
r
t
s
e
r
f
o
g
n
i
t
s
e
V
s
n
o
i
t
p
o
k
c
o
t
s
f
o
e
s
i
c
r
e
x
E
s
s
o
l
e
v
i
s
n
e
h
e
r
p
m
o
c
r
e
h
t
O
s
s
o
l
t
e
N
2
2
0
2
,
1
3
r
e
b
m
e
c
e
D
t
a
e
c
n
a
l
a
B
.
s
t
n
e
m
e
t
a
t
s
l
a
i
c
n
a
n
i
f
d
e
t
a
d
i
l
o
s
n
o
c
e
s
e
h
t
f
o
t
r
a
p
l
a
r
g
e
t
n
i
n
a
e
r
a
s
e
t
o
n
g
n
i
y
n
a
p
m
o
c
c
a
e
h
T
Mersana Therapeutics, Inc.
Consolidated Statements of Cash Flows
(in thousands)
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Net amortization of premiums and discounts on marketable securities
Stock-based compensation
Other non-cash items
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses
Operating lease right-of-use assets
Operating lease liabilities
Deferred revenue
Other liabilities
Net cash used in operating activities
Cash flows from investing activities
Maturities of marketable securities
Purchase of marketable securities
Purchase of property and equipment
Net cash used in investing activities
Cash flows from financing activities
Net proceeds from public offering of common stock
Net proceeds from at-the-market facilities
Proceeds from exercise of stock options
Proceeds from purchases of common stock under ESPP
Payment of employee tax obligations related to vesting of restricted stock units
Proceeds from issuance of debt, net of issuance costs
Repayment of debt
Payments under finance lease obligations
Net cash provided by financing activities
Increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental disclosures of non-cash activities:
Purchases of property and equipment in accounts payable and accrued expenses
Debt financing costs in accrued expenses
Common stock issuance costs in accounts payable and accrued expenses
Cash paid for interest
Right-of-use assets obtained in exchange for operating lease liabilities
Right-of-use assets obtained in exchange for financing lease liabilities
Year ended December 31,
2021
2020
2022
$
(204,212) $
(170,060) $
(88,045)
927
(1,462)
21,522
763
(30,000)
3,863
—
947
13,594
2,777
(2,539)
143,709
748
(49,363)
97,000
(247,519)
(2,197)
(152,716)
—
150,893
1,331
1,065
—
—
—
(272)
153,017
855
—
18,409
723
—
(2,734)
(718)
483
12,570
1,829
(1,827)
(43)
525
(139,988)
—
—
(648)
(648)
—
43,087
1,837
640
(259)
24,042
(5,486)
(215)
63,646
(49,062)
178,425
129,363 $
(76,990)
255,415
178,425 $
753 $
150 $
131 $
2,463 $
298 $
— $
— $
— $
— $
429 $
3,783 $
609 $
$
$
$
$
$
$
$
1,010
(86)
7,172
148
—
(1,950)
(700)
942
7,280
1,642
(1,281)
(828)
—
(74,696)
37,500
—
(473)
37,027
163,990
63,036
3,138
561
—
(197)
—
(116)
230,412
192,743
62,672
255,415
102
—
—
234
9,980
—
The accompanying notes are an integral part of these consolidated financial statements.
110
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
1. Nature of Business and Basis of Presentation
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates
("ADCs") that offer a clinically meaningful benefit for cancer patients with significant unmet need. The Company has
leveraged over 20 years of industry learning in the ADC field to develop three proprietary and differentiated platforms that
enable it to develop ADCs that are designed to have improved efficacy, safety and tolerability relative to existing ADCs and
other approved therapies. The Company’s platforms include Dolaflexin and Dolasynthen, each of which deliver the novel and
proprietary auristatin DolaLock payload, as well as Immunosynthen, which delivers the novel stimulator of interferon genes
("STING") agonist ImmunoLock payload.
The Company's lead product candidate, upifitamab rilsodotin ("UpRi"), is a first-in-class Dolaflexin ADC targeting NaPi2b, an
antigen broadly expressed in ovarian cancer and other cancers. The Company is currently evaluating UpRi in platinum-resistant
ovarian cancer in a single-arm registrational trial, referred to as UPLIFT. The Company is also conducting a placebo-controlled
Phase 3 clinical trial, referred to as UP-NEXT, to investigate UpRi as a monotherapy maintenance treatment following
treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Additionally, the Company is conducting a
Phase 1 combination trial, referred to as UPGRADE-A. UPGRADE-A is exploring the combination of UpRi with carboplatin, a
standard platinum chemotherapy broadly used in the treatment of platinum-sensitive ovarian cancer.
The Company is also investigating XMT-1660, a B7-H4-directed Dolasynthen ADC, in a Phase 1 clinical trial enrolling patients
with solid tumors, including in breast, endometrial and ovarian cancers, and XMT-2056, an Immunosynthen STING-agonist
ADC that is designed to target a novel epitope of human epidermal growth factor receptor 2 ("HER2"), in a Phase 1 clinical
trial enrolling previously treated patients with advanced/recurrent solid tumors expressing HER2, including breast, gastric,
colorectal and non-small cell lung cancers. The Company also has two additional earlier stage preclinical candidates, XMT-
2068 and XMT-2175, that leverage the Company's Immunosynthen platform.
The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, the need for
additional capital, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval and
reimbursement for any drug product candidate that it may identify and develop, the need to successfully commercialize and
gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology,
compliance with government regulations, development of technological innovations by competitors, reliance on third party
manufacturers and the ability to transition from pilot-scale production to large-scale manufacturing of products.
The Company has incurred cumulative net losses since inception. The Company’s net loss was $204.2 million, $170.1 million
and $88.0 million for the years ended December 31, 2022, 2021 and 2020, respectively. The Company expects to continue to
incur operating losses for at least the next several years. As of December 31, 2022, the Company had an accumulated deficit of
$654.7 million. The future success of the Company is dependent on, among other factors, its ability to identify and develop its
product candidates and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of
its financial resources and efforts to research and development and general and administrative expense to support such research
and development. Net losses and negative operating cash flows have had, and will continue to have, an adverse effect on the
Company’s stockholders’ equity and working capital.
The Company believes that its currently available funds will be sufficient to fund the Company’s operations through at least the
next twelve months from the issuance of this Annual Report on Form 10-K. Management’s belief with respect to its ability to
fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from
management’s estimates, the Company may need to seek additional funding.
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States ("U.S. GAAP") and the rules and regulations of the Securities and Exchange Commission
("SEC"). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the
Accounting Standards Codification ("ASC") and Accounting Standards Updates ("ASU") of the Financial Accounting
Standards Board ("FASB").
111
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
2. Summary of Significant Accounting Policies
Principles of Consolidation
The accompanying consolidated financial statements include those of the Company and its wholly owned subsidiary, Mersana
Securities Corp. All intercompany balances and transactions have been eliminated.
Use of Estimates
The preparation of the Company's consolidated financial statements in conformity with U.S. GAAP requires management to
make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related
disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and
expenses during the reporting period. On an ongoing basis, the Company's management evaluates its estimates which include,
but are not limited to, management's judgments with respect to the identification of performance obligations and standalone
selling prices of those performance obligations within its revenue arrangements, accrued preclinical, manufacturing and clinical
expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.
Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for
evaluation by the chief operating decision-maker, or decision making group, in deciding how to allocate resources and assess
performance. The Company views its operations and manages its business as a single operating segment, which is the business
of discovering and developing ADCs.
Research and Development
Research and development costs are expensed as incurred and include:
•
•
•
•
•
•
•
•
employee-related expenses, including salaries, bonuses, benefits, travel and stock-based compensation expense;
fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities
in connection with the conduct of preclinical studies, clinical trials and related services;
the cost of acquiring, developing and manufacturing ADC product candidates, clinical trial materials and other
research and development materials;
fees and costs related to regulatory filings and activities;
costs associated with collaboration agreements and license fees and milestone payments related to license agreements;
costs associated with creating and obtaining approval for the NaPi2b companion or complementary diagnostic
biomarker;
facilities, depreciation and other expenses, which include direct and allocated expenses for rent, utilities, maintenance
of facilities, insurance and other supplies; and
other costs associated with clinical, preclinical, discovery and other research activities.
Costs for certain development activities, such as preclinical studies, clinical trials and manufacturing development activities, are
recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical
site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort
expended. Payments for these activities are based on the terms of the individual arrangements, which may differ from the
pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued preclinical, manufacturing
and clinical expenses.
112
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Revenue Recognition
The Company enters into collaboration agreements which are within the scope of ASC 606, Revenue from Contracts with
Customers ("ASC 606"), under which the Company licenses rights to its technology and certain of the Company’s product
candidates and performs research and development services for third parties. The terms of these arrangements typically include
payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs;
development, regulatory and commercial milestone payments; and royalties on net sales of licensed products.
Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount
that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the
appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company
performs the following five steps: (i) identification of contract(s) with a customer; (ii) determination of whether the promised
goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable
consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or
as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is
probable that the entity will collect consideration to which it is entitled in exchange for the goods or services it transfers to the
customer.
The promised good or services in the Company’s arrangements typically consist of license rights to the Company’s intellectual
property and research and development services. The Company also has optional additional items in contracts, which are
considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the
customer, unless the option provides a material right which would not be provided without entering into the
contract. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the
customer. Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its
own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other
promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as
the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual
property on their own and the availability of the required expertise.
The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods
or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception
of each arrangement that includes variable consideration and at each reporting period, the Company evaluates the amount of
potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount
method or expected value method to estimate the amount expected to be received based on which method better predicts the
amount of consideration to which the Company will be entitled. If it is probable that a significant revenue reversal would not
occur, the variable consideration is included in the transaction price. We assessed each of our revenue generating arrangements
in order to determine whether a significant financing component exists and concluded that a significant financing component
does not exist in any of our arrangements because: (a) the promised consideration approximates the cash selling price of the
promised goods and services; and (b) timing of payment approximates the transfer of goods and services and performance is
over a relatively short period of time within the context of the entire term of the contract.
The Company’s contracts often include development and regulatory milestone payments. At contract inception and at each
reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the
amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue
reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not
within the Company’s control or the licensee’s control, such as regulatory approvals, are not included in the transaction
price. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such
development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any
such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and
earnings in the period of adjustment.
113
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is
deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the
related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been
satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the
Company’s collaboration arrangements.
The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance
obligations or in the case of certain variable consideration to one or more performance obligations. The Company must develop
assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the
contract. The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable
transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance
obligation. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when
the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts
allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each
performance obligation.
For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of
the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a
point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-
refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the
measure of performance and related revenue recognition. If the license to the Company’s intellectual property is determined to
be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from
non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to
use and benefit from the license.
The Company receives payments from its customers based on billing schedules established in each contract. Such billings
generally have 30-day terms. Up-front payments and fees are recorded as a contract liability (deferred revenue) upon receipt or
when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable
when the right to consideration is unconditional and only the passage of time is required before payment is due. If the right to
consideration is subject to a condition other than the passage of time, then the amount is recorded as a contract asset until the
right to payment becomes unconditional. In accordance with ASC 606, the Company presents contract assets and contract
liabilities on a net basis by customer contract.
Collaborative Arrangements
The Company records the elements of its collaboration agreements that represent joint operating activities in accordance with
ASC 808, Collaborative Arrangements ("ASC 808"). Accordingly, the elements of the collaboration agreements that represent
activities in which both parties are active participants and to which both parties are exposed to the significant risks and rewards
that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. The Company also
considers the guidance in ASC 606 by analogy in determining the appropriate treatment for the transactions between the
Company and its collaborators and the transactions between the Company and third parties. Generally, the classification of
transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement
along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, the
Company will recognize its share of the net sales on a gross basis if it is deemed to be the principal in the transactions with
customers, or on a net basis if it is instead deemed to be the agent in the transactions with customers, consistent with the
guidance in ASC 606.
114
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Fair Value Measurements
Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market
participants at measurement dates. ASC 820, Fair Value Measurement, establishes a three-level valuation hierarchy for
instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability
as of the measurement date. The three levels are defined as follows:
Level 1—Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2—Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and
inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial
instrument.
Level 3—Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
Marketable Securities
The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit
quality standards outlined in the Company’s investment policy. Short-term marketable securities consist of investments in debt
securities with maturities greater than three months and less than one year from the balance sheet date. The Company classifies
all of its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value. Fair value is
determined based on quoted market prices. Amortization and accretion of discounts and premiums are recorded as interest
income within other income (expense), net. Realized gains and losses are included in other income (expense), net.
The Company assesses its available-for-sale debt securities under the available-for-sale debt security impairment model in ASC
326, Financial Instruments - Credit Losses, as of each reporting date in order to determine if a portion of any decline in fair
value below carrying value recognized on its available-for-sale debt securities is the result of a credit loss. The Company
records credit losses in the consolidated statements of operations and comprehensive loss as a component of other income
(expense), net, which is limited to the difference between the fair value and the amortized cost of the security. To date, the
Company has not recorded any credit losses on its available-for-sale debt securities.
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original maturity, or a remaining maturity at the time of purchase,
of three months or less to be cash equivalents. The Company invests excess cash primarily in money market funds, commercial
paper and government agency securities, which are highly liquid and have strong credit ratings. These investments are subject
to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.
115
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Accounting for Stock-based Compensation
its stock-based compensation
The Company accounts for
in accordance with ASC 718, Compensation—Stock
Compensation ("ASC 718"). ASC 718 requires all stock-based payments to employees, directors and non-employees to be
recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the fair
value of options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires inputs
based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the calculation of expected term of
the award, (c) the risk-free interest rate and (d) expected dividends. The expected stock price volatility is calculated based on a
period of time commensurate with the expected term assumption. Historically, due to the lack of a public market for the
Company's common stock prior to completion of its initial public offering and a lack of company-specific historical and
implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of
similar companies that are publicly traded. The computation of expected volatility is based on the historical volatility of a
representative group of companies with similar characteristics to the Company, including stage of product development and life
science industry focus. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107,
Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical
exercise data to provide a reasonable basis upon which to estimate the expected term. During 2022, the Company began to
estimate its volatility by using a blend of its stock price history for the length of time it has market data for its stock and the
historical volatility of similar public companies for the expected term of each grant. For option grants with an expected term for
which sufficient stock price history for the Company exists, expected stock price volatility is calculated using the average of
volatilities for the period of the expected term prior to the grant date. For options granted to non-employees, the Company
utilizes the contractual term of the option arrangement as the basis for the expected term assumption. The risk-free interest rate
is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend
yield is assumed to be zero as the Company has never paid dividends and has no current plans to do so.
The Company determines the fair value of each restricted stock unit ("RSU") at its grant date based on the closing market price
of the Company’s common stock on that date or, if the date of grant is not a day on which the Company's primary trading
market was open, the immediately preceding trading day. For stock-based compensation subject to service-based vesting
conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based
compensation on a straight-line basis over the requisite service period.
The Company records forfeitures as a cumulative adjustment in the period in which they occur.
Property and Equipment
Property and equipment is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line
method over the estimated useful life of each asset as follows:
Computer equipment, office equipment and software
Laboratory equipment
Leasehold improvements
3 years
5 years
Shorter of useful life or life of lease
Upon retirement or sale, the cost of the disposed assets and the related accumulated depreciation are eliminated from the
balance sheet, and related gains or losses are reflected in the statement of operations. There were no material sales of assets
during the years ended December 31, 2022, 2021 and 2020.
The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that
the carrying amount of the assets may not be fully recoverable. If the Company performs an impairment review to evaluate an
asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and
eventual disposition of the asset to its carrying value. If the carrying amount of the asset exceeds its estimated undiscounted
future net cash flows, the Company recognizes an impairment charge in the amount by which the carrying amount of the asset
exceeds the fair value of the asset. The Company did not recognize impairment charges during the years ended December 31,
2022, 2021 and 2020.
116
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Leases
Consistent with ASC 842, Leases, the Company determines if an arrangement is a lease at inception. Operating leases are
included in right-of-use lease assets ("ROU assets"), current portion of lease obligations and long-term lease obligations on the
Company’s consolidated balance sheets. Assets subject to finance leases are included in property and equipment, and the related
lease obligation is included in other current liabilities and other long-term liabilities on the Company’s consolidated balance
sheets. Lease assets are tested for impairment in the same manner as long-lived assets used in operations. Lease expense for
operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing
leases is recognized as depreciation expense and interest expense using the effective interest method. The Company has elected
the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities
and ROU assets on the consolidated balance sheets for leases with an original term of twelve months or less.
ROU assets represent the Company’s right to use an underlying asset for the lease term, and lease obligations represent the
Company’s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU
assets are initially recorded based on the present value of lease payments over the expected remaining lease term. When
determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the
option will be exercised. Certain adjustments to the ROU asset may be required for items such as incentives received. The
interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could
borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar
economic environment. Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any incentives
received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect
as of the lease commencement or transition date.
The Company accounts for lease agreements with lease and non-lease components separately.
Patent Costs
The Company expenses patent application and related legal costs as incurred and classifies such costs as general and
administrative expenses in the accompanying consolidated statements of operations.
Income Taxes
The Company accounts for income taxes in accordance with ASC 740, Accounting for Income Taxes, which provides for
deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the financial statements or tax returns. The Company determines
its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities,
which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to
reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some
or all of the deferred tax assets will not be realized.
The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained.
Recognized income tax positions are measured at the largest amount that is more likely than not to be realized. Changes in
recognition or measurement are reflected in the period in which the change in judgment occurs.
Comprehensive Income (Loss)
Comprehensive income (loss) comprises net loss and other comprehensive loss. For the years ended December 31, 2022 and
2020, other comprehensive income (loss) consisted of changes in unrealized income and loss on marketable securities. For the
year ended December 31, 2021, comprehensive loss equaled net loss.
117
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Concentration of Credit Risk and Off-balance Sheet Risk
Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents
and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating,
maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company does
not believe that it is subject to any significant concentrations of credit risk from these financial instruments. The Company has
no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign
hedging arrangements.
Recently Issued Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies, and the Company
adopts such pronouncements as of the specified effective date. Unless otherwise discussed below, the Company does not
believe that the adoption of recently issued standards has had or may have a material impact on the Company's consolidated
financial statements or disclosures.
118
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
3. Collaboration Agreements
GSK
On August 6, 2022, the Company entered into a Collaboration, Option and License Agreement (the "GSK Agreement") with
GlaxoSmithKline Intellectual Property (No. 4) Limited ("GSK"), pursuant to which the Company granted GSK an exclusive
option to obtain an exclusive license (the “Option”) to co-develop and to commercialize products containing XMT-2056 (the
"Licensed Products"), exercisable within a specified time period (the “Option Period”) after the Company delivers to GSK data
resulting from completion of dose escalation with enrichment for breast cancer patients in a Phase 1 single-agent clinical trial of
XMT-2056. GSK’s exercise of the Option may require clearance under the Hart-Scott-Rodino Antitrust Improvements Act of
1976 (“HSR Clearance” and GSK’s exercise of the Option following any applicable HSR Clearance, the “GSK Option
Exercise”). Prior to the GSK Option Exercise, the Company will lead and will be responsible for the costs of manufacturing,
research, and early clinical development related to its XMT-2056 program. After the GSK Option Exercise, if any, GSK may
elect to manufacture XMT-2056, and GSK and the Company will co-develop XMT-2056 aimed at the approval of Licensed
Product(s) in the United States and the European Union, with GSK being responsible for the majority of the development costs.
GSK will be responsible for all development costs aimed solely at gaining approval outside the United States and European
Union.
Pursuant to the GSK Agreement, following the GSK Option Exercise and subject to certain exceptions and specified payment
obligations, the Company’s aggregate shared development costs are capped at a fixed amount, with any amounts in excess to be
borne by GSK unless and until the Company exercises its option to receive (or bear) a specified share of U.S. profits (or losses)
for any Licensed Products (“Profit Share Election”). The excess development costs will accrue interest as specified in the GSK
Agreement and will later either be repaid by the Company or offset against future regulatory and sales milestones or royalty
payments that may become due to the Company. If the Company exercises its Profit Share Election, the cap on the Company’s
share of development costs shall no longer apply, and the Company must pay any then-outstanding excess plus accrued interest
costs. Additionally, if the Company exercises its Profit Share Election, it may also simultaneously elect to co-promote any
Licensed Products in the United States.
Pursuant to the GSK Agreement, GSK paid the Company a non-refundable, upfront fee of $100.0 million in August 2022.
Following the GSK Option Exercise, if any, GSK is obligated to pay the Company an option exercise payment of $90.0 million
(the "Option Payment"). The Company is eligible to receive future development, regulatory, and commercial milestone
payments up to approximately $1.3 billion and, if the Company does not exercise its Profit Share Election, tiered royalties up to
the mid-twenty percent range based on global sales of Licensed Products. Included in the aggregate milestone payments amount
is $30 million that the Company is eligible to earn upon the satisfaction of early clinical development milestones that may occur
prior to the GSK Option Exercise. If the Company exercises its Profit Share Election, the Company will be eligible to receive
reduced development, regulatory, and commercial milestone payments and reduced royalty rates on sales outside of the United
States. Whether or not the Company exercises its Profit Share Election, GSK will be responsible for certain milestone payments
or royalties due to specified third parties with which the Company currently has agreements that relate to the XMT-2056
program.
The GSK Agreement will terminate at the end of the Option Period if GSK does not exercise its Option. In the event of the
GSK Option Exercise, unless earlier terminated, the GSK Agreement will continue in effect until the date on which the royalty
term and all payment obligations with respect to all Licensed Products in all countries have expired.
Accounting Analysis
The Company assessed the GSK Agreement in accordance with ASC 606 and concluded that the contract counterparty, GSK, is
a customer. The Company identified the following two material performance obligations under the GSK Agreement: (i)
development activities, including manufacturing, research and early clinical development activities, necessary to deliver the
package of data, information and materials specified in the GSK agreement (the "Development Activities") and (ii) the Option
to co-develop and to commercialize Licensed Products (the "License Option").
119
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
The Company concluded that the Development Activities are one distinct performance obligation, as the underlying activities
are not distinguishable in the context of the contract and are inputs to an integrated development program that will generate data
and information providing value to GSK in determining whether to exercise the Option. The License Option is considered a
material right as the value of the license exceeds the Option Payment, and is therefore a distinct performance obligation.
In accordance with ASC 606, the Company determined that the initial transaction price under the GSK Agreement equals
$100.0 million, consisting of the upfront, non-refundable and non-creditable payment paid by GSK. None of the early clinical
development milestones that may occur prior to the GSK Option Exercise have been included in the initial transaction price, as
all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous
factors, including stage of development and the remaining risks associated with the development required to achieve the
milestones, as well as whether the achievement of the milestones is outside the control of the Company or GSK. The GSK
Option payment is excluded from the initial transaction price at contract inception along with any future development,
regulatory, and commercial milestone payments (including royalties) following the GSK Option Exercise.
Consistent with the allocation objective under ASC 606, the Company allocated the $100.0 million fixed upfront payment in the
transaction price to the Development Activities and the License Option based on each performance obligation’s relative
standalone selling price. The standalone selling price for the Development Activities was calculated using a cost-plus margin
approach for the estimated pre-option development timeline. For the standalone selling price of the License Option, the
Company utilized an income-based approach which included the following key assumptions: post-option development timeline
and costs, revenue forecast, discount rates and probabilities of technical and regulatory success.
The Company is recognizing revenue related to the Development Activities performance obligation over the estimated period of
the pre-option development using a proportional performance model as the underlying activities are performed. The Company
measures proportional performance based on the costs incurred relative to the total costs expected to be incurred.
The Company will defer revenue recognition related to the License Option. If the License Option is exercised and GSK obtains
an exclusive license, the Company will recognize revenue as it fulfills its obligations under the GSK Agreement. If the Option
is not exercised, the Company will recognize the entirety of the revenue in the period when the Option expires.
During the year ended December 31, 2022, the Company recorded collaboration revenue of $2.0 million related to its efforts
under the GSK Agreement. As of December 31, 2022, the Company had recorded $98.0 million in deferred revenue related to
the unsatisfied performance obligations under the GSK Agreement. This deferred revenue will be recognized over the
remaining performance period and classified as current or noncurrent on the consolidated balance sheets based upon the
expected timing of satisfaction of the performance obligations.
Janssen
In February 2022, the Company entered into a research collaboration and license agreement with Janssen Biotech, Inc.
("Janssen" and such agreement, the "Janssen Agreement") focused on the research, development and commercialization of
novel ADCs for three oncology targets by leveraging Mersana’s ADC expertise and Dolasynthen platform with Janssen’s
proprietary antibodies. Upon execution of the Janssen Agreement, the Company received a non-refundable upfront payment of
$40.0 million from Janssen. Pursuant to the Janssen Agreement, the Company granted Janssen two exclusive, nontransferable,
worldwide licenses - a research license and a commercialization license (together, the "Janssen Licenses"). The research license
that forms a part of the Janssen Licenses provides Janssen, on a target-by-target basis, rights under the Company’s technology
and the Company’s interest in the technology developed jointly through the collaboration solely to conduct Janssen’s activities
under the research and Chemistry, Manufacturing and Controls ("CMC") plans with respect to each target. The
commercialization license that forms a part of the Janssen Licenses is a royalty-bearing license granted on a target-by-target
basis under the Company’s technology and the Company’s interest in the technology developed jointly through the
collaboration to develop, manufacture, commercialize and otherwise exploit licensed ADCs and any licensed products
containing licensed ADCs directed toward a target. Janssen may select up to three targets and may substitute each target once
prior to a substitution deadline. Janssen is not required to pay a fee for its first substitution right, but must pay a one-time fee for
access to the subsequent substitution rights following its exercise of its second substitution right.
Pursuant to mutually agreed research and CMC plans, the Company will perform bioconjugation, production development,
preclinical manufacturing, and certain related research and preclinical development activities, in order to progress the targets
120
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
through investigational new drug application ("IND") submission for further development, manufacture and commercialization
by Janssen. Janssen will have sole responsibility for IND-enabling studies, IND submission, clinical development, regulatory
activities and commercialization of the licensed ADCs. Both the Company and Janssen will have equal representation on a Joint
Research Committee and Joint Manufacturing Committee to oversee the research and CMC activities. The Company estimates
that its activities under the research plans for the targets will be performed through 2024.
The Company's CMC activities will be compensated by Janssen at agreed upon rates. Assuming successful development and
commercialization of all three targets by Janssen, the Company could receive up to an additional $505 million in development
and regulatory milestones and $530 million in sales milestones as well as tiered mid single-digit to low double-digit royalties on
aggregate net sales of the ADC products.
Unless earlier terminated, the Janssen Agreement will expire upon the expiration of the last royalty term for a product under the
Janssen Agreement. The Janssen Agreement contains customary provisions for termination by either party, including in the
event of breach of the Janssen Agreement, subject to cure, by Janssen for convenience and by Mersana upon a challenge of the
licensed patents, and customary provisions regarding the effects of termination.
Janssen may request that the Company perform clinical manufacturing services under a separate clinical supply agreement.
Janssen may also request that the Company perform a technology transfer of bioconjugation and manufacturing process
technology, at Janssen's cost, at an agreed upon rate.
Accounting Analysis
The Company assessed the Janssen Agreement in accordance with ASC 606 and concluded that the contract counter party,
Janssen, is a customer. The Company identified the following seven material performance obligations under the Janssen
Agreement: (i) exclusive Janssen Licenses and research activities for each of the three designated targets, (ii) CMC activities
for each of the three designated targets and (iii) the first target substitution right.
The Company concluded that the Janssen Licenses and research activities are one combined performance obligation for each
target as the Janssen Licenses are not capable of being distinct from the research activities given their proprietary nature. The
CMC activities are considered a distinct performance obligation for each target as the activities could be performed by a third-
party provider. The first target substitution right is considered a material right as there is no option exercise fee and, as such, is a
distinct performance obligation.
In accordance with ASC 606, the Company determined that the initial transaction price under the Janssen Agreement equals
$40.0 million, consisting of the upfront, non-refundable and non-creditable payment. None of the development and the
regulatory milestones were included in the initial transaction price, as all milestone amounts were fully constrained. As part of
its evaluation of the constraint, the Company considered numerous factors, including stage of development and the remaining
risks associated with the development required to achieve the milestones, as well as whether the achievement of the milestones
is outside the control of the Company or Janssen. Any consideration related to sales-based milestones (including royalties) will
be recognized when the related sales occur as such milestones were determined to relate predominantly to the license granted to
Janssen and therefore have also been excluded from the transaction price. As of December 31, 2022, the revised total
transaction price for the Janssen Agreement was $42.0 million. During 2022, the Company revised the estimated transaction
price by $2.0 million based on the reassessment of the constraint of certain development milestones and the remaining risks
associated with the development required to achieve the milestones.
The Company determined that the consideration for CMC activities represents variable consideration. The Company has not
included potential cost reimbursements within the transaction price as no CMC activities for any of the three targets have been
initiated. The Company elected to apply the Right to Invoice practical expedient under ASC 606. As such, the Company will
recognize revenue related to the CMC activities when the services are performed.
Consistent with the allocation objective under ASC 606, the Company allocated the total transaction price to the Janssen
Licenses and research activities and first substitution right based on each performance obligation’s relative standalone selling
price. Each of the standalone selling prices for the Janssen Licenses and research activities and for the first substitution right
were estimated utilizing an income approach, along with the likelihood of exercise for the substitution right and included the
121
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
following key assumptions: the development timeline, revenue forecast, discount rate and probabilities of technical and
regulatory success.
The Company is recognizing revenue related to the Janssen Licenses and research services performance obligation over the
estimated period of the research services using a proportional performance model. The Company measures proportional
performance based on the costs incurred relative to the total costs expected to be incurred.
The Company will recognize revenue related to the first target substitution right over time in congruence with the Janssen
Licenses and research activities, upon the exercise of the option. If the first target substitution option is not exercised, the
Company will recognize the entirety of the revenue in the period when the option expires.
During the year ended December 31, 2022, the Company recorded collaboration revenue of $24.2 million related to its
performance obligations under the Janssen Agreement. As of December 31, 2022, the Company had recorded $15.8 million in
deferred revenue related to the Janssen Agreement that will be recognized over the remaining performance period and classified
as current or noncurrent on the consolidated balance sheets based upon the expected timing of satisfaction of respective
performance obligations.
Merck KGaA and affiliates
Immunosynthen Agreement
In December 2022, the Company entered into a research collaboration and license agreement with Ares Trading S.A.
("MRKDG" and such agreement, the "2022 Merck KGaA Agreement"), a wholly owned subsidiary of Merck KGaA,
Darmstadt, Germany, focused on the research, development and commercialization of novel ADCs for up to two specific target
antigens by leveraging Mersana’s ADC expertise and Immunosynthen platform with MRKDG’s proprietary antibodies. Within
45 days of execution of the 2022 Merck KGaA Agreement, the Company received a non-refundable upfront payment of
$30.0 million. Pursuant to the 2022 Merck KGaA Agreement, the Company granted MRKDG two exclusive, non-transferable,
worldwide licenses - a research license and a commercialization license (together, the "MRKDG Licenses"). The research
license that forms a part of the MRKDG Licenses provides MRKDG, on a target-by-target basis, rights under the Company’s
technology and the Company’s interest in the technology developed jointly through the collaboration solely to conduct
MRKDG’s activities under the research and CMC plans with respect to each target. The commercialization license that forms a
part of the MRKDG Licenses is a royalty-bearing license granted on a target-by-target basis under the Company’s technology
and the Company’s interest in the technology developed jointly through the collaboration to develop, manufacture,
commercialize and otherwise exploit licensed ADCs and any licensed products containing licensed ADCs directed toward a
target.
Pursuant to mutually agreed research and CMC plans, the Company will perform bioconjugation, production development,
preclinical manufacturing, and certain related research and preclinical development activities, in order to progress the targets
through IND (or foreign equivalent) submission for further development, manufacture and commercialization by MRKDG.
MRKDG will have sole responsibility for IND-enabling studies, IND submission, clinical development, regulatory activities
and commercialization of the licensed ADCs. Both the Company and MRKDG will have equal representation on a Joint
Research Committee and Joint Manufacturing Committee to oversee the research and CMC activities. The Company estimates
that its activities under the research plans for the targets will be performed through 2026.
The Company's CMC activities will be compensated by MRKDG at agreed upon rates. Assuming successful development and
commercialization of the two targets by MRKDG, the Company could receive up to an additional $200 million in development
and regulatory milestones and $600 million in sales milestones as well as tiered single-digit to low double-digit royalties on
aggregate net sales of the ADC products. To date, the Company has not achieved any of the specified milestones.
Unless earlier terminated, the 2022 Merck KGaA Agreement will expire upon the expiration of the last royalty term for a
product under the 2022 Merck KGaA Agreement. The 2022 Merck KGaA Agreement contains customary provisions for
termination by either party, including in the event of breach of the 2022 Merck KGaA Agreement, subject to cure, by MRKDG
for convenience and by Mersana upon a challenge of the licensed patents, and customary provisions regarding the effects of
termination.
122
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
MRKDG may request that the Company perform clinical manufacturing services under a separate clinical supply agreement.
MRKDG may also request that the Company perform a technology transfer of bioconjugation technology, at MRKDG's cost, at
an agreed upon rate.
Accounting Analysis
The Company assessed the 2022 Merck KGaA Agreement in accordance with ASC 606 and concluded that the contract counter
party, MRKDG, is a customer. The Company identified the following four material performance obligations under the 2022
Merck KGaA Agreement: (i) exclusive MRKDG Licenses and research activities for each of the two designated targets and (ii)
CMC activities for each of the two designated targets.
The Company concluded that the MRKDG Licenses and research activities are one combined performance obligation for each
target as the MRKDG Licenses are not capable of being distinct from the research activities given their proprietary nature. The
CMC activities are considered a distinct performance obligation for each target as the activities could be performed by a third-
party provider.
In accordance with ASC 606, the Company determined that the initial transaction price under the 2022 Merck KGaA
Agreement equals $32.0 million, consisting of the $30.0 million upfront, non-refundable and non-creditable fee and certain
near-term discovery milestones. As the $30.0 million upfront fee was not received by the Company as of December 31, 2022,
the Company recorded an accounts receivable for $30.0 million with a corresponding deferred revenue liability. The Company
subsequently received this payment in February 2023. The development and the regulatory milestones not included in the
transaction price were constrained. As part of its evaluation of the constraint, the Company considered numerous factors,
including stage of development and the remaining risks associated with the development required to achieve the milestones, as
well as whether the achievement of the milestones is outside the control of the Company or MRKDG. Any consideration related
to sales-based milestones (including royalties) will be recognized when the related sales occur as such milestones were
determined to relate predominantly to the license granted to MRKDG and therefore have also been excluded from the
transaction price.
The Company determined that the consideration for CMC activities represents variable consideration. The Company has not
included potential cost reimbursements within the transaction price as no CMC activities for either of the two targets have been
initiated. The Company elected to apply the Right to Invoice practical expedient under ASC 606. As such, the Company will
recognize revenue related to the CMC activities when the services are performed.
Consistent with the allocation objective under ASC 606, the Company allocated the $32.0 million estimated transaction price to
the MRKDG Licenses and research activities based on each performance obligation’s relative standalone selling price. Each of
the standalone selling prices for the MRKDG Licenses and research activities were estimated utilizing an adjusted market
assessment approach, which was established based on comparable transactions.
The Company is recognizing revenue related to the MRKDG Licenses and research services performance obligation over the
estimated period of the research services using a proportional performance model. The Company measures proportional
performance based on the costs incurred relative to the total costs expected to be incurred.
The Company did not record collaboration revenue related to the 2022 Merck KGaA Agreement during the year ended
December 31, 2022. As of December 31, 2022, the Company had recorded $30.0 million in deferred revenue related to the
unsatisfied performance obligations under the 2022 Merck KGaA Agreement. This deferred revenue will be recognized over the
remaining performance period and classified as current or noncurrent on the consolidated balance sheets based upon the
expected timing of satisfaction of respective performance obligations.
Dolaflexin Platform Agreement
In June 2014, the Company entered into a collaboration and commercial license agreement with Merck KGaA (the "2014
Merck KGaA Agreement"). Upon the execution of the 2014 Merck KGaA Agreement, Merck KGaA paid the Company a non-
refundable technology access fee of $12.0 million for the right to develop ADCs directed to six exclusive targets over a
specified period of time. No additional fees are due when a target is designated and the commercial license to the target is
123
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
granted. Merck KGaA will be responsible for the product development and marketing of any products resulting from this
collaboration.
Under the terms of the 2014 Merck KGaA Agreement, the Company and Merck KGaA develop research plans to evaluate
Merck KGaA's antibodies as ADCs incorporating the Company's technology. The Company receives reimbursement for its
efforts under the research plans. The goal of the research plans is to provide Merck KGaA with sufficient information to
formally nominate a development candidate and begin IND-enabling studies.
In addition to the payments received for research and development activities performed on behalf of Merck KGaA, the
Company could be eligible to receive up to a total of $780.0 million in future milestones related to all targets under the 2014
Merck KGaA Agreement, plus low to mid-single digit royalties on the commercial sales of any resulting products during the
applicable royalty term. The total milestones are categorized as follows: development milestones $84.0 million; regulatory
milestones $264.0 million; and sales milestones $432.0 million. There are six individual development milestones per target,
payable upon the completion of various activities, from the delivery of ADCs meeting defined specifications, through the
dosing in a Phase 3 clinical trial. There are five regulatory milestones, which are payable upon regulatory approvals for a first
indication in each of the U.S., European Union and Japanese markets and regulatory approvals for both a second and a third
indication in the United States. There are three individual commercial milestones, which are payable upon the attainment of
certain defined thresholds for annual net sales.
All six targets were designated prior to 2018. The Company has previously received $3.0 million related to development
milestones under the 2014 Merck KGaA Agreement. There have been no additional milestone payments in the years ended
December 31, 2022 or 2021.
Unless earlier terminated, the 2014 Merck KGaA Agreement will expire upon the expiration of the last royalty term for a
product under the 2014 Merck KGaA Agreement, after which time, Merck KGaA will have a perpetual, royalty-free license, or
if Merck KGaA does not designate any ADC product candidates produced by the Company under the 2014 Merck KGaA
Agreement as preclinical development candidates, upon the expiration of the last to expire research program. Merck KGaA may
terminate the 2014 Merck KGaA Agreement in its entirety or with respect to any target for convenience upon 60 days' prior
written notice. Each party may terminate the 2014 Merck KGaA Agreement in its entirety upon bankruptcy or similar
proceedings of the other party or upon an uncured material breach of the 2014 Merck KGaA Agreement by the other party.
However, if such breach only relates to one target, the agreement may only be terminated with respect to such target.
In May 2018, the Company entered into a Supply Agreement with Merck KGaA (the "2018 Merck KGaA Supply Agreement").
Under the terms of the 2018 Merck KGaA Supply Agreement, the Company will provide Merck KGaA preclinical non-good
manufacturing practice ("non-GMP") ADC drug substance and clinical good manufacturing practice ("GMP") drug substance
for use in clinical trials associated with one of the antibodies designated under the 2014 Merck KGaA Agreement. The
Company receives fees for its efforts under the 2018 Merck KGaA Supply Agreement and reimbursement equal to the supply
cost. The Company may also enter into future supply agreements to provide clinical supply material should Merck KGaA
pursue clinical development of any other candidates nominated under the 2014 Merck KGaA Agreement.
Accounting Analysis
The Company concluded that Merck KGaA is a customer and accounted for the 2014 Merck KGaA Agreement in accordance
with ASC 606. The Company identified the following performance obligations under the 2014 Merck KGaA Agreement:
(i) exclusive license and research services for six designated targets, (ii) rights to future technological improvements and
(iii) participation of project team leaders and providing joint research committee services.
The Company has concluded that each license for a designated target is not distinct from the research services performed
related to the designated target as Merck KGaA cannot obtain the benefit of the license without the related research
services. Each license for a designated target and the related services performance obligation is considered distinct from every
other license for a designated target and related services performance obligation as each research plan is pursued independent of
every other research plan for other designated targets.
124
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
The Company utilizes the expected value approach to estimate the amount of consideration related to the payment of fees
associated with development and research services. The Company utilizes the most likely amount approach to estimate any
development and regulatory milestone payments to be received. As of the date of initial application of ASC 606, there were no
milestones payments that had not already been received, included in the estimated transaction price. The Company considered
the stage of development and the remaining risks associated with the remaining development required to achieve the milestone,
as well as whether the achievement of the milestone is outside the control of the Company or Merck KGaA. The milestone
payment amounts were fully constrained, as a result of the uncertainty whether any of the associated milestones would be
achieved. The Company has determined that any commercial milestones and sales based royalties will be recognized when the
related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded
from the transaction price.
The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of
each performance obligation or in the case of certain variable consideration to one or more performance obligations. The
estimated standalone selling prices for performance obligations, that include a license and research services, were developed
using the estimated selling price of the license and an estimate of the overall effort to perform the research service and an
estimated market rate for research services. The estimated standalone selling price of the licenses was established based on
comparable transactions. The estimated standalone selling price for the rights to future technological improvements was
developed based on the estimated selling prices of a license or rights received, as well as considering the probability that
additional technology would be made available or the probability the counterpart would utilize the technology. The estimated
standalone selling price for the joint research committee services was developed using an estimate of the time and costs
incurred to participate in the committees.
The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other changes
in circumstances occur. As of December 31, 2022 and 2021, the total estimated transaction price for the 2014 Merck KGaA
Agreement was $21.3 million.
The Company is recognizing revenue related to the exclusive license and research and development services performance
obligation over the estimated period of the research and development services using a proportional performance model. The
Company measures proportional performance based on the costs incurred relative to the total costs expected to be incurred. To
the extent that the Company receives fees for the research services as they are performed, these amounts are recorded as
deferred revenue. Revenue related to future technological improvements and joint research committee services will be
recognized ratably over the performance period (which in the case of the joint research committee services approximate the
time and cost incurred each period), which are 10 and 5 years, respectively. The Company is continuing to reassess the
estimated remaining term at each subsequent reporting period.
As of December 31, 2022, the Company has completed its research service obligations associated with four of the six
designated targets and the joint research committee services. Collaboration revenue recognized during the years ended
December 31, 2022 and 2021 was immaterial. During the year ended December, 31 2020, the Company recorded collaboration
revenue of $0.8 million related to its efforts under the 2014 Merck KGaA Agreement. There was no collaboration revenue or
corresponding research and development expense recognized during the years ended December 31, 2022, 2021, and 2020
related to the 2018 Merck KGaA Supply Agreement.
As of each of December 31, 2022 and 2021, the Company had recorded $3.9 million in deferred revenue related to the 2014
Merck KGaA Agreement and 2018 Merck KGaA Supply Agreement, in the aggregate, that will be recognized over the
remaining performance period.
125
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Summary of Contract Assets and Liabilities
The following table presents changes in the balances of the Company's contract liabilities:
Year ended December 31, 2022
Contract liabilities:
Total deferred revenue
Year ended December 31, 2021
Contract liabilities:
Total deferred revenue
Balance at
Beginning
of Period
Additions
Deductions
Balance at
End of Period
$
3,944 $
170,000 $
26,291 $
147,653
$
3,987 $
— $
43 $
3,944
The Company did not record any contract assets associated with its collaboration agreements as of December 31, 2022 and
December 31, 2021.
During the years ended December 31, 2022 and 2021 the Company recognized the following revenues as a result of changes in
the contract liability balances in the respective periods:
Revenue recognized in the period from:
Amounts included in the contract liability at the beginning of the period
Performance obligations satisfied in previous periods
Other Revenue
Year ended December 31,
2021
2022
$
$
43 $
— $
43
—
The Company has provided limited services for a collaborator, Asana BioSciences, LLC ("Asana Biosciences"). During the
year ended December 31, 2022, the Company recognized revenue of $0.3 million related to these services and did not recognize
revenue related to these services during the years ended 2021 and 2020. The next potential milestone the Company is eligible to
receive is $2.5 million upon dosing the fifth patient in a Phase 1 clinical trial by Asana BioSciences. While the first patient was
dosed in April 2022, as of December 31, 2022, the Company considered this next milestone to be fully constrained as there was
considerable judgment involved in determining whether it is probable that a significant revenue reversal would occur. As part of
its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestone
is outside the control of the Company and there was a high level of uncertainty in achieving this milestone, as the collaborator
continues to evaluate its candidate in the Phase 1 trial.
126
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
4. Fair Value Measurements
The following table presents information about the Company's assets measured at fair value on a recurring basis and indicates
the level within fair value hierarchy of the valuation techniques utilized to determine such value. The Company had no
marketable securities as of December 31, 2021.
(in thousands)
Cash equivalents
Money market funds
U.S. government agency securities
Marketable securities
U.S. treasury securities
U.S government agency securities
December 31, 2022
Quoted Prices
in Active
Markets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
$
$
50,471 $
9,993
60,464 $
50,471 $
—
50,471 $
— $
9,993
9,993 $
$ 107,810 $ 107,810 $
—
$ 151,827 $ 107,810 $
44,017
— $
44,017
44,017 $
—
—
—
—
—
—
There were no changes in valuation techniques or transfers between fair value measurement levels during the year ended
December 31, 2022.
Investments classified as Level 1 within the valuation hierarchy generally consist of U.S. treasury securities and money market
funds, as the fair value is readily determinable based on active daily markets for identical securities. Investments classified as
Level 2 within the valuation hierarchy generally consists of U.S. government agency securities, as the fair value is readily
determinable based on active daily markets for similar securities and other observable inputs. The Company estimates the fair
values of investments by taking into consideration valuations obtained from third-party pricing sources.
The carrying amounts reflected in the consolidated balance sheets for prepaid expenses and other current assets, accounts
receivable, accounts payable and accrued expenses approximate their fair values due to their short-term nature.
As of December 31, 2022 and 2021, the carrying value of the Company’s outstanding borrowing under the New Credit Facility
(as defined in Note 8) approximated fair value (a Level 2 fair value measurement), reflecting interest rates currently available to
the Company. The New Credit Facility is discussed in more detail in Note 8, Debt.
127
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
5. Cash, Cash Equivalents, and Short-Term marketable securities
Cash and cash equivalents
The following table summarizes the Company's cash, cash equivalents, and restricted cash as of December 31, 2022 and 2021.
(in thousands)
Cash and cash equivalents
Restricted cash included in other assets, noncurrent
Year Ended
December 31, 2022
Year ended December 31, 2021
Beginning
of period
End
of period
Beginning
of period
End
of period
$
177,947 $
478
128,885 $
478
255,094 $
321
177,947
478
Total cash, cash equivalents and restricted cash per statement
of cash flows
$
178,425 $
129,363 $
255,415 $
178,425
Marketable securities
The following table summarizes the Company's marketable securities held at December 31, 2022. The Company had no
marketable securities as of December 31, 2021.
(in thousands)
Marketable securities
U.S. treasury securities
U.S. government agency securities
Amortized
Cost
December 31, 2022
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
$
$
107,964 $
44,016
151,980 $
7 $
24
31 $
(161) $
(23)
(184) $
107,810
44,017
151,827
All of the Company's marketable securities are due within one year or less. The Company did not realize any gains or losses
recognized on the sale of marketable securities during the year ended December 31, 2022, and, as a result, the Company did not
reclassify any amounts out of accumulated comprehensive loss.
As of December 31, 2022, the Company's debt security portfolio consisted of 17 securities that were in an unrealized loss
position and had an aggregate fair value of $92.8 million. There were no securities in an unrealized loss position for greater
than 12 months as of December 31, 2022. The unrealized losses on the Company's marketable securities were caused by market
interest rate increases. The Company has the intent and ability to hold such securities until recovery. As a result, the Company
did not record any charges for credit-related impairments for its marketable securities during the year ended December 31,
2022.
128
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
6. Property and Equipment
Property and equipment consists of the following as of December 31, 2022 and 2021:
(in thousands)
Laboratory equipment
Leasehold improvements
Computers, software, and office equipment
Total property and equipment at cost
Less: Accumulated depreciation
December 31,
2022
December 31,
2021
$
$
7,960 $
1,943
1,824
11,727
(7,742)
3,985 $
6,725
1,906
1,019
9,650
(7,682)
1,968
Depreciation expense for the years ended December 31, 2022, 2021 and 2020 was $0.9 million, $0.9 million and $1.0 million,
respectively.
7. Accrued Expenses
Accrued expenses consist of the following as of December 31, 2022 and 2021:
(in thousands)
Accrued clinical expenses
Accrued manufacturing expenses
Accrued payroll and related expenses
Accrued research and non-clinical expenses
Accrued professional fees
Accrued other
8. Debt
December 31,
2022
December 31,
2021
$
$
14,822 $
11,536
11,558
2,767
1,865
636
43,184 $
7,879
8,476
7,319
3,848
909
285
28,716
On May 8, 2019, the Company entered into a loan and security agreement (the "Prior Credit Facility") with Silicon Valley Bank
("SVB"), pursuant to which the Company borrowed $5.0 million. The Prior Credit Facility accrued interest at a floating per
annum rate equal to the greater of (i) 4.0% and (ii) 1.50% below the Prime Rate. The Prior Credit Facility had an interest-only
period through August 31, 2020.
On August 28, 2020, the Company entered into a second amendment (the "Second Amendment") to the Prior Credit Facility.
Pursuant to the Second Amendment, the Company drew $5.2 million upon execution of the Second Amendment, the proceeds
of which were used to repay the Company’s existing balance under the Prior Credit Facility and satisfy its obligations to SVB.
The Prior Credit Facility, as amended by the Second Amendment, accrued interest at a floating per annum rate equal to the
greater of (i) 4.25% and (ii) 1.00% above the Prime Rate.
129
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
On October 29, 2021, the Company entered into a loan and security agreement (the "New Credit Facility") with SVB and
Oxford ("Oxford" and, together with SVB and the other lenders from time to time a party thereto, the "Lenders"). Pursuant to
the New Credit Facility, as amended on February 17, 2022, October 17, 2022, and December 27, 2022, the Company can
borrow term loans in an aggregate amount of $100.0 million, which includes (i) $40.0 million available at the option of the
Company in up to four principal advances through June 30, 2023, (ii) an additional $40.0 million in one principal advance, if
the Company reaches certain development milestone events, through September 30, 2023 and (iii) an additional tranche of
$20.0 million, subject to conditional approval from the Lenders. The New Credit Facility is secured by substantially all of the
Company's personal property owned or later acquired, excluding intellectual property (but including the rights to payments and
proceeds from intellectual property), and a negative pledge on intellectual property. The Company drew $25.0 million upon
execution of the New Credit Facility, of which $5.5 million of the proceeds was used to repay the existing balance under the
Prior Credit Facility and satisfy its obligations to SVB. Upon entering into the New Credit Facility, the Company terminated all
commitments by SVB to extend further credit under the Prior Credit Facility and all guarantees and security interests granted by
the Company to SVB under the Prior Credit Facility.
The New Credit Facility bears interest at a floating per annum rate equal to the greater of (i) 8.50% and (ii) 5.25% above the
Prime Rate. Interest is payable monthly in arrears on the first day of each month. The Company is obligated to make interest-
only payments through November 1, 2024, followed by equal monthly principal payments and applicable interest through the
maturity date of October 1, 2026 (the Maturity Date). If certain development milestones are met, then the interest-only period
will be extended to November 1, 2025.
The Company is also required to make a final payment to the Lenders equal to 4.25% of the principal amount of the term loans
then extended to the Company. This final payment is accreted under the effective interest method over the life of each term
loan. The term loans are secured by substantially all of the Company’s assets, except for its intellectual property which is
subject to a negative pledge, and certain other customary exclusions.
At the Company’s option, it may prepay the outstanding principal balance of any term loans in whole but not in part, subject to
a prepayment fee of: (a) 3.0% of the term loans then extended to the Company if the prepayment occurs on or prior to the first
anniversary of the funding date of such term loan, (b) 2.0% of the term loans then extended to the Company if the prepayment
occurs after the first anniversary of the funding date of such term loan but on or prior to the second anniversary of the funding
date of such term loan, or (c) 1.0% of the term loans then extended to the Company if the prepayment occurs after the second
anniversary of the funding date of such term loan but before the Maturity Date. The New Credit Facility includes customary
affirmative and restrictive covenants applicable to the Company. Affirmative covenants include, among others, covenants
requiring the Company to maintain its corporate existence and governmental approvals, deliver certain financial reports,
maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The restrictive covenants include,
among others, requirements relating to the Company’s ability to transfer collateral, incur additional indebtedness, engage in
mergers or acquisitions, pay dividends or make other distributions, make investments, create liens, sell assets and agree to a
change in control, in each case subject to certain customary exceptions.
The Company’s payment obligations under the New Credit Facility are subject to acceleration upon the occurrence of specified
events of default, which include, but are not limited to, the occurrence of a material adverse change in the Company’s business,
operations, or financial or other condition. Amounts outstanding upon the occurrence of an event of default are payable upon
the Lenders' demand and shall accrue interest at an additional rate of 5.0% per annum of the past due amount outstanding. As of
December 31, 2022, the Company was in compliance with all covenants under the New Credit Facility. As such, as of
December 31, 2022, the classification of the loan balance as stated on the balance sheet was based on the timing of defined
future payment obligations.
130
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
The following is a summary of obligations under the New Credit Facility as of December 31, 2022:
(in thousands)
Total debt
Less: Current portion of long-term-debt
Total debt, net of current portion
Debt financing costs, net of accretion
Accretion related to final payment
Long-term debt, net
As of December 31, 2022, the estimated future principal payments due are as follows:
(in thousands)
2023
2024
2025
2026
Total debt
December 31,
2022
$
$
$
$
25,000
—
25,000
(324)
253
24,929
—
2,083
12,500
10,417
25,000
Interest expense related to the New Credit Facility for the year ended December 31, 2022 was $3.2 million. The Company did
not recognize any interest expense related to the New Credit Facility during the year ended December 31, 2021. Interest
expense related to the Prior Credit Facility for the year ended December 31, 2021 was $0.8 million. The Company did not
recognize any interest expense related to the Prior Credit Facility during the year ended December 31, 2022.
9. Stockholders’ Equity
Preferred stock
As of December 31, 2022, the Company had 25,000,000 shares of authorized preferred stock. No shares of preferred stock have
been issued.
At-the-market ("ATM") equity offering program
In May 2020, the Company established an ATM equity offering program (the "2020 ATM"), pursuant to which it was able to
offer and sell up to $100.0 million of its common stock from time to time at prevailing market prices. During the year ended
December 31, 2021, the Company sold 3,961,074 shares of common stock, resulting in net proceeds of $43.1 million. During
the first quarter of 2022, the Company sold 11,740,210 shares of common stock resulting in net proceeds of $54.8 million under
the 2020 ATM. As of March 31, 2022, the 2020 ATM had been fully utilized.
In February 2022, the Company established a new ATM equity offering program (the "February 2022 ATM"), pursuant to which
it was able to offer and sell up to $100.0 million of its common stock from time to time at prevailing market prices. During the
year ended December 31, 2022, the Company sold 18,757,665 shares of common stock, resulting in net proceeds of
$96.4 million under the February 2022 ATM. As of December 31, 2022, approximately $1.6 million remained unsold and
available for sale under the February 2022 ATM.
In November 2022, the Company established an additional ATM equity offering program (the "November 2022 ATM"),
pursuant to which it is able to offer and sell up to $150.0 million of its common stock from time to time at prevailing market
prices. As of December 31, 2022, the Company had not sold any shares of common stock under the November 2022 ATM.
131
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Follow-on offering
In June 2020, the Company sold 9,200,000 shares of common stock in an underwritten public offering at a price to the public of
$19.00 per share. Net proceeds to the Company after deducting fees, commissions and other expenses related to the offering
were $164.0 million.
Warrants
In connection with a 2013 Series A-1 Preferred Stock issuance, the Company granted to certain investors warrants to purchase
129,491 shares of common stock. The warrants have a $0.05 per share exercise price and a contractual life of 10 years. The fair
value of these warrants was recorded as a component of equity at the time of issuance. As of December 31, 2022 and 2021 there
were outstanding warrants to purchase 22,590 and 39,474 shares of common stock, respectively. During the year ended
December 31, 2022, the Company issued 16,654 shares of common stock upon the net exercise of warrants.
Exchange warrants
On November 26, 2019, the Company entered into an exchange agreement with entities affiliated with Biotechnology Value
Fund, L.P. (the "Exchanging Stockholders"), pursuant to which the Exchanging Stockholders exchanged an aggregate of
2,575,000 shares of common stock for warrants (the "Exchange Warrants") to purchase an aggregate of 2,575,000 shares of
common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, merger or consolidation,
change of control, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of
$0.0001 per share.
In accordance with ASC Topic 505, Equity, the Company recorded the retirement of the common stock exchanged as a
reduction of common shares outstanding and a corresponding debit to additional paid-in-capital at the fair value of the
Exchange Warrants on the issuance date. While outstanding, the Exchange Warrants were classified as equity in accordance
with ASC Topic 480, Distinguishing Liabilities from Equity, and the fair value of the Exchange Warrants was recorded as a
credit to additional paid-in capital and is not subject to remeasurement. The Company determined that the fair value of the
Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible
exercise price for the Exchange Warrants. On March 2, 2020, the Exchanging Stockholders exercised the Exchange Warrants in
full on a net cashless exercise basis, resulting in the issuance of 2,574,971 shares of common stock.
Common Stock
At the Company's 2022 Annual Meeting of Stockholders on June 9, 2022, the Company's stockholders approved an amendment
to the Company’s Fifth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of
common stock, $0.0001 par value per share, from 175,000,000 to 350,000,000. This increase became effective upon filing of a
Certificate of Amendment with the Secretary of State of the State of Delaware on June 9, 2022.
The holders of the common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive
dividends, unless declared by the Board of Directors of the Company (the "Board").
As of December 31, 2022 and 2021 there were 11,944,664 and 9,199,512, respectively, shares of common stock reserved for
the exercise of outstanding stock options, restricted stock units ("RSUs") and warrants.
Stock options
Restricted stock units
Warrants
December 31,
2022
10,051,283
1,870,791
22,590
11,944,664
December 31,
2021
8,342,429
817,609
39,474
9,199,512
132
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
10. Stock-based Compensation
Stock incentive plans
As of June 30, 2017, there were 3,141,625 stock options outstanding under the Company’s 2007 Stock Incentive Plan (the
"2007 Plan") The 2007 Plan expired in June 2017. Any cancellations or forfeitures of options granted under the 2007 Plan will
increase the options available under the 2017 Stock Incentive Plan (the "2017 Plan"), as described below.
In June 2017 the Company’s stockholders approved the 2017 Plan. Under the 2017 Plan initially, up to 2,255,000 shares of
common stock could be granted to the Company's employees, officers, directors, consultants and advisors in the form of
options, RSUs or other stock-based awards. The number of shares of common stock issuable under the 2017 Plan will be
cumulatively increased annually on January 1 by the lesser of (a) 4% of the outstanding shares on the immediately preceding
December 31 or (b) such other amount specified by the Board. The terms of the awards are determined by the Board, subject to
the provisions of the 2017 Plan. Any cancellations or forfeitures of options granted under the 2007 Plan, which expired in June
2017, would increase the number of shares that could be granted under the 2017 Plan. On January 1, 2022, the number of shares
of common stock issuable under the 2017 Plan was increased by 2,948,362 shares. During the year ended December 31, 2022,
the Company granted 3,541,558 RSUs and options to purchase shares of common stock to employees and non-employee
directors under the 2017 Plan. As of December 31, 2022 there were 1,501,829 shares available for future issuance under the
2017 Plan.
Under the 2017 Plan, both with respect to incentive stock options and nonqualified stock options, the exercise price per share
will not be less than the fair market value of the common stock on the date of grant, and the vesting period for options granted
to employees is generally four years. Options granted under the 2017 Plan expire no later than 10 years from the date of grant.
Options under the 2007 Plan were granted at an exercise price established by the Board (or an authorized committee thereof)
that was not less than the fair market value of the underlying common stock on the date of grant and subject to such vesting
provisions determined by the Board (or an authorized committee thereof). The Board may accelerate vesting or otherwise adjust
the terms of granted options in the case of a merger, consolidation, dissolution, or liquidation of the Company.
Inducement awards
From time to time, the Company grants to its employees, upon approval by the Board or an authorized committee thereof,
options to purchase shares of common stock and/or RSUs as an inducement to employment in accordance with Nasdaq Listing
Rule 5635(c)(4). Prior to February 2022, only options were granted, and they were granted outside of an existing equity
incentive plan. These options are subject to terms substantially the same as the 2017 Plan.
In February 2022, the Board adopted the Company's 2022 Inducement Stock Incentive Plan (the "Inducement Plan"), which
provides for the grant of nonstatutory options, stock appreciation rights, restricted stock, RSUs and other stock-based awards,
with respect to an aggregate of 2,000,000 shares of the Company's common stock (subject to adjustment as provided in the
Inducement Plan). During the year ended December 31, 2022, the Company granted 713,025 RSUs and options to purchase
shares of common stock to newly hired employees under the Inducement Plan. As of December 31, 2022, there were 1,342,175
shares available for future issuance under the Inducement Plan.
As of December 31, 2022 there were options to purchase 757,500 shares of common stock outstanding which were granted as
inducement awards prior to establishment of the Inducement Plan.
133
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Stock option activity
A summary of stock option activity is as follows:
Outstanding at January 1, 2022
Granted
Exercised
Cancelled
Outstanding at December 31, 2022
Exercisable at December 31, 2022
Number
of Shares
8,342,429 $
2,793,659 $
(414,914) $
(669,891) $
10,051,283 $
5,410,541 $
Weighted-
Average
Exercise Price
11.25
5.43
3.21
13.09
9.84
9.45
Weighted
Average
Remaining
Contractual
Term
Aggregate
Intrinsic Value
8,458
7.2 $
7.2 $
6.1 $
8,197
6,076
The weighted-average grant date fair value of options granted during the years ended December 31, 2022, 2021 and 2020, was
$3.97, $11.71 and $7.99 per share, respectively. The total intrinsic value of options exercised during the years ended
December 31, 2022, 2021 and 2020, was $1.5 million, $4.3 million, and $11.1 million, respectively. The aggregate intrinsic
value represents the difference between the exercise price and the selling price received by option holders upon the exercise of
stock options during the period.
Cash received from the exercise of stock options was $1.3 million, $1.8 million and $3.1 million for the years ended
December 31, 2022, 2021 and 2020, respectively.
Restricted stock units
The Company periodically issues RSUs with a service condition to certain officers and other employees that typically vest
between one year and four years from the grant date.
A summary of the RSU activity is as follows:
Unvested at January 1, 2022
Granted
Vested
Forfeited
Unvested at December 31, 2022
Weighted-
Average
Remaining
Contractual
Term
Aggregate
Intrinsic Value
Weighted-
Average
Grant Date
Fair Value
1.5 $
—
—
—
1.5 $
5,086 $
$
$
$
10,963 $
15.68
5.70
15.62
8.54
8.55
Number
of Shares
817,609
1,460,924
(235,591)
(172,151)
1,870,791
The total fair value of RSUs vested during the years ended December 31, 2022, 2021 was $1.5 million and $5.8 million,
respectively. No RSUs vested during the year ended December 31, 2020.
134
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Employee stock purchase plan
During the year ended December 31, 2017, the Board adopted, and the Company's stockholders approved the 2017 employee
stock purchase plan (the "2017 ESPP"). The Company initially reserved 225,000 shares of common stock for issuance under the
2017 ESPP, plus an annual increase, to be added as of January 1st of each year, equal to the least of (i) 450,000 shares of
common stock; (ii) one percent of the number of shares of common stock outstanding as of the close of business on the
immediately preceding December 31st; and (iii) the number of shares of common stock determined by the Board on or prior to
such date for such year, up to maximum of 4,725,000 shares of common stock in the aggregate. On January 1, 2022, no shares
were added to the 2017 ESPP. During the years ended December 31, 2022 and 2021 the Company issued 270,774 and 78,253
shares, respectively, under the 2017 ESPP. As of December 31, 2022, there were 295,791 shares available for issuance under the
2017 ESPP.
Stock-based compensation expense
The Company uses the provisions of ASC 718 to account for all stock-based awards to employees and non-employees.
Stock-based compensation expense is recognized over the requisite service period, which is generally the vesting period, using
the straight-line method.
The following table presents stock-based compensation expense by award type included within the Company’s consolidated
statements of operations and comprehensive loss:
(in thousands)
Stock options
Restricted stock units
Employee stock purchase plan
Stock-based compensation expense included in total operating expenses
Year ended December 31,
2021
2020
2022
$
$
15,814 $
5,175
533
21,522 $
14,528 $
3,522
359
18,409 $
5,725
1,187
260
7,172
The following table presents stock-based compensation expense as reflected in the Company’s consolidated statements of
operations and comprehensive loss:
(in thousands)
Research and development
General and administrative
Stock-based compensation expense included in total operating expenses
Year ended December 31,
2021
2020
2022
$
$
11,386 $
10,136
21,522 $
9,984 $
8,425
18,409 $
3,841
3,331
7,172
As of December 31, 2022, there was $30.4 million and $11.6 million of unrecognized stock-based compensation expense
related to unvested stock options and unvested RSUs, respectively, that is expected to be recognized over a weighted average
period of 2.0 years and 2.6 years, respectively.
The fair value of each option award is estimated on the date of grant using the Black–Scholes option pricing model with the
following weighted average assumptions:
Risk-free interest rate
Expected dividend yield
Expected term (years)
Expected stock price volatility
135
2022
December 31,
2021
2020
2.1 %
— %
5.99
88 %
0.9 %
— %
6.06
82 %
1.2 %
— %
6.05
74 %
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Expected volatility for the Company’s common stock is determined based on a blended rate of its historical volatility combined
with the historical volatility of comparable publicly traded companies. The risk-free interest rate is based on the yield of U.S.
Treasury securities consistent with the expected term of the option. No dividend yield was assumed as the Company has not
historically and does not expect to pay dividends on its common stock. The expected term of the options granted is based on the
use of the simplified method, in which the expected term is presumed to be the mid-point between the vesting date and the end
of the contractual term.
The fair value of RSUs is determined based on the closing price of the Company’s common stock on the date of grant.
136
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
11. Net Loss per Share
Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the
weighted-average number of shares of common stock outstanding during the period, without further consideration for
potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common
stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the
period determined using the treasury stock method.
For purposes of the diluted net loss per share calculation, stock options, unvested RSUs and warrants to purchase common
stock are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share
because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods
presented.
The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of
diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):
Stock options
Unvested restricted stock units
Warrants
2022
10,051,283
1,870,791
22,590
11,944,664
Year ended December 31,
2021
8,342,429
817,609
39,474
9,199,512
2020
6,112,948
716,767
39,474
6,869,189
137
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
12. Leases
The Company has an operating lease for its office and lab space in Cambridge, Massachusetts and operating and finance leases
for certain equipment. In March 2020, the Company entered into the Seventh Amendment to the office and lab space lease ("the
Office Lease") to extend the term of the lease through March 2026. The Company has an option to extend the lease term of the
Office Lease for an additional five years.
On April 5, 2021, the Company entered into an Eighth Amendment to the Office Lease, which granted the Company additional
office space in its existing building for five years, beginning July 1, 2021, and committed the Company to lease payments of
$5.0 million over that period (the "Expansion Lease"). Independent from the option under the Office Lease, the Company has
an option to extend the lease term of the Expansion Lease for an additional five years. The Company’s exercise of the options to
extend the lease terms of both the Office Lease and Expansion Lease were not considered reasonably certain as of
December 31, 2022.
The Expansion Agreement is a lease modification accounted for as a separate contract, because it expands the scope of the
Office Lease and the additional lease payments are commensurate with market rents. The Company assessed the lease
classification of the Expansion Lease as of the date of signing and determined that the Expansion Lease should be accounted for
as an operating lease. The right-of-use asset and corresponding operating lease liability have been calculated based on the
present value of lease payments over the lease term. The Company determined the appropriate incremental borrowing rate to
utilize as a discount rate by using a synthetic credit rating which was estimated based on an analysis of outstanding debt of
companies with similar credit and financial profiles. Since the operating lease is a net lease, as the non-lease components (i.e.,
common area maintenance) are paid separately from rent based on actual costs incurred, such non-lease components were not
included in the ROU asset and liability and are reflected as an expense in the period incurred.
The Company had a standby letter of credit agreement for the benefit of its landlord in the amount of $0.5 million in connection
with the Office Lease and Expansion Lease as of December 31, 2022 and 2021.
The Company has remaining finance lease terms of one year to five years for certain equipment, some of which include options
to purchase at fair value.
The components of lease expense included in research and development and general and administrative expenses in the
statement of operations were as follows:
(in thousands)
Operating lease cost
Finance lease cost:
Amortization of right-of-use assets
Interest on lease liabilities
Supplemental balance sheet information related to leases was as follows:
Years ended December 31,
2021
2022
2020
3,793 $
3,502 $
2,755
194 $
28
222 $
169 $
28
197 $
101
21
122
$
$
$
138
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Operating leases:
Operating lease right-of-use assets
Operating lease liabilities, current
Operating lease liabilities
Finance leases:
Property and equipment, gross
Property and equipment, accumulated depreciation
Other liabilities, current
Other liabilities
Weighted-average remaining lease term:
Operating leases
Finance leases
Weighted-average discount rate:
Operating leases
Finance leases
Supplemental cash flow information related to leases was as follows:
(in thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases
Operating cash flows from finance leases
Financing cash flows from finance leases
$
$
$
$
$
$
$
Year ended December 31,
2021
2022
10,475
2,798
8,575
$
$
$
12,889
2,303
11,247
$
1,038
(539) $
$
240
$
203
1,038
(345)
239
449
3.3 years
2.0 years
4.3 years
4.0 years
10.8 %
5.4 %
10.8 %
5.4 %
Year ended December 31,
2021
2022
$
$
$
3,865 $
28 $
272 $
3,241
28
215
Future minimum lease payments under non-cancellable leases as of December 31, 2022 were as follows:
(in thousands)
2023
2024
2025
2026
2027 and thereafter
Total lease payments
Present value adjustment
Present value of lease liabilities
Operating leases Finance leases
$
3,857 $
4,146
4,187
1,310
—
13,500
(2,127)
11,373 $
262
141
48
8
—
459
(15)
444
$
139
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
13. Income Taxes
For the years ended December 31, 2022, 2021 and 2020, the Company recorded no income tax benefit for the net operating
losses ("NOLs") incurred in each year, due to the Company’s operating losses and a full valuation allowance on deferred tax
assets.
A reconciliation of the effective tax rate for the years ended December 31, 2022 and 2021 is as follows:
Statutory US Federal Rate
State taxes, net of federal benefit
Permanent differences
General business credits
Stock compensation
Change in valuation allowance
2022
2021
21.0 %
5.7 %
(0.1) %
4.4 %
(1.4) %
(29.6) %
— %
21.0 %
6.3 %
(0.2) %
3.8 %
0.1 %
(31.0) %
— %
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities
for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net
deferred tax assets as of December 31, 2022 and 2021 are as follows:
(in thousands)
Deferred tax assets:
Net operating losses
R&D capitalization
Tax credit carryforwards
Stock-based compensation
Accrued expenses
Lease liabilities
Capitalized licenses
Deferred revenue
Depreciation
Other
Total gross deferred tax assets
Valuation allowance
Net deferred tax assets less valuation allowance
Deferred tax liabilities
Right-of-use assets
Total gross deferred tax liabilities
Net deferred taxes
$
2022
2021
113,981 $
40,380
21,429
6,522
3,340
3,096
3,077
1,062
437
116
193,440
(190,588)
2,852
106,055
—
12,424
5,018
1,874
3,698
2,775
1,076
493
71
133,484
(130,051)
3,433
(2,852)
(2,852)
— $
(3,433)
(3,433)
—
$
The Company has incurred NOLs since inception. At December 31, 2022, the Company had federal and state NOL
carryforwards of approximately $432.8 million and $365.3 million, respectively. Of the $432.8 million of federal NOL
carryforwards, $34.1 million expire at various dates through 2037. The remaining $398.7 million of federal NOL carryforwards
do not expire. The state NOL carryforwards expire at various dates through 2042. At December 31, 2022, the Company had
federal and state research and development tax credit carryforwards of approximately $17.4 million and $5.1 million,
respectively, which expire at various dates through 2042.
140
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
As required by ASC 740, management of the Company has evaluated the evidence bearing upon the reliability of its deferred
tax assets. Based on the weight of available evidence, both positive and negative, management has determined that it is more
likely than not that the Company will not realize the benefits of all of these assets. Accordingly, the Company recorded a
valuation allowance of $190.6 million and $130.1 million at December 31, 2022 and December 31, 2021, respectively. The
valuation allowance increased by $60.5 million during the year ended December 31, 2022, primarily a result of the Company's
current year NOL.
Utilization of the NOLs and research and development tax credit carryforwards may be subject to a substantial annual
limitation under Section 382 due to ownership change limitations that have occurred previously or that could occur in the future
in accordance with Section 382, as well as similar state provisions. These ownership changes may limit the amount of NOLs
and research and development tax credit carryforwards that can be utilized annually to offset future taxable income and tax,
respectively. If a change in control as defined by Section 382 has occurred at any time since the Company’s formation,
utilization of its NOLs or research and development tax credit carryforwards would be subject to an annual limitation under
Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by
the applicable long-term tax-exempt rate, which could then be subject to additional adjustments, as required. Any limitation
may result in expiration of a portion of the NOLs or research and development tax carryforwards before their utilization. The
Company has determined that ownership changes have occurred in the past and that certain NOLs and research and
development tax credit carryforwards will be subject to limitation. The amounts presented do not include NOLs or research and
development tax credit carryforwards that will expire unused due to ownership changes.
The Company applies the accounting guidance in ASC 740 related to accounting for uncertainty in income taxes. The
Company’s reserves related to taxes are based on a determination of whether, and how much of, a tax benefit taken by the
Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies
present related to the tax benefit. As of December 31, 2022 and 2021, the Company had no unrecognized tax benefits.
The Company has not conducted a study of its research and development credit carryforwards. This study may result in an
adjustment to research and development credit carryforwards; however, until a study is completed and any adjustment is
known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the
Company’s research and development credits and, if an adjustment is required, this adjustment would be offset by an
adjustment to the valuation allowance. Thus, there would be no impact to the balance sheets or statements of operations if an
adjustment were required.
Interest and penalties related to uncertain tax positions would be classified as income tax expense in the accompanying
statements of operations. As of December 31, 2022 and 2021, the Company had no accrued interest or penalties related to
uncertain tax positions.
The Company files income tax returns in the United States federal tax jurisdiction and eight state jurisdictions. The Company
did not have any foreign operations during the years ended December 31, 2022, 2021 and 2020. The statute of limitations for
assessment by the Internal Revenue Service and state tax authorities is closed for tax years prior to 2018, although carryforward
attributes that were generated prior to tax year 2018 may still be adjusted upon examination to the extent utilized in a future
period. There are no federal or state audits currently in progress.
14. Employee Benefit Plan
The Company has a defined contribution plan established under Section 401(k) of the Internal Revenue Code ("401(k) Plan"),
which covers substantially all employees. Employees who have attained the age of 21 and have worked more than 1,000 hours
are eligible to participate in the 401(k) Plan. Employees may contribute up to 95% of eligible pay on a pre–tax basis up to the
federal annual limits. For the years ended December 2022, 2021, and 2020, the Company made matching contributions equal to
100% of the employee’s contributions, subject to a maximum of 4% of eligible compensation. For the years ended
December 31, 2022, 2021 and 2020, the Company recorded expense of $1.1 million, $0.8 million and $0.5 million,
respectively, related to its contribution to its 401(k) Plan.
141
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
15. Commitments
License agreements
During the years ended December 31, 2022, 2021 and 2020, the Company recorded research and development expense related
to non-refundable license payments of $1.5 million, $3.1 million, and $0.3 million, respectively.
During the years ended December 31, 2022, 2021 and 2020, the Company recorded research and development expense related
to development milestones of $0.7 million, $2.1 million and $0.8 million, respectively. The 2022, 2021, and 2020 development
milestones were associated with XMT-1660, UpRi, and XMT-1592, respectively.
See Note 12, Leases, for the Company’s future obligations related to leases as of December 31, 2022.
142
ITEM 9.
None.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
ITEM 9A.
CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange
Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the
reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time
periods specified in the Securities and Exchange Commission’s rules and forms and (2) accumulated and communicated to our
management, including our principal executive and principal financial officer, as appropriate to allow timely decisions
regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and
operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its
judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures
are designed to provide reasonable assurance of achieving their control objectives.
Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the
effectiveness of our disclosure controls and procedures as of December 31, 2022, the end of the period covered by this Annual
Report on Form 10-K. Based upon such evaluation, our principal executive officer and principal financial officer have
concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.
Internal Control Over Financial Reporting
Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal
control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process
designed by, or under the supervision of, our principal executive and principal financial officers and effected by our board of
directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles,
or GAAP. Our internal control over financial reporting includes those policies and procedures that:
•
•
•
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and
dispositions of our assets;
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements
in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with
authorizations of our management and directors; and
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition
of our assets that could have a material effect on our financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2022. In making
this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO) in its 2013 Internal Control — Integrated Framework. Based on our assessment, our management has
concluded that, as of December 31, 2022, our internal control over financial reporting is effective based on those criteria.
Changes in Internal Control over Financial Reporting
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act)
occurred during the three months ended December 31, 2022 that has materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.
143
ITEM 9B.
OTHER INFORMATION
None.
ITEM 9C.
DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not applicable.
144
PART III
ITEM 10.
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Other than as noted below, the information required by this item is incorporated by reference to the information set forth in the
sections titled "Proposal No. 1 – Election of Directors," "Executive Officers," and "Information Regarding the Board of
Directors and Corporate Governance" and "Delinquent Section 16(a) Reports," if any, in our definitive proxy statement for our
2023 annual meeting of stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of
our fiscal year ended December 31, 2022, or the 2023 Proxy Statement.
We post our Code of Business Conduct and Ethics, which applies to our directors, officers, and employees, including our
principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar
functions, in the “Corporate Governance” sub-section of the “Investors & Media” section (https://ir.mersana.com) of our
corporate website https://mersana.com/. We intend to disclose on our website any amendments to, or waivers from, the Code of
Business Conduct and Ethics that are required to be disclosed pursuant to the disclosure requirements of Item 5.05 of Form 8-
K.
ITEM 11.
EXECUTIVE COMPENSATION
The information required by this item (other than the information required by Item 402(v) of Regulation S-K) is incorporated
by reference to the information set forth in the sections titled "Executive Compensation" and "Information Regarding the Board
of Directors and Corporate Governance - Compensation Committee Interlocks and Insider Participation" in our 2023 Proxy
Statement.
ITEM 12.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
The information required by this item is incorporated by reference to the information set forth in the sections titled "Security
Ownership of Certain Beneficial Owners and Management" and "Securities Authorized for Issuance Under Equity
Compensation Plans" in our 2023 Proxy Statement.
ITEM 13.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE
The information required by this item is incorporated by reference to the information set forth in the sections titled "Certain
Relationships and Related Party Transactions" and "Information Regarding the Board of Directors and Corporate Governance –
Director Independence" in our 2023 Proxy Statement.
ITEM 14.
PRINCIPAL ACCOUNTANT FEES AND SERVICES
The information required by this item is incorporated by reference to the information set forth in the section titled "Principal
Accountant Fees and Services" in our 2023 Proxy Statement.
145
ITEM 15.
EXHIBIT AND FINANCIAL STATEMENT SCHEDULES
(a)(1) Financial Statements
PART IV
Our consolidated financial statements are listed in the "Index to Consolidated Financial Statements" under Part II, Item 8 of this
Annual Report on Form 10-K.
(a)(2) Financial Statement Schedules
All schedules are omitted because they are not required or are not applicable or because the information required is included in
the consolidated financial statements or the notes thereto.
(a)(3) Exhibits
Exhibit
Number
3.1
3.2
4.1
4.2
4.3*
10.1†
10.2
10.3
10.4
10.5+
10.6+
10.7+
Description of Exhibit
Fifth Amended and Restated Certificate of Incorporation, as amended, as of June 9, 2022 (incorporated
by reference to Exhibit 5.03 to the Current Report on Form 8-K (File No. 001-38129) filed with the
Securities and Exchange Commission (the "SEC") on June 10, 2022).
Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Current Report on Form
8-K (File No. 001-38129) filed with the SEC on July 10, 2017).
Form of Common Stock Warrant (incorporated by reference to Exhibit 4.1 to the Registration Statement
on Form S-1 (File No. 333-218412) filed with the SEC on June 1, 2017).
Form of Exchange Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K
(File No. 001-38129) filed with the SEC on November 27, 2019).
Description of Securities.
Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 to Amendment No. 1 to
Registration Statement on Form S-1 (File No. 333-218412) filed with the SEC on June 16, 2017).
Commercial Lease, dated February 24, 2009, between Mersana Therapeutics, Inc. and Rivertech
Associates II, LLC (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1
(File No. 333-218412) filed with the SEC on June 1, 2017).
Seventh Lease Extension and Modification Agreement to the Lease Between Rivertech Associates II
LLC and Mersana Therapeutics, Inc., dated March 10, 2020, by and between Mersana Therapeutics, Inc.
and Rivertech Associates II LLC (incorporated by reference to Exhibit 10.1 to the Quarterly Report on
Form 10-Q (File No. 001-38129) filed with the SEC on May 8, 2020).
Eighth Lease Modification Agreement to the Lease Between Rivertech Associates II LLC and Mersana
Therapeutics, Inc., effective as of April 5, 2021, by and between Mersana Therapeutics, Inc. and
Rivertech Associates II LLC (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form
10-Q (File No. 001-38129) filed with the SEC on May 10, 2021).
Collaboration and Commercial License Agreement, dated June 23, 2014, by and between Mersana
Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.4 to the Registration
Statement on Form S-1 (File No. 333-218412) filed with the SEC on June 1, 2017).
Amendment 1 to the Collaboration and Commercial License Agreement, dated June 1, 2016, by and
between Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.5 to the
Registration Statement on Form S-1 (File No. 333-218412) filed with the SEC on June 1, 2017).
Amendment 2 to the Collaboration and Commercial License Agreement, dated August 12, 2016, by and
between Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.6 to the
Registration Statement on Form S-1 (File No. 333-218412) filed with the SEC on June 1, 2017).
146
10.8+
10.9
10.10+
10.11
10.12+
10.13+
10.14+
10.15+
10.16+
10.17+
10.18*+
10.19+
10.20+
10.21*+
10.22*
Amendment 3 to the Collaboration and Commercial License Agreement, dated February 28, 2017, by and
between Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.7 to the
Registration Statement on Form S-1 (File No. 333-218412) filed with the SEC on June 1, 2017).
Amendment 4 to Collaboration and Commercial License Agreement dated May 15, 2018, by and
between Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.1 to the
Quarterly Report on Form 10-Q (File No. 001-38129) filed with the SEC on August 14, 2018).
License, Development and Commercialization Agreement, dated July 9, 2015, by and between Mersana
Therapeutics, Inc. and Recepta Biopharma S.A. (incorporated by reference to Exhibit 10.8 to the
Registration Statement on Form S-1 (File No. 333-218412) filed with the SEC on June 1, 2017).
First Amendment to the License, Development and Commercialization Agreement, dated August 19,
2019, by and between Mersana Therapeutics, Inc. and Recepta Biopharma S.A. (incorporated by
reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-38129) filed with the SEC
on November 6, 2019).
Second Amendment to the License, Development and Commercialization Agreement, dated September
28, 2021, by and between Mersana Therapeutics, Inc. and Recepta Biopharma S.A. (incorporated by
reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-38129) filed with the SEC
on November 9, 2021).
Agreement Regarding LICR Technology, dated July 9, 2015, by and between Ludwig Institute for Cancer
Research, Recepta Biopharma S.A. and Mersana Therapeutics, Inc. (incorporated by reference to Exhibit
10.9 to the Registration Statement on Form S-1 (File No. 333-218412) filed with the SEC on June 1,
2017).
Amended and Restated Commercial License and Option Agreement, dated November 23, 2021, by and
between Synaffix B.V. and Mersana Therapeutics, Inc. (incorporated by reference to Exhibit 10.15 to
Annual Report on Form 10-K (File No. 001-38129) filed with the SEC on February 28, 2022).
Amendment No. 1 to the Amended and Restated Commercial License and Option Agreement, dated
February 2, 2022, between Mersana Therapeutics, Inc. and Synaffix B.V. (incorporated by reference to
Exhibit 10.3 to the Quarterly Report on Form 10-Q (File No. 001-38129) filed with the SEC on May 9,
2022).
Research Collaboration and License Agreement, dated February 2, 2022, between Mersana Therapeutics,
Inc. and Janssen Biotech, Inc. (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form
10-Q (File No. 001-38129) filed with the SEC on May 9, 2022).
Collaboration, Option and License Agreement, dated August 6, 2022, between Mersana Therapeutics,
Inc. and GlaxoSmithKline Intellectual Property (No. 4) Limited (incorporated by reference to Exhibit
10.1 to the Quarterly Report on Form 10-Q (File No. 001-38129) filed with the SEC on November 7,
2022).
Collaboration and Commercial License Agreement, dated December 22, 2022, between Mersana
Therapeutics, Inc. and Ares Trading S.A.
Loan and Security Agreement, dated October 29, 2021, by and between Oxford Finance LLC, Silicon
Valley Bank and Mersana Therapeutics, Inc. (incorporated by reference to Exhibit 10.14 to Annual
Report on Form 10-K (File No. 001-38129) filed with the SEC on February 28, 2022).
First Amendment to Loan and Security Agreement, dated February 17, 2022, between Oxford Finance
LLC, the Lenders named therein including Silicon Valley Bank, and Mersana Therapeutics, Inc.
(incorporated by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q (File No. 001-38129)
filed with the SEC on May 9, 2022).
Second Amendment to Loan and Security Agreement, dated October 17, 2022, between Oxford Finance
LLC, the Lenders named therein including Silicon Valley Bank, and Mersana Therapeutics, Inc.
Third Amendment to Loan and Security Agreement, dated December 27, 2022, between Oxford Finance
LLC, the Lenders named therein including Silicon Valley Bank, and Mersana Therapeutics, Inc.
147
10.23
10.24†
10.25†
10.26†
10.27†
10.28†
10.29†
10.30†
10.31†
10.32†
10.33†
10.34†
10.35†
10.36†
10.37†
10.38†
10.39†
Sales Agreement, dated November 7, 2022, between Mersana Therapeutics, Inc. and Cowen and
Company, LLC (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K (File No.
001-38129) filed with the SEC on November 7, 2022).
Amended and Restated Offer Letter, by and between Mersana Therapeutics, Inc. and Anna Protopapas,
dated March 17, 2017 (incorporated by reference to Exhibit 10.16 to the Registration Statement on Form
S-1 (File No. 333-218412) filed with the SEC on June 1, 2017).
Amended and Restated Offer Letter, by and between Mersana Therapeutics, Inc. and Timothy B.
Lowinger, dated March 8, 2017 (incorporated by reference to Exhibit 10.18 to the Registration Statement
on Form S-1 (File No. 333-218412) filed with the SEC on June 1, 2017).
Offer Letter, by and between Mersana Therapeutics, Inc. and Brian DeSchuytner, dated June 10, 2019
(incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q (File No. 001-38129)
filed with the SEC on May 8, 2020).
Offer Letter, by and between Mersana Therapeutics, Inc. and Arvin Yang, dated November 5, 2020
(incorporate by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q (File No. 001-38129)
filed with the SEC on May 10, 2021).
Offer Letter, dated March 5, 2021, by and between Mersana Therapeutics, Inc. and Alejandra Carvajal
(incorporated by reference to Exhibit 10.5 to the Quarterly Report on Form 10-Q (File No. 001-38129)
filed with the SEC on May 9, 2022).
Offer Letter, dated June 15, 2021, between Mersana Therapeutics, Inc. and Tushar Misra (incorporated
by reference to Exhibit 10.6 to the Quarterly Report on Form 10-Q (File No. 001-38129) filed with the
SEC on May 9, 2022).
2007 Stock Incentive Plan, as amended (incorporated by reference to Exhibit 10.19 to the Registration
Statement on Form S-1 (File No. 333-218412) filed with the SEC on June 1, 2017).
Form of Incentive Stock Option under the 2007 Stock Incentive Plan (incorporated by reference to
Exhibit 10.20 to the the Registration Statement on Form S-1 (File No. 333-218412) filed with the SEC
on June 1, 2017).
Form of Nonqualified Stock Option under the 2007 Stock Incentive Plan (incorporated by reference to
Exhibit 10.21 to the the Registration Statement on Form S-1 (File No. 333-218412) filed with the SEC
on June 1, 2017).
2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.22 to Amendment No. 1 to
Registration Statement on Form S-1 (File No. 333-218412) filed with the SEC on June 16, 2017).
Form of Incentive Stock Option under the 2017 Stock Incentive Plan (incorporated by reference to
Exhibit 10.23 to Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-218412) filed
with the SEC on June 16, 2017).
Form of Nonqualified Stock Option under the 2017 Stock Incentive Plan (incorporated by reference to
Exhibit 10.24 to Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-218412) filed
with the SEC on June 16, 2017).
Form of Restricted Stock Unit under the 2017 Stock Incentive Plan (incorporated by reference to Exhibit
10.1 to the Quarterly Report on Form 10-Q (File No. 333-38129) filed with the SEC on August 6, 2021).
2022 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.28 to the Annual Report
on Form 10-K (File No. 001-38129) filed with the SEC on February 28, 2022).
Form of Inducement Restricted Stock Unit under the 2022 Inducement Stock Incentive Plan
(incorporated by reference to Exhibit 10.29 to the Annual Report on Form 10-K (File No. 001-38129)
filed with the SEC on February 28, 2022).
Form of Non-statutory Stock Option under the 2022 Inducement Stock Incentive Plan (incorporated by
reference to Exhibit 10.30 to the Annual Report on Form 10-K (File No. 001-38129) filed with the SEC
on February 28, 2022).
10.40*†
2017 Employee Stock Purchase Plan, as amended
148
10.41†
10.42*†
21.1*
23.1*
31.1*
31.2*
32.1**
97*†
101.INS*
101.SCH*
101.CAL*
101.DEF
101.LAB*
101.PRE*
104*
2017 Cash Bonus Plan (incorporated by reference to Exhibit 10.26 to Amendment No. 1 to Registration
Statement on Form S-1 (File No. 333-218412) filed with the SEC on June 16, 2017).
Non-Employee Director Compensation Policy, effective as of December 1, 2022.
Subsidiaries of Mersana Therapeutics, Inc.
Consent of Ernst & Young LLP, independent registered public accounting firm.
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the
Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the
Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Clawback Policy
Inline XBRL Instance Document
Inline XBRL Taxonomy Extension Schema Document
Inline XBRL Taxonomy Extension Calculation Linkbase Document
Inline XBRL Taxonomy Extension Definition Linkbase Document
Inline XBRL Taxonomy Extension Label Linkbase Document
Inline XBRL Taxonomy Extension Presentation Linkbase Document
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL
document (included in Exhibit 101).
*
**
†
+
Filed herewith.
The certification attached as Exhibit 32.1 accompanying this Annual Report on Form 10-K is not deemed filed with
the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made
before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language
contained in such filing.
Indicates a management contract or compensatory plan.
Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
ITEM 16.
FORM 10-K SUMMARY
None.
149
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized.
SIGNATURES
Date: February 28, 2023
Mersana Therapeutics, Inc.
/s/ Anna Protopapas
Anna Protopapas
President and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following
persons on behalf of the registrant and in the capacities and on dates indicated.
Signature
/s/ ANNA PROTOPAPAS
Anna Protopapas
/s/ BRIAN DESCHUYTNER
Brian DeSchuytner
/s/ ASHISH MANDELIA
Ashish Mandelia
/s/ DAVID MOTT
David Mott
/s/ LAWRENCE M. ALLEVA
Lawrence M. Alleva
/s/ WILLARD H. DERE, M.D.
Willard H. Dere, M.D.
/s/ ALLENE M. DIAZ
Allene M. Diaz
/s/ ANDREW A. F. HACK
Andrew A. F. Hack, M.D., Ph.D.
/s/ KRISTEN HEGE
Kristen Hege, M.D.
/s/ MARTIN H. HUBER, M.D.
Martin H. Huber, M.D.
Title
President, Chief Executive Officer and Director
(Principal Executive Officer)
Senior Vice President, Chief Financial Officer (Principal
Financial Officer)
Date
February 28, 2023
February 28, 2023
Vice President, Controller (Principal Accounting Officer) February 28, 2023
February 28, 2023
February 28, 2023
February 28, 2023
February 28, 2023
February 28, 2023
February 28, 2023
February 28, 2023
Chairman of the Board
Director
Director
Director
Director
Director
Director
150
EXECUTIVE OFFICERS
DIRECTORS
CORPORATE INFORMATION
Anna Protopapas
Chief Executive Officer and
President, Director
Brian DeSchuytner
Senior Vice President,
Chief Financial Officer
Alejandra Carvajal
Senior Vice President,
Chief Legal Officer
Timothy B. Lowinger, Ph.D
Senior Vice President,
Chief Science and Technology
Officer
Tushar Misra, Ph.D.
Senior Vice President,
Chief Manufacturing Officer
Arvin Yang, M.D., Ph.D.
Senior Vice President,
Chief Medical Officer
David Mott
Chair of the Board of Directors;
Private Investor, Mott Family
Capital
Transfer Agent and Registrar
Computershare Trust Company, N.A.
150 Royall Street
Canton, MA 02021
Anna Protopapas
Chief Executive Officer and
President
Lawrence M. Alleva
Former Partner,
PricewaterhouseCoopers LLP
Willard H. Dere, M.D
Professor Emeritus of Internal
Medicine, University of Utah
Allene M. Diaz
Commercial Strategy and Portfolio
Management Consultant,
AMD Consulting
Andrew A. F. Hack, M.D., Ph.D.
Managing Director,
Bain Capital Life Sciences
Kristen Hege, M.D.
Former Senior Vice President, Early
Clinical Development, Hematology/
Oncology & Cell Therapy,
Bristol Myers Squibb Company
Martin Huber, M.D.
President and Head of R&D,
Xilio Therapeutics, Inc.
Form 10-K Requests
Our Annual Report on Form 10-K
for the fiscal year ended
December 31, 2022 has been filed
with the Securities and Exchange
Commission, and additional
copies are available without
charge upon written request by
contacting us at our Corporate
Headquarters, attention: Secretary.
Corporate Headquarters
840 Memorial Drive
Cambridge, Massachusetts 02139
Common Stock Data
Nasdaq Global Select Market
Symbol: MRSN
Investor Relations
Jason Fredette
SVP, Investor Relations &
Corporate Communications
(617) 498-0020
Jason.Fredette@mersana.com
Annual Meeting
Our annual meeting of stockholders
will be held on Thursday, June 8,
2023 at 10:00 a.m. Eastern Time via
the internet at
www.virtualshareholdermeeting.com/
MRSN2023.
Independent Registered Public
Accounting Firm
Ernst & Young LLP
Boston, Massachusetts